capecitabine has been researched along with deoxycytidine in 3302 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 47 (1.42) | 18.2507 |
| 2000's | 1411 (42.73) | 29.6817 |
| 2010's | 1796 (54.39) | 24.3611 |
| 2020's | 48 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Sawada, N; Sekiguchi, F | 1 |
| Allman, D; Banken, L; Cassidy, J; Dirix, L; Osterwalder, B; Reigner, B; Roos, B; Twelves, C; Utoh, M; Verweij, J; Weidekamm, E | 1 |
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Nishida, M; Sawada, N; Yoshikubo, T | 1 |
| Behr, J; Berghorn, E; Budman, DR; Creaven, PJ; Gordon, RJ; Griffin, T; Lichtman, SM; Meropol, NJ; Osterwalder, B; Reigner, B | 1 |
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Nishida, M; Sawada, N; Sekiguchi, F; Utoh, M | 1 |
| McCann, J | 1 |
| Fukase, Y; Ishikawa, T; Ishitsuka, H; Sekiguchi, F; Yamamoto, T | 1 |
| Punt, CJ | 2 |
| Garcia, L; Goodwin, AL; Von Hoff, DD | 1 |
| Allman, D; Griffin, T; Kaye, S; Mackean, M; Osterwalder, B; Planting, A; Reigner, B; Schellens, J; Twelves, C; Verweij, J | 1 |
| Allman, D; Bissett, D; Cassidy, J; Dirix, L; Griffin, T; Osterwalder, B; Reigner, B; Van Oosterom, AT | 1 |
| Bunnell, CA; Winer, EP | 1 |
| Ajani, JA | 1 |
| Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M | 2 |
| Ishikawa, T; Ishitsuka, H; Miwa, M; Mori, K; Nishida, M; Sawada, N; Shimma, N; Umeda, I; Ura, M | 1 |
| Meropol, NJ | 1 |
| Banken, L; Cassidy, J; Clive, S; Goggin, T; Jodrell, D; Mulligan, T; Reigner, B; Roos, B; Schulz, R; Utoh, M; Weidekamm, E | 1 |
| Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C | 1 |
| Saeki, T; Takashima, S | 2 |
| González Barón, M | 1 |
| Davis, WM; Waters, IW | 1 |
| Timmerman, D | 1 |
| Frye, DK; Mrozek-Orlowski, ME; Sanborn, HM | 1 |
| Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E | 1 |
| Kaye, SB | 1 |
| Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH | 1 |
| Verweij, J | 1 |
| Blum, JL | 2 |
| Cottu, PH; Cuvier, C; Espie, M; Lerebours, F; Marty, M | 1 |
| Cassidy, J | 6 |
| Dooley, M; Goa, KL | 1 |
| Endo, M; Fukase, Y; Ishikawa, T; Ishitsuka, H; Sawada, N; Shinbori, N; Tanaka, Y | 1 |
| Lamont, EB; Schilsky, RL | 1 |
| Adjei, AA | 1 |
| Macdonald, JS | 1 |
| Ishikawa, T; Ishitsuka, H; Sawada, N; Sekiguchi, F; Tanaka, Y | 1 |
| Banken, L; Bush, E; Cameron, D; Cassidy, J; Goggin, T; Jodrell, D; Jones, D; O'Byrne, K; Reigner, B; Roos, B; Steward, W; Twelves, C; Weidekamm, E | 1 |
| Aherne, W; Beale, PJ; Bush, E; Crompton, T; Jones, D; Judson, IR; Reigner, B; Trigo, JM | 1 |
| Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Berlin, JD; Freeberg, BL; Johnson, CL; Kolesar, JM; Schiller, JH | 1 |
| Cao, S; Rustum, YM | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| Horii, I; Ishitsuka, H; Shimma, N | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J | 1 |
| Batchelder, KF | 1 |
| Banken, L; Cassidy, J; Dumont, E; Durston, S; Mori, K; Reigner, B; Roos, B; Schüller, J; Utoh, M; Weidekamm, E | 1 |
| Aoyagi, S; Fujii, H; Fukuda, M; Hasegawa, M; Hirakawa-YS Chung, K; Ikeda, T; Imamoto, H; Kameyama, M; Kinoshita, H; Kitamura, M; Kubota, T; Makuuchi, H; Manabe, T; Mizutani, K; Mori, K; Murai, M; Nagasue, N; Nakao, A; Nakashima, Y; Nishida, M; Ogawa, M; Oka, M; Onishi, Y; Ozono, S; Sasaki, H; Shimada, Y; Takasaki, K; Toi, M; Toma, H; Tono, T; Yamana, H | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Di Costanzo, F; Gasperoni, S; Sdrobolini, A | 1 |
| Atzpodien, J; Buer, J; Franzke, A; Hoffmann, R; Kirchner, H; Oevermann, K; Patzelt, T; Schrader, A | 1 |
| Maeda, Y; Sasaki, T | 2 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Arasaki, M; Horii, I; Ishitsuka, H; Kohchi, Y; Kuruma, I; Masubuchi, K; Miwa, M; Murasaki, C; Sawada, N; Shimma, N; Tahara, H; Umeda, I; Ura, M | 1 |
| Fraunfelder, FT; Henner, WD; Waikhom, B; Walkhom, B | 1 |
| Tanaka, C; Toi, M | 1 |
| Schilsky, RL | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 2 |
| Peeters, M; Van Cutsem, E | 1 |
| Anthoney, A; Twelves, C | 1 |
| Harstrick, A | 1 |
| Awada, A; Piccart, MJ | 1 |
| Ishitsuka, H | 1 |
| Budman, DR | 3 |
| Lewis, NL; Meropol, NJ | 2 |
| Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L | 1 |
| Donehower, RC | 1 |
| Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
| Fan, J; Tang, Z; Zhou, J | 1 |
| Marshall, JL | 2 |
| Gradishar, WJ | 3 |
| Mokbel, K | 1 |
| Seitz, JF | 1 |
| Blesch, K; Reigner, B; Weidekamm, E | 1 |
| Barker, C; Boyer, M; Cassidy, J; Findlay, M; Hieke, K; Jamieson, C; Osterwalder, B; Twelves, C; Weitzel, C | 1 |
| Matsuzaki, A; Morita, T; Tokue, A | 1 |
| de Bono, JS; Twelves, CJ | 1 |
| Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R | 1 |
| Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T | 1 |
| Cunningham, D; James, RD | 1 |
| Moiseenko, VM; Orlova, RV; Semenova, AI | 1 |
| Casado, FJ; Fernández-Veledo, S; García-Manteiga, JM; Guillén-Gómez, E; Larrayoz, IM; Lloberas, J; Lostao, MP; Mata, JF; Pastor-Anglada, M | 1 |
| Leonard, RC | 1 |
| Koizumi, W | 1 |
| Blum, JL; Diab, S; Elledge, R; Griffin, T; Jones, SE; Khoury, P; Kraynak, M; Kromelis, P; Moczygemba, J; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, D | 1 |
| Collao Lamb, C; Popova, N; Sappino, AP; Schnetzler, B | 1 |
| Royce, ME; Schomer, DF; Theriault, RL; Wang, ML; Yung, WK | 1 |
| Chen, GY; Chen, WC; Chen, YH; Hsu, MM; Tsao, CJ | 1 |
| Gershanovich, ML; Semiglazova, TIu | 1 |
| Coleman, R; Cunningham, D | 1 |
| Cunningham, D; Hoff, PM; Maroun, J; Van Cutsem, E | 1 |
| Cassidy, J; Hoff, PM; Schmoll, HJ | 1 |
| Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H | 1 |
| Cunningham, D; Maroun, J; Van Cutsem, E; Vanhoefer, U | 1 |
| Cassidy, J; Schmoll, HJ | 1 |
| Debus, J; Glynne-Jones, R | 1 |
| Twelves, C | 3 |
| Horii, I; Ishitsuka, H; Kato, Y; Kusuhara, H; Sugiyama, Y; Tsukamoto, Y; Ura, M | 1 |
| Johnston, PG; Kaye, S | 1 |
| Bell, KA; Hsu, S; Perna, AG | 1 |
| Lawrence, TS; McGinn, CJ | 1 |
| Aguayo, A; Patt, YZ | 1 |
| Mayer, RJ | 3 |
| Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C | 1 |
| Schwetz, BA | 1 |
| Leyland-Jones, B | 1 |
| Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Heinemann, V; Schmid-Wendtner, MH; Volkenandt, M; Wendtner, CM | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Horii, I; Ishikawa, T; Ishitsuka, H; Kato, Y; Sugiyama, Y; Tsukamoto, Y; Ura, M | 1 |
| Lokich, J | 2 |
| Goa, KL; McGavin, JK | 1 |
| Cartwright, TH; Chen, YM; Cohn, A; Cox, JV; Schulz, JJ; Szatrowski, TP; Varkey, JA | 1 |
| Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD | 1 |
| Ball, ED; Bashey, A; Corringham, S; Jones, V; Lancaster, D; Law, P; Silva-Gietzen, J; Sundaram, S | 1 |
| Venturini, M | 1 |
| O'Shaughnessy, J | 2 |
| Wilke, H | 1 |
| Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M | 1 |
| Diasio, RB | 1 |
| Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Taguchi, T | 1 |
| Ratain, MJ | 1 |
| Bontenbal, M; Smorenburg, CH; Verweij, J | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Adlard, JW; Quirke, P; Richman, SD; Seymour, MT | 1 |
| Hargreaves, D; Ng, T; Nguyen-Van-Tam, J; Twelves, C | 1 |
| Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M | 1 |
| Floeter, MK; Grem, JL; Lehky, T; Quinn, MG; Thomas, RR; Wilson, RH | 1 |
| Fujimoto-Ouchi, K; Sekiguchi, F; Tanaka, Y | 1 |
| Banken, L; Cassidy, J; Gardiner, J; Harper, P; Johnston, P; Monkhouse, J; Poole, C; Reigner, B; Twelves, C; Weidekamm, E | 1 |
| Duan, Y; Guan, Z; Liu, X; Song, S; Wu, S; Yang, L; Yu, J | 1 |
| Bokemeyer, C; Jakob, A; Kanz, L; Knop, S; Mayer, F; Schupp, M | 1 |
| Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S | 1 |
| Fujiwaki, R; Hata, K; Iwanari, O; Katabuchi, H; Miyazaki, K; Moriyama, M; Nakayama, K; Okamura, H; Sakai, E | 1 |
| Abt, M; Blum, JL; Hoff, PM; Osterwalder, B; Van Cutsem, E | 1 |
| Heinemann, V; Schalhorn, A; Stemmler, J | 1 |
| Kerr, DJ | 1 |
| Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, D; Zhang, W | 1 |
| Hwang, JJ; Marshall, JL | 1 |
| Clinton, S; Erdal, S; Hauger, M; Kraut, E; Monk, P; Nadella, P; Otterson, GA; Shah, M; Shapiro, C; Stanek, M; Villalona-Calero, MA | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Baselga, J; Bisset, D; Cassidy, J; Díaz-Rubio, E; Eatock, M; Evans, TR; Regueiro, P; Sastre, J; Tabemero, J | 1 |
| Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E | 1 |
| Ben-Josef, E; Du, W; Levin, KJ; Philip, PA; Shields, AF; Vaishampayan, UN; Vaitkevicius, VK | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Andrasch, H; Beck, FJ; Frickhofen, N; Fuhr, HG; Jung, B; Sigmund, M | 1 |
| Cassidy, J; Twelves, CJ | 1 |
| Hohenberg, G; Ortmann, E | 1 |
| Croockewit, AJ; de Boer, JE; Koopmans, PP; van Loenhout, JW | 1 |
| Aabo, K; Adimi, P; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E | 1 |
| Maroun, JA | 1 |
| O'Shaughnessy, JA | 2 |
| Malet-Martino, M; Martino, R | 1 |
| Blesch, KS; Gieschke, R; Reigner, B; Steimer, JL | 1 |
| Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M | 1 |
| Bolognia, JL; Glusac, EJ; Willey, A | 1 |
| Bogenrieder, T; Landthaler, M; Schölmerich, J; Stolz, W; Weitzel, C | 1 |
| Cho, MJ; Kim, JS; Song, KS; Yoon, WH | 2 |
| Dunst, J; Frings, S; Hinke, A; Kölling-Schlebusch, K; Reese, T; Sutter, T; Zühlke, H | 1 |
| Camidge, R; Price, A | 1 |
| Twelves, CJ; Wright, TL | 1 |
| Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C | 1 |
| Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B | 1 |
| Desmoulin, F; Gilard, V; Malet-Martino, M; Martino, R | 2 |
| Baker, C; Chun, HG; Fehn, K; Goel, S; Hoffman, A; Hopkins, U; Jhawer, M; Landau, L; Makower, D; Mani, S; Rajdev, L; Wadler, S | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Bearss, D; Von Hoff, DD | 1 |
| Hudis, CA | 1 |
| Livingston, R | 1 |
| Adjei, AA; Dy, GK | 1 |
| Eng, C; Kindler, HL; Schilsky, RL | 1 |
| D'Orazio, AI; Gambill, BD | 1 |
| Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Fisher, MD | 1 |
| Bolton, M; Chu, E; Copur, MS; Ledakis, P; Morse, AK; Muhvic, J; Norvell, M; Werner, T | 1 |
| Grem, JL; Xu, Y | 1 |
| Liu, CY | 1 |
| Borradori, L; Piguet, V | 1 |
| Pentheroudakis, G; Twelves, C | 1 |
| Ahn, JH; Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Yook, JH | 1 |
| Aapro, M; Seidman, AD | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Misset, JL; O'Shaughnessy, J; Seidman, AD | 1 |
| Biganzoli, L; Martin, M; Twelves, C | 1 |
| Chu, E | 2 |
| Aubert, C; Bezulier, K; Ciccolini, J; Cuq, P; Evrard, A; Fina, F; Giacometti, S; Martin, PM; Romain, S; Roussel, M | 1 |
| Bharara, S; Blanquicett, C; Buchsbaum, DJ; Diasio, RB; Gillespie, GY; Johnson, MR; Miller, CR; Nabors, LB | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Clark, JW; Fuchs, CS; Garcia-Carbonero, R; Michaelson, MD; Paul Eder, J; Ryan, DP; Supko, JG | 1 |
| Brunner, M; Eichler, HG; Locker, G; Mader, RM; Mueller, M; Rizovski, B; Schrolnberger, C; Steger, GG; Wenzel, C | 2 |
| Borner, M; Herrmann, R; Hess, V; Ludwig, C; Morant, R; Roth, AD; Salzberg, M | 1 |
| Goa, KL; Ibbotson, T; Wagstaff, AJ | 1 |
| Chen, G; Chi, GY; Li, N; Rothmann, M; Temple, R; Tsou, HH | 1 |
| Kerr, D | 1 |
| Rothenberg, ML | 1 |
| Rich, T | 1 |
| Ayers, GD; Lin, E; Morris, JS | 1 |
| Gross, E; Hellebrand, H; Kiechle, M; Lutz, V; Mayr, J; Neubauer, S; Ratanaphan, A; Seck, K; Stockinger, H | 1 |
| Kornek, GV; Locker, GJ; Mader, RM; Pluschnig, U; Scheithauer, W; Steger, GG; Wenzel, C | 1 |
| Cullen, KJ; Diasio, RB; Frost, A; Salesiotis, A; Soong, R | 1 |
| Heinemann, V | 1 |
| Black, CA; El-Rayes, BF; Ensley, JF | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Eda, H; Endoh, M; Hattori, K; Horii, I; Ishikawa, T; Ishitsuka, H; Kawashima, A; Kohchi, Y; Miwa, M; Oikawa, N; Shimma, N; Suda, H; Tanimura, H; Ura, M | 1 |
| Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL | 1 |
| Gerbrecht, BM | 1 |
| Depisch, D; Kornek, GV; Kovats, E; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B | 1 |
| Au, GK; Chua, DT; Sham, JS | 1 |
| Koizumi, W; Saigenji, K; Sakata, Y; Taguchi, T; Terashima, M; Ujiie, S | 1 |
| Seidman, AD | 1 |
| Gradishar, WJ; Kaklamani, VG | 1 |
| Batist, G; Cohen, V; Morin, I; Panet-Raymond, V; Rozen, R; Sabbaghian, N | 1 |
| Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P | 1 |
| Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P | 1 |
| Hehlmann, R; Hochhaus, A; Hofheinz, RD; Weisser, A; Willer, A | 1 |
| Ilersich, AL; Verma, S | 1 |
| Mayor, S | 1 |
| Bridgewater, J; Grange, S; Kimura, M; Kuranami, M; Lucraft, H; McAleer, J; Monkhouse, J; Poole, C; Reigner, B; Saeki, T; Sasaki, Y; Schüller, J; Watanabe, T; Weidekamm, E; Yorulmaz, C | 1 |
| Gershanovich, ML; Makhnova, EV | 1 |
| Chang, TW; Chen, GY; Chen, WC | 1 |
| Hoff, PM | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Porschen, R | 1 |
| Chang, HM; Kang, YK; Kim, JH; Kim, JS; Kim, MH; Kim, TW; Lee, JL; Lee, SK | 1 |
| Meehan, S; Moskovits, T; Pui, JC | 1 |
| Amato, RJ | 1 |
| Ahn, JH; Chang, HM; Kang, HJ; Kang, YK; Kim, JH; Kim, TW; Lee, JR; Lee, JS; Ryu, MH | 1 |
| Crucitta, E; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Misino, A; Silvestris, N | 1 |
| Eda, H; Endo, M; Hattori, K; Ishikawa, T; Ishitsuka, H; Miwa, M; Miyazaki-Nose, T; Shimma, N; Tanimura, H; Ura, M; Yamada-Okabe, H | 1 |
| Androulakis, N; Ardavanis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N; Varveris, C | 1 |
| Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G | 1 |
| Blesch, KS; Burger, HU; Gieschke, R; Reigner, BG; Steimer, JL; Tsukamoto, Y | 1 |
| Ernst, A; Grem, JL; Quinn, MG; Saif, MW; Thomas, RR | 1 |
| Rich, TA; Shepard, R | 1 |
| Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Rödel, C; Sauer, R; Schmoll, HJ | 1 |
| Brickell, K; Porter, D; Thompson, P | 1 |
| Jones, KL; Valero, V | 1 |
| Cunningham, D; Gillbanks, A; Harper-Wynne, C; Hill, M; Norman, AR; Sumpter, K | 1 |
| Buckley, N; Buyck, HC; Leslie, MD; Plowman, PN | 1 |
| Clippe, C; Freyer, G; Milano, G; Trillet-Lenoir, V | 1 |
| Barceló, R; Ferreiro, J; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Couch, LS; Groteluschen, DL; Mulkerin, DL; Stewart, JA | 1 |
| Cognetti, F; Ferraresi, V; Gabriele, A; Gamucci, T; Giannarelli, D; Nardoni, C; Pino, MS; Zeuli, M | 1 |
| Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ | 1 |
| Langer, SW; Risum, S | 1 |
| Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH | 1 |
| Blum, JL; Fumoleau, P; Reichardt, P | 1 |
| Chamorey, E; Giroux, B; Guardiola, E; Magné, N; Milano, G; Mouri, Z; Otto, J; Pivot, X; Schneider, M; Thyss, A | 1 |
| Fuchs, CS | 1 |
| Maino, KL; Norwood, C; Stashower, ME | 1 |
| Maeda, Y; Sasaki, E; Sasaki, T | 1 |
| Miwa, K; Nishimura, G | 1 |
| Hosokawa, A | 1 |
| Doi, T; Ohtsu, A | 1 |
| Murakami, M; Naito, M; Ota, T; Shimizu, N; Tsukuda, K | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Chung, JH; Kim, SA; Lee, HJ; Park, YH; Ryoo, BY | 1 |
| Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| O'Neil, BH | 1 |
| Willett, CG; Zhu, AX | 2 |
| Bartsch, R; Hussian, D; Kramer, G; Lintner, C; Locker, GJ; Mader, R; Marberger, M; Pluschnig, U; Rauchenwald, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S | 1 |
| Kaye, SB; McMahon, L; Paul, J; Reed, N; Vasey, PA | 1 |
| Begbie, S; Borner, M; Burns, WI; Burris, HA; Cassidy, J; Garcia-Alfonso, P; Jodrell, D; Koralewski, P; Levine, EL; Maroun, J; Marschner, N; McKendrick, J; Scheithauer, W; Tujakowski, J; Twelves, C; Van Hazel, G; Wong, A; Zaluski, J | 1 |
| Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW | 1 |
| Nishida, M | 1 |
| Bar-Ziv, J; Siegelmann-Danieli, N; Stein, M | 1 |
| Kurokawa, S; Matsuzaki, A; Morita, T; Tokue, A | 1 |
| Orel, NF | 1 |
| Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH | 1 |
| Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J | 1 |
| Giglio, P; Groves, MD; Tremont-Lukats, IW | 1 |
| Cai, GY; Li, TH; Wu, JW; Zhuang, CP | 1 |
| Maung, K | 1 |
| Kornek, GV; Scheithauer, W; Schüll, B | 1 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Davis, ID; Green, M; Jefford, M; McClure, B; Michael, M; Rosenthal, MA; Smith, J; Waite, B; Zalcberg, J | 1 |
| Cats, A | 1 |
| Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Seidman, A | 1 |
| Remer, SE; Rogers, LR; Tejwani, S | 1 |
| Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K | 1 |
| Audhuy, B; Clippe, C; Culine, S; Curé, H; Dièras, V; Fumoleau, P; Largillier, R; Lesimple, T; Montestruc, F; Morère, JF; Mouri, Z; Namer, M; Orfeuvre, H; Serin, D; Vuillemin, E | 1 |
| Hahn, P; Jensen, HA; Pfeiffer, P | 1 |
| Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B | 1 |
| Beijnen, JH; Boot, H; Kuppens, IE; Labadie, J; Schellens, JH | 1 |
| Lewis, KG; Lewis, MD; Pan, TD; Robinson-Bostom, L | 1 |
| Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E | 1 |
| Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M | 1 |
| Folprecht, G; Köhne, CH | 4 |
| Engin, H; Eren, OO; Güler, N; Kurt, M | 1 |
| Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M | 1 |
| Choi, SJ; Kim, HT; Park, YH; Ryoo, BY | 1 |
| Feng, FY; Fu, Q; Guan, ZZ; Huang, JJ; Liu, DG; Ruan, QL; Shi, D; Sun, SR; Wei, YQ; Wu, G; Wu, WQ; Wu, XD; Xiong, HH; Yang, CY; Yu, BM; Yu, SY; Zhang, P; Zhao, Y; Zheng, S; Zhuang, W; Zou, LQ | 1 |
| Ironside, JA; MacDougall, RH; Mais, KL; Slevin, NJ; Sykes, AJ | 1 |
| Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Sakamoto, J; Toi, M | 1 |
| Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J | 1 |
| Banken, L; Bellibas, SE; Brivet, B; Bush, ED; Chamorey, E; Kircher, C; Milano, G; Nave, S; Patel, I; Renée, N | 1 |
| Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S | 1 |
| Haanen, JB; Hooiveld, EA; van Kuilenburg, AB; Westermann, AM | 1 |
| Miller, KD | 1 |
| Green, MR; Herndon, JE; Kindler, HL; Otterson, GA; Watson, D | 1 |
| Brun, EA; Levitz, JS; Lichtman, SM; Sugarbaker, PH | 1 |
| Cao, KJ; Chen, QY; Deng, MQ; Guo, L; Hong, MH; Huang, PY; Jiang, Y; Luo, DH; Mai, HQ; Mo, HY; Qiu, F; Sun, R | 1 |
| Friedlander, M; Harnett, P; Martin, A; Phillips, KA; Quinn, M; Richardson, G; Rischin, D | 1 |
| Kondo, Y; Sato, A; Taguchi, T; Terashima, M | 1 |
| Bauer, A; Francis, GL; Helms, A; Patel, A; Pluim, T; Tuttle, RM | 1 |
| Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V | 1 |
| Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K | 1 |
| Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM | 1 |
| Bremnes, Y; Mjaaland, I; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA | 1 |
| Stadler, WM | 1 |
| Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D | 1 |
| Brunet, R; Butts, C; Cassidy, J; Conroy, T; Debraud, F; Díaz-Rubio, E; Figer, A; Grossmann, J; Sawada, N; Schöffski, P; Sobrero, A; Tabernero, J; Twelves, C; Van Cutsem, E | 1 |
| Mosley, ST; Rich, TA; Shepard, RC | 1 |
| Chung, YL; Griffiths, JR; Harris, AL; Judson, IR; Leach, MO; Leek, R; Stubbs, M; Troy, H | 1 |
| Carlson, HE; Narula, HS | 1 |
| Rugo, HS | 1 |
| Bajetta, E; Biasco, G; Brandi, G; Calabrese, C; Di Battista, M; Pantaleo, MA; Poggi, R | 1 |
| Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH | 1 |
| Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D | 1 |
| Chiba, K; Hosakawa, M; Katoh, M; Nakajima, M; Tabata, T; Tokudome, S; Yokoi, T | 1 |
| Grothey, A; Jordan, K; Kegel, T; Kellner, O; Schmoll, HJ | 1 |
| Hoff, PM; Pazdur, R | 1 |
| Goldberg, RM; Penland, SK | 1 |
| O'Connell, MJ | 1 |
| Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N | 1 |
| Herrmann, R; Niemann, B; Pless, M; Rochlitz, C | 1 |
| Bokemeyer, C; Gnad, U; Hartmann, JT; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Oechsle, K; Saussele, S; Willer, A | 1 |
| Baurain, JF; Duck, L; Henry, S; Machiels, JP | 1 |
| Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N | 1 |
| Katoh, M; Nakajima, M; Tabata, T; Tokudome, S; Yokoi, T | 1 |
| Grem, JL; Leonard, GD; Quinn, MG; Wagner, MR | 1 |
| Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA | 1 |
| Ferrero, JM; François, E; Milano, G | 1 |
| Aldaz, A; Giráldez, J; Zufía, L | 1 |
| Reddy, GK | 2 |
| Hamilton, M; Karvellas, CJ; Mackey, JR; Sawyer, M | 1 |
| Leong, T; Lim Joon, D; Mackay, J; McKendrick, J; Michael, M; Ngan, SY; Zalcberg, JR | 1 |
| Fujimura, T; Fushida, S; Miwa, K; Morita, A; Nagai, N; Ninomiya, I; Nishimura, G; Ohta, T; Takino, T; Terada, I; Yoshizumi, T | 1 |
| Ahn, JH; Ahn, SH; Kang, YK; Kim, SB; Kim, SM; Kim, TW; Kim, WK; Lee, JS; Park, JM | 1 |
| Jiang, ZF; Shen, G; Song, ST; Wang, T; Yu, JX; Zhang, SH | 1 |
| Guo, L; Guo, X; Hong, MH; Li, FY; Li, Q; Lin, HX; Luo, DH; Qiu, F | 1 |
| Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY | 1 |
| Brendel, E; Orth, M; Ortling, A; Siethoff, C; Wagner-Redeker, W | 1 |
| Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB | 1 |
| Holland, M; Reichardt, P; Sternberg, CN | 1 |
| Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E | 1 |
| Hoff, P; Lassere, Y | 1 |
| Chau, I; Fumoleau, P; Legge, S | 1 |
| Deery, P; Faithfull, S | 1 |
| Gerbrecht, BM; Kangas, T | 1 |
| Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH | 1 |
| Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ | 1 |
| Rustum, YM | 1 |
| Aksu, G; Fayda, M; Kapran, Y; Sakar, B | 1 |
| Hong, YS; Kang, JH; Kim, GY; Lee, KS; Lee, MA; Shim, KH; Woo, IS | 1 |
| Scheithauer, W | 1 |
| Im, YH; Jung, CW; Kang, WK; Kim, K; Lee, J; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Nam, E; Park, J; Park, JO; Park, K; Park, SH; Park, YS; Yoon, SS | 1 |
| Blum, J; Scheithauer, W | 1 |
| Leonard, R; Miles, D; Reichardt, P; Twelves, C | 1 |
| Cameron, D; Fumoleau, P | 1 |
| Diasio, RB; McGee, PJ; Saif, MW; Wood, TE | 1 |
| Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J | 1 |
| A'hern, R; Eisen, T; Gore, M; Hackett, S; James, M; Moss, C; Pyle, L; Waters, JS | 1 |
| Ayoub, JP; Cervantes, G; Liu, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, JA; Van Hazel, G; Vukelja, S | 1 |
| Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS | 1 |
| Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ | 1 |
| Baba, T; Fujii, S; Mandai, M | 1 |
| Aebi, S; Ballabeni, P; Brauchli, P; Mingrone, W; Pestalozzi, BC; Rauch, D; Rijken, N; Rochlitz, C; Uhlmann, C | 1 |
| Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B | 1 |
| Chen, AJ; Hu, MD; Li, L; Li, XY; Ran, JH; Sun, F; Tang, JH | 1 |
| Barats, JC; Baticle, JL; Brewer, Y; Chollet, P; Fumoleau, P; Gil-Delgado, M; Goudier, MJ; Martin, D; Namer, M; Pierga, JY; Sutherland, W; Turpin, FL; Zelek, L | 1 |
| Brandariz, A; Cortés-Funes, H; Hitt, R; Jimeno, A; López-Martín, A; Millán, JM; Peña, C; Rodríguez-Peralto, JL; Rodríguez-Pinilla, M | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Gerber, B; Heinrich, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Löhr, A; Raab, G; von Minckwitz, G; Zuna, I | 1 |
| Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A | 1 |
| Iqbal, S; Lenz, HJ | 1 |
| Fei, X; Hutchins, GD; Miller, KD; Sledge, GW; Wang, JQ; Zheng, QH | 1 |
| Palmieri, FM; Perez, EA; Tack, DK | 1 |
| Rini, BI; Small, EJ; Weinberg, V | 1 |
| Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A | 1 |
| Hansel, G; Koch, A; Köstler, E; Wollina, U | 1 |
| Akimoto, T; Hasegawa, K; Kishimoto, Y; Morimoto, Y; Sawai, T | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 2 |
| Hitre, E; Láng, I | 1 |
| Casaretti, R; Comella, P; Farris, A; Gambardella, A; Leo, S; Lorusso, V; Maiorino, L; Massidda, B; Natale, D; Tafuto, S | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Bocci, G; Danesi, R; Di Paolo, A | 1 |
| Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M | 1 |
| Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
| Chap, LI; Cobleigh, MA; Dickler, M; Fehrenbacher, L; Holmes, FA; Langmuir, V; Marcom, PK; Miller, KD; Overmoyer, BA; Reimann, JD; Rugo, HS; Sing, AP | 1 |
| Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J | 1 |
| Gnad, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kraus-Tiefenbacher, U; Müldner, A; Post, S; von Gerstenberg-Helldorf, B; Wenz, F; Willeke, F | 1 |
| Becerra, CR | 1 |
| Bosron, WF; Davis, WI; Hurley, TD; Murry, DJ; Quinney, SK; Sanghani, SP; Sun, Z | 1 |
| Mayer, RJ; Meyerhardt, JA | 1 |
| Grothey, A; Hieke, K; Kleeberg, UR; Stauch, M | 2 |
| Aksoy, S; Dinçer, M; Karaca, B; Yalçin, S | 1 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Bajetta, E; Buzzoni, R; Catena, L; Celio, L; Della Torre, S; Gattinoni, L; Longarini, R; Mariani, L; Procopio, G; Ricotta, R; Zilembo, N | 1 |
| Blessing, JA; Darcy, KM; Garcia, AA; Husseinzadeh, N; Lenz, HJ; Mannel, RS; Miller, DS | 1 |
| Belani, CP; Chatta, GS; Egorin, MJ; Fakih, M; Friedland, DM; Jacobs, SA; Jung, LL; Potter, DM; Ramalingam, S; Ramanathan, RK; Shin, DM; Strychor, S; Tutchko, S; Zamboni, WC | 1 |
| Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Fukuyama, Y; Koizumi, W; Nomura, N; Ohno, S; Osaki, A; Saeki, T; Satoh, A; Taguchi, T; Takashima, S; Terashima, M; Toge, T; Toi, M | 1 |
| Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ | 1 |
| Kaplow, R | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Doyle, D; Wilkes, GM | 1 |
| Criswell, T; Diasio, R; Kindwall-Keller, T; Neki, A; Nuovo, G; Otterson, GA; Soong, R; Villalona-Calero, MA; Young, D | 1 |
| Bertheault-Cvitkovic, F; Bugat, R; Canal, P; Chatelut, E; Cornen, X; Delord, JP; Dieras, V; Guimbaud, R; Lochon, I; Lokiec, F; Mery-Mignard, D; Mouri, Z; Pierga, JY; Turpin, FL | 1 |
| Lindley, C; Walko, CM | 1 |
| Vega-Stromberg, T | 1 |
| Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Coward, J; Cunningham, D; Maisey, N | 1 |
| Chen, E; Feld, R; Hedley, D; Knox, JJ; Moore, MJ; Nematollahi, M; Oza, A; Pond, GR; Siu, LL; Zhang, J | 1 |
| Bae, JM; Choi, IJ; Choi, JY; Chun, JH; Hwangbo, B; Kim, CG; Kim, HK; Kim, YW; Lee, HG; Lee, JS; Park, SR; Ryu, KW | 1 |
| Catalano, V; Jirillo, E; Mazzone, F; Passantino, L; Patruno, R; Pellecchia, A; Penna, A; Ranieri, G; Valerio, P; Zito, AF | 1 |
| Gaffney, EA | 1 |
| Chong, G; Cunningham, D | 1 |
| Ebi, H; Igarashi, T; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Sigeoka, Y; Ueda, R; Usubuchi, N | 1 |
| Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A | 1 |
| Clarke, SJ; Li, KM; Rivory, LP | 1 |
| Atkinson, EN; Bodurka, DC; Brown, J; Jenkins, AD; Johnston, T; Levenback, C; Ramondetta, LM; Sun, C; Wolf, JK | 1 |
| Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V | 1 |
| Hornberger, J; Jamieson, C; Jones, S; Maraninchi, D; Martín, M; McKendrick, J; Miles, D; O'Shaughnessy, J; Twelves, C; Verma, S | 1 |
| Chan, S; Curto, J; Habeshaw, T; Joynson, C; Reed, N; Stokes, Z; Symonds, P | 1 |
| Barry, S; Cohen, A; Debourdeau, P; Teixeira, L; Tournigand, C | 1 |
| Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Ahn, SD; Chang, HM; Choi, EK; Kim, HC; Kim, JC; Kim, JH; Kim, JS; Kim, TW; Lee, SW; Park, JH; Ryu, MH; Shin, SS; Yu, CS | 1 |
| Han, JY; Hong, EK; Lee, DH; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Beretta, GD; Labianca, R; Milesi, L; Mosconi, S; Pessi, MA | 1 |
| Di Costanzo, F; Doni, L | 1 |
| Cunningham, D; Harper-Wynne, C; Hickish, T; Hill, M; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Rao, S; Sumpter, K; Tebbutt, N; Ward, C | 1 |
| Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ | 1 |
| Wu, WQ; Yu, BM | 1 |
| Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW | 1 |
| Bredenkamp, R; Duyster, J; Hennig, M; Lersch, C; Lordick, F; Lorenzen, S; Peschel, C; von Delius, S | 1 |
| Fujioka, A; Fukushima, M; Ikeda, K; Kitazato, K; Nakagawa, F; Ohshimo, H; Okabe, H; Takechi, T | 1 |
| Araki, K; Kobayashi, M; Moriki, T; Namikawa, T; Okabayashi, T; Okamoto, K; Sugimoto, T; Tochika, N | 1 |
| Aggarwal, S; Chu, E | 1 |
| Cannone, M; Casaretti, R; Comella, P; Farris, A; Gambardella, A; Leo, S; Lorusso, V; Maiorino, L; Massidda, B; Natale, D; Tafuto, S | 1 |
| Kahlert, S; Konecny, G; Rueckert, S; Ruehl, I; Untch, M | 1 |
| Coutsouvelis, J; McKendrick, J | 1 |
| Cunningham, D; Ng, M; Norman, AR | 1 |
| Abt, M; Burris, H; Carrato, A; Cassidy, J; Cervantes, A; Fagerberg, J; Georgoulias, V; Husseini, F; Jodrell, D; Koralewski, P; Kröning, H; Maroun, J; Marschner, N; McKendrick, J; Nowacki, MP; Pawlicki, M; Rosso, R; Scheithauer, W; Schüller, J; Seitz, JF; Stabuc, B; Tujakowski, J; Twelves, C; Van Hazel, G; Wong, A; Zaluski, J | 1 |
| Allegra, C; Sargent, DJ | 1 |
| Ben-Josef, E; Chang, AE; Colletti, LM; Hejna, GF; Lawrence, TS; McGinn, CJ; Normolle, DP; Schneider, BJ; Zalupski, MM | 1 |
| Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Longhi, S; Munzone, E; Nolè, F; Pagani, O; Ruggeri, M; Sessa, C; Thürlimann, B | 1 |
| Fähling, H; Felix, R; Ganter, H; Gellermann, J; Hildebrandt, B; Nadobny, J; Nicolau, A; Rau, B; Tilly, W; Wlodarczyk, W; Wust, P | 1 |
| Blum, JL; Clark, RS; Liepa, AM; Melemed, AS; Mennel, RG; O'Shaughnessy, JA; Snyder, D; Yardley, DA; Ye, Z | 1 |
| Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A | 1 |
| Hikino, H; Johbara, K; Obayashi, N; Ozaki, N; Yamada, T | 1 |
| Moody, JS; Russo, SM; Saif, MW | 1 |
| Baek, JH; Jung, HY; Kim, DH; Kim, JG; Kim, TB; Lee, KB; Park, JY; Sohn, SK; Sung, WJ; Yu, W | 1 |
| Janney, LM; Waterbury, NV | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Bang, SM; Cho, EK; Im, SA; Lee, JH; Lee, SN; Lee, WK; Park, DK; Park, SH; Park, YH; Shin, DB | 1 |
| Fontana, J; Forman, J; Frazier, A; Patel, B; Pontes, E; Vaishampayan, U | 1 |
| Alexandrescu, DT; Dutcher, JP; Wiernik, PH | 1 |
| Abt, M; Camidge, R; Cassidy, J; Grange, S; Jodrell, D; Reigner, B; Weidekamm, E | 1 |
| Cheng, CW; Ching Chan, S; Chow, LW; Ngor Wong, L; Tong, DK | 1 |
| Chen, Y; Fan, L; Liu, DH; Liu, WC; Pan, BR; Ren, J; Yu, ZC; Zhang, YJ | 1 |
| Haim, N; Isaacs, K | 1 |
| Leong, LA; Rosales, J | 1 |
| Cassidy, J; Filipovic-Ljeskovic, I; Jelic, S; Nikolic-Tomasevic, Z; Tomasevic, Z | 1 |
| Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY | 1 |
| Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY | 1 |
| Almerud, A; Gubanski, M; Lideståhl, A; Lind, PA; Naucler, G | 1 |
| Bolunwu, N; Chan, S; Kendall, A; Pandha, H; Plunkett, T; Somaiah, N; Spicer, J | 1 |
| Fujimoto-Ouchi, K; Hata, K; Hiraga, T; Ikeda, F; Kitagaki, J; Tanaka, Y; Yoneda, T | 1 |
| Andronikidis, I; Bitzilekis, D; Eleftheriadis, D; Eleftheriadis, N; Kouloulias, V; Papaloukas, C; Pistevou-Gompaki, K | 1 |
| Amato, RJ; Rawat, A | 1 |
| Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B | 1 |
| Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N | 1 |
| Saif, MW | 4 |
| Braud, Fd; Brunet, R; Butts, CA; Cassidy, J; Conroy, T; Diaz-Rubio, E; Figer, A; Grossmann, J; Schoffski, P; Sobrero, AF; Tabernero, JM; Twelves, CJ; Van Cutsem, EJ | 1 |
| Creaven, PJ; Fakih, MG; French, RA; Javle, M; Ramnath, N; Repinski, TV; Schwarz, JK; Strychor, S; Trump, D; Zamboni, BA; Zamboni, WC | 1 |
| Hamada, K; Kakihara, Y; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tachibana, M; Tagaya, N | 1 |
| Anan, K; Mitsuyama, S; Ono, M | 1 |
| Cho, JY; Lee, DK; Lee, SJ; Nam, JS; Paik, YH; Park, MS; Yoon, DS; Yu, JS | 1 |
| Clemons, M; Dranitsaris, G; Joy, AA; MacKey, JR; Trudeau, M; Verma, S | 1 |
| Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C | 1 |
| Hochster, HS | 1 |
| Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA | 1 |
| Arnold, D | 2 |
| Carrato-Mena, A; Guillén-Ponce, C; Maciá-Escalante, S; Molina-Garrido, MJ | 1 |
| Erkisi, M; Kara, IO; Sahin, B | 1 |
| Guichard, SM; Jodrell, DI; Mayer, I | 1 |
| Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK | 1 |
| Gerold, M; Melzer, S; Rainer, W; Vrecl, R; Weitzer, W | 1 |
| Le Pen, C; Maurel, F; Priol, G | 1 |
| Coleman, RE; El-Helw, L | 1 |
| Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN | 1 |
| Aydin, S; Baurain, JF; Canon, JL; Coche, JC; Coster, B; Duck, L; Gilbeau, L; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Octave-Prignot, M; Remouchamps, V; Scalliet, P; Sempoux, C; Van Maele, P | 1 |
| Aarons, L; Karlsson, M; Man, A; Mentré, F; Nygren, P; Racine, A; Rombout, F; Schaefer, H; Steimer, JL; Troconiz, I; van Peer, A | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Baddi, L; Beck, AC; Blumenthal, DT; Chua-Adajar, R; Futterer, S; Gradishar, W; Raizer, JJ; Semenov, I; Simuni, T; Tellez, C; Videnovic, A | 1 |
| Jin, J; Li, N; Li, T; Li, YX; Liu, XF; Liu, YP; Song, YW; Wang, WH; Yu, ZH | 1 |
| Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D | 1 |
| Baek, JH; Chae, YS; Jeon, SB; Kim, DH; Kim, JC; Kim, JG; Lee, KB; Park, IK; Park, JS; Sohn, JH; Sohn, SK | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| Ayav, A; Habib, N; Jiao, LR | 1 |
| Bokhian, BIu; Lichinitzer, MR; Petrovichev, NN; Stepanova, EV | 1 |
| Beretta, GD; Chiara, S; Corvò, R; De Paoli, A; Del Prete, S; Friso, ML; Frustaci, S; Innocente, R; Luppi, G; Mantello, G; Pasetto, L; Rosso, R; Santantonio, M; Sarti, E | 1 |
| Baker, LH; Griffith, KA; Hayes, DF; Rae, JM; Schott, AF; Sterns, V | 1 |
| Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P | 1 |
| Falk, SJ; Glynne-Jones, R; Maughan, TS; McDonald, AC; Sebag-Montefiore, D | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Glasmacher, A; Lamberti, C; Sauerbruch, T | 1 |
| Chang, HJ; Choi, HS; Hong, CW; Jeong, SY; Jung, KH; Kim, DH; Kim, DW; Kim, DY; Kim, TH; Lim, SB; Park, JG; Sohn, DK | 1 |
| Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D | 1 |
| Boyer, JC; Ciccolini, J; Dahan, L; Dales, JP; Durand, A; Evrard, A; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Park, CG | 1 |
| Chang, YS; Cho, JY; Chung, JB; Lee, DK; Lee, SJ; Paik, YH; Park, MS; Song, SY; Yoon, DS; Yu, JS | 1 |
| Hurwitz, H; Kabbinavar, F | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM | 1 |
| Adamoli, L; Blanchot, G; Catania, C; Goldhirsch, A; Imadalou, K; Longerey, B; Munzone, E; Nolè, F; Sanna, G | 1 |
| Barstis, JL; Black, AC | 1 |
| Blanquicett, C; Carpenter, M; Diasio, RB; Eloubeidi, MA; Fiveash, J; Johnson, MR; Russo, S; Saif, MW; Steg, A; Thornton, J | 1 |
| Bai, LY; Chen, PM; Poh, SB | 1 |
| Alabiso, O; Ardine, M; Beano, A; Berruti, A; Bertetto, O; Bonardi, S; Bottini, A; Bretti, S; Castiglione, F; Donadio, M; Generali, D; Mistrangelo, M; Polimeni, MA | 1 |
| Morse, MA | 1 |
| Herbst, F; Scheithauer, W; Widder, J | 1 |
| Chua, YJ; Cunningham, D; Formica, V; Leary, A | 1 |
| Bang, SM; Cho, EK; Lee, JH; Lee, JN; Park, SH; Park, YH; Shin, DB | 1 |
| Gollins, S; Grieve, R; Samuel, L; Twelves, C | 1 |
| Ebi, H; Minami, H | 1 |
| Marutaka, M; Miyake, M; Suguri, T; Yoshimura, K | 1 |
| Fukumitsu, T; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Sasatomi, T; Shirouzu, K; Torigoe, S; Yamashita, N; Yanagawa, T | 1 |
| Gill, S; Ho, C; Ng, K; O'Reilly, S | 1 |
| Fumoleau, P; Levy, C | 1 |
| Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Amarantidis, K; Chatzaki, E; Kakolyris, S; Karayiannakis, A; Maltezos, E; Romanidis, K; Toromanidou, M; Trichas, M; Tsaroucha, A; Vasiliadis, M | 1 |
| Fakih, MG | 1 |
| Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U | 1 |
| Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JN; Lee, Y; Park, SH; Park, YH; Shin, DB | 1 |
| Cao, D; Pizzorno, G; Wan, L; Yan, R; Zeng, J | 1 |
| Hoff, PM; Varadhachary, GR | 1 |
| Cheng, JD; Cohen, SJ; Eisenberg, D; Engstrom, P; Freedman, G; Haluszka, O; Hoffman, J; Konski, A; McGarrity, E; Meropol, NJ; Sigurdson, E; Watson, JC | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| Jensen, SA; Sørensen, JB | 1 |
| Chin, K; Hyodo, I; Koizumi, W; Kojima, H; Kondo, K; Sakamoto, J; Terashima, M; Tsujinaka, T; Yamamura, Y | 1 |
| Guichard, SM; Jodrell, DI; Macpherson, JS | 1 |
| Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D | 1 |
| Brown, G; Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, AR; Oates, J; Ross, PJ; Tait, D; Tebbutt, N; Wotherspoon, A | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B | 1 |
| Aurilio, G; Bianco, R; Carlomagno, C; Catalano, G; Ciardiello, F; D'Agostino, D; De Placido, S; De Vita, F; Ferrara, C; Martinelli, E; Orditura, M; Pepe, S; Romano, C; Tortora, G | 1 |
| Jensen, SA; Lønborg, JT; Sørensen, JB | 1 |
| Lim, ST; Ong, S; Quek, R | 1 |
| Ackermann Shiff, SP; Alford, SH; Quesenberry, CP; Tsai, AL; Wells, KE; Yood, MU; Yood, SM | 1 |
| Dubielzig, R; McAnulty, J; Penzo, C; Schmiedt, C; Schwab, M | 1 |
| Ershler, WB | 2 |
| Chin, S; Feld, R; Haider, M; Hu, H; Knox, J; Krzyzanowska, MK; Oza, AM; Siu, LL; Tsao, MS | 1 |
| Goyle, S; Maraveyas, A | 1 |
| Asproudis, I; Gorezis, S; Peschos, D; Psilas, K; Stefaniotou, M | 1 |
| Choi, Y; Hur, WJ; Jung, GJ; Kim, HJ; Kim, JS; Kim, MC; Kim, SH; Kwon, HC; Lee, HS; Lee, JH | 1 |
| Alliot, C | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK | 1 |
| Dunst, J; Glynne-Jones, R; Sebag-Montefiore, D | 1 |
| Akcali, Z; Basturk, B; Ozyilkan, O; Yildirim, Y | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Abbruzzese, JL; Amos, C; Charnsangavej, C; Crane, CH; Delclos, ME; Ellis, LM; Evans, DB; Ho, L; Lee, JE; Ng, C; O'Reilly, M; Pisters, PW; Tamm, EP; Wolff, RA; Xiong, HQ | 1 |
| Muss, HB; Perez, E | 1 |
| Hyodo, I | 1 |
| Diasio, R; Ledbetter, L; Saif, MW; Shah, HR | 1 |
| Diasio, R; Saif, MW | 1 |
| Beijnen, JH; Bosch, TM; Jörger, M; Schellens, JH; Sparidans, RW | 1 |
| Atkinson, N; Bodurka, DC; Branham, D; Gershenson, DM; Jenkins, AD; Sun, CC; Verschraegen, C; Wolf, JK | 1 |
| Kimura, T; Saeki, T; Taguchi, T; Toi, M | 1 |
| Cardinale, D; Colombo, A; Colombo, N | 1 |
| Apostolakis, S; Ekonomidou, F; Tsoussis, S; Vourliotaki, I | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Crane, CH; Evans, DB; Pisters, PW; Varadhachary, G; Wolff, RA | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F | 1 |
| Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R | 1 |
| Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A | 1 |
| Kim, BS; Park, YH; Ryoo, BY; Yang, SH | 1 |
| Black, G; Diasio, R; Johnson, M; Russo, S; Saif, MW | 1 |
| Cassidy, J; O'Neill, VJ | 1 |
| de Jager, J; Stebbing, J | 1 |
| Bajetta, E; Beretta, E; Buzzoni, R; Di Bartolomeo, M; Dognini, G; Ferrario, E; Mancin, M; Mariani, L; Valvo, F | 1 |
| Adamoli, L; Ascione, G; Catania, C; Goldhirsch, A; Minchella, I; Munzone, E; Nolè, F; Rocca, A; Sanna, G; Verri, E; Zampino, MG | 1 |
| Abraham, J; Higa, GM; Kovach, RF | 1 |
| Tuma, RS | 1 |
| Chew, HK; Gandara, D; Juhasz, A; Vassilakos, A; Yen, Y | 1 |
| Bernhard, H; Harbeck, N; Heinemann, V; Lässig, D; Schmitt, M; Schoenberg, S; Stemmler, HJ; Willems, A | 1 |
| Dieringer, P; Jonasch, E; Mathew, P; Pagliaro, LC; Rodney, A; Tannir, N | 1 |
| Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Yoon, SJ; Yoon, SM | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Beham, A; Bertetto, O; Bustová, I; Cassidy, J; Cowell, W; Coxon, F; Díaz-Rubio, E; Douillard, JY; Dufour, P; Figer, A; Fountzilas, G; Garrison, LP; Jelic, S; Johnston, PG; Lesniewski-Kmak, K; Malzyner, A; Maughan, TS; McKendrick, JJ; Patel, KK; Scheithauer, W; Twelves, C | 1 |
| Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C | 1 |
| Abad, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Tabernero, J | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Abdalla, EK; Eng, C; Madary, A; Vauthey, JN | 1 |
| Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
| Barten, M; Fietkau, R; Klautke, G; Prall, F; Schiffmann, L; Wöhlke, M | 1 |
| Barone, C; Cassano, A; Crea, F; Lanza, GA; Pozzo, C; Sestito, A; Sgueglia, GA | 1 |
| Gibb, RK; Grigsby, PW; Mutch, DG; Powell, MA; Rader, JS; Viviano, D; Wright, JD | 1 |
| Fuentes-Pradera, J; Gordón-Santiago, Mdel M; Moreno-Vega, AL; Vargas-Machuca, JC | 1 |
| McAlister, H; Thompson, PI; Wijesinghe, N | 1 |
| Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J | 1 |
| Brenner, B; Dreznik, Z; Dror, Y; Fenig, E; Figer, A; Idelevich, E; Loven, D; Nudelman, I; Shani, A; Stemmer, SM; Sulkes, A; Yerushalmi, R | 1 |
| Gugerli, O; Leupin, N | 1 |
| Cao, D; Pizzorno, G; Wan, L; Yan, R | 1 |
| Hildebrand, J | 1 |
| Berrios, M; Cordova, A; de Aretxabala, X; Gallardo, J; Hepp, J; Leon, J; Maluenda, F; Roa, I; Roa, JC | 1 |
| Neale, G; Qureshi, F | 1 |
| Gruenberger, B; Gruenberger, T; Scheithauer, W | 1 |
| Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D | 1 |
| Fakih, MG; Lawrence, DD; Pendyala, L; Rajput, A; Rustum, YM; Smith, JL; Toth, K; Yang, GY | 1 |
| Carrato Mena, A; Gallego Plazas, J; Maciá Escalante, S; Martínez Banaclocha, N; Rodríguez Lescure, A | 1 |
| Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR | 1 |
| Calabrese, R; Colucci, G; Giampaglia, M; Guida, M; Latorre, A; Lorusso, V; Misino, A; Monticelli, G; Sambiasi, D; Spada, M | 1 |
| Blum, JL; O'Shaughnessy, JA | 1 |
| Ito, Y; Tokudome, N | 1 |
| Ajani, J | 1 |
| Assenat, E; Duffour, J; Ychou, M | 1 |
| Gill, S; Renouf, D | 1 |
| Smith, IE | 1 |
| Bearz, A; Berretta, M; Di Benedetto, F; Lleshi, A; Spina, M; Tirelli, U | 1 |
| Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D | 1 |
| Elledge, R; Hinckley, L; Teh, BS; Tham, YL | 1 |
| Cowan, J; Kaltenthaler, E; Marples, M; Orr, B; Seymour, MT; Ward, SE | 1 |
| Eng, C; Shalan, N | 1 |
| Agnihotri, SA; Aminabhavi, TM | 1 |
| Arai, Y; Doi, T; Hatake, K; Hyodo, I; Mishima, H; Nakagawa, K; Shirao, K; Takemiya, S; Takiuchi, H; Tamura, T; Yamaguchi, K | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Clarke, SJ; Hoskins, J; Li, KM; Rivory, LP; Sharma, R | 1 |
| Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Cho, MJ; Kim, JM; Kim, JS; Kim, KH; Li, S; Nam, JS; Song, KS; Yeo, SG; Yoon, WH | 1 |
| Aksoy, S; Guler, N; Kurt, M | 1 |
| Neoptolemos, JP; Smith, DB | 1 |
| Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
| Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J | 1 |
| Aurilio, G; Carlomagno, C; Catalano, G; Ciardiello, F; De Placido, S; De Vita, F; Galizia, G; Lieto, E; Martinelli, E; Orditura, M; Vecchione, L | 1 |
| Hague, JS; Ilchyshyn, A | 1 |
| Coras, B; Hafner, C; Landthaler, M; Reichle, A; Vogt, T | 1 |
| Hengge, UR; Marini, A | 1 |
| Monga, DK; O'Connell, MJ | 1 |
| Chao, TC; Chen, PM; Hsiao, LT; Lin, PC; Wang, WS; Yang, MH; Yen, CC | 1 |
| Atzpodien, J; Fornara, P; Gertenbach, U; Hauser, S; Heinzer, H; Heynemann, H; Huland, E; Kirchner, H; Leiber, C; Metzner, B; Müller, SC; Raschke, R; Rebmann, U; Reitz, M; Roigas, J; Salm, S; Schwindl, B; Siebels, M; Siemer, S; Soder, M | 1 |
| Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G | 1 |
| Barrier, R; Davila, E; Ernstoff, MS; Halabi, S; Picus, J; Rini, B; Small, EJ; Stadler, WM | 1 |
| Gilliam, LK; Kohn, AD; Lalani, T; Livingston, RB; Patel, A; Pickett, CA; Swanson, PE; Vasko, V | 1 |
| Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y | 1 |
| Asmar, L; Blum, JL; Boehm, KA; Chacko, A; Dees, EC; Doane, L; Ethirajan, S; Hopkins, J; Ilegbodu, D; McMahon, R; Merten, S; Negron, A; Neubauer, M; O'Shaughnessy, JA | 1 |
| Berg, DT | 1 |
| Bajetta, E; Bajetta, R; Bichisao, E; Catena, L; De Dosso, S; Ferrari, L; Formisano, B; Martinetti, A; Platania, M; Procopio, G; Verzoni, E | 1 |
| McLeod, HL; O'Neil, BH | 1 |
| Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R | 1 |
| Caricato, M; Coppola, R; Di Seri, M; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Horii, I; Kawashima, A; Kobayashi, K; Nakano, K; Shindoh, H; Shishido, N | 1 |
| Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S | 1 |
| Chan, S; Dhadda, AS | 1 |
| Wardley, A | 1 |
| Jackisch, C | 1 |
| Chan, A; Gelmon, K; Harbeck, N | 1 |
| Dinter, D; Grobholz, R; Heeger, S; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Post, S; Wenz, F; Willeke, F; Woernle, C | 1 |
| Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S | 1 |
| Carmona-Bayonas, A | 1 |
| Curtiss, FR | 1 |
| Ciccolini, J; Etienne-Grimaldi, MC; Ferrero, JM; Foa, C; Formento, JL; Francoual, M; Ginot, A; Lacarelle, B; Largillier, R; Milano, G; Namer, M; Nebbia, JF; Renée, N | 1 |
| Kang, BY; Kim, HA; Kim, KH; Lee, RA | 1 |
| Cognetti, F; Di Segni, S; Fontana, A; Gelibter, AJ; Labianca, R; Lonardi, S; Loupakis, F | 1 |
| Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y | 1 |
| Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K | 1 |
| Brown, TD; Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Feig, BW; Hamilton, SR; Hoff, PM; Janjan, NA; Krishnan, S; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Skibber, JM; Vadhan-Raj, S; Wolff, RA | 1 |
| Bashir, T; Budman, DR; Mandelblat, J | 1 |
| Gressett, SM; Hardwicke, F; Stanford, BL | 1 |
| Diasio, R; Elfiky, A; Saif, MW | 1 |
| Asmar, L; Boehm, KA; Ilegbodu, D; Kolodziej, M; Mull, S; Neubauer, MA; Perrine, G; Pluenneke, RE; Rousey, SR | 1 |
| Arnold, D; Schmoll, HJ | 1 |
| Chilcott, J; Eggington, S; Paisley, S; Pandor, A; Saunders, M; Seymour, M; Sutcliffe, P; Tappenden, P | 1 |
| Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K | 1 |
| Anderluh, F; Oblak, I; Strojan, P; Velenik, V; Zakotnik, B | 1 |
| Chun, JH; Han, JY; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Delaunay, M; Jouary, T; Kaiafa, A; Lepreux, S; Lipinski, P; Taïeb, A; Vergier, B | 1 |
| Jin, J; Li, N; Li, T; Li, YX; Liu, YP; Song, YW; Wang, WH | 1 |
| Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L | 1 |
| Amatori, F; Bocci, G; Boldrini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Fontanini, G; Lastella, M; Vannozzi, F | 1 |
| Eggington, S; Paisley, S; Pandor, A; Sutcliffe, P; Tappenden, P | 1 |
| Blessing, JA; Darcy, KM; Garcia, AA; Hannigan, E; Lenz, HJ; Moore, DH; Zhang, W | 1 |
| Alomar, A; Dalmau, J; Fernández-Figueras, MT; Peramiquel, L; Puig, L; Roé, E | 1 |
| Bhatia, S; Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Feig, BW; Hoff, PM; Janjan, NA; Krishnan, S; Lin, EH; Rodriguez-Bigas, MA; Skibber, JM; Wolff, RA | 1 |
| Abbruzzese, JL; Baschnagel, A; Crane, CH; Das, P; Delclos, ME; Evans, DB; Janjan, NA; Krishnan, S; Varadhachary, GR; Vauthey, JN; Wolff, RA | 1 |
| Ockenfels, HM; Saborowski, A; Sauter, C | 1 |
| Bosch, RJ; Herrera, E; López, N; Tejera, A | 1 |
| Ando, H; Bykowski, C; Dhananjeyan, MR; Erhardt, PW; Liu, J; Sarver, JG; Trendel, JA | 1 |
| Agelaki, S; Androulakis, N; Chatzidaki, D; Georgoulias, V; Gioulbasanis, J; Kalbakis, K; Kalykaki, A; Kotsakis, AP; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Tsetis, D; Tzardi, M; Vamvakas, L; Vardakis, N | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Bouriel, C; Bridji, B; Campion, L; Campone, M; Chatal, JF; Clouet, M; Delecroix, V; Devillers, A; Doutriaux, I; Ferrer, L; Garin, E; Kerbrat, P; Resche, I; Ricaud, M; Rouquette, S; Rousseau, C; Sagan, C | 1 |
| Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M | 1 |
| Chang, HJ; Choi, HS; Hong, CW; Jeong, JY; Jeong, SY; Jung, KH; Kim, DW; Kim, DY; Kim, TH; Kim, YH; Lim, SB; Park, JG; Sohn, DK; Son, SH; Yun, T | 1 |
| Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL | 1 |
| Bentzen, JD; Hansen, HS | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Athanasiadou, ZS; Ballas, KD; Demertzidis, CI; Economou, LD; Konstantinidis, HD; Pissanidou, TT; Sakadamis, AK; Sioga, AC; Slavakis, AP | 1 |
| Bergonzi, P; Fasola, G; Minisini, AM; Pauletto, G | 1 |
| Heerschap, A; Kamm, Y; Klomp, D; Scheenen, T; van Laarhoven, H | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS | 1 |
| Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H | 1 |
| Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G | 1 |
| Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E | 1 |
| Branch, A; Cassidy, J; MacDonald, L; MacLeod, A; McDonald, A; Mohammed, N | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Muss, HB | 1 |
| Cartwright, T; de Braud, F; Figer, A; Haller, DG; Hill, M; Lim, R; Maroun, J; McKendrick, J; Nowacki, MP; Park, YS; Price, T; Schmoll, HJ; Sirzén, F; Soler-Gonzalez, G; Tabernero, J; Topham, C; Van Cutsem, E | 1 |
| Arnold, D; Bieker, M; Ewald, H; Flentje, M; Fürst, A; Haier, J; Hellmich, G; Hermann, RM; Hipp, M; Hohenberger, W; Liersch, T; Lordick, F; Reese, T; Rödel, C; Sauer, R; Schwella, N; Sülberg, H | 1 |
| Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S | 1 |
| Ahn, SD; Chang, HM; Choi, EK; Choi, WS; Jang, SJ; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, SW; Ryu, MH; Shin, SS; Yu, CS | 1 |
| Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D | 1 |
| Honma, H | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| García-Foncillas, J; Gil, C; Monreal, I; Rodríguez, J; Salgado, J; Zabalegui, N | 1 |
| Boonnuch, W; Chinswangwatanakul, V; Jivapaisarnpong, P; Lertbutsayanukul, C; Lertsanguansinchai, P; Lohsiriwat, D; Lorvidhaya, V; Panichevaluk, A; Phromratanapongse, P; Rojanasakul, A; Thavichaigarn, P; Veerasarn, V | 1 |
| Aydin, S; Bonny, MA; Canon, JL; Coche, JC; Coster, B; Daisne, JF; Duck, L; Haustermans, K; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Peeters, M; Roels, S; Scalliet, P; Sempoux, C; Van Cutsem, E | 1 |
| Bentley, E; Dubielzig, RR; Gendron-Fitzpatrick, AP; McAnulty, JF; Milovancev, M; Schmiedt, CW; Schwab, M | 1 |
| Joensuu, H; Kellokumpu-Lehtinen, PL; Lehtinen, I; Sjöström-Mattson, J; Sunela, K | 1 |
| Twelves, CJ | 2 |
| Ciccolini, J; Mercier, C | 2 |
| Hwang, SJ; Kim, BS; Kim, GJ; Lee, SD; Nam, SH; Park, JW; Sin, CH | 1 |
| Chang, HM; Jung, JY; Kang, YK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Ryu, MH; Song, JH; Song, JS; Yook, JH | 1 |
| Bokemeyer, C; Grünwald, V; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Rick, O | 1 |
| Doyle, DP; Engelking, C | 1 |
| Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Kim, WK; Lee, JL; Lee, JS; Lee, SS; Ryu, MH | 1 |
| Amorim, G; Arcuri, RA; Biasoli, I; Djahjah, C; Gaui, MF; Moreira, D; Pereira, G; Spector, N | 1 |
| Schellens, JH | 1 |
| Fakih, MG; Reddy, N; Yu, J | 1 |
| DeSimone, P; Sapp, CM | 1 |
| Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A | 1 |
| Boumba, VA; Fountzilas, G; Golfinopoulos, V; Marselos, M; Nikiforidis, L; Nikolaidou, M; Pappas, P; Pavlidis, N; Pentheroudakis, G; Siarabi, O; Tzamakou, E; Vougiouklakis, T | 1 |
| Wang, Y; Xu, RR | 1 |
| Aebi, S; Ballabeni, P; Gick, U; Hess, V; Lanz, D; Mingrone, W; Pestalozzi, B; Rauch, D; Rochlitz, C | 1 |
| Dhillon, S; Scott, LJ | 1 |
| Kang, YK | 1 |
| Holcombe, RF; Ou, SH | 1 |
| Akahane, T; Chiba, T; Hashimoto, Y; Yano, H | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ | 1 |
| López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
| Banerji, U; Johnston, SR; Kendall, A; O'Brien, M; Smith, IE; Walsh, G; Yap, YS | 1 |
| Amare, M; Asmar, L; Blum, JL; Dees, EC; Gill, DP; Ilegbodu, D; McMahon, RT; O'Shaughnessy, JA; Vukelja, SJ | 1 |
| Callahan, E; Cheng, J; Cohen, S; Freedman, GM; Hoffman, J; Konski, A; Lewis, N; Meropol, NJ; Price, R; Rogatko, A; Sigurdson, ER; Watkins-Bruner, D | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, HR; Lee, J; Lee, JK; Lee, KT; Lim, DH; Lim, HY; Park, BB; Park, JO; Park, K; Park, YS | 1 |
| Ahlgren, J; Bergh, J; Bergström, D; Blomqvist, C; Lidbrink, E; Lindh, B; Malmberg, L; Nordgren, H; Ohd, JF; Villman, K | 1 |
| Bateman, ND; Buchanan, D; Clark, RC; Cuthbert, M; Kerr, S; Maxwell, SR; Steinke, D; Webb, DJ | 1 |
| Sonpavde, G | 1 |
| Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G | 1 |
| Aravindan, N; Dang, A; Hightower, C; Ilsin, B; Mansfield, P; Rice, D; Riedel, B | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ; Yoo, NC | 1 |
| El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S | 1 |
| Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM | 1 |
| Kindler, HL | 1 |
| Glynne-Jones, R; Meadows, H; Wood, W | 1 |
| Wils, J | 1 |
| Doorn, L; Eskens, FA; van der Gaast, A; van Gameren, EC; van Meerten, E | 1 |
| Almond, J; Ralston, S | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Boige, V; Ducreux, M; Malka, D | 1 |
| André, T; de Gramont, A; Larsen, AK; Louvet, C; Tournigand, C | 1 |
| Dupont, J; Jensen, BV; Jensen, HA; Pfeiffer, P | 1 |
| Barceló, R; Carrera, S; Fernández, R; López-Vivanco, G; Martínez-Bueno, A; Muñoz, A; Rubio, I; Viteri, A | 1 |
| Baydal, R; Blanes, MD; Chirivella, I; Colio, JM; De-la-Morena, E; Laforga, J; Lluch, A; Perez-Fidalgo, JA; Roselló, S | 1 |
| Arbea, L; Coma-Canella, I; García-Foncillas, J; Martinez-Monge, R | 1 |
| Tripathy, D | 1 |
| Díaz-Rubio, E; García-Saénz, JA; Martín, M | 1 |
| Choi, IK; Chun, HJ; Jeen, YT; Kim, JS; Kim, YH; Mok, YJ; Oh, SC; Park, SS; Seo, JH; Shin, SW; Sung, HJ; Sur, HY | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Bianconi, M; Jankilevich, G; Nassif, J; Otero, S; Storino, C | 1 |
| Kim, R; Saif, MW | 1 |
| Rödel, C; Sauer, R | 1 |
| Ashton, J; Bendell, JC; Blobe, GC; Czito, BG; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Thomas, J; Tyler, DS; Willett, CG; Yu, D | 1 |
| Do, JE; Kim, YC | 1 |
| Ahmad, R; Al-Obaidi, MJ; Dawson, C; Hughes, G; O'Reilly, E; Ramesh, S; Riddle, P; Sekhar, M; Shapiro, S; Smith, J | 1 |
| Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Park, YH; Ryoo, BY; Ryu, MH; Shin, DB; Yang, SH; Yuh, YJ | 1 |
| Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH | 1 |
| Flatmark, K; Folkvord, S; Olsen, DR; Røe, K; Seierstad, T; Skretting, A | 1 |
| Fakih, MG; Raman, AK | 1 |
| Moore, MJ; Welch, SA | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Cina, S; Dietrich, D; Figer, A; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, B; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Janjan, NA; Krishnan, S; Rana, V; Varadhachary, GR; Wolff, RA | 1 |
| Choi, J; Gardner, N; Hoffe, S; Kvols, L; Strosberg, J | 1 |
| Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J | 1 |
| Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T | 1 |
| Amichetti, M; Caraul, B; Casula, G; Deidda, MA; Dessì, M; Farci, D; Farigu, R; Lay, GC; Maxia, L; Murtas, R; Orrù, S | 1 |
| Clemons, M; Dranitsaris, G; Joy, A; Mackey, J; Trudeau, M; Verma, S; Wong, NS | 1 |
| Cassidy, J; Kelly, C | 1 |
| Bukowski, R; Desai, AA; Kardinal, CG; Lewis, N; Makalinao, A; Murray, P; Poiesz, B; Quinn, DI; Stadler, WM; Torti, FM | 1 |
| Bangemann, N; Fuchs, I; Gonsch, T; Hindenburg, HJ; Hinke, A; Klare, P; Kleine-Tebbe, A; Lakner, V; Schaller, G; Weber, J | 1 |
| Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A | 1 |
| Brun, V; Gravis, G; Labidi, SI; Tarpin, C; Viens, P | 1 |
| Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
| Bilancia, D; Dinota, A; Germano, D; Manzione, L; Reggiardo, G; Romano, R; Rosati, G | 1 |
| El-Rayes, B; Griffith, KA; Kalemkerian, GP; Muler, JH; Philip, PA; Schneider, BJ; Zalupski, MM | 1 |
| Bosserman, L; Cai, C; Hortobagyi, GN; Lerzo, G; Mullaney, B; Peck, R; Perez, EA; Pivot, X; Thomas, E; Vahdat, L; Viens, P | 1 |
| Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY | 1 |
| Abrey, LE; Deangelis, LM; Ekenel, M; Hormigo, AM; Peak, S | 1 |
| Hwang, SJ; Kim, BS; Kim, HJ; Kim, YJ; Lee, SD; Nam, SH | 1 |
| Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA | 1 |
| Alexandre, J; Bertheault-Cvitkovic, F; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Raymond, E; Shah, A; Shibata, S; Weems, G | 1 |
| Sargent, D; Schmoll, HJ | 1 |
| Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ | 1 |
| Deutsch, E; Ducreux, M; Ezra, P; Mangoni, M | 1 |
| Liem, AH; Planting, AS; van Halteren, HK | 1 |
| Diehl, KM; Griffith, KA; Hayes, DF; Hayman, JA; Helvie, MA; Layman, RM; Newman, LA; Pierce, LJ; Roubidoux, MA; Sabel, MS; Schott, AF; Smerage, JB; Thomas, DG | 1 |
| Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K | 1 |
| Fujino, M; Maruhashi, K; Mitsudou, Y; Nakamura, T; Shimomatsuya, T; Shiraishi, S; Yonezawa, K | 1 |
| Murakami, S; Yamamoto, Y | 1 |
| Kurebayashi, J; Masuda, N; Nakayama, T; Noguchi, S; Sakamoto, J; Shiba, E; Taguchi, T; Takatsuka, Y; Watatani, M | 1 |
| Demertzidis, CI; Economou, LD; Konstantinidis, HD; Mpallas, KD; Pissanidou, TT; Sioga, AC | 1 |
| Cao, WG; Che, JF; Jin, YN; Li, H; Ma, T; Xi, WQ; Xu, HP; Zhao, R | 1 |
| Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M | 1 |
| Cats, A; Havenga, K; Hospers, GA; Jansen, EP; Leer, JW; Marijnen, CA; Mulder, NH; Punt, CJ; Tesselaar, ME; Van de Velde, CJ; Van Krieken, HH; Wiggers, T | 1 |
| Chung, KW; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Kwon, HS; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH | 1 |
| Albertsson, M; Carstens, H | 1 |
| Sharma, SP | 1 |
| Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Cameron, D | 1 |
| Baehring, JM; Fulbright, RK | 1 |
| Masuda, N | 1 |
| Chrenko, V; Frgala, T; Kocakova, I; Krejci, E; Kubosova, K; Roubalova, E; Sefr, R; Slampa, P; Svoboda, M; Zaloudik, J | 1 |
| Bartelink, H; Boot, H; Cats, A; Crosby, TD; Dubbelman, R; Jansen, EP; Saunders, MP; Verheij, M | 1 |
| Kimura, Y; Morohashi, H; Morohashi, S; Odagiri, H; Sasaki, M | 1 |
| Baron, M; Di Fiore, F; Resch, B; Rives, N; Tenière, P | 1 |
| Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD | 1 |
| Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S | 1 |
| Amato, RJ; Khan, M | 1 |
| Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ | 1 |
| Kern, E; Kopp, B; Locker, GJ; Schmidinger, M | 1 |
| Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N | 1 |
| Barrett-Lee, P; Bliss, JM; Cameron, D; Canney, P; Johnson, L | 1 |
| Chahine, G; Farhat, F; Gasmi, J; Ghosn, M; Kattan, J; Moukadem, W; Nasr, F; Younes, F | 1 |
| Hartley, A; Ho, K; Muscroft, T; Sanghera, P | 1 |
| Ben-Josef, E; Desai, SP; El-Rayes, BF; Greenson, JK; Griffith, KA; Huang, EH; Knol, JA; McGinn, CJ; Philip, PA; Zalupski, MM | 1 |
| Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H | 1 |
| Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR | 1 |
| Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM | 1 |
| Filip, DJ; Grossniklaus, HE; Lee, WB; Sy, HM | 1 |
| Kondoh, K; Mori, K; Sawada, N | 1 |
| Astrup Jensen, S; Mård, D; Sørensen, JB; Thomsen Lønborg, J; Vilmar, A | 1 |
| Allendorf, JD; Bill, A; Chabot, JA; DiGiorgi, M; Fine, RL; Goetz, N; Hall, M; Lauerman, M; Remotti, H; Schrope, B; Sherman, W; Vakiani, E | 1 |
| Aleksić, P; Avramović, S; Dimitrijević, J; Latković, Z; Milivojević, M; Stojković, R; Vukosavljević, M | 1 |
| Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S | 1 |
| Bentley, E; Dubielzig, R; McAnulty, J; Milovancev, M; Schmiedt, C; Zarfoss, M | 1 |
| Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M | 1 |
| Beijnen, JH; Copalu, W; Etienne-Grimaldi, MC; Huitema, AD; Milano, G; Schellens, JH; Siegel-Lakhai, WS; Zandvliet, AS | 1 |
| Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R | 1 |
| Blanc, JF; Boige, V; Bouché, O; Dahan, L; Ducreux, M; Dupouy, N; Jouve, JL; Pignon, JP; Raoul, JL | 1 |
| Arnold, D; Dellas, K; Hermann, RM; Hinke, A; Hipp, M; Hohenberger, W; Iesalnieks, I; Liersch, T; Lordick, F; Rödel, C; Sauer, R | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osako, T; Takahashi, S; Tokudome, N | 1 |
| Albiin, N; Almström, M; Byström, P; Isaksson, B; Johnsson, A; Lind, PA; Permert, J | 1 |
| Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K | 1 |
| Guzin, G; Yucel, I | 1 |
| Bendell, JC; Chino, JP; Clough, RW; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG | 1 |
| Cantore, M; Del Freo, A; Fiorentini, G; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T | 1 |
| Ammann, M; Duquesne, A; Fürstenberger, G; Schmid, P; Senn, HJ | 1 |
| Cristalli, A; Geuder, M; Klinger, A; Lemerle, P | 1 |
| Cooper, J; Coughlin, S; Das, S; Lee, J | 1 |
| Chow, LW; Loo, WT; Sasano, H | 2 |
| Ajani, JA; Cen, P | 1 |
| Almhanna, K; Hashmi, S; Kim, R; Saif, MW; Zelterman, D | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Ozturk, B; Polat, M; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| A-Manaf, A; Foo, KF; Koo, WH; Lim, WT; Quek, R; Toh, HC | 1 |
| Brandsma, D; De Jong, FA; Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Abeshima, S; Hasegawa, N; Ichimura, T; Kaneko, H; Kawabata, M; Konishi, K; Nakayama, T | 1 |
| Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T | 1 |
| Luo, Y; Walla, M; Wyatt, MD | 1 |
| Bendell, JC; Czito, BG; Willett, CG | 1 |
| Gel-Moreno, B; Hernández-Borlan, R; Ibeas-Rollan, R; Martínez-Ródenas, F; Monzó-Planella, M; Moreno-Solórzano, I; Moreno-Solórzano, J; Navarro-Vigo, M; Ortigosa-Rodríguez, S; Pou-Sanchis, E | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, SB; Kim, YH; Lee, GH; Lee, SS; Park, SI; Ryu, JS; Shin, JH; Song, HY | 1 |
| Kuenen, BC; van der Vliet, HJ | 1 |
| Chau, I; Cunningham, D; Okines, A | 2 |
| Tavares-Bello, R | 1 |
| Boeck, HP; Boeck, S; Geissler, M; Golf, A; Heinemann, V; Hochhaus, A; Hoehler, T; Kettner, E; Ko, Y; Kojouharoff, G; Lordick, F; Mahlberg, R; Neugebauer, S; Schmid, B; Schoppmeyer, K; Seipelt, G; Stauch, M; Wein, A | 1 |
| Chau, KK; Choy, TS; Fu, YT; Law, CC; So, PF; Wong, KH | 1 |
| Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B | 1 |
| Buechele, T | 1 |
| Basaran, G; Blot, E; Bogaerts, J; Cameron, D; Canney, P; Coleman, R; Cufer, T; Ellis, P; Marreaud, S; Pajk, B; Piccart, M; Vermorken, J | 1 |
| Bhatia, S; Crane, CH; Das, P; Delclos, ME; Evans, DB; Janjan, NA; Krishnan, S; Pisters, PW; Rana, V; Varadhachary, G; Wolff, RA | 1 |
| Saif, MW; Tejani, MA | 2 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Byrne, P; Cooper, R; Craven, I; Crellin, A; Melcher, A; Sebag-Montefiore, D | 1 |
| Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A | 1 |
| Benjapibal, M; Inthasorn, P; Leelaphatanadit, C; Therasakvichya, S; Thirapakawong, C | 1 |
| Bozionelou, V; Georgoulias, V; Gioulbasanis, I; Kalykaki, A; Karabeazis, A; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B | 1 |
| Bell, R; Nortier, JW; Paridaens, R; Rodrigues, H; Rossner, D; Salzberg, M; Vaslamatzis, MM; Venturini, M | 1 |
| Audisio, RA; Bruce, C; Köhne, CH | 1 |
| Thompson, CA | 1 |
| Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S | 1 |
| Baldwin, J; Basche, M; Britten, CD; Camidge, DR; Darstein, C; Finn, RS; Gail Eckhardt, S; Gore, L; Holden, SN; Leong, S; Musib, L; O'Bryant, CL; Thornton, D | 1 |
| Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G | 1 |
| Gibson, DE; Szetela, AB | 1 |
| Arends, J; Drevs, J; Frost, A; Häring, B; Hennig, J; Medinger, M; Mross, K; Steinbild, S; Strecker, R; Unger, C | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Geboes, K; Van Cutsem, E | 1 |
| Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S | 1 |
| Alami, N; Belanger, S; Grieshaber, CK; Juste, S; Leyland-Jones, B; Paterson, J | 1 |
| Alexander, S; Dodds, M; Guichard, SM; Jodrell, DI; Macpherson, JS; Mayer, I; Muir, M; Reid, E | 1 |
| Ben-Josef, E | 1 |
| Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY | 1 |
| Kilickap, S; Sendur, MA | 1 |
| Arbea, L; Aristu, JJ; Azcona, JD; Díaz-González, JA; García-Foncillas, JM; Hernández-Lizoain, JL; Martínez-Monge, R; Moreno, M; Rodriguez, J; Sola, JJ | 1 |
| Rödel, C; Sauer, R; Weiss, C | 1 |
| Coxon, F; Cunningham, D; Daniel, F; Iveson, T; Middleton, G; Nicolson, M; Norman, AR; Oates, J; Rao, S; Starling, N | 2 |
| Chang, HM; Cho, JY; Do, YR; Hong, DS; Kim, SY; Kim, YH; Lee, KE; Lee, KH; Ryu, MH; Song, HS | 1 |
| Chen, Y; Deng, YM; He, YJ; Hu, GQ; Jiang, WQ; Li, YH; Lin, Q; Wang, FH; Xiang, XJ; Xu, DM | 1 |
| O'Neil, BH; Tepper, JE | 1 |
| Alomar, A; Dalmau, J; Puig, L; Roé, E | 1 |
| Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J | 1 |
| Collingridge, D | 1 |
| Douillard, JY; Dufour, P; Husseini, F; Lafuma, A; Maes, P; Perrocheau, G; Seitz, JF; Tilleul, P; Ychou, M | 1 |
| Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Saji, S; Sakamoto, J; Toi, M | 1 |
| de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
| Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P | 1 |
| B, DY; Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Oguz, M; Ozkan, M; Uner, A; Yaman, E; Yildiz, R | 1 |
| Alkis, N; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Er, O; Uner, A; Yamac, D; Yildiz, R | 1 |
| Artells, R; Gel, B; Hernandez, R; Ibeas, R; Martinez, F; Monzo, M; Moreno, I; Moreno, J; Navarro, A; Navarro-Vigo, M | 1 |
| Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A | 1 |
| Bradley, D; Dunn, RL; Friedman, J; Hussain, M; Montie, J; Sarkar, FH; Shah, RB; Vaishampayan, U; Wood, D; Wu, A | 1 |
| Barriuso, J; Belda, C; Brunello, A; Casado, E; Chiappori, A; de Castro, J; Feliu, J; González-Barón, M; Sereno, M | 1 |
| Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Ranieri, G; Ribatti, D; Roccaro, AM; Vacca, A | 1 |
| Daemen, A; De Bie, T; De Moor, B; Debucquoy, A; Gevaert, O; Haustermans, K; Machiels, JP | 1 |
| Barrueco, J; Fuchs, CS; Marshall, J | 1 |
| Clarke, SJ; Hoskins, JM; Liddle, C; London, R; Rivory, LP; Sharma, R; Zucknick, M | 1 |
| Borghesi, S; Hawkins, MA; Tait, D | 1 |
| Bajetta, E; Bodoky, G; Dietrich, D; Figer, A; Glimelius, B; Grawe, P; Herrmann, R; Hess, V; Ruhstaller, T; Saletti, P; Scheithauer, W | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Beretta, GD; Labianca, R; Milesi, L; Mosconi, S; Pessi, MA; Quadri, A | 1 |
| Diasio, RB; Ledbetter, L; Saif, MW; Tomita, M | 1 |
| Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D | 1 |
| Gruenberger, B; Gruenberger, T; Hacker, S; Kandutsch, S; Klinger, M; Wrba, F | 1 |
| Asselah, J; Cottu, PH; Diéras, V; Lae, M; Mignot, L; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A | 1 |
| Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH | 1 |
| Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C | 1 |
| Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T | 1 |
| Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M | 1 |
| Cho, SJ; Choi, IJ; Han, HS; Kim, CG; Kim, NK; Kim, SY; Kook, MC; Lee, JR; Lee, JS; Park, SR; Park, YI | 1 |
| Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M | 1 |
| Fujii, H; Inoue, A; Inoue, M; Inoue, S; Kunitomo, K; Takahashi, H | 1 |
| de Bruin, AF; de Wilt, JH; Ferenschild, FT; Nuyttens, JJ; Planting, AS; Verhoef, C | 1 |
| Bruguerolle, B; Semmar, N; Simon, N; Urien, S | 1 |
| Autret-Leca, E; Blasco, H; Boisdron-Celle, M; Bougnoux, P; Calais, G; Ciccolini, J; Le Guellec, C; Tournamille, JF | 1 |
| Cascinu, S | 1 |
| James, WD; Krathen, M; Treat, J | 1 |
| Bando, Y; Hirose, T; Honda, J; Moriya, T; Nagao, T; Sasa, M; Takahashi, M; Tangoku, A | 1 |
| Leeksma, O; Lieuw-a-Fa, M; Peringa, J; Terpstra, W | 1 |
| Beretta, GD; Bonetti, F; Kildani, B; Lombardi, C; Merlin, F; Pasolini, G; Prochilo, T | 1 |
| Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E | 1 |
| Clark, JW; Zuckerman, DS | 1 |
| Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Hofman, P; Lacour, JP; Lassalle, S; Mari, M; Milano, G | 1 |
| Hachisuka, Y; Hatano, H; Johira, H; Kamei, Y; Kawata, N; Kimura, M; Miyata, N; Ohmori, K; Umeoka, T; Uomoto, M; Watanabe, R; Yunoki, S | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
| Kim, YT | 1 |
| Bieri, G; Burkhard, R; Heitzmann, F; Hess, V; Koeberle, D; Neuweiler, J; Ruhstaller, T; Rust, C; Terraciano, L; Toepfer, M; von Moos, R; Winterhalder, R | 1 |
| Fariña, MC; Haro, R; Requena, L; Trindade, F | 1 |
| Chu, E; Lee, JJ | 3 |
| Cohen, DJ; Hochster, HS | 1 |
| Han, CJ | 1 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM | 1 |
| Vahdat, L | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Barbuzza, O; Guarneri, B; Guarneri, F; Vaccaro, M | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G | 1 |
| Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA | 1 |
| Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C | 1 |
| Cassidy, J; Glen, H | 1 |
| Barbet, N; Falandry, C; Freyer, G; Glehen, O; Heudel, P; Romestaing, P; You, B | 1 |
| Mukesh, M; Murray, P | 1 |
| Kang, YK; Lee, JL | 1 |
| Au, GK; Chua, D; Sham, JS; Wei, WI | 1 |
| Burris, HA | 1 |
| Vahdat, LT | 1 |
| Beijnen, JH; Diéras, V; Girre, V; Huitema, AD; King, A; Milano, G; Richmond, E; Schellens, JH; Siegel-Lakhai, WS; Tibben, MM; Wanders, J; Zandvliet, AS | 1 |
| Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG | 1 |
| Bennamoun, M; Dupuis, O; Hennequin, C; Jacob, JH; Lledo, G; Noirclerc, M; Vie, B | 1 |
| Rocha-Lima, CM | 1 |
| Katirtzoglou, NA; Saif, MW; Syrigos, KN | 1 |
| Akiyama, S; Fukushima, M; Oka, T; Ooyama, A; Yamamoto, M; Zhao, HY | 1 |
| Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, L; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS | 1 |
| Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, LB; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS | 1 |
| Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R | 1 |
| Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B | 1 |
| Papadopoulos, CA; Wilson, H | 1 |
| Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH | 1 |
| Gruenberger, B; Gruenberger, T; Punzengruber, R; Scheithauer, W; Tamandl, D; Zielinski, C | 1 |
| Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A | 1 |
| Arnheim, KE | 1 |
| Perez, EA | 1 |
| Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E | 1 |
| Thomas, ES | 1 |
| Cartwright, TH; Chu, E | 1 |
| Cassidy, J; Schmoll, HJ; Van Cutsem, E | 1 |
| Abad, A; Aparicio, J; Aranda, E; Díaz-Rubio, E; García, T; Ginés, A; Gómez-España, A; Guino, E; Maestu, I; Manzano, JL; Martinez-Balibrea, E; Martínez-Cardús, A; Sastre, J | 1 |
| Folprecht, G; Goldberg, RM; Köhne, CH; Mitry, E; Rougier, P | 1 |
| Bölke, E; Budach, W; Peiper, M | 1 |
| Albanell, J; Beech, J; Brewster, M; Gascon, P; Jones, ET; Mellado, B; Montagut, C; Pronk, L; Saunders, MP; Valle, JW; Zugmaier, G | 1 |
| Fang, H; Jin, J; Li, YX; Liu, YP; Wang, JW; Wang, K; Wang, WH; Yu, ZH; Zhou, AP; Zhou, ZX | 1 |
| Avallone, A; Casaretti, R; Comella, P; Franco, L; Sandomenico, C | 1 |
| Falces, C; Martí, V; Monell, J; Seixo, F | 1 |
| Krop, IE; Winer, EP | 1 |
| Michelin, OC; Paiva, CE | 1 |
| Saadati, H; Saif, MW | 1 |
| Glynne-Jones, R; Gollins, S; Leslie, M; Levine, E; McDonald, AC; Meadows, H; Myint, S; Samuel, L; Sebag-Montefiore, D; Wan, S | 1 |
| Amato, RJ; Mohammad, T | 1 |
| Alba, E; Carabantes, F; Dueñas, R; González, E; López-Siles, J; Márquez, A; Ribelles, N; Sánchez, A; Sánchez, MJ; Sánchez-Rovira, P; Sevilla, I | 1 |
| Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z | 1 |
| Aogi, K; Fujiuchi, N; Matsuura, K; Misumi, M; Okubo, K; Osaki, A; Saeki, T; Sano, H; Shigekawa, T; Takeuchi, H | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP | 1 |
| Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W | 1 |
| Liauw, SL; Minsky, BD | 1 |
| Antonini, N; Koopman, M; Mol, L; Punt, C; Simkens, L; Tol, J; van Krieken, H | 1 |
| Heinemann, V; Moosmann, N | 1 |
| Cabral, S; Federico, MH; Filho, Ude P; Franke, FA; Gampel, O; Perdicaris, MR; Ribeiro, Rde A; Segalla, JG; Skare, NG; Van Eyll, B | 1 |
| Alschuler, L; Block, KI; Gyllenhaal, C; Kranz, S; Roddy, GD; Rubin, D | 1 |
| Han, HS; Kang, HS; Kim, SW; Lee, DH; Lee, ES; Lee, H; Lee, KS; Nam, BH; Ro, J; Seo, JA | 1 |
| Azria, D | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Ballonoff, A; Kane, M; Kavanagh, B; McCarter, M; Nash, R; Pearlman, N; Raben, D; Schefter, TE; Shah, RJ | 1 |
| Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL | 1 |
| Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Mai, S; Möhler, M; Post, S; Schwarzbach, M; Staiger, W; Wenz, F; Willeke, F | 1 |
| Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Besnard, T; Etienne-Grimaldi, MC; François, E; Milano, G; Renée, N | 1 |
| Cowman, S; Stebbing, J; Tuthill, M | 1 |
| Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY | 1 |
| Cameron, DA; Stein, S | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Choo, SP; Chowbay, B; Ngeow, JY; Prakash, KM; Quek, ST | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 1 |
| Anthoney, DA; Bradley, C; Brown, JM; Brown, S; Crawford, SM; Hennig, IM; Jackson, DP; Melcher, AM; Naik, JD; Seymour, MT; Szubert, A | 1 |
| Barone, C; Pozzo, C | 1 |
| Abdelsalam, M; Ajarim, D; Bazarbashi, S; El-Bassiouni, M; Fagih, M; Jabbar, AA; Manji, M; Sanea, NA; Soudy, H | 1 |
| Pérez-Cejudo, JA; Pérez-Díaz, MJ; Piqué-Duran, E | 1 |
| Fakih, MG; Patel, A; Puthillath, A; Yang, G | 1 |
| Batista, N; Cruz, J; Dómine, M; Estévez, LG; León, A; Provencio, M; Rodríguez, M; Sánchez-Rovira, P; Velasco, A | 1 |
| Abdullah, S; Doliny, P; Gautam, U; Gluck, S; Hurley, J; Lobo, C; Lopes, G; Morgenzstern, D; Reis, I; Santos, E; Silva, O; Slingerland, J; Welsh, C | 1 |
| Duhoux, F; Mano, MS | 1 |
| Bennouna, J; Douillard, JY; Senellart, H | 1 |
| Aberer, E; Gerger, A; Kränke, B; Salmhofer, W; Weger, W | 1 |
| Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R | 1 |
| Chang, SC; Liao, JW | 1 |
| Jonasch, E; Mathew, P; Ng, CS; Pagliaro, L; Siefker-Radtke, A; Tannir, NM; Thall, PF; Wang, X; Wood, C; Wooten, L | 1 |
| Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L | 1 |
| Bar-Sela, G; Haim, N | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM | 1 |
| Hampton, T | 1 |
| Bunnell, C; Gralow, J; Klimovsky, J; Peck, R; Poulart, V; Schwartzberg, L; Thomas, E; Vahdat, L | 1 |
| Chu, E; Gibson, TB; Grothey, E | 1 |
| Baek, JH; Chang, HM; Kang, HJ; Kang, WK; Kang, YK; Kim, JG; Kim, TW; Lee, JL; Lee, KH; Min, YJ; Park, SR; Ryoo, BY; Ryu, MH; Shin, DB; Zang, DY | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F | 1 |
| Baum, MS; Goldsmith, YB; Roistacher, N | 1 |
| Paoletti, P | 1 |
| Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I | 1 |
| Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M | 1 |
| Farquharson, AL; O'Dwyer, ST; Pranesh, N; Renehan, AG; Rout, S; Saunders, MP; Swindell, R; Taylor, MB; Wilson, MS; Witham, G | 1 |
| Bernhardt, G; Cerwenka, H; Kornprat, P; Mischinger, HJ; Schöllnast, H; Werkgartner, G | 1 |
| Hyodo, I; Koizumi, W; Kojima, H; Okayasu, I; Sakamoto, J | 1 |
| Hang, X; Liu, C; Sun, Q; Wang, D; Zhong, B | 1 |
| Alhasan, S; Baranowski, K; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, U | 1 |
| Dvorak, J; Izakovicova Holla, L; Kocakova, I; Sefr, R; Svoboda, M; Tichy, B; Vrtkova, I | 1 |
| Grouls, V | 1 |
| Harada, T; Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N | 1 |
| Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y | 1 |
| Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S | 1 |
| Abali, H; Budakoglu, B; Hayran, M; Oksuzoglu, B; Yildirim, N; Zengin, N | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Abbruzzese, JL; Blais, JC; Hess, KR; Varadhachary, GR; Wolff, RA; Xiong, HQ | 1 |
| Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F | 1 |
| Abbas, R; Boni, J; Bukowski, R; Croghan, G; Donehower, R; Erlichman, C; Hidalgo, M; Jimeno, A; Laheru, D; Martins, P; Messersmith, W; Pelley, R; Rudek, M; Zacharchuk, C | 1 |
| Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C | 1 |
| Bosnjak, SM; Radulovic, S; Susnjar, S | 1 |
| Amadori, D; Antonuzzo, L; Barone, C; Bertetto, O; Carlo Merlano, M; Di Costanzo, F; Gasperoni, S; Labianca, R; Longo, F; Luppi, G; Mansueto, G; Ravasio, R; Sobrero, A; Vinante, O | 1 |
| Arnold, D; Bovenschulte, H; Coutelle, O; Fries, JW; Hacker, U; Stippel, D; Weihrauch, MR | 1 |
| Bagnardi, V; Bertolini, F; Campagnoli, E; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Mancuso, P; Pietri, E; Rocca, A; Scarano, E; Shaked, Y; Torrisi, R | 1 |
| Koukourakis, GV; Koukourakis, MJ; Kouloulias, V; Kouvaris, J; Zabatis, H; Zacharias, GA | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Kamei, T; Kaneda, Y; Kurata, S; Miyamoto, S; Nakayasu, K; Suto, R; Zenpo, N | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Alabiso, O; Amoroso, D; D'Alonzo, L; Donati, S; Fornasiero, A; Forti, L; Iacono, C; Lalli, A; Lopatriello, S; Lucenti, A; Negrini, C; Smergo, A | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osaki, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
| Röcken, C | 1 |
| Boehm, KA; Cartwright, T; Richards, DA | 1 |
| Damianovich, D; Looi, KL; Sidebotham, D; Taylor, GB; To, AC; White, HD | 1 |
| Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO | 1 |
| Booth, C | 1 |
| Hang, X; Ma, S; Sun, Q; Wang, D; Yang, Y; Ying, JE; Yong, D; Zhang, Y; Zhong, B; Zhong, H | 1 |
| Harshman, LC; Li, M; Srinivas, S | 1 |
| Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E | 1 |
| Cianfrocca, M | 1 |
| Alberti, DB; Attia, S; Bailey, HH; Campbell, TC; Cleary, JF; Eickhoff, JC; Holen, KD; Huie, MS; Liu, G; McFarland, TA; Morgan-Meadows, S; Mulkerin, DL; Schelman, WR; Tevaarwerk, AJ; Traynor, AM; Wilding, G | 1 |
| Curzen, NP; Ferchow, L; Hobson, A; Scott, PA | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F | 1 |
| Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R | 1 |
| Ayuso, JR; Castells, A; Conill, C; de Lacy, A; Delgado, S; Gallego, R; Ginés, A; Maurel, J; Miquel, R; Tosca, M; Ugidos, L | 1 |
| Bekaii-Saab, T; Haghighat, P | 1 |
| Kerr, DJ; Midgley, R | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Kaufman, DA; Lam, MS; Russin, MP | 1 |
| Borg, C; Chaigneau, L; Demarchi, M; Fagnoni-Legat, C; Kantelip, JP; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Villanueva, C | 1 |
| Huh, JW; Jung, EJ; Kwon, JE; Lee, KY; Park, YA; Sohn, SK | 1 |
| Boonnuch, W; Chinswangwatanakul, V; Lohsiriwat, D; Mahamadsolaeh, P; Veerasarn, V | 1 |
| Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K | 1 |
| Saif, MW; Wasif, N | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Kim, GH; Seol, YM; Shin, HJ; Song, GA; Song, MK | 1 |
| Kang, X; Wang, J; Yang, B; Yang, F; Zhang, Q | 1 |
| Glück, S; McKenna, EF; Royce, M | 1 |
| Cohen, SJ; Konski, A; Li, T; Meropol, NJ; Sigurdson, E; Small, W; Spies, S; Stryker, S; Wahl, A; Yu, JQ | 1 |
| Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H | 1 |
| Cardenal Escarcena, A; Fernández Sarabia, MT; García Bernardo, L; Rodríguez García, JM; Serrano Vicente, J | 1 |
| Budach, W; Debus, J; Dunst, J; Hinke, A; Hoelscher, T; Mose, S; Reese, T; Roedel, C; Rudat, V; Wulf, J; Zuehlke, H | 1 |
| Arens, A; Beets, GL; Beets-Tan, RG; Buijsen, J; de Ruysscher, D; Driessen, A; Kessels, AG; Lammering, G; Oellers, M; van Baardwijk, A; Vanhauten, B; Vliegen, RF | 1 |
| Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ | 1 |
| Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV | 1 |
| Bessell, EM; Dhadda, AS; Zaitoun, AM | 1 |
| Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S | 1 |
| Saif, MW; Sandoval, A | 1 |
| Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP; Salanti, G | 1 |
| Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J | 1 |
| Leonard, RC; Morishita, M | 1 |
| Yardley, DA | 1 |
| Albain, K; Barlow, WE; Chew, HK; Gown, A; Gralow, J; Hayes, DF; Hortobagyi, GN; Lew, D; Livingston, R | 1 |
| Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N | 1 |
| Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP | 1 |
| Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M | 1 |
| Fukushima, M; Ishida, T; Ishioka, C; Ishiwata, R; Kiba, T; Masuda, N; Matsuyama, K; Noguchi, S; Ohuchi, N; Takatsuka, Y; Takeda, M; Teramukai, S | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Elshazly, WG; Farouk, M; Samy, M | 1 |
| Dilulio, J; Ganju, V; Khamly, K; Leong, T; Matera, A; Michael, M; Milner, AD; Muller, A; Ngan, SY; Price, T; Strickland, AH; Zalcberg, JR | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, MJ; Kim, TY; Lee, SH; Oh, DY | 1 |
| Danenberg, KD; Danenberg, PV; Grem, JL; Uchida, K | 1 |
| Blesius, A; Ciccolini, J; Duffaud, F; Dupuis, C; Fanciullino, R; Frances, N; Giacometti, S; Iliadis, A; Mercier, C; Padovani, L; Yang, CG | 1 |
| Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L | 1 |
| Abad, A; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; García, T; Gómez-España, A; González-Flores, E; Losa, F; Maestu, I; Massutí, B; Queralt, B; Reina, JJ; Rivera, F; Sanchez-Rovira, P; Sastre, J; Tabernero, J | 1 |
| Khan, K; Li, D; Li, G; O'Malley, BW; Rhee, J; Ronson, S; Saito, K; Suntharalingam, M; Van Echo, D; Yu, SZ | 1 |
| Hay, JW; Le, QA | 1 |
| Abakar-Mahamat, A; Baize, N; Berthier, F; Caroli-Bosc, FX; Mounier, N | 1 |
| Alberti, D; Eickhoff, J; Feierabend, C; Holen, KD; Kolesar, J; LoConte, NK; Marnocha, R; Mulkerin, D; Oliver, K; Thomas, JP; Wilding, G | 1 |
| Capalbo, G; Rödel, C; Rödel, F; Weiss, C | 1 |
| Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C | 1 |
| Büchler, P; Endlicher, E; Geissler, M; Gregor, M; Harder, J; Heinemann, V; Hofheinz, R; Kanzler, S; Klöppel, G; Mihaljevic, A; Schmiegel, W; Seufferlein, T | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Frye, DK | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kohles, J; Kolinsky, K; Packman, K; Shen, BQ; Zhang, YE; Zioncheck, TF | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Buffart, TE; Carvalho, B; Eijk, PP; Koopman, M; Meijer, GA; Peters, GJ; Postma, C; Punt, CJ; van Krieken, JH; Ylstra, B | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA | 1 |
| Chen, J; Forster, G; Guan, Z; Kang, WK; Kang, YK; Khasanov, R; Lichinitser, M; McCloud, PI; Philco-Salas, M; Santamaria, J; Shin, DB; Suarez, T; Wang, J; Xiong, J; Zheng, L | 1 |
| Amonkar, MM; Cameron, D; Cella, D; Geyer, CE; Segreti, A; Stein, S; Walker, M; Zhou, X | 1 |
| Bucci, L; Cannella, L; Carlomagno, C; D'Armiento, FP; D'Armiento, MR; De Placido, S; De Stefano, A; Farella, A; Pacelli, R; Pepe, S; Pesce, G; Solla, R | 1 |
| Gibson, OJ; Larsen, ME; Pearson, S; Rowntree, J; Smith, J; Tarassenko, L; Weaver, A; Young, AM | 1 |
| Abbruzzese, JL; Adinin, R; Eng, C; Kopetz, S; Lin, E; Morris, JS; Overman, MJ; Varadhachary, GR; Wolff, RA | 1 |
| Chau, I; Cunningham, D; Harper, P; Hawkins, R; Hickish, T; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Seymour, M | 1 |
| Adams, RA; Fisher, D; Kaplan, RS; Kay, E; Kenny, S; Madi, A; Maughan, TS; Meade, AM | 1 |
| Antonini, NF; Hoogerbrugge, N; Koopman, M; Kortman, GA; Ligtenberg, MJ; Mekenkamp, L; Punt, CJ; van Krieken, JH | 1 |
| Hofer, S; Krähenbühl, S; Ludwig, C; Rätz Bravo, AE | 1 |
| Crane, CH; Evans, DB; Fleming, JB; Settle, SH; Varadhachary, G; Wolff, RA | 1 |
| Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J | 1 |
| Boehnke Michaud, L | 1 |
| Shao, ZY; Zhang, JD | 1 |
| Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y | 1 |
| Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Brandely, M; Crivellari, D; Foa, P; Fougeray, R; Goldhirsch, A; Mattioli, R; Nolè, F; Pinotti, G; Verri, E | 1 |
| Chu, E; Schulman, KL; Song, X; Zelt, S | 1 |
| Antonini, NF; Cats, A; Creemers, GJ; Dalesio, O; Dijkstra, JR; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Richel, DJ; Rodenburg, CJ; Schrama, JG; Sinnige, HA; Tol, J; van Groeningen, CJ; van Krieken, JH; Vink-Börger, ME; Voest, EE; Vos, AH | 1 |
| Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Ledbetter, L; Saif, MW; The, A | 1 |
| Akyürek, N; Benekli, M; Büyükberber, S; Coşkun, U; Demirci, U; Oztürk, B; Tonyali, O; Yildiz, R; Yilmaz, G | 1 |
| Chiappa, A; de Braud, F; Fazio, N; Leonardi, MC; Luca, F; Magni, E; Nolè, F; Orecchia, R; Petazzi, E; Petralia, G; Santoro, L; Trovato, C; Zampino, MG | 1 |
| Fountzilas, G; Fragoulakis, V; Maniadakis, N; Pectasides, D | 1 |
| Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK | 1 |
| Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A | 1 |
| Chiba, A; Fukahori, M; Inaba, M; Inari, H; Ino, H; Yoshida, A | 1 |
| Foo, KF; Wang, ML | 1 |
| Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D | 1 |
| An, GL; Gu, SZ; Li, XH; Lian, JW; Pan, BR; Qin, TJ; Tian, F; Zhao, XH | 1 |
| Cleeland, CS; Crane, CH; Das, P; Delclos, ME; Hundal, M; Janjan, NA; Krishnan, S; Lin, EH; Mendoza, TR; Park, HC; Vadhan-Raj, S; Wang, XS; Zhang, Y | 1 |
| Gruenberger, B; Gruenberger, T; Herberger, B; Kaczirek, K; Tamandl, D | 1 |
| Clark, KR; Javle, MM; LeVea, C; Nava, HR; Nwogu, CE; O'Malley, L; Pendyala, L; Prey, JD; Schiff, MD; Smith, PF; Vinjamaram, S; Wilding, GE; Yang, G | 1 |
| Bicakci, K; Paydas, S; Yavuz, S | 1 |
| Jensen, BY; Jensen, HA; Larsen, O; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Baselga, J; Benson, M; Cunningham, D; Hill, A; Kurek, R; Lüpfert, C; Oates, J; Rao, S; Starling, N; Wotherspoon, A | 1 |
| Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I | 1 |
| Aprile, G; Mazzer, M; Moroso, S; Puglisi, F | 1 |
| Casaretti, R; Comella, P; de Portu, S; Franco, L; Menditto, E | 1 |
| Greil, R; Menzel, C; Mlineritsch, B; Moik, M; Namberger, K; Reitsamer, R; Ressler, S; Stoll, M | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, MK; Kim, SB; Kim, YH; Lee, GH; Park, SI; Ryu, JS; Shin, JH; Song, HJ; Song, HY | 1 |
| Beneduce, G; Breda, E; Di Maio, M; Forestieri, V; Gallo, C; Gebbia, V; Greggi, S; Lauria, R; Losito, S; Morabito, A; Pignata, S; Pisano, C; Scalone, S; Scaltriti, L; Sorio, R; Zagonel, V | 1 |
| Ahn, BM; Chae, YS; Jeon, SW; Kim, JC; Kim, JG; Lee, EB; Lee, SJ; Moon, JH; Park, IK; Sohn, SK | 1 |
| Moore, S | 1 |
| Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT | 1 |
| Kolluri, RB; Raouf, S; Tipples, K | 1 |
| Bowen, C; Licea-Perez, H; Wang, S | 1 |
| Harold, L; Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Andersson, M; Bauer, W; Baumann, KH; Clemens, MR; Cufer, T; de Jongh, FE; du Bois, A; Duerr, R; Kaufmann, M; Loibl, S; Maartense, E; Maass, N; Nekljudova, V; Schmidt, M; Stein, RC; Uleer, C; von Minckwitz, G; Zielinski, C | 1 |
| Elenitsas, R; Fernandes, NF; Kist, JM; Rosenbach, M | 1 |
| Burstein, HJ; Gelman, RS; Harris, LN; Mayer, EL; Partridge, AH; Schumer, ST; Winer, EP | 1 |
| Imai, S; Kobayashi, A; Koyama, H; Matsuyama, T; Tokugawa, T | 1 |
| Ghosal, N; Misra, V | 1 |
| Darodes, N; Genet, D; Labourey, JL; Le Brun-Ly, V; Martin, J; Tubiana-Mathieu, N; Venat-Bouvet, L | 1 |
| Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA | 1 |
| Chow, WA; Doroshow, JH; Frankel, P; Gandara, DR; Lenz, HJ; Leong, LA; Lim, D; Margolin, KA; Morgan, RJ; Newman, EM; Shibata, SI; Somlo, G; Synold, TW; Yen, Y | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kolinsky, K; Packman, K; Zhang, YE | 1 |
| Filip, S; Finek, J; Holubec, L; Kormunda, S; Kozevnikova, R; Pavlikova, I; Sediva, M; Sefrhansova, L; Svoboda, T; Votavova, M | 1 |
| Hillner, BE; Smith, TJ | 1 |
| Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA | 1 |
| Aydin, S; Daemen, A; De Moor, B; Debucquoy, A; Gevaert, O; Haustermans, K; Libbrecht, L; Machiels, JP; McBride, WH; Penninckx, F; Scalliet, P; Sempoux, C; Stroh, C; Tejpar, S; Vlassak, S | 1 |
| Dinter, D; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Ströbel, P | 1 |
| Des Guetz, G; Morere, JF; Nicolas, P; Schischmanoff, O; Uzzan, B | 1 |
| Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K | 1 |
| Bon, D; Claparols, C; Desmoulin, F; Larrieu, G; Malet-Martino, M; Martino, R | 1 |
| Folprecht, G; Gruenwald, V; Huebner, G; Koehne, CH; Kretzschmar, A; Link, H; Schuette, K; Stahl, M | 1 |
| Marrero, JA; Singal, A; Welling, TH | 1 |
| Finn, RS; Zhu, AX | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Murphy, KC | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Fabian, P; Garajová, I; Kocák, I; Kocáková, I; Slabý, O; Svoboda, M; Vyzula, R | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Haller, DG; Teitelbaum, UR | 1 |
| AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA | 1 |
| Lau, SC; Shibata, SI | 1 |
| Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E | 1 |
| Boda-Heggemann, J; Hermes, P; Hieber, U; Hochhaus, A; Hofheinz, RD; Lohr, F; Mai, SK; Massner, B; Mennemeyer, P; Post, S; Weiss, C; Wenz, F; Wertz, H | 1 |
| Ben-Josef, E; Chang, AE; Colletti, L; Desai, S; Francis, IR; Greenson, JK; Griffith, KA; Hampton, J; Lawrence, TS; Simeone, D; Zalupski, MM | 1 |
| Becze, E | 1 |
| Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Brunetti, IM; Bursi, S; Chiara, S; Cupini, S; Di Donato, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Allum, W; Ashley, S; Benson, M; Brown, G; Chau, I; Cunningham, D; Oates, J; Okines, A; Riddell, A; Starling, N; Stavridi, F; Thomas, J; Thompson, J; Wotherspoon, A | 1 |
| Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC | 1 |
| Goff, LW; Mernaugh, RL; Pohlmann, PR | 1 |
| Easaw, JC; Vickers, MM | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T | 1 |
| Cantore, M; Danesi, R; Del Freo, A; Del Tacca, M; Giovannetti, E; Mambrini, A; Nannizzi, S; Orlandi, M; Pacetti, P; Tartarini, R | 1 |
| Di Maio, M; Falcone, A; Loupakis, F | 1 |
| Copur, MS; Norvell, M; Obermiller, A | 1 |
| Al Hasan, SA; Cher, ML; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, UN | 1 |
| Berry, H; Dodwell, DJ; Gillibrand, A; Kumar, S; Perren, TJ; Velikova, G; Waters, SH | 1 |
| Casado-Jiménez, M; Feito-Rodriguez, M; Feltes, RA; Floristan, U; Ramírez-Marín, P; Sendagorta, E; Vidaurrázaga, C | 1 |
| Arima, K; Hasegawa, Y; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y; Yamada, Y | 1 |
| Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S | 1 |
| Inaba, T; Kashiwaba, M; Komatsu, H; Takeda, Y; Takiyama, I; Tomisawa, Y; Wakabayashi, G | 1 |
| Fujii, T; Inoue, Y; Matsubayashi, RN; Momosaki, S; Sawada, Y; Shirouzu, K; Takahashi, H; Toh, U; Uesugi, N; Yokoyama, G | 1 |
| Gutiérrez-Pascual, M; López-Estebaranz, JL; Pinedo, F; Sols-Candela, M | 1 |
| Chan, A; Verrill, M | 1 |
| Chang, GJ; Crane, CH; Das, P; Ellis, LM; Eng, C; Feig, BW; Hamilton, S; Janjan, NA; Krishnan, S; Maru, DM; Rodriguez-Bigas, MA; Skibber, JM; Wolff, RA | 1 |
| Gibbons, S; Tansley, S | 1 |
| Choo, SP; Tan, EH; Wong, M | 1 |
| Ashley, S; Chau, I; Cunningham, D | 1 |
| Bilek, M; Bouskova, K; Fidlerova, J; Kleibl, Z; Kleiblova, P; Kormunda, S; Novotny, J; Sevcik, J | 1 |
| Cunningham, D; Kang, YK; McCloud, P; Norman, AR; Okines, AFC | 1 |
| Denz, H; Fiegl, M; Gradl, J; Gratzl, M; Hutarew, G; Sun, WL | 1 |
| Gao, P; Ma, B; Tian, JH; Yang, KH; Zhao, G | 1 |
| Clark, JI; Crawford, DE; Gandour-Edwards, R; Hussey, M; Lange, MK; Lara, PN; Mack, PC; Van Veldhuizen, PJ | 1 |
| Alonso, V; Calduch, L; Jordá, E; Martín, JM; Pinazo, MI; Villalón, G | 1 |
| Grimison, PS; Hudson, HM; Simes, RJ; Stockler, MR | 1 |
| Fukuda, T; Shiroiwa, T; Tsutani, K | 3 |
| Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J | 1 |
| Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY | 1 |
| Halverson, AL; Hogg, ME; Kiel, KD; Popowich, DA; Stryker, SJ; Wang, EC | 1 |
| Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA | 1 |
| Elsayed, MI; Elwanis, MA; Maximous, DW; Mikhail, NN | 1 |
| Eskola, M; Ilveskoski, E; Nikus, K; Tanner, M | 1 |
| Bernstein Molho, R; Grisaru, D; Inbar, M; Levy, T; Menzcher, J; Safra, T | 1 |
| Falleti, J; Fortuna, G; Leuci, S; Mignogna, MD | 1 |
| Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M | 1 |
| Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R | 1 |
| Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G | 1 |
| Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR | 1 |
| Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ | 1 |
| Johnstone, E; Kerr, D; Midgley, R; Swanton, C; Tomlinson, I; Walther, A | 1 |
| Balducci, M; D'Agostino, GR; Dinapoli, N; Mantini, G; Massaccesi, M; Mattiucci, GC; Meduri, B; Micciché, F; Nardone, L; Salvi, G; Valentini, V | 1 |
| Alfonso, PG; Cañón, EP; Carrión, JB; Manga, GP; Pereira, RQ; Peron, YI; Plaza, MI; Shahi, PK; Ureña, MM; Val, RG | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T | 1 |
| Fujimoto-Ouchi, K; Mori, K; Yamashita, Y; Yanagisawa, M; Yorozu, K | 1 |
| Landherr, L; Nagykálnai, T | 2 |
| Li, J; Saif, MW | 2 |
| Sherman, WH | 1 |
| Dong, N; Jiang, W; Li, H; Liu, Z; Wang, M; Xu, X | 1 |
| Gunderson, HD; Leung, N; Shaikh, A; Wiisanen, ME | 1 |
| Achilli, F; Farina, A; Malafronte, C; Valsecchi, MA | 1 |
| Becquart, D; Bougnoux, P; Chan, A; Conte, PF; Espie, M; Majois, F; Morand, M; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G | 1 |
| Chow, LW; Hirakawa, H; Ishida, T; Loo, WT; Ohuchi, N; Ono, K; Sasano, H; Suzuki, T | 1 |
| Giannopoulos, A; Gogas, H; Markopoulos, C; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N | 1 |
| Levine, PA; Petroni, G; Read, P; Reibel, J; Thomas, CY | 1 |
| Daum, S; Ebert, MP; Flieger, D; Galle, PR; Geissler, M; Hoehler, T; Kanzler, S; Moehler, M; Raedle, J; Seufferlein, T | 1 |
| Saltz, L | 1 |
| Jordá, E; López, V; Martín, JM | 1 |
| Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD | 1 |
| Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF | 1 |
| Dong, NN; Liu, ZF; Wang, MY; Zhang, Q | 1 |
| Ang, BW; Cheng, CL; Chou, N; Lee, KM; Lee, SC; Wong, AL | 1 |
| Cathomas, R; von Moos, R | 1 |
| Bjerregaard, B; Fokstuen, T; Glimelius, B; Jensen, BV; Keldsen, N; Larsen, FO; Mejer, J; Nielsen, SE; Pfeiffer, P; Qvortrup, C | 1 |
| Aggarwal, BB; Anand, P; Deorukhkar, A; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Kuzhuvelil, HB | 1 |
| Chen, XQ; He, YJ; Li, YH; Pan, ZZ; Qiu, MZ; Ruan, DY; Teng, KY; Wan, DS; Xu, RH | 1 |
| Saltz, LB; Segal, NH | 1 |
| Ansaloni, L; Bazzoli, F; Cennamo, V; Ceroni, L; Eusebi, LH; Fuccio, L; Laterza, L; Martoni, AA; Minardi, ME; Mutri, V; Pinna, AD; Salfi, N | 1 |
| Barrett-Lee, P; Bidard, FC; Pierga, JY | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJA | 1 |
| Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N | 1 |
| Moen, MD | 1 |
| Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA | 1 |
| Bruno, R; Claret, L; Fagerberg, J; Girard, P; Hoff, PM; Jorga, K; Van Cutsem, E; Zuideveld, KP | 1 |
| Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, J; Mroue, RM; Nasr, FL; Younes, FC | 1 |
| Beijnen, JH; Rosing, H; Schellens, JH; Vainchtein, LD | 1 |
| Albain, KS; Bedard, PL; Cardoso, F; Costa, A; Cufer, T; Fallowfield, LJ; Kyriakides, S; Pagani, O; Senkus-Konefka, E; Winer, EP | 1 |
| Bekaii-Saab, T; Campbell, A; Hill, M; Kosuri, K; Thomas, J; Villalona-Calero, M | 1 |
| Mendiola, C; Vaz, MA | 1 |
| Cupino, N; de Los Reyes, R; Domingo, E; Jin, K; Kamnerdsupaphon, P; Lertbutsayanukul, C; Lertsanguansinchai, P; Lorvidhaya, V; Syortin, T; Tharavichitkul, E; Vito-Cruz, E; Yoshihara, M | 1 |
| Fukuda, T; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Tsutani, K | 1 |
| Bell, D; Diasio, RB; Hashmi, S; Saif, MW | 1 |
| Jones, A; Nowara, E; O'Brien, M; Perraud, K; Pham, ML; Pienkowski, T; Rolski, J; Sommer, H; Trillet-Lenoir, V; Welt, A | 1 |
| Schmidt, C | 1 |
| Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J | 1 |
| Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG | 1 |
| Hoimes, C; Merl, M; Pham, T; Saif, MW | 1 |
| Endrizzi, BT; Lee, PK | 1 |
| Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Jassem, J; Li, RK; Mukhopadyay, P; Pivot, XB; Roché, HH; Thomas, ES | 1 |
| Górnaś, M; Szczylik, C | 1 |
| Boot, H; Cats, A; Dubbelman, R; Jansen, EPM; Verheij, M | 1 |
| Gollins, SW; Haylock, B; Levine, E; Mason, L; Morris, J; Myint, S; Samuel, L; Susnerwala, S; Swindell, R; Topham, C; Wise, M | 1 |
| Amadori, D; Aquilina, M; Cecconetto, L; Ibrahim, T; Maltoni, R; Massa, I; Nanni, O; Passardi, A; Pietri, E; Ridolfi, R; Rocca, A; Sarti, S | 1 |
| Bodnar, L; Stec, R; Szczylik, C | 1 |
| Bedi, M; Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Feig, BW; Krishnan, S; Rodriguez-Bigas, MA; Skibber, JM | 1 |
| Warmerdam, LV; Yucel, H | 1 |
| Mortimer, J; Pal, SK | 1 |
| Quinn, B; Salvage, AV | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, DC; Lam, WK; Wong, MK | 1 |
| Brearley, SG; Craven, O; Molassiotis, A; Saunders, M; Swindell, R | 1 |
| Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G | 1 |
| Cho, YB; Chun, HK; Kim, HC; Lee, WY; Yun, HR; Yun, SH | 1 |
| Zeng, YC | 1 |
| Ding, PR; Li, LR; Lin, JZ; Pan, ZZ; Peng, ZH; Wan, DS; Wu, XJ; Zhou, ZG | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
| Altundag, K; Dede, DS; Dizdar, O | 1 |
| Anderson, RT; Balkrishnan, R; Camacho, FT; Kimmick, G; Wei, W; Wu, J | 1 |
| Gong, HY; Huang, W; Li, BS; Li, HS; Lin, HQ; Sun, HF; Wang, LY; Wang, ZT; Wei, YM; Yi, Y; Zhang, ZC; Zhou, T | 1 |
| Kakar, M; Olsen, DR; Røe, K; Seierstad, T | 1 |
| Bendell, JC; Cartwright, T; Chu, E; Shi, N; Wei, W | 1 |
| Garcia-Alfonso, P; Gonzalez-Flores, E; Mendez-Ureña, M; Muñoz-Martin, A; Perez-Manga, G; Quiben-Pereira, R | 1 |
| Hasegawa, N; Iimura, Y; Kaneko, H; Kawabata, M; Konishi, K; Shoji, Y | 1 |
| Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R | 1 |
| Saif, MW; Shi, N; Zelt, S | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Kellokumpu-Lehtinen, PL; Koskinen, S; Sunela, KL | 1 |
| Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J | 1 |
| Koopman, M; Punt, CJ | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Lee, SJ; Min, SY; Nam, BH; Park, C; Park, IH; Ro, J; Shin, KH | 1 |
| Chen, XQ; He, YJ; Li, YH; Luo, HY; Qiu, MZ; Shi, YX; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Jager, A; Sleijfer, S; Verweij, J | 1 |
| Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N | 1 |
| Frampton, JE | 1 |
| Arenas-Hernandez, M; Fairbanks, L; Loganayagam, A; Marinaki, AM; Ross, P; Sanderson, JD | 1 |
| Hang, M; Hang, X; Li, M; Mao, W; Sun, Q; Xu, W; Zhang, J | 1 |
| Teng, KY; Xu, RH | 1 |
| Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Chang, M; George, TJ; Grobmyer, S; Hochwald, S; King, J; Larson, B; Marsh, Rde W; Mendenhall, WM; Siddiqui, T; Zlotecki, RA | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jun, HJ; Kang, WK; Kim, HS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS; Yi, SY | 1 |
| Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; Weide, R | 1 |
| Ahmad, A; Gounaris, I | 1 |
| Amarantidis, K; Chatzaki, E; Chelis, L; Chiotis, A; Kakolyris, S; Karakitsos, P; Kortsaris, A; Polychronidis, A; Tentes, A; Xenidis, N | 1 |
| Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R | 1 |
| Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C | 1 |
| Cheng, YC; Chu, E; Foo, A; Jiang, Z; Liu, SH; Rose, M; Saif, MW; So, S; Su, T; Yen, Y | 1 |
| Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG | 1 |
| Hayashida, T; Ikeda, T; Jinno, H; Kitagawa, Y; Mukai, M; Sakata, M; Takahashi, M | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Andreu, J; Carles, J; Serrano, C; Suárez, C | 1 |
| Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J | 1 |
| Puglisi, F | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Aboagye, EO; Al-Nahhas, A; Contractor, KB; Coombes, RC; Kenny, LM; Palmieri, C; Shousha, S; Stebbing, J | 1 |
| Cats, A; Creemers, GJ; Koopman, M; Miller, MC; Nagtegaal, ID; Punt, CJ; Terstappen, LW; Tibbe, A; Tol, J; Vos, AH | 1 |
| Baldi, GG; Cupini, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Salvatore, L; Stasi, I; Vasile, E | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A | 1 |
| Aygerinos, K; Baltatzis, G; Bamias, A; Beroukas, K; Boskos, CS; Dimopoulos, MA; Korkolis, D; Lamproglou, I; Liacos, C; Papasavvas, P; Stoupa, E; Terpos, E | 1 |
| Beal, K; Damast, S; Elkin, E; Fornier, MN; Ho, AY; Ishill, N; McCormick, B; Montgomery, L | 1 |
| Bartos, J; Czudek, S; Gruna, J; Kycina, R; Parvez, J; Skrovina, M; Soumarova, R; Wendrinski, A | 1 |
| Bergaglio, M; Ceribelli, A; De Placido, S; Del Prete, S; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Merola, G; Milella, M; Montella, L; Palmieri, G; Petillo, L | 1 |
| Amari, M; Ishida, T; Ohuchi, N; Takeda, M | 1 |
| Gohler, T; Hesse, T; Nusch, A; Siedentopf, F; Sulberg, H | 1 |
| Caponi, S; Falcone, A; Fornaro, L; Ginocchi, L; Loupakis, F; Masi, G; Vasile, E | 1 |
| Guarneri, V | 1 |
| Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA | 1 |
| Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Quinkler, M; Ritter, C; Wortmann, S | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Hemminki, A; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Lahtela, SL; Lehtiö, K; Leinonen, M; Lindman, H; Nilsson, G; Nuortio, L; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N | 1 |
| Brearley, S; Craven, O; Farrell, C; Luker, K; Molassiotis, A; Saunders, M; Swindell, R; Todd, C; Wardley, A | 1 |
| Adenis, A; Bennouna, J; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Llédo, G; Rebischung, C; Ychou, M | 1 |
| Schwartz, J | 1 |
| Castaneda, CA; Gómez, HL | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C | 1 |
| Brouste, V; Debled, M; Donamaria, C; Durand, M; Floquet, A; Madranges, N; Mauriac, L; Trainaud, A | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Chang, DK; Cho, YB; Chun, HK; Kang, WK; Kim, DS; Kim, HC; Kim, JY; Kim, ST; Kim, YH; Lee, J; Lee, WY; Lim, HY; Park, JO; Park, SH; Park, YS; Rhee, PL; Yun, H; Yun, SH | 1 |
| Hymes, SR; Paravar, T | 1 |
| Kang, YK; Ryu, MH | 1 |
| Straub, JO | 1 |
| Bruce, JN; Fine, RL; Freda, PU; Isaacson, SR; Lee, Y; Thearle, MS | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, C; Kim, TW; Lee, JL; Lim, HY; Park, YS; Ryoo, BY; Ryu, MH | 1 |
| Dohn, LH; Jensen, BV; Larsen, FO | 1 |
| Angus, E; Fincher, S; Garg, R | 1 |
| Camphausen, K; Hunter, K; Korde, LA; Lebowitz, PF; Lukes, L; Lusa, L; McShane, L; Parker, JS; Swain, SM; Zujewski, JA | 1 |
| Lee, C; Saunders, M | 1 |
| Uña, E | 1 |
| Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R | 1 |
| Goodin, S; Toppmeyer, DL | 1 |
| Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Kosuri, KV; Otterson, GA; Villalona-Calero, MA; Wang, L; Wu, X | 1 |
| An, X; Feng, F; He, YJ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH; Zhao, Y | 1 |
| Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM | 1 |
| Anderluh, F; Oblak, I; Ocvirk, J; Velenik, V | 1 |
| Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH | 1 |
| Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL | 1 |
| Kohles, J; Rugo, HS; Schulman, KL | 1 |
| Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yun, J | 1 |
| Georgoulias, V; Mauri, D; Mavroudis, D; Patsopoulos, NA; Polyzos, NP; Valachis, A | 1 |
| Alonso, V; Aparicio, J; Arias, F; Escudero, P; Estevan, R; Fernández-Martos, C; Gallen, M; Hernandez, A; Marcuello, E; Massuti, B; Maurel, J; Mengual, JL; Mira, M; Pericay, C; Polo, S; Safont, M; Saigi, E; Salud, A; Serra, J; Vera, R | 1 |
| Cummins, MM; Ganju, V; Gebski, V; Gibbs, D; Sourjina, T; Stockler, M; Strickland, A; Tebbutt, NC; Van Hazel, G; Zalcberg, J | 1 |
| Kopper, L; Tímár, J | 1 |
| Pikó, B | 1 |
| Anan, K; Masuda, N; Mitsuyama, S; Nishimura, R; Ohno, S; Takamatsu, Y; Tamura, K; Tanaka, M; Yamamoto, Y | 1 |
| Nakayama, T; Noguchi, S | 1 |
| Bhupalam, L; Kloecker, GH; Laber, DA; Miller, DM; Rabinowits, G | 1 |
| Ashley, S; Brown, G; Chau, I; Cunningham, D; Gillbanks, A; Karanjia, N; Mudan, SS; Norman, AR; Watkins, DJ | 1 |
| Clive, S; Dawson, LK; Fallon, MT; McLean, CM; Phillips, HA; Sakala, M; Storey, DJ; Wall, LR | 1 |
| Bae, SH; Chae, YS; Choi, GS; Jun, SH; Kang, BW; Kim, JG; Kim, NS; Moon, JH; Park, JH; Park, JY; Ryoo, HM; Sohn, SK | 1 |
| Chay, WY; Chew, L; Tan, MH; Yeoh, TT | 1 |
| Cheng, YC; Elligers, K; Grant, N; Jiang, ZL; Lamb, L; Lansigan, F; Liu, SH; Mezes, M; Ruta, S; Saif, MW | 1 |
| Crivellari, D; Lestuzzi, C; Meneguzzo, N; Rigo, F; Viel, E | 1 |
| Orphanos, GS; Picolos, MK; Stavrou, NG | 1 |
| Sun, W | 1 |
| Jung, KY; Kim, CW; Kim, JC; Kim, JH; Kim, TW; Lim, SB; Park, JS; Shin, US; Yoon, SN; Yu, CS | 1 |
| Barbachano, Y; Brown, G; Chau, I; Chua, YJ; Cunningham, D; Massey, A; Oates, JR; Tait, D; Tebbutt, NC; Wotherspoon, A | 1 |
| Arai, T; Hirai, H; Imagaki, K; Iwasawa, Y; Kobayashi, M; Kotani, H; Mizuarai, S; Nishibata, T; Ohtani, J; Okada, M; Sakai, N; Sakai, T; Yoshizumi, T | 1 |
| Genda, T; Hori, S; Miki, A; Nakajima, M; Satoh, H; Sawada, Y; Suehira, M | 1 |
| Buijsen, J; de Ruysscher, D; Janssen, MH; Lambin, P; Lammering, G; Ollers, MC; van den Bogaard, J; van Stiphout, RG | 1 |
| Stein, A | 1 |
| Andersen, RF; Brandslund, I; Garm Spindler, KL; Hansen, TF; Jakobsen, A; Lindebjerg, J | 1 |
| Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M | 1 |
| Chandrasekhar, R; Fakih, M; Gibbs, JF; Iyer, RV; Khushalani, NI; May, KS; McCloskey, SA; Thomas, CR; Wilding, GE; Yang, GY; Yendamuri, SS | 1 |
| Arnold, D; Dellas, K; Fietkau, R; Hinke, A; Hipp, M; Liersch, T; Rödel, C; Sauer, R; Weiss, C | 1 |
| Njiaju, UO; Truica, CI | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Jia, W; Li, J; Li, L; Sun, T; Tian, J; Yang, K; Yi, K; Zhang, P | 1 |
| Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD | 1 |
| Chao, TY; Chen, PJ; Cheng, AL; Epstein, RJ; Hsiao, LT; Hsu, C; Hsu, CH; Lin, ZZ; Toh, HC; Yang, TS | 1 |
| Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA | 1 |
| Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E | 1 |
| Chiuri, V; Ciccarese, M; Cinieri, S; Colucci, G; Gasparini, G; Giampaglia, M; Lorusso, V; Manca, C; Silvestris, N; Tinelli, A | 1 |
| Ferraz, MB; Puga, ME; Riera, R; Soárez, PC | 1 |
| Clivio, A; Cozzi, L; Fogliata, A; Nicolini, G; Pesce, G; Richetti, A; Salati, E; Vanetti, E | 1 |
| Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Glynne-Jones, R; Harrison, M; Mawdsley, S | 1 |
| Jørgensen, JT | 1 |
| Macková, D | 1 |
| Azria, D; Bécouarn, Y; Berdah, JF; Bouché, O; Conroy, T; de La Roche, G; Denis, B; Dupuis, O; Etienne, PL; François, E; Gérard, JP; Gourgou-Bourgade, S; Hennequin, C; Lledo, G; Mahé, MA; Martel-Laffay, I; Mineur, L; Mirabel, X; Montoto-Grillot, C; Vendrely, V | 1 |
| Ashley, S; Cunningham, D; Okines, AF | 1 |
| Glynne-Jones, R | 1 |
| Hashmi, AH; Tunio, MA | 1 |
| Barton, J; Burris, HA; Farley, C; Greco, FA; Hainsworth, JD; Macias-Perez, IM; Shipley, D; Spigel, DR | 1 |
| Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA | 1 |
| Ferrari, G; Gemignani, F; Macaluso, C | 1 |
| Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Meirovitz, A; Sonnenblick, A | 1 |
| Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C | 1 |
| Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J | 1 |
| Fraga, G; Gadzia, J; Latif, S | 1 |
| Aneiros-Cachaza, J; Aneiros-Fernandez, J; Arias-Santiago, S; Escobar Gómez-Villalva, F; Husein-ElAhmed, H; Nicolae, A; O'Valle Ravassa, F | 1 |
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
| Abildgaard, J; Daugaard, G; Møller, AK; Pedersen, KD; Petersen, BL | 1 |
| Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW | 1 |
| Naughton, M | 1 |
| Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Messersmith, WA; Murphy, KM; Nallapareddy, S; Norris-Kirby, A; Rudek, MA; Weekes, CD | 1 |
| Bauerfeind, I; Blohmer, JU; Dan Costa, S; du Bois, A; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kühn, T; Loibl, S; Mehta, K; Rezai, M; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 2 |
| Barbieri, V; Colosimo, F; Di Mizio, G; Di Nunzio, C; Gallelli, L; Loiacono, D; Rende, P; Ricci, P | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
| Gralow, J; Martin, M; Zielinski, C | 1 |
| He, BF; Jia, YZ; Liao, H; Min, N; Zhang, LS | 1 |
| Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG | 1 |
| Chan, AK; Jenken, DA; Wong, AO | 1 |
| Aogi, K; Barrios, CH; Brickman, MJ; Ferrero, JM; Harbeck, N; Iwata, H; Kern, KA; Lee, SC; Liu, MC; Lugo-Quintana, R; Martin, M; Pivot, X; Tabei, T; Vanlemmens, L; Zhang, K | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Burris, HA; Clark, BL; Farley, C; Gray, JR; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Abadie-Lacourtoisie, S; Brain, E; Esterni, B; Fargeot, P; Geneve, J; Joly, F; Laguerre, B; Luporsi, E; Retornaz, F; Rousseau, F; Servent, V | 1 |
| Chen, XQ; Li, FH; Li, YH; Luo, HY; Qiu, MZ; Wang, F; Xu, RH; Zhou, ZW | 1 |
| Grossgoupil, M; Ravaud, A | 1 |
| Mehta, SP | 1 |
| Bakker, B; Boot, H; Cats, A; Dikken, JL; Hartgrink, HH; Jansen, EP; Kranenbarg, EM; Peeters, KC; Putter, H; van de Velde, CJ; Verheij, M | 1 |
| Archer, L; Berry, D; Gralow, J; Grenier, D; Hudis, C; Kastrissios, H; Kornblith, AB; Muss, H; Partridge, AH; Perez, E; Wang, X; Winer, E; Wolff, AC | 1 |
| Boehm, KA; Cartwright, T; McCollum, D | 1 |
| Best, JH; Garrison, LP | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H | 1 |
| Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE | 1 |
| Uña Cidón, E | 1 |
| Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM | 1 |
| Caprino, P; Caravatta, L; Cellini, N; Deodato, F; Di Lullo, L; Giglio, G; Ingrosso, M; Ippolito, E; Macchia, G; Massaccesi, M; Mattiucci, GC; Mignogna, S; Morganti, AG; Picardi, V; Sofo, L; Tambaro, R; Valentini, V | 1 |
| Alexander, R; David, V; Garofalo, M; Hanna, N; Jabbour, S; Pandya, N; Poppe, M; Regine, WF; Yovino, S | 1 |
| Fang, F; Li, DC; Lu, GC | 1 |
| Eidtmann, H; Fehm, T; Hilfrich, J; Holms, F; Huober, J; Komor, M; Loibl, S; Müller, V; Pantel, K; Rau, T; Riethdorf, S; Roller, M; Schrader, I; Tesch, H; Untch, M; von Minckwitz, G; Zhang, L | 1 |
| Angelini, PD; Arribas, J; Aura, C; Baselga, J; Cameron, D; Chandarlapaty, S; Ellis, C; Gagnon, R; Geyer, C; Gomez, H; Guzman, M; Jimenez, J; Koehler, M; Parra, JL; Prudkin, L; Rosen, N; Sánchez, G; Scaltriti, M | 1 |
| Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y | 1 |
| Angeli, A; Badalamenti, G; Berruti, A; Daffara, F; De Francia, S; Del Buono, S; Dogliotti, L; Ferrero, A; Intrivici, C; Kalomirakis, E; Papotti, M; Priola, A; Ratti, R; Santini, D; Sperone, P; Terzolo, M; Vincenzi, B; Volante, M; Zaggia, B | 1 |
| Kawaguchisakita, N; Kohno, Y; Tsubota, Y; Tsuyuki, S; Ukikusa, M | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T | 1 |
| Adams, J; Blaszkowsky, LS; DeLaney, TF; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Mamon, HJ; Mino-Kenudson, M; Ryan, DP; Winrich, B; Yeap, B | 1 |
| Block, S | 1 |
| Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy | 1 |
| Feng, M; Qiu, F; Xiang, XJ; Xiong, JP; Yu, F; Zhan, ZY; Zhang, L | 1 |
| Bolaños, M; Bosch, C; Castro-Carpeño, J; Escudero, P; Feliu, J; García-Girón, C; Gil, M; González-Barón, M; Llombart, A; López, R; Losa, F; Madroñal, C; Safont, MJ; Salud, A | 1 |
| Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L | 1 |
| Andersen, M; Jensen, HA; Pfeiffer, P; Schønnemann, KR; Vestermark, LW; Yilmaz, M | 1 |
| Emiliani, A; Losanno, T; Manna, G; Seminara, P | 1 |
| Arnold, D; Bruch, HP; Kirchner, T; Kubicka, S; Reinacher-Schick, A; Ridwelski, K; Schmoll, HJ; Trarbach, T | 1 |
| Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE | 1 |
| Chefrour, M; Ciccolini, J; Ferri-Dessens, RM; Fischel, JL; Formento, P; Francoual, M; Giacometti, S; Marouani, H; Mercier, C; Milano, G; Renée, N | 1 |
| Lin, C; Rughani, AI; Tranmer, BI; Wilson, JT | 1 |
| Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R | 1 |
| Brauchli, P; Dedes, KJ; Matter-Walstra, KW; Pestalozzi, BC; Schwenkglenks, M; Szucs, TD | 1 |
| Hicks, RJ; Hubble, D; Johnson, V; Kong, G; Michael, M; Ramdave, S | 1 |
| Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P | 1 |
| Chan, VF; Chung, HC; Fein, LE; Gomez, HL; Hortobagyi, GN; Hurtado de Mendoza, F; Jassem, J; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Vahdat, LT; Xu, B | 1 |
| Cantor, A; Fathallah-Shaykh, HM; Fiveash, J; Grunda, JM; Johnson, MR; Nabors, LB; Palmer, CA | 1 |
| Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
| Boku, N; Doi, T; Hamamoto, Y; Kato, K; Koizumi, W; Komatsu, Y; Mizunuma, N; Muro, K; Sato, A; Takiuchi, H; Yamaguchi, K | 2 |
| Eriksson, B | 1 |
| Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M | 1 |
| Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J | 1 |
| Andreesen, R; Berand, A; Reichle, A; Rogenhofer, S; Vogelhuber, M; Walter, B; Wieland, WF | 1 |
| Fan, Y; Wang, J; Xu, B | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Czejka, M; Farkouh, A; Gruenberger, B; Scheithauer, W; Schueller, J | 1 |
| Archer, C; Beadman, C; Cunningham, D; Gilligan, D; Kurek, R; Oates, J; Rao, S; Ruhstaller, T; Starling, N; Sumpter, K; Valladares-Ayerbes, M; Wilke, H | 1 |
| Hudis, C; Norton, L; Traina, T | 1 |
| Cristofanilli, M | 1 |
| Buchholz, TA; Debeb, BG; Woodward, WA; Xu, W | 1 |
| Balboa, E; Barros, F; Carracedo, A; Celeiro-Muñoz, C; Duran, G; Gomez-Caamaño, A; Lamas, MJ; Lopez, R | 1 |
| Kelly, RJ; Sharon, E; Szabo, E | 1 |
| Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D | 1 |
| Dugan, U; Higgins, B; Hudis, CA; Kolinsky, K; Norton, L; Theodoulou, M; Traina, TA | 1 |
| Goldberg, RM | 1 |
| Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L | 1 |
| Bérard, M; Demarchi, M; Kantelip, JP; Montange, D; Muret, P; Piédoux, S; Royer, B | 1 |
| Pavlakis, N; Stewart, T; Ward, M | 1 |
| Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B | 1 |
| Blobe, GC; Dugan, E; Favaro, J; Fernando, NH; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Petros, WP; Truax, R | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J; Punt, CJ; van der Straaten, T | 1 |
| Alberola Candel, V; Cerezuela Fuentes, P; Gasent Blesa, JM; Giner Marco, V; Giner-Bosch, V | 1 |
| Pownall, M | 1 |
| Aggarwal, S; Goel, G; Jauhri, M; Negi, A | 1 |
| Bozzarelli, S; Carnaghi, C; Colombo, P; De Vincenzo, F; Giorgetti, PL; Rimassa, L; Santoro, A; Sclafani, F | 1 |
| Braun, M; Jaehde, U; Ko, YD; Kuhn, W; Mey, UJ; Ringsdorf, S; Schmidt-Wolf, I; Schwindt, PF; Simons, S | 1 |
| Allali, M; Bergmann, U; Kummer, G; Riebeling, J; Schultheis, B; Sendler, A; Sendler, U; Strumberg, D; Tannapfel, A | 1 |
| Czejka, M; Farkouh, A; Scheithauer, W; Schueller, J | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Choi, H; Choi, IB; Han, CW; Jang, JW; Ji, JS; Kang, YN; Kay, CS; Kim, BW; Kim, JY; Lee, BI | 1 |
| Chloropoulou, PA; Giatromanolaki, A; Kouklakis, G; Koukourakis, MI; Lyratzopoulos, N; Manolas, K; Pitiakoudis, M; Sivridis, E; Tsoutsou, P | 1 |
| Foster, J; Lee, J; Urba, S; Worden, F; Zhang, J | 1 |
| Altman, RB; Carrillo, MW; Klein, TE; Marsh, S; McLeod, HL; Thorn, CF | 1 |
| Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z | 1 |
| Chang, HJ; Choi, HS; Hong, YS; Jeong, JY; Jeong, SY; Jung, KH; Kim, DH; Kim, DY; Lim, SB; Park, JG; Sohn, DK | 1 |
| Blackman, G; Bridgewater, J; Collis, C; Gillmore, R; Goodchild, K; Laurence, V; Meyer, T; Raouf, S; Tobias, J | 1 |
| Montazeri, A; Ramani, VS; Sun Myint, A; Wong, H | 1 |
| Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH | 1 |
| Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N | 1 |
| Cameron, JL; Herman, JM; Horowitz, DP; Hsu, CC; Makary, MA; Pawlik, TM; Robinson, R; Schulick, RD; Wang, J; Winter, JM | 1 |
| Eickhoff, JC; Holen, KD; Jumonville, A; Loconte, NK; Lubner, SJ; Mulkerin, DL; Schelman, W; Seo, S; Thomas, JP | 1 |
| Eberhardt, S; Fekrazad, MH; Jones, DV; Lee, FC | 1 |
| Berglund, A; Brünner, N; Christensen, IJ; Frederiksen, C; Glimelius, B; Jensen, BV; Keldsen, N; Nielsen, HJ; Nielsen, SE; Pfeiffer, P; Qvortrup, C | 1 |
| Dai, Y; Shao, ZY; Yu, JM; Zhang, JD | 1 |
| Chitapanarux, I; Hsieh, CY; Kamnerdsupaphon, P; Lertsanguansinchai, P; Lorvidhaya, V; Phromratanapongse, P; Sukthomya, V; Tharavichitkul, E | 1 |
| Chauvin, F; Guastalla, JP; Jacquin, JP; Nourissat, A; Poirson, J; Regnier Denois, V | 1 |
| Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA | 1 |
| Anton, A; Bermejo, B; Casado, A; Gayo, J; Lao, J; Lluch, A; Martin, M; Muñoz, M; Paules, AB; Provencio, M | 1 |
| Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK | 1 |
| Foley, EF; Friel, CM; Koc, M; Moskaluk, CA; Rich, TA; Romney, DA; Unger, KR | 1 |
| Clive, S; Michie, CO; Rivans, I; Sakala, M; Strachan, MW | 1 |
| Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z | 1 |
| Boender, PJ; de Wijn, R; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Johansen, M; Nesland, JM; Ree, AH; Ruijtenbeek, R | 1 |
| Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T | 1 |
| Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Tham, CK; Toh, HC; Wang, ML | 1 |
| Ashley, SE; Chau, I; Chua, YJ; Cunningham, D; Oates, J; Okines, AF; Saffery, C; Turner, A; Webb, J | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 2 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Isufi, I; Kaley, K; Saif, MW; Syrigos, K | 1 |
| Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Ahn, MJ; Do, IG; Ko, YH; Park, K; Park, YH; Won, YW | 1 |
| Belau, A; Darb-Esfahani, S; Denkert, C; Hauschild, M; Högel, B; Huober, J; Khandan, F; Loibl, S; Mehta, K; Tesch, H; Thomssen, C; von Minckwitz, G; Weiss, E; Zahm, DM | 1 |
| Ahn, JS; Ahn, YC; Cho, EY; Im, YH; Kim, K; Kim, KH; Lee, S; Park, K; Park, YH; Shim, YM | 1 |
| Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT | 1 |
| Amant, F; Christiaens, MR; Debrock, G; Neven, P; Paridaens, R; Renard, V; Smeets, A; Squifflet, P; Van Eenoo, L; van Limbergen, E; Weltens, C; Wildiers, H; Wynendaele, W | 1 |
| Borowicz, H; Glados, M; Heilmann, V; Hinke, A; Jackisch, C; Lehnert, A; Möbus, V; Müller, V; Schmidt, M; Thomssen, C | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Marshall, JL; Mikhail, SE; Sun, JF | 1 |
| Xu, JM | 1 |
| Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A | 1 |
| de Jongh, FE; Eskens, FA; Konings, IR; Sleijfer, S; van der Gaast, A; van der Wijk, LJ | 1 |
| Aprile, G; Bang, YJ; Chung, HC; Feyereislova, A; Hill, J; Kang, YK; Kulikov, E; Lehle, M; Lordick, F; Ohtsu, A; Omuro, Y; Rüschoff, J; Satoh, T; Sawaki, A; Shen, L; Van Cutsem, E | 1 |
| Matouskova, E; Mladkova, J; Sanda, M; Selicharova, I | 1 |
| Bergin, P; Damianovich, D; Findlay, M; Hanning, F; Hill, A; McKeage, MJ; Thompson, P | 1 |
| Flatmark, K; Ree, AH | 1 |
| Glynne-Jones, R; Sebag-Montefiore, D | 1 |
| Cameron, D; Casey, M; Geyer, CE; Imwalle, B; Newstat, B; Oliva, C | 1 |
| Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W | 1 |
| Arbea, L; Aristu, J; Díaz-González, JA; Hernandez-Lizoain, JL; Martínez-Monge, R; Moreno, M; Sola, J; Subtil, JC | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J | 1 |
| Matsuoka, M; Mishima, H; Muro, K; Oba, K; Oriuchi, N; Sakamoto, J; Satoh, T | 1 |
| Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR | 1 |
| Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF | 1 |
| Hu, W; Li, L; Sheng, Y; Shi, J; Su, D; Wang, CK | 1 |
| Chang, HM; Choi, YH; Kang, BW; Kang, YK; Kim, C; Kim, TW; Lee, JL; Ryu, MH | 1 |
| Bernal, P; Byrd, J; Malik, I | 1 |
| Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H | 1 |
| Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Eipeldauer, S; Gruenberger, B; Gruenberger, T; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D | 1 |
| Hasan, M; Hashmi, A; Mohsin, R; Mubarak, M; Qayyum, A; Rafi, M; Sattar, A; Tunio, MA | 1 |
| Andretta, V; Bennicelli, E; Bordignon, C; Caprioni, F; Comandini, D; Fornarini, G; Guglielmi, A; Lambiase, A; Mammoliti, S; Mazzola, G; Pessino, A; Sciallero, S; Sobrero, AF | 1 |
| Cannistra, SA; Disis, ML; Verweij, J | 1 |
| Albanell, J; Berk, L; Capri, G; Cerny, T; Corradino, I; Cresta, S; Gianni, L; Haluska, F; Hess, D; Locatelli, A; Marsoni, S; Maur, M; Perotti, A; Rivera, VM; Rojo, F; Sessa, C; Viganò, L | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Benner, RJ; Benson, AB; Berlin, JD; Denis, LJ; Goff, LW; LoRusso, PM; Rothenberg, ML; Tan, AR; Yin, D | 1 |
| Khattak, A; Price, TJ; Townsend, AR | 1 |
| Bai, CM; Guan, M; Zhang, L; Zhao, L | 1 |
| Ai, B; Ding, L; Li, L; Wu, JY; Wu, XN; Zhao, YB; Zhou, MZ | 1 |
| Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G | 1 |
| Baas, J; Bloemendal, HJ; Boven, E; de Graaf, H; Hop, WC; Kroep, JR; Linn, SC; Mandjes, IA; Nortier, JW; Schröder, CP; Smit, WM; van den Bosch, J; Vermeulen, GJ | 1 |
| Midgley, RS; Yanagisawa, Y | 1 |
| Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
| Aneiros-Fernandez, J; Arias-Santiago, S; Husein-ElAhmed, H; Naranjo-Sintes, R | 1 |
| Egerton, N | 1 |
| Chung, HC; Jeung, HC | 1 |
| Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N | 1 |
| Chang, HJ; Choi, HS; Hong, YS; Im, SA; Jeong, SY; Jung, KH; Kim, DY; Kim, JH; Kim, SY; Kim, TW; Lee, KS; Lim, SB; Yun, T | 1 |
| Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM | 1 |
| Anderluh, F; Oblak, I; Velenik, V | 1 |
| Fornier, M | 1 |
| Cartwright, T; Chu, E; McKenna, EF; Schulman, KL | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Jeong, JH; Jung, SY; Kang, HS; Kim, EA; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Aarntzen, EA; Adema, GJ; de Boer, A; de Vries, IJ; Figdor, CG; Lesterhuis, WJ; Preijers, FW; Punt, CJ; Scharenborg, NM; van de Rakt, M; van Spronsen, DJ | 1 |
| Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Bang, YJ; Cha, Y; Ham, HS; Han, SW; Im, SA; Im, YH; Kim, HP; Kim, TY; Lee, KS; Oh, DY; Park, IH; Park, JW; Rhee, J; Ro, J | 1 |
| Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H | 1 |
| Bohn, B; Erben, P; Hanfstein, B; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Popa, J; Post, S; Ströbel, P; Wenz, F | 1 |
| Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B | 1 |
| Bell, D; Black, G; Ferrucci, LM; Heimburger, DC; McCorkle, R; Saif, MW; Thornton, J | 1 |
| Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M | 1 |
| Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH | 1 |
| Blum, JL; Glück, S; Hu, S; Kaye, JA; Kohles, J; McKenna, E; Odom, D; Scotto, N | 1 |
| Arra, C; Avallone, A; Bruzzese, F; Budillon, A; Chianese, MI; de Ruggiero, I; Di Cintio, A; Di Gennaro, E; Franco, R; Luciano, A; Moccia, T; Piro, G | 1 |
| Eastwood, A; Norman, G; Peura, P; Rice, S; Sculpher, M; Soares, M; Suh, D; Wright, K | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J; Punt, CJA; van der Straaten, T; Wessels, JAM | 1 |
| Arjona-Sánchez, A; Cruz, A; Muñoz, Mdel C; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, J; Túnez, I; Vázquez, R | 1 |
| Brayshaw, PA; Claringbold, PG; Price, RA; Turner, JH | 1 |
| Boban, M; Hrabar, A; Omrčen, T; Vrdoljak, E | 1 |
| Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL | 1 |
| Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S | 1 |
| Imholz, AL; Knijn, N; Koopman, M; Mol, L; Punt, CJ; Teerenstra, S; Tol, J; Valster, FA; Vincent, AD; Werter, MJ | 1 |
| Akerman, M; Assaraf, YG; Bram, EE; Mandel-Gutfreund, Y; Stark, M | 1 |
| Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Güzel, E; Sentürk, S | 1 |
| Giaccone, G; Rajan, A | 1 |
| Gossage, JA; Hale, PC; Mamidanna, R; Manifold, DK; Newman, G; Pantling, AZ; Robinson, A | 1 |
| Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Bories, E; de Chaisemartin, C; Delpero, JR; Esterni, B; Farnault, B; Giovannini, M; Lelong, B; Monges, G; Moureau-Zabotto, L; Salem, N; Turrini, O; Viens, P; Viret, F | 1 |
| Fujita, T | 1 |
| Dong, CM; Kang, MF; Liu, Y; Luo, MQ | 1 |
| Blasiak, J; Bloch, K; Chojnacki, J; Drzewoski, J; Kaczmarczyk, D; Kasznicki, J; Krupa, R; Morawiec-Sztandera, A; Sliwinski, T; Wisniewska-Jarosinska, M | 1 |
| Cennamo, V; Fuccio, L | 1 |
| Chen, G; Lu, SX; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Chay, WY; Choo, SP; Gao, F; Koo, WH; Lo, YL; Ng, HC; Ong, SY; Tan, SH | 1 |
| Jang, JS; Kim, HJ; Kim, KH; Kim, MC; Kim, SH; Kwon, HC; Kwon, KA; Lee, HS; Lee, S; Oh, SY | 1 |
| Guan, ZZ; Guo, GF; Wan, DS; Wu, PH; Xia, JC; Xia, LP; Zeng, YX; Zhang, B | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Dowell, JE; Martin, R; Shah, SR; Ussery, SM | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Han, SS; Hong, EK; Kim, DY; Kim, SH; Kim, TH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM; Yoo, T | 1 |
| Bouché, O; Penault-Llorca, F | 1 |
| Boot, H; Cats, A; Deenen, MJ; Schellens, JH; Terpstra, WE | 1 |
| Aftimos, P; Chahine, G; Farhat, FS; Ghosn, M; Haddad, N; Hanna, C; Kattan, JG; Nasr, F | 1 |
| Alvarez, S; Barrueco, N; Cortejoso, L; García, MI; García-Alfonso, P; Gonzalez-Haba, E; Jiménez, JL; López-Fernández, LA; López-Lillo, C; Martín, ML; Muñóz-Fernández, MA; Sanjurjo, M | 1 |
| Hassan, M; Osman, MM | 1 |
| Guillén-Ponce, C; Molina-Garrido, MJ | 1 |
| Inoue, H; Murakami, M; Nishizaki, T; Shimabukuro, R; Shiraishi, T; Takahashi, I; Yano, H | 1 |
| Hao, XS; Hou, Y; Li, LF; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Xie, CH; Zhang, HL; Zhou, SY | 1 |
| Chiu, YF; Ko, JC; Kuo, YH; Lin, YW; Su, YC; Tsai, MS; Weng, SH | 1 |
| Arkenau, HK | 1 |
| Ahn, JS; Cho, EY; Choi, YL; Im, YH; Kim, ST; Lee, SJ; Park, YH | 1 |
| Jonasch, E; Lim, ZD; Ng, C; Richey, SL; Tannir, NM | 1 |
| Arjona, A; Montilla, P; Muntané, J; Padillo, J; Perea, D; Ruiz-Rabelo, J; Túnez, I; Vázquez, R | 1 |
| Cone, MM; Diggs, BS; Herzig, DO; Lu, KC; Oommen, SC; Rea, JD | 1 |
| Bachelot, T; Biron, P; Blay, JY; Favier, B; Galy, G; Guastalla, JP; Labidi-Galy, SI; Latour, JF; Perol, D; Ray-Coquard, I; Tredan, O | 1 |
| Bauer, J; Boehm, S; Droege, C; Gallerani, E; Herrmann, R; Hess, D; Jeckelmann, S; Marsoni, S; Miani, M; Sessa, C; Sperka, S | 1 |
| Czejka, M; Ettlinger, D; Farkouh, A; Georgopoulos, A; Scheithauer, W; Schueller, J | 1 |
| Borojevic, N; Gavrilovic, D; Kecmanovic, D; Kezic, I; Krivokapic, Z; Micev, M; Nikolic, V; Popov, I; Radosevic-Jelic, L; Stojanovic, S | 1 |
| Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Baumann, I; Darb-Esfahani, S; Denkert, C; Grasshoff, ST; Heinrich, G; Hoffmann, G; Kronenwett, R; Loibl, S; Müller, BM; Noske, A; Roller, M; Steffen, J; Ulmer, HU; von Minckwitz, G; von Toerne, C; Wirtz, R | 1 |
| Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N | 1 |
| Adams, RB; Bauer, TW; de Lange, EE; Nolan, NJ; Rich, TA; Stelow, EB; Stokes, JB; Walters, DM; Weiss, GR | 1 |
| Alfonso, R; Corona, J; Custodio, A; de las Heras, M; Dıaz-Rubio, E; Ortega, L; Puente, J; Rodriguez, L; Sanchez, JC; Sastre, J | 1 |
| Zhang, SZ | 1 |
| Chen, D; Chen, DS; Cobleigh, MA; Harris, AL; Hillan, KJ; Jubb, AM; Koeppen, H; Langmuir, VK; Miller, KD; Reimann, JD; Rugo, HS; Schmidt, M | 1 |
| Kamimura, K; Kojima, K; Mizutani, M; Shioiri, M; Watanabe, Y; Yamamoto, S | 1 |
| Ng, S; O'bichere, A; Platell, C; Tebbutt, N | 1 |
| Berti, P; Daniele, S; Frezza, AM; Picardi, A; Tonini, G; Vespasiani, U; Vincenzi, B | 1 |
| Black, JM; Boh, EE; Farris, PK; Hodari, KT; Lewis, AT; Rogers, N | 1 |
| Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J | 1 |
| Czaykowski, P; Gordon, VL; Harding, GA | 1 |
| Cats, A; Gerhards, MF; Heuff, G; Marijnen, CA; Swellengrebel, HA; van Geloven, AA; van Tets, WF; Verheij, M; Verwaal, VJ; Vincent, A | 1 |
| He, S; Hong, L; Niu, D; Niu, L; Shen, J | 1 |
| Caparro, M; Giantonio, B; Haller, DG; Mykulowycz, K; O'Dwyer, PJ; Olthoff, K; Reddy, R; Rosen, M; Shaked, A; Sohal, D; Soulen, MC; Sun, W; Teitelbaum, UR | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Devries, AF; Eisterer, W; Fastner, G; Gnant, M; Greil, R; Jäger, R; Kapp, KS; Keil, F; Offner, F; Ofner, D; Rabl, H; Schaberl-Moser, R; Thaler, J; Tschmelitsch, J; Zitt, M | 1 |
| Elghissassi, I; Errihani, H; Inrhaoun, H; Ismaili, N; M'rabti, H | 1 |
| Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS | 1 |
| Advani, PP; Fakih, MG | 1 |
| Boban, M; Boskovic, L; Fridl-Vidas, V; Hrepic, D; Omrcen, T; Vrdoljak, E | 1 |
| Barbachano, Y; Brown, G; Chau, I; Chua, YJ; Compton, S; Cunningham, D; Hickish, T; Khan, A; Mudan, S; Saffery, C; Strimpakos, AS; Thomas, J; Valle, J; Wong, R; Wotherspoon, A | 1 |
| Belli, C; Cereda, S; Reni, M; Villa, E | 1 |
| Guan, X; Guo, J; He, Z; Li, F; Mao, W; Tucker, S; Wang, J; Wu, S | 1 |
| Chang, HJ; Choi, HS; Kim, DY; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Archer, L; Bennett, S; Casey, R; Cohen, HJ; Hudis, C; Kimmick, G; Kornblith, AB; Lan, L; Muss, HB; Partridge, A; Winer, E | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K | 1 |
| Patel, PA | 1 |
| Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K | 1 |
| Cassidy, J; Lindsay, CR | 1 |
| Rather, A; Shah, A; Shah, NR | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J | 1 |
| Kim, JC; Kim, JH; Kim, TW; Park, JH; Yoon, SM; Yu, CS | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C | 1 |
| Kim, CW; Kim, JC; Kim, JH; Kim, TW; Lim, SB; Shin, US; Yoon, SN; Yoon, YS; Yu, CS | 1 |
| Bakers, FC; Barbaro, B; Beets, GL; Beets-Tan, RG; Haustermans, K; Lambrecht, M; Lambregts, DM; Maas, M; Valentini, V; Vandecaveye, V | 1 |
| Atkinson, BJ; Byfield, SD; Feng, C; Jonasch, E; Lal, LS; Miller, LA; Pagliaro, LC; Tannir, NM | 1 |
| Paglino, C; Porta, C | 1 |
| Beach, DF; Somer, R | 1 |
| Bennouna, J; Conroy, T; Dominguez, S; Douillard, JY; Ducreux, M; Faroux, R; Florentin, V; Hebbar, M; Lledo, G; Perrocheau, G; Ychou, M | 1 |
| Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I | 1 |
| Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L | 1 |
| Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC | 1 |
| de Braud, F; Gilberg, F; Haller, DG; Hill, M; Maroun, J; Price, T; Rittweger, K; Schmoll, HJ; Tabernero, J; Van Cutsem, E | 1 |
| Dai, Y; Li, L; Shao, ZY; Sun, DS; Yu, JM; Zhang, JD | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Davies, JM; Farrugia, D; Hayward, N; Kirichek, O; Medley, L; Morel, AN; Reed, N; Talbot, DC; Thakker, RV | 1 |
| Gambier, N; Gillet, P; Javot, L; Petitpain, N; Scala-Bertola, J; Spaëth, D | 1 |
| Feigin, K; Gajria, D; Geneus, S; Hudis, CA; Norton, L; Patil, S; Tan, LK; Theodoulou, M; Traina, TA | 1 |
| Boc, M; Hlebanja, Z; Ocvirk, J; Reberšek, M; Skof, E | 1 |
| Boot, H; de Hingh, IH; Klaver, YL; Verwaal, VJ | 1 |
| Ezaki, T; Iguchi, T; Kono, M; Maeda, T; Matsukuma, A; Mori, E; Nozoe, T | 1 |
| Arima, N; Shigaki, N; Sugita, H; Suzuki, S; Yamashita, H; Yokoyama, S | 2 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Abenhardt, W; Brudler, O; Brugger, W; diGioia, D; Freier, W; Gitsch, G; Heinemann, V; Hurtz, HJ; Jonat, W; Kettner, E; Rösel, S; Stemmler, HJ; Tesch, H; Tessen, HW | 1 |
| Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J | 1 |
| Backshall, A; Clarke, SJ; Keun, HC; Sharma, R | 1 |
| Cassidy, J; Cunningham, D; Gilberg, F; Hoff, P; Kang, Y; Saini, JP; Saltz, L; Twelves, C; Van Cutsem, E | 1 |
| Gilbar, P; Sorour, N | 1 |
| Ashley, S; Dolly, S; Johnston, S; Kotsori, AA; Parton, M; Shaunak, N; Sheri, A; Smith, IE; Walsh, G | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Alfa-Wali, M; Allen-Mersh, T; Antoniou, A; Bower, M; Gazzard, B; Nelson, M; Newsom-Davis, T; Tait, D | 1 |
| Conn, CE; Danon, SJ; Drummond, CJ; Gong, X; Moghaddam, MJ; Sagnella, SM; Waddington, LJ | 2 |
| Alexander, HR; Camphausen, K; Citrin, D; Denobile, J; Libutti, SK; Pingpank, JF; Quezado, M; Royal, RE; Seidel, G; Shuttack, Y; Steinberg, SM; Wood, BJ | 1 |
| Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S | 1 |
| Arriví, A; Guasch, I; Losa, F; Moreno, I; Nogué, M; Pericay, C; Ponce, J; Roca, JM; Ruiz, A; Safont, MJ; Salud, A; Vicente, P | 1 |
| Bruno, R; Claret, L; Frances, N; Iliadis, A | 1 |
| Friedlander, ML; Goldstein, D; Kiernan, MC; Krishnan, AV; Lin, CS; Park, SB | 1 |
| Bouma, G; Imholz, AL | 1 |
| Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C | 1 |
| Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A | 1 |
| Bertucci, F; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Jacquemier, J; Madroszyk, A; Tarpin, C; Viens, P | 1 |
| Morita, S | 1 |
| Crucitti, P; Falcone, A; Frezza, AM; Galluzzo, S; Graziano, F; Loupakis, F; Muda, AO; Perrone, G; Rabitti, C; Rizzo, S; Russo, A; Ruzzo, AM; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| De Bruijn, MT; Hinrichs, J; Kranenburg, O; Punt, CJ; Raats, DA; Rinkes, IH; Teerenstra, S; Tol, J | 1 |
| Hermanek, P; Junginger, T; Maurer, C; Merkel, S; Ptok, H; Ruppert, R; Strassburg, J | 1 |
| Barni, S; Cabiddu, M; Petrelli, F | 1 |
| Arakawa, A; Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Orihata, G; Ozawa, S; Saito, M; Sasai, K | 1 |
| Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
| Anne, PR; Berger, AC; Chervoneva, I; Kennedy, EP; Mitchell, EP; Rosato, EL; Showalter, TN; Yeo, CJ; Zhan, T | 1 |
| Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Kim, CW; Kim, JC; Kim, KH; Lim, SB; Yang, SS; Yoon, SN; Yoon, YS; Yu, CS | 1 |
| Beeram, M; Patnaik, A; Saif, MW; Sarantopoulos, J; Takimoto, C; Tolcher, AW | 1 |
| Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP | 1 |
| Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C | 1 |
| Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T | 1 |
| Fukui, E; Kawahara, K; Sakurai, M; Ueda, R; Yamada, R | 1 |
| Brewster, AE; Langley, RE; Maughan, TS; Middleton, G; O'Mahony, MS; Parmar, M; Seymour, MT; Shepherd, SF; Thompson, LC; Wasan, HS | 1 |
| Adua, D; Basile, ML; De Sanctis, R; Del Signore, E; Di Seri, M; Gori, B; Grassi, P; Longo, F; Quadrini, S; Stumbo, L | 1 |
| Chen, YB; Feng, XY; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ; Zhou, ZW | 1 |
| Chen, DY; Qi, Q; Zhao, WY | 1 |
| Borštnar, S; Cwiertka, K; Das Gupta, A; Greil, R; Koza, I; Linn, M; Marcou, Y; Petráková, K; Pikiel, J; Steger, GG; Wojtukiewicz, MZ | 1 |
| Alvarez, RH; Hortobagyi, GN; Valero, V | 1 |
| Gao, J; Li, YY; Lu, M; Shen, L; Yu, JW | 1 |
| Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L | 1 |
| Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C | 1 |
| Bell, JA; Conte, P; Corey-Lisle, PK; Hortobagyi, G; Mukhopadhyay, P; Orsini, L; Peck, R; Revicki, DA; Roche, H; Safikhani, S | 1 |
| Schmoll, HJ | 1 |
| Chang, HJ; Kim, BC; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J | 1 |
| Baghel, NS; Basu, S | 1 |
| Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D | 1 |
| Arkenau, HT; Baraniskin, A; Graeven, U; Meier, D; Munding, J; Porschen, R; Reinacher-Schick, A; Schmiegel, W; Schulmann, K; Tannapfel, A | 1 |
| Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K | 1 |
| Girard, P; Paule, I; Tod, M | 1 |
| Boc, M; Ocvirk, J; Rebersek, M | 1 |
| Damante, G; Di Loreto, C; Pandolfi, M; Puglisi, F; Puppin, C | 1 |
| Donders, AR; Oostendorp, LJ; Ottevanger, PB; Stalmeier, PF; van der Graaf, WT | 1 |
| Chefrour, M; Ciccolini, J; Denden, A; Fischel, JL; Formento, P; Giacometti, S; Iliadis, A; Milano, G; Renée, N | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA | 1 |
| Buzdar, AU; Cheporov, S; Digumarti, R; Goedhals, L; Gotovkin, E; Hoersch, S; Hu, X; Miles, DW; O'Shaughnessy, J; Rittweger, K; Semiglazov, V; Tjulandin, S; Xu, B | 1 |
| Adams, RA; Bridgewater, J; Cheadle, JP; Claes, B; Fisher, D; Harris, R; Idziaszczyk, S; James, MD; Jasani, B; Kaplan, R; Kay, E; Kennedy, MJ; Kenny, SL; Lambrechts, D; Madi, A; Maughan, TS; Meade, AM; Mitchell, JK; Seymour, MT; Smith, CG; Wilson, RH | 1 |
| Cunningham, D; Hewish, M | 1 |
| Chua, A; Cummins, MM; Hardingham, JE; Lee, CK; Murone, C; Price, TJ; Shivasami, A; Tebbutt, NC; Townsend, AR; Weickhardt, A; Wrin, JW | 1 |
| Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A | 1 |
| Ross, JS | 1 |
| Berry, S; Easaw, J; Hay, J; Kennecke, H; Post, J; Rao, S; Tankel, K; Wong, R; Zhou, C | 1 |
| Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Cassidy, J; Clarke, S; Díaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, L; Scheithauer, W; Wong, R | 1 |
| Ajani, JA; Blum, M; Suzuki, A | 1 |
| Guo, H; Hu, X; Jia, Z; Shao, Z; Sun, S; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Iwaki, R; Motohiro, T; Oishi, M; Yamamichi, K; Yoh, T | 1 |
| Buyse, ME; Dy, PA; Geyer, CE; Jacobs, SA; Liepman, MK; Mamounas, EP; Melnik, MK; Pajon, ER; Piette, F; Posada, JG; Rastogi, P; Robidoux, A; Swain, SM; Wolmark, N | 1 |
| Garcipérez de Vargas, FJ; Gómez Barrado, JJ; Mendoza Vázquez, J; Ortiz Cortés, C | 1 |
| Amonkar, MM; Browning, D; Cameron, D; Delea, TE; Karnon, J; Sofrygin, O; Tappenden, P; Walker, MD | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Abd-Ellatif, EA; El-Hadaad, HA; Wahba, HA | 1 |
| Cui, YH; Li, W; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, ZM; Yu, YY | 1 |
| Bugnon, O; Jeanneret, LA; Lüthi, F; Schneider, MP; Troxler, S | 1 |
| Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C | 1 |
| Anderluh, F; Kompan, L; Mlakar Mastnak, D; Možina, B; Oblak, I; Rotovnik Kozjek, N; Soeters, P; Velenik, V; Zadnik, V | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Chau, J; Chua, DT; Lee, AW; Lee, V; McGhee, SM; Ng, WT; Tse, VC | 1 |
| De Vries, A; Eisterer, W; Gnant, M; Jagoditsch, M; Öfner, D; Rabl, H; Resch, G; Thaler, J | 1 |
| Andersson, M; Barinoff, J; Baumann, KH; Bischoff, J; Cufer, T; de Jongh, FE; Harbeck, N; Loibl, S; Lück, HJ; Maartense, E; Maass, N; Mundhenke, C; Nekljudova, V; Schmidt, M; Schwedler, K; Stein, RC; von Minckwitz, G; Zielinski, C | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Holt, K | 1 |
| Cataldo, P; Chan, E; Garcia-Aguilar, J; Marcet, J; Medich, D; Oommen, S; Pigazzi, A; Posner, MC; Shi, Q; Thomas, CR | 1 |
| Gao, MQ; Huang, AM; Zhuo, LJ | 1 |
| Brown, M; O'Reilly Zwald, F | 1 |
| Almeida da Cruz, L; Ferrari, CL; Hoff, PM; Riechelmann, RS | 1 |
| Chen, SZ; Chen, XM; Ding, Y; Mo, KL; Wang, XC; Zhang, F | 1 |
| Oyamatsu, M; Sakamoto, T; Sato, K; Shimada, Y; Tani, T | 1 |
| Hatakeyama, K; Iiai, T; Kameyama, H; Nogami, H; Saitou, K; Umezu, H; Yagi, Y | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, L; Lee, RJ; Meropol, NJ; Mitchell, E; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Winter, K; Wong, SJ | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Giannini, OH; González, ME; González, P; Saldaña, B | 1 |
| Bai, C; Chen, S; Guan, M; Jia, N; Qiu, H; Shao, Y; Xiao, Y; Yang, T; Zhang, F; Zhao, L; Zhong, G | 1 |
| Absenger, G; Benhaim, L; Bohanes, P; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Lenz, HJ; Ning, Y; Paez, D; Singh, H; Wilson, PM; Winder, T; Yang, D; Zhang, W | 1 |
| Bichev, D; Blau, I; Breithaupt, K; Dogan, Y; Grieser, C; Grothoff, M; Kretzschmar, A; Reichardt, P; Rothmann, F; Schwaner, I; Thuss-Patience, PC | 1 |
| Creemers, GJ; Dudink, RL; Glynne-Jones, R; Kusters, M; Lemmens, VE; Martijn, H; Martijnse, IS; Nieuwenhuijzen, GA; Quirke, P; Rutten, HJ; Sebag-Montefiore, D; van de Velde, CJ; van Lijnschoten, I; Vermeer, TA; West, NP | 1 |
| Deng, J; Jin, J; Li, X; Lu, W; Meng, H; Wang, F; Xu, X; Xue, Z; Zhang, H; Zhou, G | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Bosset, JF; Créhange, G; Maingon, P | 1 |
| Bennouna, J; Borg, C; Bouché, O; Delord, JP; Douillard, JY; Faroux, R; François, E; Goldwasser, F; Husseini, F; Kraemer, S; Senellart, H; Trillet-Lenoir, V; Ychou, M | 1 |
| Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ | 1 |
| Goto, H; Inoue, M; Ishiguro, S; Ishizuka, N; Kobayashi, S; Maeda, A; Nagino, M; Nakao, A; Omiya, N; Sakamoto, E; Tojima, Y; Uehara, K | 1 |
| Ishigai, M; Nakano, K; Shindoh, H; Yoshida, T | 1 |
| Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW | 1 |
| Freyer, G; Girard, P; Hénin, E; Paule, I; Tod, M; You, B | 1 |
| Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG | 1 |
| Krotova, OA; Polysalov, VN; Rutkin, IO; Tlostanova, MS | 1 |
| Boot, H; Cats, A; Dikken, JL; Jansen, EP; Lind, PA; Maurits Swellengrebel, HA; Putter, H; van de Velde, CJ; van Grieken, NC; van Sandick, JW; Verheij, M | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Deftereos, S; Dimopoulos, P; Kakolyris, S; Karanikas, M; Karayiannakis, A; Michailidis, P; Tentes, A; Xenidis, N | 1 |
| Bang, SM; Chang, HJ; Kang, SB; Kim, DW; Kim, JH; Kim, YJ; Lee, JS; Lee, KW | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Dalton, RS; Daniels, IR; Gee, AS; Harries, S; Osborne, ME; Thomas, R; Velineni, R | 1 |
| Lolkema, MP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Verhage, RJ | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Beckford, A; Demierre, MF; Goldberg, L; Jalisi, S; Lerner, A; Ugent, S | 1 |
| Kang, YK; Langer, B; Lim, HY; Ohtsu, A; Park, SR; Rha, SY; Sawaki, A; Shah, MA; Starnawski, M; Van Cutsem, E; Wu, J; Yamada, Y | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
| Bohn, B; Erben, P; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kähler, G; Kienle, P; Post, S; Schwaab, J; Ströbel, P; Wenz, F | 1 |
| Ashley, S; Chau, I; Cunningham, D; Gujral, DM; Hawkins, MA; Leonulli, BG; Tait, D | 1 |
| Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS | 1 |
| Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N | 1 |
| Balaban, EP; Crandall, TL; Kane, P; Lembersky, BC; Pinkerton, RA; Potter, DM; Rajasenan, KK; Ramanathan, RK; Schmotzer, A; Sehgal, R; Zeh, H | 1 |
| Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N | 1 |
| Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Yusuf, SW | 1 |
| Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z | 1 |
| Anderluh, F; Bracko, M; Brecelj, E; Edhemovic, I; Kropivnik, M; Music, M; Oblak, I; Ocvirk, J; Omejc, M; Velenik, V | 1 |
| Aliev, VA; Barsukov, IuA; Glebovskaia, VV; Gordeev, SS; Kuz'michev, DV; Malikhov, AG; Oltarzhevskaia, ND; Osombaev, MSh; Perevoshchikov, AG; Tkachev, SI; Tsariuk, VF | 1 |
| Al-Niaimi, F; Lyon, C | 1 |
| Di Fiore, F; Michel, P | 1 |
| Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T | 1 |
| Brecelj, E; Cemazar, M; Edhemovic, I; Gadzijev, EM; Gasljevic, G; Gorjup, V; Jarm, T; Kos, B; Mali, B; Marcan, M; Miklavcic, D; Music, M; Pavliha, D; Sersa, G; Snoj, M; Vavpotic, TP; Zupanic, A | 1 |
| Cassidy, J; Díaz-Rubio, E; Gilberg, F; McKendrick, J; Scheithauer, W; Seitz, JF; Twelves, C; Van Hazel, G; Wong, A | 1 |
| Chen, C; D'Andrea, G; Drullinsky, P; Feigin, K; Gajria, D; Gonzalez, J; Hudis, CA; Lake, D; Norton, L; Patil, S; Theodoulou, M; Traina, TA | 1 |
| Peeters, M; Price, T | 1 |
| Bu, ZD; Cai, Y; Dou, FY; Ji, JF; Li, JL; Li, XF; Li, YH; Li, ZY; Tham, IW; Wu, AW; Wu, H; Xu, B | 1 |
| de Los Ríos la Rosa, F; Privitera, M | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z | 1 |
| Hamasu, S; Konishi, S; Manaka, D; Nishitai, R; Sakamoto, K; Uehara, M | 1 |
| Amstutz, U; Froehlich, TK; Largiadèr, CR | 1 |
| Baglin, TP; Ford, H; Hardwick, RH; Peters, CJ; Rollins, KE; Safranek, PM | 1 |
| Ceschia, A | 1 |
| Alcántara-González, J; Alonso-Castro, L; Fleta-Asín, B; Jaén-Olasolo, P; Truchuelo-Díez, M | 1 |
| Basche, M; Cleere, D; Eckhardt, SG; Elsayed, YA; Eppers, S; Gore, L; Grolnic, S; Li, J; Moulder-Thompson, SL; O'Bryant, C; Rivera, E | 1 |
| Chan, AK; Choo, BA; Glaholm, J | 1 |
| Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO | 1 |
| Campone, M; Fein, L; Jassem, J; Karwal, M; Peck, R; Poulart, V; Vahdat, L | 1 |
| Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I | 1 |
| Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D | 1 |
| Ma, Y; Tang, L; Wang, HX; Xu, YC; Zhang, FC | 1 |
| Cao, D; Flynn, S; Gach, M; Kim, B; McCabe, J; Pizzorno, G; Wan, L; Yan, R; Ziemba, A | 1 |
| Albouzidi, A; Ali, AA; Debbagh, A; Elkaoui, H; Errihani, H; Essaidi, I; Fetohi, M; Ichou, M; Kadiri, H; Mahi, M; Moussaid, Y; Oukabli, M; Sbitti, Y; Slimani, K | 1 |
| Beckeringh, JJ; Boven, E; Hugtenburg, JG; Timmers, L; van Herk-Sukel, MP | 1 |
| Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, SB; Kim, YH; Koo, DH; Lee, GH; Park, SI; Shin, JH; Song, HJ; Song, HY; Yoon, DH | 1 |
| Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ | 1 |
| Goto, H; Hara, K; Higuchi, K; Hijioka, S; Kawai, H; Kondo, S; Mizuno, N; Nakamura, M; Niwa, Y; Ogura, T; Sawaki, A; Tajika, M; Yamao, K | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Ellidokuz, H; Eren, M; Koca, D; Oztop, I; Salman, T; Unek, IT; Yilmaz, U | 1 |
| Avoranta, ST; Korkeila, EA; Minn, HR; Pyrhönen, SO; Sundström, JT; Syrjänen, KJ | 1 |
| Ackland, SP; Byrne, MJ; Coates, AS; Fitzharris, B; Fong, A; Forbes, JF; Francis, PA; Gainford, MC; Gebski, V; Grimison, PS; Harvey, VJ; Nowak, AK; Paksec, L; Simes, RJ; Sourjina, T; Stockler, MR; Van Hazel, G; Wilcken, NR; Zannino, D | 1 |
| Booth, C; Booth, JA; Crawford, SM | 1 |
| Croom, KF; Dhillon, S | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Ackland, SP; Broad, A; Cassidy, J; Ganju, V; Price, TJ; Robinson, BA; Simes, RJ; Tebbutt, NC; Van Hazel, GA; Wilson, K; Zannino, D | 1 |
| Bonneterre, J; Bourbouloux, E; Campone, M; Fumoleau, P; Isambert, N; Milano, G; Roché, H | 1 |
| Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R | 1 |
| Beets, GL; Beets-Tan, RG; Buijsen, J; Engelen, SM; Hulsewé, KW; Jansen, RL; Lambregts, DM; Lammering, G; Leijtens, JW; Maas, M; Nelemans, PJ; Sosef, M; van Dam, RM | 1 |
| Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H | 1 |
| Chua, DT; Hong, RL; Krishnan, G; Kurnianda, J; Ng, AW; Ng, WT; Seetalarom, K; Shotelersuk, K; Sze, WK; Wang, CH; Yang, MH; Yiu, HH | 1 |
| Arbea, L; Aristu, J; Cambeiro, M; Chopitea, A; Díaz-González, JA; García-Foncillas, J; Gaztañaga, M; Hernández, JL; Martínez-Monge, R; Moreno, M; Nuñez, J; Ramos, LI; Rodríguez, J; Sola, JJ; Subtil, JC | 1 |
| Aparicio, J; Díaz-Rubio, E; Feliu, J; García-Carbonero, R; González-Flores, E; Grande, E; Pérez-Hoyos, T; Salud, A; Torres, E; Valero, M; Valladares-Ayerbes, M; Vieitez, JM | 1 |
| van Tienhoven, G; Wilmink, JW | 1 |
| Colucci, G; D'Amico, C; Di Lauro, L; Giannarelli, D; Giotta, F; Latorre, A; Mariani, L; Pizzuti, L; Sergi, D; Vici, P; Vizza, E | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Earl, HM | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Chen, G; Chen, R; Ding, KF; Li, J; Song, YM; Yan, M; Ying, XJ; Zhou, JJ | 1 |
| Boku, N; Hamamoto, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, T; Tamura, T | 1 |
| Bang, YJ | 1 |
| Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM | 1 |
| Koopman, M; Mol, L; Punt, CJ; Redekop, WK; Uyl-de Groot, CA; van Gils, CW | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Bellavia, T; Damodaran, S; Khushalani, NI; Sait, SN; Wang, ES; Wetzler, M | 1 |
| Fan, WF; Liu, FY; Meng, LJ; Pu, XL; Wang, J; Yang, M | 1 |
| Ajani, JA; Beddar, AS; Briere, TM; Chakravarty, T; Crane, CH; Das, P; Delclos, ME; Krishnan, S; Mansfield, PF; Mok, H; Reed, VK | 1 |
| Aggarwal, BB; Gupta, SC; Kim, JH; Park, B; Yadav, VR | 1 |
| Arnold, D; Stein, A | 1 |
| Arena, FP; Epperson, AL; Mintzer, DM; Schwartzberg, LS; Walker, MS | 1 |
| Amatu, A; Bernardo, A; Bernardo, G; Frascaroli, M; Montagna, B; Palumbo, R; Poggi, G; Riccardi, A; Sottotetti, F; Strada, MR; Tagliaferri, B; Teragni, C | 1 |
| Carlomagno, C; D'Incalci, M; De Placido, S; De Stefano, A; Della Vittoria Scarpati, G; Falcetta, F; Marchini, S; Pepe, S; Singh, VK; Ubezio, P | 1 |
| Abe, T; Baba, E; Boku, N; Hamamoto, Y; Hatake, K; Miyata, Y; Nishina, T; Ohashi, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamaguchi, K | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Ahn, YC; Bae, JM; Choi, MG; Jung, SH; Kang, WK; Kim, KM; Kim, S; Lee, J; Lim, DH; Lim, HY; Noh, JH; Park, CK; Park, JO; Park, SH; Park, YS; Sohn, I; Sohn, TS | 1 |
| Ciccolini, J; Dahan, L; Evrard, A; Iliadis, A; Lacarelle, B; Mbatchi, L; Mercier, C; Norguet, E; Ouafik, L; Ries, P; Seitz, JF; Tibbitts, J | 1 |
| Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ | 1 |
| Hashmi, A; Shoaib, M; Tunio, MA | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Lau, PC; Ng, WT; Yu, SC; Zheng, SF | 1 |
| Kishi, S; Matsumoto, A; Morise, M; Suzuki, H; Suzuki, T; Takeshita, T; Tsutsui, A; Yoneyama, K | 1 |
| Amano, R; Fuyuhiro, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Ide, Y; Makino, S; Murata, K | 1 |
| Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T | 1 |
| Ballestrero, A; Berardi, R; Cascinu, S; Gasparini, G; Mori, Y; Morosini, P; Nagayama, S; Shishido, J; Toi, M; Torino, F; Troiani, T; Ueno, T; Yoshizawa, A | 1 |
| Kato, K | 1 |
| Bang, YJ; Button, P; Cho, JY; Chung, HC; Ji, J; Kim, YH; Kim, YW; Lee, KH; Lee, KW; Mok, YJ; Noh, SH; Noh, SI; Park, YK; Sirzén, F; Yang, HK; Yeh, TS | 1 |
| Abad, A; Antón, A; Aranda, E; Arrivi, A; Benavides, M; Cervantes, A; Díaz-Rubio, E; Dueñas, R; Escudero, P; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Lacasta, A; Llanos, M; López-Ladrón, A; Losa, F; Marcuello, E; Martínez de Prado, P; Massutí, B; Rivera, F; Safont, MJ; Sastre, J; Tabernero, JM; Valladares, M | 1 |
| Bargagli, G; Conca, R; Francini, E; Francini, G; Licchetta, A; Marzocca, G; Miano, ST; Pascucci, A; Petrioli, R; Roviello, G | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Akagi, Y; Ando, K; Emi, Y; Kakeji, Y; Kitazono, M; Maehara, Y; Morita, M; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Samura, H; Shirouzu, K; Sirzen, F; Tokunaga, S | 1 |
| Chung, HC; Jeung, HC; Jung, I; Kim, GM; Kim, HS; Lee, KH; Nam, BH; Rha, SY | 1 |
| Farmer, A; Larsen, ME; Tarassenko, L; Weaver, A; Young, A | 1 |
| Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C | 1 |
| Chang, SJ; Chen, CF; Chen, MJ; Huang, CJ; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, CH; Yeh, YS | 1 |
| Alidoosti, A; Ameri, A; Aref, S; Fadavi, P; Moghadam, MM; Rasouli, HA; Sheybani, KM; Tabatabaiefar, M; Taslimi, F | 1 |
| Albain, KS; Barlow, WE; Chew, HK; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lanier, KS; Lew, DL; Livingston, RB; Schott, AF; Wade, JL | 1 |
| Broadwater, G; Clough, RW; Czito, BG; Guy, CD; Papalezova, KT; Papavassiliou, P; Tyler, DS; White, RR; Willett, CG; Zagar, TM | 1 |
| Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Marchianò, A; Pellegrinelli, A; Pietrantonio, F | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F | 1 |
| Bhattacharya, D; Easthall, C; Small, M; Watson, S; Willoughby, KA | 1 |
| Al-Ahwal, MS | 1 |
| An, HJ; Chang, HM; Hong, YS; Kang, BW; Kang, YK; Kim, JC; Kim, JH; Kim, TW; Lee, JL; Park, JH; Ryu, MH; Yu, CS; Yun, SC | 1 |
| Beath, KJ; Bulger, D; Gebski, V; Heller, GZ; Kifley, A; Ma, J | 1 |
| Feng, M; Qiu, F; Xiang, XJ; Xiong, JP; Yan, J; Yu, F; Zhan, ZY; Zhang, L; Zhao, JG | 1 |
| Kornek, G; Lemaire, C; Radonjic, D; Selzer, E; Vormittag, L | 1 |
| Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Imai, A; Mizuta, N; Nakatsukasa, K; Sakaguchi, K; Taguchi, T | 1 |
| Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH | 1 |
| Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Feng, XZ; Han, JQ; Sheng, W | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Luini, A; Mancuso, P; Montagna, E; Pastrello, D; Sandri, MT | 1 |
| Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S | 1 |
| Fong, CW; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Tan, P | 1 |
| O'Shaughnessy, JA; Perez, EA; Rugo, HS | 2 |
| Kondo, C; Matsuo, K; Mizota, A; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
| Aranda, E; Benavides, M; Díaz-Rubio, E; Grávalos, C; Hidalgo, M; Manzano, JL; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Valladares-Ayerbes, M | 1 |
| Klümpen, HJ; Kordes, S; Richel, DJ; Stevens, AJ; Weterman, MJ; Wilmink, JW | 1 |
| Hansen, TF; Jakobsen, A; Jensen, LH; Lindebjerg, J; Ploen, J | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Alberola Candel, V; Alberola, A; Garde Noguera, J; Gasent Blesa, JM; Giner Bosch, V; Laforga Canales, JB; Peris Godoy, M; Provencio Pulla, M; Sanchez, JL; Soler Tortosa, M | 1 |
| Bitzer, M; Boeck, S; Buechler, P; Endlicher, E; Geissler, M; Harder, J; Heinemann, V; Hofheinz, R; Ihorst, G; Kloeppel, G; Moehler, M; Reinacher-Schick, A; Röcken, C; Schmoor, C | 1 |
| Han, HS; Jung, S; Kang, HS; Kim, SW; Lee, H; Lee, KS; Lee, S; Park, IH; Ro, J | 1 |
| Bunnell, CA; Fornier, MN; Hortobagyi, GN; Martín, M; Mukhopadhyay, P; Peck, RA; Perez, EA; Roché, HH; Sparano, JA; Thomas, ES; Vahdat, LT; Yelle, L | 1 |
| Jennings, BA; Kwok, CS; Loke, YK; Matthews, V; Wawruch, P; Willis, G | 1 |
| Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J | 1 |
| Flombaum, C; Jhaveri, KD; Latcha, S; Shah, M | 1 |
| Arrangoiz, R; Cooper, H; Farma, JM; Konski, A; Li, T; Nitzkorski, JR; Shanmugan, S; Sigurdson, ER; Yu, JQ | 1 |
| Du, Y; Jiang, Y; Lu, J; Shao, Z; Shen, Z; Yan, T; Yin, W; Zhou, L; Zhou, Q | 1 |
| Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB | 1 |
| Chen, XF; Guo, RH; Li, J; Røe, OD; Shu, YQ; Wang, R; Wu, T; Yin, YM; Zhu, LJ | 1 |
| Hochster, HS; Levinson, B; Muggia, F; Newman, E; Ryan, T; Wu, J | 1 |
| Agharbi, FZ; Benhemmne, H; Daoudi, K; Elmesbahi, O; Mernissi, FZ; Meziane, M; Mikou, O | 1 |
| Knoblich, J; Winkler, J; Zimmermann, F; Zipp, L | 1 |
| Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B | 1 |
| Bazan, JG; Chang, DT; Koong, AC; Luxton, G; Mok, EC | 1 |
| Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Deshpande, V; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Warshaw, AL; Willett, CG; Zhu, AX | 1 |
| Dalivoust, P; Debled, M; Harbeck, N; Kaufmann, M; O'Shaughnessy, JA; Robert, NJ; Siedentopf, F | 1 |
| Bloemendal, HJ; Kok, EE; Polinder-Bos, HA; Spiering, W; van de Wiel, A; Wielders, JP | 1 |
| Fukuda, M; Hanada, K; Hata, H; Ikai, I; Kubo, K; Moriyama, S; Murakami, T; Ogiso, S; Okazaki, S; Okuchi, Y; Otani, T; Sakata, S; Setoguchi, Y; Tanaka, M; Tani, M; Une, Y; Yamaguchi, T; Yamato, T; Yasui, H | 1 |
| Govindarajan, R; Hung, SW; Mody, HR | 1 |
| Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B | 1 |
| Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T | 1 |
| Li, B; Sun, PL; Ye, QF | 1 |
| Nørgaard, H | 1 |
| Battisti, S; Beomonte Zobel, B; Cazzato, RL; Cellini, F; Del Vescovo, R; Giurazza, F; Grasso, RF; Ramella, S; Sansoni, I; Trodella, L; Trodella, LE | 1 |
| Ancukiewicz, M; Blaszkowsky, LS; Chen, RC; Crowley, EM; Hong, TS; Killoran, JH; Mamon, HJ; Ryan, DP; Wo, JY | 1 |
| Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC | 1 |
| Allred, JB; Bernath, AM; Fishkin, PA; Fitch, TR; Flynn, P; Perez, EA; Salim, M; Stella, PJ; Tan, WW; Wiesenfeld, M | 1 |
| Imai, E; Ito, I; Ito, Y; Kosugi, T; Maruyama, S; Matsuo, S; Mizuno, M; Ozaki, T; Sato, W; Suzuki, Y; Tsuboi, N; Yasuda, K; Yasuda, Y | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S | 1 |
| Brittain, EH; Fay, MP; Follmann, DA | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Barbachano, Y; Brown, G; Capdevila, J; Cervantes, A; Chau, I; Chua, YJ; Cunningham, D; Dewdney, A; Glimelius, B; Gonzalez de Castro, D; Oates, J; Tabernero, J; Tait, D; Wong, R; Wotherspoon, A | 1 |
| Fromm, A; Høgdall, E; Jensen, BV; Langhoff, J; Larsen, FO; Linnemann, D; Nielsen, DL; Rasch, L; Schou, JV; Vistisen, K | 1 |
| Hasegawa, K; Kato, R; Kawamura, K; Kobayashi, Y; Okamoto, H; Sekiya, T; Udagawa, Y | 1 |
| Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY | 1 |
| Bains, S; Madhavarao, B; Mutyala, V; Patil, C | 1 |
| Agolli, L; Bracci, S; De Sanctis, V; Enrici, RM; Minniti, G; Monaco, F; Osti, MF; Tubin, S | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Burkholder, I; Constantin, C; Fritz, E; Gencer, D; Grunewald, M; Hartmann, JT; Hartung, G; Hieber, U; Hipp, M; Hochhaus, A; Hofheinz, RD; Kettner, E; Kienle, P; Kremers, S; Laechelt, S; Lindemann, HW; Link, H; Matzdorff, A; Moehler, M; Müller, L; Post, S; Wenz, F | 1 |
| Iwasaki, Y; Kamura, M; Kimura, M; Matsushita, H; Mizumoto, T; Uchitani, S; Yatate, M; Yokoi, M | 1 |
| Asari, M; Honjoh, Y; Kasahara, A; Masuda, M; Miura, Y; Numata, K; Osaragi, T; Osawa, E; Rino, Y; Shibuya, H; Takizawa, K; Tsuchida, K; Yamamoto, Y; Yoneyama, K; Yoshida, T; Yoshie, K | 1 |
| Fukuhara, Y; Ikarashi, T; Kawachi, Y; Kawahara, M; Makino, S; Nikkuni, K; Nishimura, A; Sato, A; Sato, T; Tomidokoro, T; Tonoike, Y; Watanabe, S | 1 |
| Aiba, S; Fujimura, T; Haga, T; Hashimoto, A; Hidaka, T; Mizuashi, M; Onami, K; Watabe, A | 1 |
| Fang, H; Qiao, J | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Maughan, T | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Burns, WI; Dowling, AJ; Liew, D; McLachlan, SA; Newnham, GM; Ng, SL; Snyder, RD | 1 |
| Abe, C; Furusawa, H; Hirata, M; Kawaguchi, Y; Morita, S; Okamoto, Y; Sakamoto, J; Takami, M; Takao, S; Yamashita, S; Yoshimoto, M | 1 |
| Brown, G; Glynne-Jones, R; Kjell, P; Patel, UB; Peeters, M; Quirke, P; Ricci, S; Rullier, E; Rutten, H; Sebag-Montefiore, D; Van Cutsem, E; Van de Velde, C; West, N | 1 |
| Bo, X; Dexiang, Z; Haifu, W; Haohao, L; Jia, F; Jianmin, X; Lechi, Y; Li, L; Li, R; Qinghai, Y; Shenyong, Z; Tianshu, L; Xiangou, P; Xinyu, Q; Ye, W; Yunshi, Z | 1 |
| Barbachano, Y; Chau, I; Cunningham, D; Dewdney, A | 1 |
| Ishikawa, T; Tukamoto, Y; Yasaki, S; Yoshii, F; Yuasa, N | 1 |
| Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M | 1 |
| Kondo, C; Matsuo, K; Muro, K; Niwa, Y; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Berk, V; Elmalı, F; Er, O; Inanç, M; Karaca, H; Ozkan, M; Saraymen, R | 1 |
| Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T | 1 |
| Fujita, H; Ikeda, H; Iwakawa, K; Kato, H; Kobayashi, K; Kodera, M; Mizuno, K; Nishie, M; Oishi, M; Seshimo, K; Shibagaki, K; Takeda, H; Takita, K; Tanaka, N; Taniguchi, H; Toshima, T; Yamamura, M; Yamashita, Y | 1 |
| Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M | 1 |
| Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK | 1 |
| Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z | 1 |
| Cejas, P; Feliu, J; Fernández-Martos, C; Machancoses, AH; Moreno-García, V; Nogué, M | 1 |
| Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ | 1 |
| Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M | 1 |
| El-Rayes, BF; Zafar, SF | 1 |
| Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A | 1 |
| Gibson, B; Matherne, R; Wiesenthal, A | 1 |
| Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G | 1 |
| Beets, GL; Beets-Tan, RG | 1 |
| Bosserman, L; Gómez, H; Li, RK; Manikhas, A; Medina, C; Mukhopadhyay, P; Opatt, D; Ro, J; Sparano, JA; Thomas, E; Vahdat, L; Valero, V; Vrdoljak, E; Xu, B | 1 |
| Buonadonna, A; Corona, G; Frustaci, S; Lo Re, G; Miolo, G; Tabaro, G; Toffoli, G; Torrisi, E; Tumolo, S; Turchet, E | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Baek, JY; Chang, HJ; Hong, YS; Im, SA; Jung, KH; Kim, DY; Kim, JH; Kim, SY; Kim, TW; Shim, EK; Yeo, HY | 1 |
| Bergenfeldt, M; Hermann, KL; Jensen, BK; Jensen, BV; Nelausen, KM; Nielsen, DL; Nørgaard, H; Pfeiffer, P; Vestermark, LW | 1 |
| Ellemann, AC; Kofoed, SC; Lundsgaard, M; Svendsen, LB | 1 |
| Arnold, D; Dellas, K; Dunst, J; Reese, T; Richter, M | 1 |
| Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH | 1 |
| Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Ebe, K; Fujita, N; Honma, K; Ikarashi, T; Koide, N; Miyazawa, T | 1 |
| Aldea, M; Berindan-Neagoe, I; Cristea, V; Dudea, M; Florea, A; Irimie, A; Kacso, G; Mosteanu, O; Orza, A; Pall, E; Petrushev, B; Soritau, O; Susman, S; Tomuleasa, C | 1 |
| Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC | 1 |
| Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S | 1 |
| Arasaradnam, RP; Borman, RA; Goodyear, SJ; James, S; Jarvie, EM; Nwokolo, CU; Sanger, GJ; Snead, D; Sung, EZ | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J | 1 |
| Smorenburg, CH; Tomlow, B; Voll, ML | 1 |
| Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J | 1 |
| Archer, LE; Cohen, HJ; Hudis, CA; Muss, HB; Partridge, AH; Pitcher, BN; Ruddy, KJ; Winer, EP | 1 |
| Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yoon, SJ | 1 |
| Abe, T; Baba, E; Boku, N; Chin, K; Doi, T; Hamamoto, Y; Koizumi, W; Komatsu, Y; Miyata, Y; Nishina, T; Ohtsu, A; Omuro, Y; Saji, S; Sato, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamada, Y; Yamaguchi, K | 1 |
| Baek, JY; Hong, YS; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Kim, TY; Lee, J; Lee, JL; Lee, KW; Park, JO; Park, SH; Park, YS | 1 |
| Begent, R; Gafson, AR; Goodkin, O | 1 |
| Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E | 1 |
| Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S | 1 |
| Hema Kumar, K; Jagadeeswarareddy, K; Jhansi Rani, V; Kishore, P; Nanda Kumar, Y; Raghavendra, A | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Ramfidis, VS; Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G | 1 |
| Kobayashi, M; Kodera, Y; Morita, S; Sakamoto, J; Shitara, K; Tsuburaya, A; Yamaguchi, K; Yoshida, K; Yoshikawa, T; Yoshino, S | 1 |
| Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM | 1 |
| Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR | 1 |
| Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J | 1 |
| Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S | 1 |
| Dokmanovic, L; Janic, D; Krstovski, N; Lazic, J; Paripovic, L; Rodic, P | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J | 1 |
| Bernstine, H; Brenner, B; Goldberg, N; Gordon, N; Groshar, D; Idelevich, E; Kundel, Y; Morgenstern, S; Purim, O; Sulkes, A; Wasserberg, N | 1 |
| Alonso, V; Aranda, E; Benavides, M; Escudero, P; Gallén, M; Gómez, A; González, E; Losa, F; Majem, M; Massutí, B; Navarro, M; Rivera, F; Salazar, R | 1 |
| Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R | 1 |
| Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I | 1 |
| Alcantara, MP; Arias, F; de las Heras, M; del Moral-Avila, R; Gómez-Millán, J; Jiménez, E; Tisaire, JL; Wals, A | 1 |
| Baranger, B; Bollet, MA; Cacheux, W; Farkhondeh, F; Mariani, P; Servois, V; Zefkili, S | 1 |
| Cox, NJ; Dolan, ME; Gamazon, ER; Gorsic, L; Huang, RS; Im, HK; McIlwee, BE; O'Donnell, PH; Stark, AL; Wheeler, HE | 1 |
| Alberti, P; Argyriou, AA; Briani, C; Bruna, J; Cacciavillani, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Kalofonos, HP; Lonardi, S; Santos, C; Velasco, R | 1 |
| Ahn, JB; Hong, YS; Jung, KH; Kim, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Park, YS; Shim, BY; Zang, DY | 1 |
| Carrié, S; Cottu, P; De Rycke, Y; Falcou, MC; Llambrich, C; Medjbari, M | 1 |
| Alberda, WJ; Ayez, N; Burger, JW; Dwarkasing, RS; Eggermont, AM; Nuyttens, JJ; Verhoef, C; Willemssen, FE | 1 |
| Crosby, T; Evans, M; Griffiths, G; Gwynne, S; Hurt, C; Joseph, G; Nixon, L; Spezi, E; Staffurth, J; Wills, L | 1 |
| Jang, SJ; Kim, CW; Kim, JC; Kim, JH; Kim, TW; Kwak, JY; Lim, SB; Yu, CS | 1 |
| Lim, E; Lin, NU | 1 |
| Hardman, J; Iqbal, MS | 1 |
| Bai, W; He, AR; Hwang, J; Marshall, J; Mikhail, S; Navarro, R; Pishvaian, M; Shivapurkar, N; Wellstein, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Inaba, S; Koyama, H; Nakatsukasa, K; Tokugawa, T | 1 |
| Stiefelhagen, P | 1 |
| Baek, JH; Cho, SH; Choi, YH; Chung, IJ; Hong, YS; Jeung, HC; Kang, HJ; Kim, BS; Kim, JS; Nam, SH; Oh, SC; Song, EK; Yang, SH; Yim, CY | 1 |
| Adams, RA; Fisher, D; Kaplan, R; Kenny, SL; Madi, A; Maughan, TS; Meade, AM; Nichols, LL; Seymour, MT; Wasan, H; Wilson, RH | 1 |
| Guillen, C; Kindem, S; Llombart, B; Requena, C; Ruiz, A; San Martin, O; Traves, V | 1 |
| Carlsson, G; Holmberg, C; Pettersson, K; Sporrong, SK | 1 |
| Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM | 1 |
| Brodowicz, T; Heinemann, V; Jung, A; Kirchner, T; Knittelfelder, R; Kurteva, G; Laubender, RP; Modest, DP; Neumann, J; Ocvirk, J; Papai, Z; Stintzing, S; Zielinski, CC | 1 |
| Rajapakse, AC; Rajapakse, S; Rodrigo, C | 1 |
| Ceruse, P; Fayette, J; Girodet, D; Péron, J; Poupart, M; Ramade, A; Zrounba, P | 1 |
| Arias, F; Arrazubi, V; Balén, E; Gómez, M; Guerrero, D; Suárez, J; Vera, R; Viúdez, A | 1 |
| Celiker, E; Eren, M; Güvenç, TS; Ilhan, E; Ozcan, KS | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G | 1 |
| Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ | 1 |
| Frances, N; Iliadis, A; Marouani, H; Mercier, C; Woloch, C | 1 |
| Azzariti, A; Basile, A; Paradiso, A; Ranieri, G; Ribatti, D; Vacca, A | 1 |
| Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Gligorov, J; Joensuu, H | 1 |
| Alexandrescu, S; Becheanu, G; Buica, F; Croitoru, A; Diculescu, M; Dinu, I; Gheorghe, L; Gramaticu, I; Herlea, V; Hrehoret, D; Luca, I; Lupescu, I; Popescu, I; Simionov, I | 1 |
| Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M | 1 |
| Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F | 1 |
| Chattopadhyay, S; Kundu, SK; Manna, A; Mondal, SK; Saha, A | 1 |
| Burkholder, I; Gencer, D; Heinemann, V; Hochhaus, A; Hofheinz, RD; Laubender, RP; Stintzing, S; von Weikersthal, LF | 1 |
| Afsar, CU; Dilli, MŞ; Duman, BB; Erçolak, V; Gunaldı, M; Haksöyler, V; Paydas, S; Tetiker, T | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Gan, Y; Gu, SY; Guo, HY; Hu, XC; Wang, BY; Wang, JL; Wang, LP; Wang, ZH; Zhang, J; Zhao, XM | 1 |
| Chen, A; He, P; Liu, Y; Sun, X; Wang, S | 1 |
| Delozier, T; Ettl, J; Finek, J; Glogowska, I; Kilar, E; Malamos, N; Palomo, AG; Sommer, H; Torrecillas, L; Vega, JM | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| Grothey, A | 1 |
| An, X; Cai, PQ; Ding, PR; Fang, YJ; Gao, YH; Goodman, K; Kong, LH; Lin, JZ; Lin, X; Pan, ZZ; Wan, DS; Wang, FH | 1 |
| Adachi, T; Goto, A; Itoh, M; Kanno, S; Kondo, Y; Mitsuhashi, K; Shinomura, Y; Suzuki, T; Wakasugi, H; Yabana, T | 1 |
| de Braud, F; Díaz-Rubio, E; Pietrantonio, F | 1 |
| Claringbold, PG; Price, RA; Turner, JH | 1 |
| Bekaii-Saab, T; Bertino, EM; Diasio, RB; Fernandez, S; Karim, NA; Otterson, GA; Villalona-Calero, MA | 1 |
| Chachad, S; Malhotra, G; Naidu, R; Purandare, S | 1 |
| Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY | 1 |
| Aprile, G; Avallone, A; Bilancia, D; Butera, A; Reggiardo, G; Rosati, G | 1 |
| Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G | 1 |
| Hezel, A; McCleary, NJ; Meyerhardt, JA; Odejide, O; Ryan, D; Szymonifka, J | 1 |
| Barrios, CH; Blum, JL; Feldman, N; Gralow, J; Lee, LF; McKenna, EF; Scotto, N; Verma, S | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isikdogan, A; Kaplan, MA; Ozkan, M; Tufan, G | 1 |
| Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Kalofonos, HP; Lonardi, S; Lucchetta, M; Velasco, R | 1 |
| Allum, WH; Blazeby, JM; Coxon, F; Cunningham, D; Evans, L; Falk, S; Ford, D; Griffin, M; Hall, M; Iveson, TJ; Langley, RE; Middleton, GW; Okines, AF; Petty, RD; Plummer, C; Seymour, M; Slater, S; Smith, D; Stenning, SP; Stevenson, L; Thompson, LC; Waters, J | 1 |
| Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD | 1 |
| Azria, D; Bécouarn, Y; Bedenne, L; Berdah, JF; Bouché, O; Conroy, T; de La Roche, G; Denis, B; Dupuis, O; Etienne, PL; François, E; Gérard, JP; Gourgou-Bourgade, S; Hennequin, C; Juzyna, B; Lledo, G; Mahé, MA; Martel-Lafay, I; Mineur, L; Mirabel, X; Seitz, JF; Vendrely, V | 1 |
| Ahn, JB; Hong, YS; Im, SA; Jung, KH; Kang, YK; Kim, JH; Kim, KP; Kim, TW; Kim, TY; Lee, JL; Lee, SS; Park, YS; Shin, SJ | 1 |
| Chen, X; Dai, C; Zhao, C | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Bartsch, R; Preusser, M | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Guduru, SR; Gunuganti, AR; Lee, L; McKenna, E; Reyes, C; Satram-Hoang, S; Yu, S | 1 |
| Baertschi, D; Benhattar, J; Bodoky, G; Borner, M; Bosman, F; Bougel, S; Burkhard, R; Gautschi, O; Gloor, B; Helbling, D; Koeberle, D; Leibundgut, EO; Madlung, A; Rauch, D; Saletti, P; Sun, H; Widmer, L; Winterhalder, R; Yan, P | 1 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Meng, L; Wang, Y; Wei, JF; Yang, H | 1 |
| Hirashima, Y; Shirao, K | 1 |
| Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A | 1 |
| Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y | 1 |
| Kay, M | 1 |
| Fabian, P; Gombosova, J; Kocakova, I; Nekvindova, J; Radova, L; Sana, J; Slaby, O; Svoboda, M; Vyzula, R | 1 |
| André, T; Bajetta, E; Bodoky, G; Cartwright, TH; Clarke, S; Cunningham, D; de Gramont, A; Hecht, JR; Hoff, PM; Im, SA; Maindrault-Goebel, F; Makrutzki, M; Moore, MJ; Rivera, F; Salazar, R; Schmoll, HJ; Shacham-Shmueli, E; Shang, A; Tabernero, J; Van Cutsem, E | 1 |
| Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Aranda, E; Arrivi, A; Bando, I; Benavides, M; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Gómez-España, A; González, E; Manzano, JL; Marcuello, E; Martínez de Prado, P; Massutí, B; Montagut, C; Reboredo, M; Rivera, F; Safont, MJ; Sastre, J | 1 |
| Chen, JX; Shen, XH | 1 |
| Pox, C; Reinacher-Schick, A; Schmiegel, W | 1 |
| Créhange, G; Dalban, C; Dewas, CV; Dewas, S; Khoury, C; Maingon, P; Martin, E; Peignaux, K; Petitfils, A; Truc, G | 1 |
| Beijnen, JH; Cats, A; Deenen, MJ; Mandigers, CM; Schellens, JH; Soesan, M; Terpstra, WE | 1 |
| Schmutz, JL; Trechot, P | 1 |
| de Ronde, JJ; Kerkhoven, R; Lips, EH; Mulder, L; Nieuwland, M; Rodenhuis, S; Sonke, GS; Vincent, AD; Vrancken Peeters, MJ; Wesseling, J; Wessels, LF | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Isıkdogan, A; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R | 1 |
| Hayashida, T; Hirose, S; Ikeda, T; Jinno, H; Kitagawa, Y; Matsuda, S; Takahashi, M | 1 |
| Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW | 1 |
| Cubillo, A; De Vicente, E; García-García, E; Hernando-Requejo, O; Hidalgo, M; López, U; López-Ríos, F; Morelli, P; Muro, A; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Rubio, C | 1 |
| Bonotto, M; Bozza, C; Di Loreto, C; Osa, EO; Poletto, E; Puglisi, F | 1 |
| Beijnen, JH; Meulenaar, J; Nuijen, B; Schellens, JH | 1 |
| Knox, JJ; Zhu, AX | 1 |
| Cai, RG; Ding, XY; Fan, Y; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Chan, AO; Chan, HY; Ng, CM; Shek, CC; Tiu, SC | 1 |
| Becker, K; Belle, S; Ebert, MP; Hofheinz, R; Krause, A; Mayr, M; Röcken, C; Schmid, RM; Schulte, N | 1 |
| Champeny, TL; Chang, JE; Hansen, RM; Kim, K; Meadows, S; Njiaju, UO; Powers, K; Stewart, JA; Tevaarwerk, AJ; Traynor, AM; Van Ummersen, L | 1 |
| Harada, N; Kurasawa, M; Mori, K; Sato, Y; Yanagisawa, M; Yasuno, H | 1 |
| Chung, K; Hanada, S; Iwata, T; Kato, T; Miura, T; Nakata, K; Toda, M | 1 |
| Hamamoto, Y; Nishi, T; Onodera, K; Uemoto, J; Warita, E; Yamanaka, Y | 1 |
| Akiyoshi, T; Arita, J; Fujimoto, Y; Fukunaga, Y; Ikeda, A; Koga, R; Konishi, T; Mizunuma, N; Mukai, T; Nagasue, Y; Nagayama, S; Oikawa, Y; Saiura, A; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T; Yamakawa, K; Yamamoto, C | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Fine, RL; Gulati, AP; Krantz, B; Moss, RA; Mowatt, KB; Moyal, WN; Schreibman, S; Tsushima, DA | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, X; Ye, LH; Zhan, YP | 1 |
| Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, U; Modest, DP; Schulz, C; Stintzing, S | 1 |
| Downs, E; Guron, G; Shaaban, H; Shakouri, P | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Gao, J; He, Q; Hua, D; Li, Y; Mao, Y; Shen, L | 1 |
| Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM | 1 |
| Cronin, EB; DeFusco, PA; Hart, J; Hegde, PU; Kane, M; Ricci, A; Tannenbaum, SH; Tavakoli, B; Xu, Y; Zhu, Q | 1 |
| Ishiba, T; Kasahara, M; Nagahara, M; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H; Tamura, N; Yamauchi, S | 1 |
| Amamori, K; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamagiwa, K; Yamanda, T | 1 |
| Beijnen, JH; Deenen, MJ; Hillebrand, MJ; Rosing, H; Schellens, JH | 1 |
| Alexander, GC; de Souza, JA; Meropol, NJ; Newcomer, LN; Perkins, M; Polite, B; Ratain, MJ | 1 |
| Nieder, C | 1 |
| Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP | 1 |
| Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G | 1 |
| Benson, AB; Cohen, SJ; Feng, Y; Landry, JC; Nimeiri, H; Prabhu, RS; Sigurdson, ER; Staley, CA; Verma, U; Whittington, R | 1 |
| Enk, AH; Gronau, M; Hassel, JC; Jäger, D | 1 |
| Cai, S; Guan, Z; Lian, P; Liang, L; Liu, F; Wang, M; Xu, J; Xu, Y; Zhang, Z; Zhu, J | 1 |
| Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J | 1 |
| Jiang, Y; Li, Q; Liu, J; Wei, W; Yang, H | 1 |
| D'Alessio, A; Daniele, G; De Luca, A; Del Giudice, A; Gallo, M; Giordano, P; La Porta, ML; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Abrahámová, J; Bláha, M; Büchler, T; Dušek, L; Kupec, M; Nohejlová Medková, A; Pavlík, T | 1 |
| Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY | 1 |
| Aono, T; Deguchi, K; Deguchi, T; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Nomura, M; Takagi, M; Tamagawa, H; Tanaka, Y; Umeda, S; Yoshida, H | 1 |
| Ebe, K; Fujita, N; Honma, K; Ikarashi, T; Ishida, M; Koide, N; Miyazawa, T | 1 |
| Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tani, S; Tani, T | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ | 1 |
| Alessi, A; Avuzzi, B; Bampo, C; Bertarelli, G; Biondani, P; Bombardieri, E; Chiruzzi, C; Crippa, F; de Braud, F; Di Bartolomeo, M; Fantini, S; Mariani, L; Milione, M; Pietrantonio, F; Valvo, F | 1 |
| Gabram, SG; Harichand-Herdt, S; Kim, S; Liu, Y; O'Regan, RM; Rizzo, M; Styblo, TM; Wood, WC; Zelnak, AB | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
| Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R | 1 |
| Chang, SL; Chen, YN; Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Zhang, ZD; Zhao, Q; Zhao, XF | 1 |
| Elghazaly, H; Rostom, Y; Tawfik, H | 1 |
| Morimoto, M; Nakagawa, M; Tangoku, A | 1 |
| Kato, T; Okamura, R; Sata, R | 1 |
| Ji, T; Jiao, S; Yang, J; Zhu, Y | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Chen, Y; Feng, Y; Li, Q; Liu, TS; Wang, ZM; Zhuang, RY | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Rieken, S; Schirmacher, P; Welzel, T; Werner, J | 1 |
| Miles, DW | 1 |
| Bubis, JA; Dragnev, KH; Gordon, SR; Gui, J; Lisovsky, M; Rigas, JR; Sutton, JE; Wood, MD; Zaki, BI | 1 |
| Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA | 1 |
| Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J | 1 |
| Ardizzoni, A; Bisagni, G; Boni, C; De Matteis, A; Gamucci, T; Gnoni, R; Gori, S; Moretti, G; Musolino, A; Nuzzo, F; Panebianco, M; Passalacqua, R | 1 |
| Ahmed, RL; Dudek, A; Endrizzi, B; Lee, P; Ray, T | 1 |
| Aisu, N; Hoshino, S; Miyake, T; Naito, M; Tanimura, S; Yamashita, Y; Yoshida, Y | 1 |
| Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR | 1 |
| Ciccolini, J; Evrard, A; Lacarelle, B | 1 |
| Huang, RS; Peng, Y; Weng, L; Zhang, L | 1 |
| Arredondo, J; Baixauli, J; Chopitea, A; González, I; Hernández-Lizoáin, JL; Pastor, C; Rodríguez, J; Vigil, C | 1 |
| Dołegowska, B; Ostapowicz, A | 1 |
| Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT | 1 |
| Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH | 1 |
| Fujiuchi, N; Misumi, M; Nakamiya, N; Osaki, A; Saeki, T; Shigekawa, T; Sugitani, I; Sugiyama, M; Takeuchi, H | 1 |
| Argenone, A; Caponigro, F; Daponte, A; Fulciniti, F; Ionna, F; Longo, F; Muto, P; Perri, F; Sandomenico, F | 1 |
| Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS | 1 |
| Chau, I; Cunningham, D; Hubner, RA; Worsnop, F | 1 |
| Bemelmans, MH; Dejong, CH; Dello, SA; Driessen, A; Jansen, RL; Olde Damink, SW; van Bijnen, AA; van den Broek, MA; Vreuls, CP; Winstanley, A | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB | 1 |
| Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A | 1 |
| Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H | 1 |
| Büchler, MW; Combs, SE; Diener, MK | 1 |
| Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Arbea, L; Arredondo, J; Baixauli, J; Beorlegui, C; Chopitea, A; Hernández-Lizoáin, JL; Rodríguez, J; Sola, JJ | 1 |
| Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J | 1 |
| Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY | 1 |
| Cho, DH; Choi, EY; Ha, YJ; Kang, TW; Kim, JC; Kim, JH; Kim, SY; Kim, TW; Kim, YS; Roh, SA | 1 |
| Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N | 1 |
| Deng, HX; Li, Q; Wei, YQ; Wen, F; Xie, Q | 1 |
| Andersen, CL; Brünner, N; Christensen, LL; Hansen, F; Hansen, TF; Hansen, TP; Jensen, BV; Jensen, NF; Lindebjerg, J; Pfeiffer, P; Qvortrup, C; Rasmussen, MH; Rømer, MU; Stenvang, J; Tarpgaard, LS; Ørntoft, TF | 1 |
| Deguchi, T; Fukui, A; Iwase, K; Kawata, J; Matsuda, C; Nezu, R; Nishikawa, K; Takagi, M; Tamagawa, H; Tanaka, Y | 1 |
| Brossart, P; Erdmann, C; Heine, A; Held, SA; Menschik, T; Schmiedel, A | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW | 1 |
| Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH | 1 |
| Beets, GL; Beukema, JC; de Jong, KP; Gelderblom, AJ; Havenga, K; Hospers, GA; Nagtegaal, ID; Rutten, HJ; Tamas, K; van de Velde, CJ; van Dijk, TH; Wiggers, T | 1 |
| Barik, S; Gupta, S; Khan, H; Negi, MP | 1 |
| Burton, A; Craven, O; Hughes, CA; Molassiotis, A; Saunders, MP | 1 |
| Behera, J; Chatterjee, S; Gajalakshmi, P; Madhuwanti, S; Muthumani, K; Pradeep, T; Priya, MK; Saran, U | 1 |
| Boda-Heggemann, J; Haneder, S; Hochhaus, A; Hofheinz, RD; Lohr, F; Michaely, H; Ronellenfitsch, U; Schneider, V; Weiss, C; Wenz, F; Wertz, H | 1 |
| Anagnostopoulos, A; Athanasiadis, A; Boukovinas, I; Georgoulias, V; Kachris, S; Lambrodimou, G; Makrantonakis, P; Polyzos, A; Saridaki, Z; Souglakos, J; Stoltidis, D | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Ilson, DH | 1 |
| Benson, AB | 1 |
| Beets, GL; Beets-Tan, RG; Breukink, SO; Dejong, CH; Engelen, SM; Jansen, RL; Lahaye, MJ; Leijtens, JW; Maas, M; van Berlo, CL; van de Velde, CJ | 1 |
| Cassidy, J; Hochster, H | 1 |
| Aschele, C; Blackstock, W; Gerard, JP; Glynne-Jones, R; van de Velde, C | 1 |
| Schaller, G | 1 |
| Heath, E; Kosjek, T; Perko, S; Žigon, D | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Nielsen, DL; Polk, A; Vaage-Nilsen, M; Vistisen, K | 1 |
| Costa, FP; Gumz, B; Pasche, B | 1 |
| Bhuva, N; Buckley, A; Harrison, M; Kelly, C; Saunders, M | 1 |
| Albini, A; Banzi, M; Boni, C; Casali, B; Farnetti, E; Focaccetti, C; Magnani, E; Nicoli, D; Savoldi, L | 1 |
| El Mahdy, MM; El-Arab, LR; Swellam, M | 1 |
| Arnold, D; Dellas, K; Dunst, J; Engel, E; Höhler, T; Reese, T; Richter, M; Rödel, C; Wagner, W; Würschmidt, F | 1 |
| Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M | 1 |
| Bilic, S; Burris, HA; de Vries, EG; Gietema, JA; Goldbrunner, M; Infante, JR; Oldenhuis, CN; Parker, K; Scott, JW; Sharma, S; Yang, L | 1 |
| Banerjee, A; Blaney, SM; Boyett, JM; Brownstein, C; Chintagumpala, M; Gururangan, S; Hussain, S; Kilburn, LB; Kocak, M; Kun, L; Meneses-Lorente, G; Paulino, AC; Schaedeli Stark, F; Thompson, PA | 1 |
| Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P | 1 |
| Bodoky, G; Celik, I; Chung, HC; Gorbunova, V; Götte, H; Kang, YK; Kurteva, G; Lordick, F; Melezínková, H; Moehler, M; Moiseyenko, VM; Oh, SC; Park, JO; Salman, P; Sawaki, A; Volovat, C | 1 |
| Barbachano, Y; Chau, I; Coxon, F; Crosby, T; Cunningham, D; Falk, S; Ferry, D; Frances, A; Gonzalez, D; Iveson, T; Mansoor, W; Middleton, G; Okines, AF; Okines, C; Peckitt, C; Saffery, C; Slater, S; Smith, D; Waddell, T; Wadsley, J; Waters, J; Wotherspoon, A | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ | 1 |
| Aglietta, M; Bertetto, O; Cassoni, P; Ciuffreda, L; Dongiovanni, V; Fanchini, L; Filippi, AR; Franco, P; Gabriele, P; Morino, M; Munoz, F; Racca, P; Ricardi, U; Rondi, N | 1 |
| Huang, Y; Li, WH; Li, YQ; Liu, N; Liu, SG; Liu, XB; Liu, YH; Wang, FL; Yu, J; Yuan, ST; Zhang, JD; Zhang, Y | 1 |
| Bashir, N; Blazeby, J; Bridgewater, JA; Crosby, T; Cunningham, D; Falk, S; Geh, JI; Gollins, S; Griffiths, G; Hurt, CN; Maughan, T; Mukherjee, S; Ray, R; Roy, R; Staffurth, J | 1 |
| Du, Z; He, J; He, X; Li, M; Li, Q; Tang, R; Wen, F; Yin, X; Zhang, P; Zhou, Y | 1 |
| Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS | 1 |
| Jeong, BG; Kim, DY; Kim, SY | 1 |
| Barker, C; Lee, L; Mais, K; McPartlin, AJ; Mitchell, K; Slevin, NJ; Swindell, R; Sykes, A; Yap, B | 1 |
| Jiao, SC; Li, JY; Wen, XY; Wu, LL; Zhang, GQ; Zhao, H | 1 |
| Ng, J; Ove, R; Russo, S; Saif, MW | 1 |
| Aprile, G; Lutrino, SE; Sobrero, A | 1 |
| Bowrey, DJ; Cunnell, M; Khanna, A; Madhusudan, S; Parsons, SL; Reece-Smith, AM; Thomas, A | 1 |
| Barsukov, YA; Fedyanin, MY; Gordeyev, SS; Perevoshikov, AG; Tkachev, SI | 1 |
| Ballman, KV; Cohen, HJ; Freedman, RA; Hudis, CA; Hurria, A; Keating, NL; Kimmick, GG; Kornblith, AB; Mandelblatt, J; Muss, HB; Pitcher, B; Winer, EP | 1 |
| Chongqing, T; Gannong, C; Jianhe, L; Lihui, O; Liubao, P; Siying, W; Xiaohui, Z; Xiaomin, W; Ziying, Z | 1 |
| Kang, YK; Kim, SY; Koo, DH; Lee, CW; Maeng, J; Na, YS; Park, I; Ryoo, BY; Ryu, MH; Yoo, C | 1 |
| Cai, G; Cai, S; Gu, W; Lian, P; Sheng, W; Shi, D; Zhang, Z; Zhu, J | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Aksu, G; Bilici, A; Cabuk, D; Gumus, M; Kaya, S; Oven Ustaalioglu, BB; Seker, M; Temiz, S; Uygun, K; Yildiz, R | 1 |
| Chen, ZB; Liao, H; Lin, Z; Ou, XQ; Peng, PJ; Peng, YL; Wang, SY; Zhang, HY | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| de Gramont, A; Green, E; Haller, DG; McCleary, NJ; Meyerhardt, JA; O'Connell, M; Saltz, LB; Sargent, DJ; Twelves, CJ; Van Cutsem, E; Yothers, G | 1 |
| He, YL; Schwarz, RE; Smith, DD; Wei, ZW; Wu, Y; Xia, GK; Zhang, CH | 1 |
| Chan, A; Conte, PF; Espie, M; Ganju, V; Gil, MG; Llombart, A; Majois, F; Petruzelka, L; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Biasco, G; Brandi, G; de Rosa, F; Derenzini, E; Di Girolamo, S; Ercolani, G; Falcone, A; Grazi, GL; Loupakis, F; Masi, G; Pantaleo, MA; Pietrabissa, A; Pinna, AD | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Seaman, SR; Wason, JM | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Akagi, Y; Fujino, S; Hong, KD; Ishibashi, Y; Kibe, S; Kinugasa, T; Mizobe, T; Ohchi, T; Oka, Y; Sasatomi, T; Shirouzu, K; Tanaka, N; Yuge, K | 1 |
| Ariad, S; Geffen, DB; Geva, S; Lazarev, I | 1 |
| Jiang, ZM; Wei, Y; Xie, DR; Yang, Q; Zhang, YD; Zhou, SW | 1 |
| Jensen, SA | 1 |
| Buta, M; de Campos-Lobato, LF; de Sousa, JB; Dietz, DW; Fazio, VW; Kalady, MF; Lavery, IC; Stocchi, L | 1 |
| Alberti, P; Angelopoulou, A; Antonacopoulou, A; Argyriou, AA; Briani, C; Bruna, J; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Genazzani, AA; Kalofonos, HP; Lonardi, S; Psaromyalou, A; Santos, C; Terrazzino, S; Velasco, R | 1 |
| Han, SS; Kim, BH; Kim, DY; Kim, JY; Kim, SS; Kim, TH; Kim, YJ; Koh, YH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM | 1 |
| Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M | 1 |
| Schrag, D | 1 |
| Chindaprasirt, J; Khuntikeo, N; Ngamprasertchai, T; Pakkhem, A; Sookprasert, A; Ungarereevittaya, P; Wirasorn, K | 1 |
| Atienza, D; Fisher, SI; Howard, JR; Man, L; Rashidi, A | 1 |
| Hansen, TF; Jakobsen, A; Nielsen, BS; Sørensen, FB | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Huber, KE; Saif, MW; Savir, G | 1 |
| Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y | 1 |
| Hashimoto, T; Kimura, S; Toyono, M; Usuba, O; Yokoyama, M | 1 |
| Field, KM; Gibbs, P; McKendrick, JJ; Shapiro, JD; Wong, HL | 1 |
| Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA | 1 |
| Arisawa, Y; Chiba, N; Hashimoto, M; Ishii, M; Ishikawa, S; Nakamura, T; Shimada, A | 1 |
| Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T | 1 |
| Boisen, MK; Dehlendorff, C; Hansen, J; Hansen, TF; Holländer, NH; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Nielsen, SE; Pfeiffer, P; Tarpgaard, LS; Østerlind, K | 1 |
| Fujitani, K | 1 |
| Aglietta, M; Artale, S; Cagnazzo, C; Capussotti, L; Cascinu, S; De Carlis, L; Di Fabio, F; Fornarini, G; Gioeni, L; Leone, F; Marino, D; Pinto, C; Pugliese, R; Sartore-Bianchi, A; Siena, S; Tampellini, M | 1 |
| Costello, B; Farrell, A; Foster, NR; Jatoi, A; Le-Lindqwister, NA; Mathew, J; Meyers, JP; Patel, K; Reynolds, J | 1 |
| Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R | 1 |
| Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M | 1 |
| Khan, R; Kilkenny, JW; Latif, N; Rana, F; Samiian, L; Tariq, K | 1 |
| Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU | 1 |
| Dumont, E; Johnson, AC; Oldenkamp, R; Sumpter, JP | 1 |
| Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J | 1 |
| Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ | 1 |
| Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR | 1 |
| Hu, K; Lin, GL; Lu, JY; Qiu, HZ; Wu, B; Xiao, Y; Xu, L; Zhang, GN | 1 |
| Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Hardingham, JE; Lee, CK; Murone, C; Price, TJ; Simes, RJ; Tebbutt, NC; Townsend, AR; Weickhardt, A; Wilson, K; Wrin, JW | 1 |
| Goto, H; Hiramatsu, K; Inoue, M; Kobayashi, S; Maeda, A; Nagino, M; Nakayama, G; Ohmiya, N; Sakamoto, E; Tojima, Y; Uehara, K; Yatsuya, H; Yoshioka, Y | 1 |
| Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K | 1 |
| Foubert, F; Matysiak-Budnik, T; Touchefeu, Y | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Saarni, O; Tanner, M; Villman, K | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Larroque-Lombard, AL; Rachid, Z | 1 |
| Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G | 1 |
| He, HW; Li, L; Li, XQ; Shao, RG; Zhang, H; Zhang, SH; Zhang, YP | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK | 1 |
| Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ | 1 |
| Li, CH; Ma, TH; Shi, SB; Tang, XY | 1 |
| Guo, HQ; Liu, YY; Yang, SJ; Yao, SN; Yao, ZH; Yuan, YD; Zhao, Y | 1 |
| Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF | 1 |
| Choi, HJ; Kim, H; Kim, HS; Kim, JH; Shin, SJ | 1 |
| Allen, JN; Berger, DL; Blaszkowsky, LS; Borger, DR; Clark, JW; Cusack, JC; Haigis, KM; Hong, TS; Kwak, EL; Liang, WY; Mamon, HJ; Russo, AL; Ryan, DP; Szymonifka, J; Wo, JY; Zhu, AX | 1 |
| Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z | 1 |
| Abad, A; Aranda, E; Benavides, M; Gallen, M; Gómez, A; López, MR; Massutí, B; Rivera, F; Rubio, ED; Sastre, J; Vidaurreta, M | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Do, IG; Jung, SH; Kang, WK; Kim, KM; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
| Ilyas, S; Saif, MW; Wasif, K | 1 |
| Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF | 1 |
| Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K | 1 |
| Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S | 1 |
| Arnold, D; Geissler, M; Grothe, W; Hofheinz, RD; Moehler, M; Reinacher-Schick, A; Schmoll, HJ; Seufferlein, T; Stein, A; Thuss-Patience, PC | 1 |
| Fang, P; Ji, TF; Liu, H; Shi, WW; Yang, B; Yang, JL; Zhu, YY | 1 |
| Fan, Y; Hou, K; Li, C; Liu, Y; Qu, X; Xu, L; Zhang, Y; Zheng, H; Zhu, Y | 1 |
| Badzek, S; Bilic, E; Golem, H; Gorsic, I; Kekez, D; Librenjak, N; Miletic, V; Plestina, S; Prejac, J | 1 |
| Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D | 1 |
| Azamfirei, L; Comsulea, M; Gurzu, S; Jung, I; Kadar, Z; Molnar, C | 1 |
| Huang, WD; Shen, SY; Zheng, MF | 1 |
| Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
| Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ | 1 |
| Fietkau, R; Gock, M; Klar, E; Klautke, G; Prall, F; Rau, B; Schiffmann, L; Wedermann, N | 1 |
| Barnadas, A; Barriuso, J; Casado, E; Gallego, R; Garcia Foncillas, J; Garcia-Albeniz, X; Iranzo, V; Juez, I; Martin-Richard, M; Maurel, J; Pericay, C; Queralt, B; Saigi, E; Visa, L | 1 |
| Arnold, D; Beretta, GD; Cervantes, A; Labianca, R; Mandalà, M; Mosconi, S; Nordlinger, B | 1 |
| Hutchinson, L | 1 |
| Alcazar-González, GA; Barrera-Saldaña, HA; Calderón-Garcidueñas, AL; Castruita-Avila, AL; Cerda-Flores, RM; Escorza-Treviño, S; Garza-Rodríguez, ML; González-Guerrero, JF; le Brun, S; Olano-Martin, E; Rubio-Hernández, G; Simon-Buela, L | 1 |
| Arnold, D; Behringer, D; Hegewisch-Becker, S; Kettner, E; Kirsch, A; Kretzschmar, A; Pflüger, KH; Stein, A; Wolff, T; Zimber, J | 1 |
| Popa, EC; Shah, MA | 1 |
| Bang, YJ; Khosravan, R; Lechuga, MJ; Lee, KW; Lee, SY; Lin, X; Oh, DY; Park, SR; Park, YI; Roh, EJ; Valota, O | 1 |
| Blum, JL; Glück, S; Hu, S; McKenna, EF; O'Shaughnessy, J; Odom, D; Russell, C | 1 |
| Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M | 1 |
| Chou, CY; Hsieh, CI; Ko, JH; Wang, KH | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Feng, M; Hwang, SY; Lawrence, TS; Sonnenday, CJ; Volk, ML; Wan, S; Welling, TH; Zalupski, MM | 1 |
| Li, X; Lin, S; Lin, W; Lin, Y; Wang, H | 1 |
| Aogi, K; Bando, H; Chow, LW; Fakhrejahani, E; Hisamatsu, K; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Kuroi, K; Masuda, N; Morimoto, T; Nakamura, S; Nakayama, T; Ohno, S; Sasano, H; Sato, N; Takahashi, F; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H; Yoshida, N | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Giessen, C; Graeven, U; Hegewisch-Becker, S; Heinemann, V; Laubender, RP; Modest, DP; Porschen, R; Reinacher-Schick, A; Schmiegel, W; Schulz, C; Stintzing, S | 1 |
| Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L | 1 |
| Cervantes, A; Chau, I; Cunningham, D; Eltahir, Z; Glimelius, B; Gonzalez de Castro, D; Oates, J; Peckitt, C; Roy, A; Sclafani, F; Tabernero, J; Wotherspoon, A | 1 |
| Bruining, A; Doll, PK; Gilhuijs, KG; Linn, SC; Lips, EH; Loo, CE; Mandjes, IA; Rigter, LS; Rodenhuis, S; Sonke, GS; van Werkhoven, E; Vrancken Peeters, MJ; Warnars, HA; Wesseling, J | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK | 1 |
| Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z | 1 |
| Akça, Z; Büyükçelik, A; Erden, A; Mutlu, H | 1 |
| Li, Z; Yang, J; Zhang, F | 1 |
| Arimoto, A; Iwamoto, S; Kanazawa, A; Kataoka, K; Kato, T; Nakajima, A | 1 |
| Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH | 1 |
| Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY | 1 |
| Isikli, L; Yoney, A | 1 |
| Bahary, N; Brand, R; Burton, SA; Heron, DE; Krasinskas, AM; Lembersky, B; Moser, AJ; Quinn, AE; Rajagopalan, MS; Wegner, RE; Zeh, HJ | 1 |
| Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T | 1 |
| Baek, JY; Chang, HJ; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Lee, SU; Oh, JH; Park, JW | 1 |
| Arnold, D; Beissbarth, T; Conradi, L; Dellas, K; Fokas, E; Ghadimi, BM; Kitz, J; Liersch, T; Middel, P; Rau, T; Rödel, C; Rödel, F; Rüschoff, J; Sauer, R; Sprenger, T; Weiss, C | 1 |
| Carter, HE; Howard, K; John Simes, R; Price, TJ; Schofield, DJ; Tebbutt, NC; Zalcberg, JR; Zannino, D | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB; Wilson, M | 1 |
| Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M | 1 |
| Bruce, JN; Carminucci, AS; Fine, RL; Gulati, AP; Lignelli, A; Remotti, H; Siegelin, M; Wardlaw, SL; Zacharia, BE | 1 |
| Ancukiewicz, M; Blaszkowsky, LS; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Lillemoe, KD; Mamon, HJ; Napolitano, BN; Ryan, DP; Swanson, RS; Tseng, YD; Wo, JY | 1 |
| Hasegawa, H; Kubo, H; Miyahara, M; Nakasuga, C; Tada, K | 1 |
| Ikeda, H; Kato, H; Kodera, M; Mizuno, K; Oishi, M; Seshimo, K; Toshima, T; Yamamura, M; Yamashita, Y | 1 |
| Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F | 1 |
| Ahn, KS; Chen, L; Kumar, AP; Li, F; Manu, KA; Sethi, G; Shanmugam, MK; Siveen, KS | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N | 1 |
| Balzano, G; Bettinardi, V; Calandrino, R; Castoldi, R; Cattaneo, GM; Cereda, S; Di Muzio, N; Gianolli, L; Gusmini, S; Longobardi, B; Passoni, P; Reni, M; Slim, N; Staudacher, C | 1 |
| Blakely, LJ; Houts, AC; Schwartzberg, LS; Somer, BG; Stepanski, EJ; Walker, MS; Wang, G; Wheeler, BM | 1 |
| Bauerfeind, I; Blohmer, JU; Costa, SD; Denkert, C; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Abad, A; Carmona, FJ; Cassingena, A; Elez, E; Esteller, M; Martínez-Balibrea, E; Martinez-Cardús, A; Moutinho, C; Musulen, E; Navarro-Pérez, V; Salazar, R; Santos, C; Sartore-Bianchi, A; Siena, S; Tabernero, J | 1 |
| Athanasiadis, A; Cantara, G; Kaufmann, M; Klag, T; Ong, P; Sechtem, U | 1 |
| Chen, KT; Cohen, SJ; Cooper, HS; Denlinger, C; Devarajan, K; Hoffman, JP; Meyer, JE; Milestone, BN | 1 |
| An, X; Cai, J; Cai, MY; Chen, G; Ding, PR; Gao, YH; Kong, LH; Lin, JZ; Liu, GC; Pan, ZZ; Sun, WJ; Tang, JH; Wu, XJ | 1 |
| Akbari Javar, H; Farjam, AS; Ibrahim Noordin, M; Kadivar, A; Kamalidehghan, B; Taghizadeh Davoudi, E | 1 |
| Annels, NE; Billingham, L; Corrie, P; Cunningham, D; Eatock, M; Gabitass, RF; Middleton, G; Neoptolemos, JP; Pandha, H; Shaw, VE; Smith, D; Valle, J; Wadsley, J | 1 |
| Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G | 1 |
| Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX | 1 |
| Bussom, S; Cheng, YC; Elligers, K; Jiang, Z; Kaley, K; Lamb, L; Li, J; Liu, SH; Saif, MW | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Boot, H; Cats, A; Jansen, EP; Ponz, OB; Stiekema, J; Trip, AK; van Sandick, JW; Verheij, M | 1 |
| Arnold, D; Buller, J; Dellas, K; Dunst, J; Görtz, GJ; Höhler, T; Keck, T; Richter, M; Zühlke, H | 1 |
| Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y | 1 |
| Beijnen, JH; Huitema, AD; Keizer, RJ; Meulenaar, J; Nuijen, B; Schellens, JH | 1 |
| Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY | 1 |
| Braun, JJ; de Graaf, H; de Groot, SM; de Jongh, FE; Hamaker, ME; Los, M; Maartense, E; Nortier, JW; Schrama, JG; Seynaeve, C; Smorenburg, CH; van Leeuwen-Stok, AE; van Tinteren, H; Wymenga, AN | 1 |
| Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN | 1 |
| Arena, MG; Barba, M; Belli, F; Di Lauro, L; Fattoruso, SI; Giannarelli, D; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ | 1 |
| Fan, Y; Li, J; Liao, Y; Peng, L; Wan, Y | 1 |
| Hirakawa, H; Kanno, N; Kikuchi, Y; Kuroki, M; Matsumura, Y; Miura, A; Nakano, E | 1 |
| Agterof, M; Borel-Rinkes, I; Lolkema, MP; Overkleeft, E; Reerink, O; Schipper, M; Siersema, P; Ubink, I; van der Sluis, P; van Hillegersberg, R; Vleggaar, F; Voest, E; Wijrdeman, H | 1 |
| Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D | 1 |
| Chen, G; Li, J; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X; Zhao, Z | 1 |
| Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC | 1 |
| He, MM; Luo, HY; Qiu, MZ; Ren, C; Wang, F; Wang, FH; Wang, ZQ; Wu, WJ; Xu, RH; Zeng, ZL; Zhang, DS | 1 |
| Azad, N; Blackford, A; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, R; Edil, BH; Faisal, F; Fishman, EK; Herman, J; Hruban, RH; Laheru, D; Le, DT; Olino, K; Rasheed, Z; Schulick, R; Tsai, HL; Wolfgang, C; Xia, C; Zheng, L | 1 |
| Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Kim, BH; Kim, CM; Kim, TH; Kim, YI; Koh, YH; Lee, WJ; Park, JW; Woo, SM | 1 |
| Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
| Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D | 1 |
| Borg, C; Cléau, D; Curtit, E; Demarchi, M; Dobi, E; Fratte, S; Guiu, B; Heyd, B; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Monnien, F; Nerich, V; Nguyen, T | 1 |
| Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T | 1 |
| Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Wang, D; Yang, PG; Zhang, ZD; Zhao, Q; Zhao, XF | 1 |
| Cmoch, P; Czerniec-Michalik, E; Krzeczyński, P; Kutner, A; Malińska, M; Trzcińska, K; Woźniak, K | 1 |
| Cao, C; Chen, J; Chen, Y; Gong, Y; Gu, D; Shen, Y; Tang, C; Zhang, Q; Zhang, X | 1 |
| Bannerji, R; Jou, YM; Joy, AA; Mita, A; Mita, MM; Sankhala, K; Shapiro, CL; Small, K; Statkevich, P; Yao, SL; Zhang, D; Zhu, Y | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W | 1 |
| Hasegawa, H; Kitagawa, Y; Kitasato, K; Murai, S; Nakadai, J; Oto, I; Shimizu, H; Yabe, N; Yoshikawa, T | 1 |
| Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kikuchi, A; Kobayashi, H; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H | 1 |
| Fukuda, S; Harada, T; Hiraki, S; Kaneko, T; Kawaoka, T; Kuwahara, T | 1 |
| Kita, I; Mukubo, H; Nakanuma, S; Sato, N; Takanaka, T; Yasui, T | 1 |
| Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kobayashi, H; Masuda, D; Matsuyama, T; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H | 1 |
| Aoyagi, H; Hasegawa, K; Isogai, J; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T | 1 |
| Asaka, S; Katsube, T; Kohno, T; Miyaki, A; Miyazawa, M; Murayama, M; Naritaka, Y; Shimakawa, T; Shimazaki, A; Shiozawa, S; Usuda, A; Yamaguchi, K; Yokomizo, H; Yoshimatsu, K | 1 |
| Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Nishigaki, T; Okada, K; Okamura, S; Okubo, H; Owada, Y; Takeoka, T; Wada, Y | 1 |
| Fukunaga, M; Furukawa, H; Kawabata, R; Kawase, T; Kimura, Y; Munakata, S; Nakata, K; Ohzato, H; Yamamoto, T | 1 |
| Aono, T; Deguchi, K; Deguchi, T; Fukui, A; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Noguchi, Y; Nomura, M; Okumura, Y; Takagi, M; Tamagawa, H; Tanaka, Y; Yoshida, H | 1 |
| Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Oshima, S | 1 |
| Hirakawa, K; Kashiwagi, S; Kawajiri, H; Noda, S; Onoda, N; Takashima, T | 1 |
| Fujii, C; Fujino, M; Fukunaga, M; Hachino, Y; Hamaguchi, Y; Imamura, H; Iseki, C; Ishizaka, T; Kamigaki, S; Kawabata, R; Kawase, T; Kimura, Y; Yamamoto, E | 1 |
| Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K | 1 |
| Arango, B; Escobar, M; Hosein, PJ; Kittaneh, M; Kyriakopoulos, C; Loaiza-Bonilla, A; Merchan, JR; Ochoa, RE; Palacio, S; Restrepo, MH; Rocha Lima, CM | 1 |
| An, X; Cai, MY; Chen, G; Ding, PR; Gao, YH; Kong, LH; Lin, JZ; Pan, ZZ; Wan, DS; Zeng, ZF; Zhang, X | 1 |
| Ghosh, S; Loree, JM; Mulder, KE; Spratlin, JL | 2 |
| Baek, JY; Chie, EK; Choi, DH; Chun, HG; Jang, HS; Kim, DY; Kim, HC; Kim, JG; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Oh, JH; Oh, ST; Park, HC; Park, JW; Park, YS | 1 |
| Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G | 1 |
| Azria, D; Conroy, T; Etienne, PL; François, E; Gerard, JP; Gourgou-Bourgade, S; Hennequin, C; Jarlier, M; Juzyna, B; Martel-Laffay, I; Seitz, JF; Vendrely, V | 1 |
| Berthou, J; Bichard, D; Borg, C; Facy, O; Ghiringhelli, F; Heyd, B; Ladoire, S; Lakkis, Z; Limat, S; Lorgis, V; Nerich, V; Orry, D; Ortega-Deballon, P; Rat, P; Vincent, J | 1 |
| Koshida, Y; Mukai, K; Nishi, T; Shimoyama, Y; Toriumi, F; Yamamoto, T; Yamanashi, T | 1 |
| Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W | 1 |
| Chen, FW; Egbert, BM; Sarin, KY; Swetter, SM; Zhou, X | 1 |
| Armstrong, G; Caplin, ME; Corrie, PG; Cunningham, D; Hardy, R; Lao-Sirieix, SH; Luong, TV; Meyer, T; Navalkissoor, S; Qian, W; Reed, N; Shaw, A; Talbot, DC; Valle, JW | 1 |
| Benzon, EV; Brünner, N; Christensen, IJ; Engelmann, BE; Gerds, TA; Hansson, SH; Holländer, NH; Højgaard, L; Kjær, A; Kristensen, MH; Löfgren, J; Loft, A; Markova, E; Nielsen, HJ; Sloth, C | 1 |
| Bai, C; Bai, Y; Cheng, Y; Fan, Q; Gong, J; Hu, B; Hu, G; Jiao, S; Liang, J; Liu, Y; Shen, L; Shi, Y; Wang, J; Xu, N; Xu, R; Zhang, F; Zhang, J; Zhang, X; Zheng, L | 1 |
| Guo, Y; Shen, X; Shi, M; Yang, C; Yang, L; Zhang, J | 1 |
| Peng, X; Wei, K; Zou, F | 1 |
| Guo, XD; Hu, DL; Sun, ZN; Zhao, YM | 1 |
| Bellon, J; Brock, J; Come, SE; Golshan, M; Guo, H; Jeong, J; Krop, IE; Morganstern, D; Tolaney, SM; Winer, EP | 1 |
| Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, PR | 1 |
| Baselga, J; Bosserman, L; Gómez, H; Li, RK; Mukhopadhyay, P; Sparano, JA; Vahdat, LT; Valero, V; Vrdoljak, E | 1 |
| Albertsson, M; Holmqvist, A; Jung, M; Sun, XF | 1 |
| Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q | 1 |
| Braun, JJ; de Graaf, H; de Groot, SM; de Jongh, FE; Hamaker, ME; Los, M; Maartense, E; Nortier, JWR; Seynaeve, C; Smorenburg, CH; van Leeuwen-Stok, AE; van Tinteren, H; Wymenga, AN | 1 |
| Albertsson, M; Holmqvist, A; Miger, J; Sun, XF | 1 |
| Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL | 1 |
| Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Gao, Y; Liu, M; Xiao, L | 1 |
| Cosson, VF; Lehle, M; Lum, BL; Ng, VW | 1 |
| Bartsch, R; Berghoff, AS; Dubsky, P; Fitzal, F; Foedermayr, M; Gnant, M; Preusser, M; Promberger, R; Rudas, M; Sebesta, M; Steger, GG; Weltermann, A; Zach, O; Zielinski, CC | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M | 1 |
| Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ | 1 |
| Bai, LY; Chao, Y; Chen, JS; Hsieh, JS; Li, CP; Su, WC; Su, YC; Tai, CJ; Wu, CC; Yeh, HT; Yeh, KH | 1 |
| Aiba, T; Kato, K; Nagino, M; Nihashi, T; Tsuzuki, T; Uehara, K; Yatsuya, H; Yoshioka, Y | 1 |
| Allen, J; Williamson, S | 1 |
| Gong, JF; Li, J; Li, Y; Lu, M; Lu, ZH; Shen, L; Wang, XC; Zhang, XT; Zhou, J | 1 |
| Şendur, MA; Uncu, D; Zengin, N | 1 |
| Cartwright, T; Cassidy, J; Chu, E; Haller, D; Lee, S; McKenna, E; Saif, MW; Schmoll, HJ; Sun, W; Twelves, C | 1 |
| Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC | 1 |
| Al-Batran, SE; Gencer, D; Hartmann, JT; Hochhaus, A; Hofheinz, RD; Kripp, M; Merx, K; Miranda, MB | 1 |
| Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Fang, H; Jin, J; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Wang, SL; Wang, WH; Wang, X; Yu, ZH | 1 |
| He, Y; Huang, C; Ji, J; Liang, H; Liu, Y; Shi, Y; Sun, Y; Wu, A; Yan, M; Ye, Y; Zhan, Y | 1 |
| Jiang, Z; Liang, Y; Liu, F; Song, X; Wang, W; Wu, P; Xing, L; Xu, D; Yu, X; Zang, Q; Zhang, J | 1 |
| Brown, G; Chau, I; Cunningham, D; Giralt, J; Glimelius, B; Gonzalez, D; Hulkki Wilson, S; Oates, J; Peckitt, C; Roselló Keränen, S; Sclafani, F; Tait, D; Wotherspoon, A | 1 |
| Diasio, RB; Lee, AM | 1 |
| Afzal, S; Boige, V; Braun, M; Church, D; Domingo, E; Enghusen, H; Etienne-Grimaldi, MC; Garcia-Foncillas, J; Garmo, H; Glimelius, B; Gonzalez-Neira, A; Green, E; Gusella, M; Jensen, SA; Johnstone, E; Jones, A; Julier, P; Kerr, D; Kleibl, Z; Lacas, B; Laurent-Puig, P; Lecomte, T; Love, S; Martin, M; Martinez-Balibrea, E; McLeod, H; Midgley, R; Milano, G; Morel, A; Nicholson, G; Palles, C; Pignon, JP; Ribelles, N; Rosmarin, D; Sargent, D; Schwab, M; Scudder, C; Seymour, M; Sharma, R; Thompson, L; Tomlinson, I; Wadelius, M; Wang, H; Zanger, UM | 1 |
| Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE | 1 |
| Bar-Sela, G; Cohensius-Kent, D; Haim, N; Vornikova, O | 1 |
| Doki, Y; Fujie, Y; Fujii, M; Hasegawa, J; Ikeda, M; Kato, T; Kim, HM; Miwa, H; Miyake, Y; Mizushima, T; Mori, M; Nezu, R; Nishimura, J; Noura, S; Sekimoto, M; Takemasa, I; Takemoto, H; Tamagawa, H; Yamamoto, H | 1 |
| Aksun, S; Alacacioglu, A; Bayoglu, IV; Coban, E; Demir, L; Dirican, A; Kucukzeybek, Y; Sutcu, R; Tarhan, MO; Varol, U | 1 |
| Fujinaga, T; Hiramatsu, N; Iijima, H; Nishida, T; Shinzaki, S; Takehara, T; Tatsumi, T; Tsujii, M; Yakushijin, T; Yamada, M; Yamada, T | 1 |
| Camp, ER; Chaudhary, UB; Cole, DJ; Esnaola, NF; Garrett-Mayer, E; Hoffman, BJ; Marshall, DT; Montero, AJ; O'Brien, P; Orwat, KP; Romagnuolo, J; Thomas, MB | 1 |
| Cai, G; Cai, S; Gu, W; Lian, P; Liu, F; Sheng, W; Shi, D; Xu, J; Zhang, Z; Zhu, J | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Becker, G; Gaertner, J | 1 |
| Bernhard, J; Bodoky, G; Dietrich, D; Glimelius, B; Herrmann, R; Scheithauer, W | 1 |
| Jennings, BA; Willis, G | 1 |
| Cunningham, SC; Gormley, PE; Iacobuzio-Donahue, CA; Kern, SE; Patel, K | 1 |
| Beegle, N; Blau, S; Cox, D; Dranitsaris, G; Faria, C; Kalberer, T | 1 |
| Amoroso, V; Berruti, A; Biasco, G; Birocco, N; Bodei, L; Brizzi, MP; D'Avolio, A; Dogliotti, L; Fazio, N; Ferrero, A; Nobili, E; Papotti, M; Priola, AM; Torta, M; Tozzi, L; Volante, M | 1 |
| Aroca, I; Bayo, E; De Luque, V; Del Mar Delgado, M; Gomez-Millan, J; Medina, JA; Perez, L; Perez, S; Ramos, S; Román, A; Torres, E | 1 |
| Fassbender, K; Keller, I; Lyros, E; Papanagiotou, P; Walter, S | 1 |
| Deng, D; Shen, L; Wang, M | 1 |
| Carracedo, A; Castells, A; Castellvi-Bel, S; Domingo, E; Fernández-Rozadilla, C; Freeman-Mills, L; Gonzalez-Neira, A; Howarth, K; Johnstone, E; Jones, A; Julier, P; Kaur, K; Kerr, D; Kerr, R; Love, S; Martin, M; Pagnamenta, A; Palles, C; Pita, G; Rosmarin, D; Ruiz-Ponte, C; Scudder, C; Taylor, J; Tomlinson, I; Wang, H | 1 |
| Railey, E; Sledge, GW; Smith, ML; White, CB | 1 |
| de Haes, JH; Henselmans, I; van Laarhoven, HW | 1 |
| Bai, L; Guo, XC; Mao, ZY; Su, D; Wang, LJ; Zhang, TT | 1 |
| Jiang, WT; Liu, YH; Pan, C; Thian, Y; Zhu, LQ | 1 |
| Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Finek, J; Majek, O; Melichar, B; Pavlik, T; Prausova, J; Slavicek, L; Tomasek, J; Vyzula, R | 1 |
| Ahn, JB; Baek, SJ; Baik, SH; Cho, MS; Chung, M; Hur, H; Kim, CW; Kim, MS; Kim, NK; Min, BS; Shin, SJ | 1 |
| Chang, H; Chen, L; Gao, Y; Huang, R; Liu, M; Qiu, B; Xiao, L; Xiao, W; You, K | 1 |
| Bates, RC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL | 1 |
| Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C | 1 |
| Arrowood, CC; Bendell, JC; Brady, JC; Broderick, S; Cushman, SM; Dellinger, A; Hsu, SD; Hurwitz, HI; Kozloff, MF; Meadows, J; Meadows, KL; Morse, MA; Murphy, J; Nixon, AB; Pang, H; Rangwala, F; Starodub, AN; Starr, A; Strickler, JH; Tourt-Uhlig, S; Uronis, HE; Wallace, J; Zafar, SY | 1 |
| Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J | 1 |
| Counsell, N; Glynne-Jones, R; Ledermann, J; Maraveyas, A; Meadows, HM; Mortensen, N; Quirke, P; Sebag-Montefiore, D | 1 |
| Gaspert, A; Montani, M; Odze, R; Reineke, T; Rogler, G; Soldini, D; Weber, A | 1 |
| Cao, KI; Kirova, YM | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO | 1 |
| Guillen-Ponce, C; Molina-Garrido, MJ; Mora-Rufete, A | 1 |
| Hayashi, M; Hironaka, H; Morita, N; Orita, M | 1 |
| Hasegawa, Y; Hatanaka, M; Iwata, H | 1 |
| Aoki, K; Endo, M; Ikenaga, SK; Kawashima, H; Miura, T; Shibasaki, I; Suto, A; Yoshikawa, T | 1 |
| Kirii, Y; Miyamoto, M; Takagi, H | 1 |
| Ibayashi, Y; Jotoku, H; Takahashi, M; Takasaki, M; Tanaka, H; Watanabe, K | 1 |
| Cai, Q; Chen, X; Ji, J; Jiang, J; Liu, B; Shi, H; Shi, M; Yu, Y; Zhang, J; Zhu, Z | 1 |
| Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M | 1 |
| Feng, Y; Hou, J; Ji, Y; Li, W; Liu, TS; Qin, XY; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, YY | 1 |
| Goto, N; Mimura, J | 1 |
| Abal, M; Barbazán, J; Candamio, S; Cano, A; Casares de Cal, Mde L; Díaz-López, A; Gómez-Tato, A; López-López, R; Muinelo-Romay, L; Vieito, M | 1 |
| Boukovinas, I; Christophylakis, C; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Karampeazis, A; Matikas, A; Polyzos, A; Souglakos, J; Vamvakas, L | 1 |
| Rau, B | 1 |
| Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Brooks, C; Gibson, O; Grainger, L; Larsen, M; Love, SB; Shanyinde, M; Shearwood, V; Tarassenko, L; Waters, R; Weaver, A; Young, AM | 1 |
| Han, GH; Huang, JX | 1 |
| Barben, CP; Grocott, MP; Jack, S; Kemp, GJ; Loughney, L; Sripadam, R; West, MA | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Allegra, CJ; Arora, A; Bahary, N; Beart, RW; Colangelo, LH; Eakle, J; Evans, LS; Landry, JC; Marchello, BT; Mohiuddin, M; Moore, DF; Mullane, MR; O'Connell, MJ; Parda, DS; Petrelli, NJ; Pitot, HC; Robertson, JM; Roh, MS; Ryan, DP; Sharif, S; Shields, AF; Soori, GS; Ward, PJ; Wolmark, N; Wozniak, TF; Yothers, G | 1 |
| Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S | 1 |
| Barquinero, J; Casacuberta-Serra, S; Ferrer, G; Hirano, M; López-Estévez, S; Mansilla, MJ; Martí, R; Martorell, L; Torres-Torronteras, J | 1 |
| Aisu, N; Hirata, K; Hoshino, S; Mogi, A; Naito, M; Tamura, K; Tanaka, T; Tanimura, S; Yamashita, Y; Yoshida, Y | 1 |
| Alacacioglu, A; Barutca, S; Degirmenci, M; Dirican, A; Karabulut, B; Oktay, E; Uslu, R; Varol, U; Yildiz, I | 1 |
| Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L | 1 |
| Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G | 1 |
| Gervasi, E; Giovanardi, F; Pezzuolo, D; Prati, G; Scaltriti, L; Scarabelli, L | 1 |
| Agolli, L; Bracci, S; De Sanctis, V; Falco, T; Masoni, L; Maurizi Enrici, R; Osti, MF; Valeriani, M | 1 |
| de Weger, VA; Griffioen-Keijzer, A; van Bunderen, CC | 1 |
| Alonso, V; Alonso-Espinaco, V; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Gallego, R; Garcia-Albeniz, X; Horndler, C; Jares, P; Lozano, JJ; Marmol, M; Maurel, J; Ortego, J; Rosell, R | 1 |
| Aloia, TA; Cooper, AB; des Bordes, JK; Fleming, JB; Fogelman, D; Holmes, HM; Katz, MH; Lee, JE; Parker, NH; Vauthey, JN | 1 |
| Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M | 1 |
| Cserni, G; Csörgő, E; Kelemen, G; Kővári, B; Lázár, P; Nyári, T; Rusz, O; Vörös, A | 1 |
| Adams, J; Allen, JN; Ancukiewicz, M; Blaszkowsky, LS; Borger, DR; Boucher, Y; Clark, JW; DeLaney, TF; Deshpande, V; Duda, DG; Fernandez-del Castillo, C; Ferrone, CR; Grillo, T; Hong, TS; Jain, RK; Kwak, EL; Mamon, HJ; Ryan, DP; Shinagare, S; Wadlow, RC; Winrich, B; Wo, JY; Yeap, BY; Zhu, AX | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 1 |
| Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV | 1 |
| Hara, K; Ishii, T; Kondo, H; Koyama, I; Morita, Y; Suzuki, A; Tashiro, J; Yamaguchi, S | 1 |
| Abrahamova, J; Benesova, V; Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kohoutek, M; Melichar, B; Obermannova, R; Pavlik, T; Usiakova, Z; Vyzula, R | 1 |
| Follwell, M; Johal, B; Kennecke, HF; Thind, G | 1 |
| Ahn, E; Ambros, T; Aruna, M; Kronish, L; Mahtani, RL; Montero, AJ; Vogel, CL; Zaravinos, J; Zeichner, SB | 1 |
| Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K | 1 |
| Konno, F; Matsumoto, H; Mitsui, K; Namiki, K; Takahashi, T; Yoshida, R | 1 |
| Bartoš, J; Dvořák, J; Richter, I | 1 |
| Barham, CP; Blazeby, JM; Brookes, ST; Crosby, T; Donovan, JL; Falk, SJ; Griffin, SM; Hollingworth, W; Hollowood, AD; Krysztopik, R; Nicklin, J; Streets, CG; Strong, S; Titcomb, D; Wilson, C | 1 |
| Konda, S; O'Bryan, KW; Patel, VA; Ratner, D | 1 |
| Hoegdall, DT; Jensen, LH; Larsen, FO; Mellergaard, AH | 1 |
| Berkel, AE; Klaase, JM; van der Palen, J; Woutersen, DP | 1 |
| Allison, DE; Han, K; Jin, J; Lowe, J; Maia, M; Sersch, MA | 1 |
| Aparicio, J; Bohn, U; Bosch, C; Carmona, A; Casado, E; Escudero, P; Feliu, J; García-Girón, C; Jorge, M; Martínez-Marín, V; Maurel, J; Pérez-Carrión, R; Safont, MJ; Salud, A; Serra, O; Vera, R | 1 |
| Cooper, A; Grey, A; Grimison, P; McNeil, C; O'Toole, S; Thompson, J | 1 |
| Grin, A; Grover, SC; Maggo, G | 1 |
| Chai, CY; Chen, CF; Huang, CJ; Huang, CM; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, CH; Yeh, YS | 1 |
| Al-Sakaff, N; Bang, YJ; Chung, HC; Gotovkin, EA; Hamamoto, Y; Hill, J; Kang, YK; Moiseyenko, VM; Ohtsu, A; Satoh, T; Urspruch, A; Van Cutsem, E; Weber, HA | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Bang, YJ; Barriuso, J; Garg, A; Kang, YK; Rha, SY; Szado, T; Tassone, P; Yu, R | 1 |
| de Braud, F; Di Bartolomeo, M; Iacovelli, R; Maggi, C; Palazzo, A; Pietrantonio, F; Ricchini, F | 1 |
| Drzymała, M; Golon, K; Karczmarek-Borowska, B | 1 |
| Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M | 1 |
| Sands, MJ; Wunderle, KA | 1 |
| Castro-Rojas, C; Ortiz-Lópezj, R; Rojas-Martínez, A | 1 |
| Czejka, M; Dittrich, C; Gintersdorfer, S; Kitzmueller, M; Lichtneckert, M; Neudorfer, C; Poxhofer, M; Schreiber, V | 1 |
| Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J | 1 |
| Astsaturov, I; Ball, DS; Cade, DN; Cohen, SJ; Dickens, A; Konski, AA; Marlow, C; Meropol, NJ; Meyer, JE; Putnam, S; Yu, JQ | 1 |
| Bekaii-Saab, T; Benson, AB; Chan, E; Chen, YJ; Cooper, HS; Engstrom, PF; Enzinger, PC; Fenton, MJ; Freedman-Cass, DA; Fuchs, CS; Gregory, KM; Grem, JL; Hunt, S; Kamel, A; Leong, LA; Lin, E; Messersmith, W; Mulcahy, MF; Murphy, JD; Nurkin, S; Rohren, E; Ryan, DP; Saltz, L; Sharma, S; Shibata, D; Skibber, JM; Sofocleous, CT; Stoffel, EM; Stotsky-Himelfarb, E; Venook, AP; Willett, CG | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Coban, E; Demir, L; Dirican, A; Erten, C; Koyuncu, B; Kucukzeybek, Y; Somali, I; Tarhan, MO; Varol, U; Yildiz, Y | 1 |
| Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, P | 1 |
| Hong, SM; Ihn, MH; Kang, SB; Kim, DW; Lee, SY; Oh, HK | 1 |
| Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE | 1 |
| Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE | 1 |
| Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ | 1 |
| Bydder, G; Bydder, M; Carmona, R; Gulaya, S; Mell, LK; Pritz, J; Vaida, F; Welch, CS; Williamson, CW; Zhu, H | 1 |
| Dong, B; Gao, J; Gong, J; Li, Y; Li, Z; Lu, Z; Shen, L; Yu, J; Zhang, X | 1 |
| Bosch, SL; Cats, A; Dewit, LG; Marijnen, CA; Nagtegaal, ID; Swellengrebel, HA; Verwaal, VJ; Vincent, AD | 1 |
| Alhamed, A; Chatterjee, A; Foster, DA; Hosny, C; Mukhopadhyay, S; Saqcena, M | 1 |
| Baiget, M; Balart, J; Barnadas, A; Berenguer-Llergo, A; Del Río, E; Martín-Richard, M; Páez, D; Salazar, J; Sebio, A; Sullivan, I; Targarona, E; Tobeña, M | 1 |
| Altundag, K; Arslan, C; Dizdar, O | 1 |
| Baranov, SB; Berlev, IV; Guseĭnov, KD; Maksimov, SIa; Mikaia, NA; Urmancheeva, AF | 1 |
| Eskandari, MR; Moghaddam, F; Pourahmad, J; Shahraki, J | 1 |
| Abbasi, S; Albaba, H; Kashashna, A | 1 |
| Lane, N; Parekh, P; Walker, G | 1 |
| Basdanis, G; Dermitzakis, EV; Eleftheraki, A; Fountzilas, G; Georgiadis, G; Kimiskidis, VK; Konstantis, A; Lazaridis, G; Tsiptsios, I | 1 |
| Blackmon, SH; Correa, AM; Eng, C; Kee, B; Subbiah, IM; Swisher, SG; Vaporciyan, AA | 1 |
| Adachi, Y; Aoshima, K; Asano, M; Funahashi, Y; Kawano, S; Kimura, T; Matsui, J; McCracken, PJ; Nomoto, K; Oda, Y; Okamoto, K; Ozawa, Y; Semba, T; Tizon, X; Tohyama, O; Uehara, T; Uesugi, M; Watanabe, H | 1 |
| Carter, GC; Johnson, BH; Landsman-Blumberg, PB; Li, L; Nicol, SJ; Sedgley, R; Shankaran, V | 1 |
| Bai, B; Cui, Y; Kuang, S; Wen, Y | 1 |
| Fitatiuk, J; Kaza, M; Pawiński, T; Piórkowska, E; Rudzki, PJ; Szlaska, I | 1 |
| Guo, X; Jiao, S; Jing, F; Li, J; Linghu, R; Liu, M; Yang, J; Zhu, Y | 1 |
| Ballman, KV; Cohen, HJ; Hudis, C; Hurria, A; Kimmick, GG; Klepin, HD; Kornblith, AB; Muss, HB; Pitcher, BN; Winer, EP | 1 |
| Bang, YJ; Cha, Y; Han, SW; Han, W; Im, SA; Kim, TY; Noh, DY; Oh, DY; Park, IA; Seol, H | 1 |
| De Iuliis, F; Lanza, R; Salerno, G; Scarpa, S; Taglieri, L; Vicinanza, R | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chang, BW; Johung, KL; Saif, MW | 1 |
| Attademo, L; Bucci, L; Carlomagno, C; Cella, AC; De Falco, S; De Placido, S; De Stefano, A; Fiore, G; Moretto, R; Pepe, S; Raimondo, L; Romano, FJ; Rosanova, M | 1 |
| Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK | 1 |
| Battisti, S; Guida, FM; Pagliara, E; Santini, D; Tonini, G; Zobel, BB | 1 |
| Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY | 1 |
| Aaron, M; Halperin, DM; Hoff, AO; Hoff, PM; Phan, AT; Yao, JC | 1 |
| Armstrong, DE; Ghosh, S; Kim, CA; Mulder, KE; Spratlin, JL | 1 |
| Chen, HC; Chen, HH; Chen, WT; Chou, YH; Fang, CY; Hsu, HH; Huang, CC; Lee, HC; Lin, BW; Lin, JK; Lin, PC; Tan, EC; Ting, WC; Yang, MC; Yeh, CH | 1 |
| Chen, J; Chen, X; Dai, C; Wu, X; Yu, B; Zhao, C; Zhou, C | 1 |
| Akgun, Z; Balik, E; Cipe, G; Gural, Z; Kaytan-Saglam, E; Kilickap, S; Okyar, A; Saglam, S; Yildiz, S; Yucel, S | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Gu, Y; Guo, R; He, X; Liu, L; Liu, P; Lu, K; Shu, Y; Yin, Y; Zhang, J; Zhang, Q; Zhu, L | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Hirai, K; Igarashi, T; Miyamae, Y; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yoshinari, D | 1 |
| Danno, K; Fujitani, K; Fukui, A; Iwase, K; Kawada, J; Kubota, M; Matsuda, C; Miyazaki, S; Takagi, M; Tanaka, Y | 1 |
| Hirakawa, K; Hosono, M; Maeda, K; Miki, Y; Nagahara, H; Shimatani, Y; Tsutsumi, S | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Beijnen, JH; Cats, A; Dewit, L; Meulendijks, D; Schellens, JH; Tomasoa, NB; van Tinteren, H | 1 |
| Lin, RF; Luo, WH; Su, M; Wei, HP; Zhu, LC; Zou, CL | 1 |
| Chen, LH; Liu, TF; Liu, XF; Sun, JQ; Yang, H; Yin, C; Zhang, H | 1 |
| Bayraktar, S; de Snoo, F; Glück, S; Royce, M; Stork-Sloots, L | 1 |
| Ding, DY; Hou, RZ; Li, YC; Song, B; Sun, LB; Zhao, GJ | 1 |
| Ahn, JB; Bello, M; Charoentum, C; Chen, LT; Cheng, AL; Ciardiello, F; de Lima Lopes, G; Ho, GF; Kim, TW; Köhne, CH; Kong, HL; Lam, KO; Li, J; Liu, TS; Ma, BB; Park, YS; Shaw, M; Sriuranpong, V; Sudoyo, AW; Teh, C; Vaid, AK; Wang, JY; Zhang, J; Zhang, SZ | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Hwang, IG; Kang, JH; Kang, WK; Kim, ST; Lee, HR; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, KW; Park, SH; Park, YS | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Cokmert, S; Demir, L; Dirican, A; Karabulut, B; Kucukzeybek, Y; Muslu, U; Tarhan, MO; Uslu, R; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Ahlgren, J; Akin, E; Bishop, C; Guebre-Xabiher, H; Kirkel, D; Patel, N; Schuck, S; Siegel, P; Siegel, R; Simmens, S | 1 |
| Dong, CX; Fu, JF; Li, XF; Ye, XY; Yuan, Y; Zhong, X | 1 |
| Bai, Y; Liang, J; Liu, H; Shen, L; Wang, J; Xu, J; Xu, N; Yang, L; Zhang, X | 1 |
| Boot, H; Cats, A; Jansen, EP; Nijkamp, J; Trip, AK; van Tinteren, H; Verheij, M | 1 |
| Baek, JY; Chie, EK; Jang, HS; Jung, JH; Kim, DY; Kim, HC; Kim, JG; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Nam, TK; Oh, JH; Oh, ST; Park, HC; Park, SC | 1 |
| Cleator, S; Dzaye, O; Nihoyannopoulos, P | 1 |
| Chen, XS; Garfield, DH; Huang, O; Shen, KW; Wu, JY; Yuan, Y | 1 |
| Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tokuyama, Y; Tsurushima, M; Uchiyama, K | 1 |
| Hara, Y; Minami, Y; Nakamura, T; Ueda, S | 1 |
| Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL | 1 |
| Fujiwara, T; Inada, R; Kishimoto, H; Kondo, Y; Mori, Y; Nagasaka, T; Toshima, T | 1 |
| Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S | 1 |
| Alba, E; Bines, J; Cortes, P; Costa, R; de Ducla, S; Doval, D; Freudensprung, U; Gligorov, J; Gupta, V; Mustacchi, G; Pierga, JY; Srock, S | 1 |
| Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
| Chiche, L; Dicostanzo, MP; Fongue, J; Harlé, JR; Lardet, D; Meunier, B; Richard, MA; Rouby, F; Terrier, JP | 1 |
| Bardy-Bouxin, N; Calles, A; Calvo, E; Campone, M; Duvillié, L; Isakoff, SJ; Leip, E; Turnbull, K; Wang, D | 1 |
| Apte, A; Deasy, JO; Goodman, KA; Oh, JH; Son, CH; Yang, TJ | 1 |
| Ayala de la Peña, F; Calvo, F; Conesa-Zamora, P; Dzhugashvili, M; Escolar, PP; García, T; González-Conejero, R; Luengo-Gil, G; Vicente, V | 1 |
| Christensen, IJ; Hammer, E; Holck, S; Larsson, LI; Nielsen, HJ | 1 |
| Bartoš, J; Blüml, A; Buka, D; Cermáková, E; Dvořák, J; Ferko, A; Melichar, B; Petera, J; Richter, I; Ryška, A; Sirák, I; Sitorová, V; Urbanec, M | 1 |
| Carmichael, L; Deming, DA; Eickhoff, J; Holen, KD; Ivy, P; Kolesar, J; Leverence, R; Liu, G; LoConte, NK; Lubner, SJ; Mulkerin, DL; Razak, AR; Schelman, WR; Siu, L; Tevaarwerk, A | 1 |
| Boisen, MK; Dehlendorff, C; Hansen, TF; Holländer, NH; Høgdall, EV; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Linnemann, D; Nielsen, BS; Nielsen, SE; Osterlind, K; Pfeiffer, P; Qvortrup, C; Tarpgaard, LS | 1 |
| Ban, T; Ikegaya, Y; Isogai, N; Kawachi, J; Miyake, K; Ogino, H; Shimoyama, R; Watanabe, K | 1 |
| Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| De Vries, A; Eisterer, W; Gnant, M; Greil, R; Höfler, G; Kapp, K; Koplmüller, R; Lukas, P; Öfner, D; Rabl, H; Schmid, R; Sedlmayer, F; Thaler, J; Tschmelitsch, J | 1 |
| Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O | 1 |
| Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T | 1 |
| Awada, A; Cortes, J; He, Y; Kaufman, PA; Olivo, M; Twelves, C; Vahdat, L | 1 |
| Chen, F; Chen, Y; Cheng, B; Fang, Y; Qu, X; Wang, Z; Xiong, B | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Goldberg, RM; Nordlinger, B; Poston, GJ | 1 |
| Boni, C; Clemens, M; Cohn, A; Dane, F; Ecstein-Fraisse, E; Follana, P; Harrison, M; Hitier, S; Massuti, B; Middleton, G; Moiseyenko, V; Pernot, S; Pimentel, FL; Prenen, H; Reichardt, P; Richards, DA; Rougier, P; Tabernero, J; Van Cutsem, E; Zaniboni, A | 1 |
| Aisu, N; Hirata, K; Hoshino, S; Kojima, D; Mogi, A; Tanimura, S; Yamada, T; Yamashita, Y; Yoshida, Y | 1 |
| Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Cavalcanti, E; D'Angelo, V; Daniele, G; Delrio, P; Di Gennaro, E; Di Maio, M; Gallo, C; Granata, C; Iaffaioli, VR; Lastoria, S; Maiolino, P; Marone, P; Maurea, N; Montano, M; Muto, P; Pecori, B; Perrone, F; Petrillo, A; Piccirillo, MC; Roca, MS; Romano, G; Silvestro, L; Tatangelo, F; Terranova Barberio, M | 1 |
| Hassan, NB; Norazwany, Y; Norhayati, I; Norsa'adah, B; Roslan, MH; Wan Nazuha, WR; Zahrina, AK | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R | 1 |
| Faez, L; Garrido, M; Jiménez-Fonseca, P; Menendez, MD; Rodriguez, D; Ruiz, AL; Sanchez Lorenzo, ML; Solis, MP; Uriol, E; Viéitez, JM | 1 |
| Cox, D; Dranitsaris, G; Faria, C; Gluck, S; Rugo, H | 1 |
| Choda, Y; Harano, M; Idani, H; Kanazawa, T; Matsukawa, H; Ninomiya, M; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Tokumoto, N | 1 |
| Aoki, J; Goto, M; Honjo, K; Ichikawa, R; Ishiyama, S; Ito, S; Kawai, M; Kojima, Y; Komiyama, H; Kure, K; Mizukoshi, K; Okazawa, Y; Okubo, H; Ro, H; Sakamoto, K; Sugimoto, K; Takahashi, M; Takehara, K; Tomiki, Y; Yaginuma, Y | 1 |
| Brufsky, A | 1 |
| Doi, T; Nishida, T | 1 |
| Bang, YJ; Chen, JS; Choi, JH; Chung, HC; Chung, IJ; Ha, S; Ji, J; Kim, HH; Kim, HK; Kim, SW; Lee, JI; Lim, Y; Noh, SH; Park, SR; Shin, DB; Yang, HK; Yu, W | 1 |
| An, X; Cai, MY; Cai, PQ; Chen, G; Ding, PR; Gao, YH; Kong, LH; Lin, JZ; Liu, GC; Luo, JL; Pan, ZZ; Tang, JH | 1 |
| Amaraneni, A; Chandana, SR; Itawi, EA; Seth, A | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, LA; Lee, RJ; Meropol, NJ; Mitchell, EP; Moughan, J; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Wong, SJ | 1 |
| Bensch, F; Reyners, AK; Schröder, CP; van Rooijen, JM | 1 |
| Baudin, E; Bengrine-Lefevre, L; Cadiot, G; Dominguez-Tinajero, S; Dromain, C; Ducreux, M; Farace, F; Kurtz, JE; Mitry, E; Rougier, P; Ruszniewski, P; Walter, T | 1 |
| Cartwright, T; Haller, D; Lee, S; McKenna, E; O'Connell, MJ; Saif, M; Schmoll, HJ; Sun, W; Twelves, C; Yothers, G | 1 |
| Bos, MM; Boven, E; Braun, JJ; de Groot, SM; Honkoop, AH; Jager, A; Kroep, JR; Lam, SW; Linn, SC; ten Tije, AJ; van den Bosch, J; van Tinteren, H | 1 |
| Bergaglio, M; Buonerba, C; Calabrese, F; Damiano, V; De Maio, AP; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Milella, M; Montella, L; Ottaviano, M; Palmieri, G; Von Arx, C | 1 |
| Abad, MM; Alcazar, JA; Bengoechea, O; Blanco, O; Fuentes, M; Garcia, J; Gónzalez, LM; González-González, M; Gutiérrez, ML; Martín, M; Muñoz-Bellvis, L; Orfao, A; Rodríguez, A; Santos-Briz, A; Sayagues, JM | 1 |
| Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T | 1 |
| Alsina, M; Aranda, E; Cano, MT; Conde, V; Díaz-Rubio, E; Galán, M; García de Paredes, ML; López, C; Manzano, JL; Martínez Galán, J; Massutí, B; Pachón, V; Reboredo, M; Rivera, F; Salcedo, M; Sastre, J; Serrano, R; Valladares-Ayerbes, M; Yuste Izquierdo, AL | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT | 1 |
| Friedrich, M; Kummer, S; Terjung, A | 1 |
| Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D | 1 |
| Graziani, C; Hegde, S; Saif, MW | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Aktas, B; Aydogdu, M; Feisel-Schwickardi, G; Höffkes, HG; Illmer, T; Janni, W; Loibl, S; Lübbe, K; Lück, HJ; Maass, N; Mehta, K; Nekljudova, V; Neunhöffer, T; Ober, A; Park-Simon, TW; Reinisch, M; Schumacher, C; Tomé, O; von Minckwitz, G; Wagner, H | 1 |
| Cai, J; Li, T; Wu, B; Xu, Y; Zhao, G | 1 |
| Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X | 1 |
| Chan, AT; Chan, LL; Chan, OS; Chappell, R; Cheng, A; Cheung, FY; Choi, H; Kwong, DL; Lee, AW; Lu, TX; Ng, WT; Ngan, RK; Tung, SY; Wong, F; Yau, S; Yiu, H; Yuen, KT | 1 |
| Chourasia, MK; Meher, JG; Pawar, VK; Singh, M; Singh, Y | 1 |
| Fuxius, S; Hahn, LJ; Hurst, U; Lerchenmüller, C; Luhn, B; Müller, V; Soeling, U; Steffens, CC; Vehling-Kaiser, U; Wohlfarth, T; Zaiss, M | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W | 1 |
| Du, ZD; He, XF; Li, Q; Tang, RL; Wen, F; Yao, K; Zhang, PF | 1 |
| Babacan, NA; Doğan, M; Kaçan, T; Kiliçkap, S; Koç, S; Seker, MM; Uysal, IO; Yüce, S | 1 |
| Aksoy, A; Arpaci, E; Bahceci, A; Bayoglu, IV; Besiroglu, M; Dane, F; Duran, AO; Hacibekiroglu, I; Inanc, M; Karaca, H; Menekse, S; Ozkan, M; Sevinc, A; Tanriverdi, O; Uysal, M; Yapici, HS; Yazilitas, D | 1 |
| Fennig, S; Greenberg, G; Leshem, Y; Talianski, E; Wolf, I | 1 |
| Fan, YT; Feng, HY; Jin, T; Ju, HX; Li, DC; Liu, LY; Liu, Y; Luo, JL; Zhou, N; Zhu, Y; Zhu, YP | 1 |
| Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R | 1 |
| Desurmont, T; Duchene, B; Duhamel, A; Gosset, P; Hebbar, M; Huet, G; Jonckheere, N; Leteurtre, E; Millet, G; Pruvot, FR; Ramdane, N; Skrypek, N; Truant, S; Van Seuningen, I | 1 |
| Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R | 1 |
| Carlsen, AL; Hansen, TF; Heegaard, NH; Jakobsen, A; Sørensen, FB | 1 |
| Cai, Y; Gu, J; Ji, JF; Li, YH; Li, ZW; Li, ZY; Sun, YS; Wang, L | 1 |
| Autorino, R; Fagotti, A; Fanfani, F; Ferrandina, G; Foti, E; Gallotta, V; Gambacorta, A; Scambia, G; Smaniotto, D; Tagliaferri, L; Valentini, V | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Baroian, N; Buchner, P; Czejka, M; Dittrich, C; Sahmanovic, A; Schreiber, V | 1 |
| Kakizawa, N; Kato, T; Noda, H; Rikiyama, T; Toyama, N; Watanabe, F | 1 |
| Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K | 1 |
| Nagai, K; Ohara, Y; Okuda, Y; Yamamoto, M | 1 |
| Aparicio, J; Bohn, U; Bosch, C; Carmona, A; Casado, E; Custodio, AB; Escudero, P; Feliu, J; García-Girón, C; Jorge, M; Losa, F; Maurel, J; Pérez-Carrión, R; Safont, MJ; Salud, A | 1 |
| Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B | 1 |
| Awada, A; Cortes, J; Dutcus, CE; He, Y; Kaufman, PA; Olivo, MS; Perez, EA; Twelves, C; Velikova, G; Yelle, L | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G | 2 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Aydin, N; Gushchin, V; Ledakis, P; Milovanov, V; Nieroda, C; Nunez, M; Sardi, A; Sittig, M | 1 |
| Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C | 1 |
| Magdy, T; Nies, AT; Schwab, M; Zanger, UM | 1 |
| Guggenberger, D; Hansen, R; Jacobs, G; Kröning, H; Schardt, C; Schmidt, P; Steffens, CC; Tschechne, B; Valdix, AR; Wohlfarth, T | 1 |
| Deng, W; Gao, J; Li, Y; Shen, L; Yuan, J; Zhou, J | 1 |
| Chung, IJ; Han, HS; Kang, SY; Kang, YK; Kim, JG; Lee, KH; Park, SR; Park, YS; Ryoo, BY; Ryu, MH; Song, EK; Yoo, C | 1 |
| Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A | 1 |
| Beijnen, JH; Boot, H; Cats, A; Cerny, TD; Doodeman, VD; Huitema, AD; Joerger, M; Meijerman, I; Meulendijks, D; Rosing, H; Schellens, JH; Smits, PH; Vainchtein, L; Zueger, M | 1 |
| Taguchi, Y; Takashima, S; Tanaka, K | 1 |
| Anderson, EM; Chang, DT; Jayachandran, P; Koong, AC; Kozak, MM; Limaye, M; Longacre, T; Pai, J; Pai, RK; Shaffer, JL; von Eyben, R; Vossler, SR | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Liang, N; Luo, H; Qiao, L; Wang, J; Xie, J; Xu, C; Zhang, J; Zhang, JX | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Huang, CM; Li, P; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH | 1 |
| Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M | 1 |
| Ami, K; Ando, M; Arai, K; Gokita, K; Hayasaka, J; Imai, K; Kitazume, A; Kondou, M; Okamoto, E; Shibayama, T; Takagi, K; Tamura, A; Tei, S; Watanabe, A | 1 |
| Doki, Y; Hamabe, A; Hata, T; Hiraki, M; Inoue, A; Kitahara, T; Miyo, M; Mizushima, T; Mokutani, Y; Mori, M; Munakata, K; Naito, A; Nishimura, J; Ogawa, H; Osawa, H; Takemasa, I; Uemura, M; Yamamoto, H | 1 |
| Hosoda, Y; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yasui, M | 1 |
| Hosaka, S; Kawamoto, S; Maeno, H; Ohara, C; Okubo, S; Umemoto, S; Yonemitsu, K; Yoshida, T | 1 |
| Doi, K; Iwatsuki, M; Ogata, K; Ogawa, K; Shimizu, K; Sugiyama, S; Takamori, H; Tanaka, H | 1 |
| Ishizu, H; Kuji, M; Masuko, H; Matsumoto, S; Takahashi, M; Takahashi, S; Tanioka, T; Yamagami, H | 1 |
| Hirakawa, K; Kitayama, K; Nishimura, J; Nishino, H; Noda, E; Nomura, S; Teraoka, H | 1 |
| Kanada, Y; Kobayashi, T; Maruyama, T; Matsuzaki, H; Miyazaki, A; Natsume, T; Otsuka, R; Satoh, Y; Satsuka, T; Shimizu, S; Tanaka, H; Yamamoto, Y; Yanagihara, A; Yokoyama, M; Yoshioka, T | 1 |
| Hanyu, T; Hashimoto, Y; Hosoi, M; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nakano, M; Nogami, H; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T | 1 |
| Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Ohkubo, Y; Shimokawa, R; Suzuki, Y; Yamamuro, W; Yoneda, M | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tomihara, H; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Adachi, S; Akagi, K; Dono, K; Hatano, H; Hirota, M; Hokonohara, K; Imamura, H; Iwazawa, T; Komori, T; Morita, S; Noda, T; Oshima, K; Takata, A; Tanida, T | 1 |
| Hatanaka, N; Honmyo, N; Inoue, M; Irei, T; Jeongho, M; Kurokawa, T; Odagiri, K; Shimizu, Y; Tanemura, M; Tominaga, H; Yamashita, S | 1 |
| Asaoka, T; Fujitani, K; Fukuda, Y; Haraguchi, N; Hirao, M; Ikeda, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Tsujinaka, T; Yamamoto, K | 1 |
| Aisu, Y; Ando, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N | 1 |
| Hanyu, T; Ichikawa, H; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nakano, M; Sakata, J; Shimada, Y; Tanaka, R; Wakai, T | 1 |
| Bruhn, MA; Cunningham, D; Gebski, V; Hardingham, JE; Lee, CK; Mann, KP; Price, TJ; Robinson, B; Simes, J; Tebbutt, NC; Townsend, AR; Van Hazel, G; Weickhardt, A; Wilson, K; Wrin, JW | 1 |
| Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T | 1 |
| Atsumi, Y; Fujikawa, Y; Hasegawa, S; Hayashi, T; Kanazawa, A; Masuda, M; Oshima, T; Rino, Y; Sato, T; Tamagawa, H; Tsuchida, K; Uchiyama, M; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A | 1 |
| Addeo, P; Bachellier, P; Belletier, C; De Blasi, V; Dufour, P; Fuchshuber, P; Oussoultzoglou, E; Rosso, E; Simone, G | 1 |
| Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B | 1 |
| Huang, F; Lv, QZ; Shen, FM; Su, R; Xu, HB | 1 |
| Barni, S; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F; Zaniboni, A | 1 |
| Chen, X; Dai, X; Deng, P; Ding, L; Ji, C; Zhong, D | 1 |
| Ishii, K; Kanamoto, A; Miyanaga, S; Noto, M; Takeda, T; Tani, T; Yagi, M | 1 |
| Endo, S; Hiraoka, K; Kim, C; Konishi, K; Matsumoto, K; Nakagawa, T; Nishijima, J; Nishikawa, K; Okuyama, M; Takeda, K; Ueda, Y; Yamada, T | 1 |
| Klümpen, HJ; Kordes, S; Richel, DJ; Schellens, JH; Weterman, MJ; Wilmink, JW | 1 |
| Ahn, KS; Alharbi, SA; Arfuso, F; Chinnathambi, A; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Siveen, KS; Zayed, ME | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D | 1 |
| Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J | 1 |
| Chavarri-Guerra, Y; Soto-Perez-de-Celis, E | 1 |
| Bencsikova, B; Bortlicek, Z; Dusek, L; Halamkova, J; Kiss, I; Melichar, B; Ostrizkova, L; Pavlik, T; Valik, D; Vyzula, R; Zdrazilova-Dubska, L | 1 |
| Chu, Y; Feng, Y; Li, W; Liu, T; Luo, F; Qian, J; Wang, Y; Yang, J; Yu, Y; Zhang, D; Zhang, W; Zhao, N; Zheng, X | 1 |
| Chen, MW; Huang, HQ; Huang, JJ; Jiang, DK; Lu, DC; Wu, FL; Yang, X; Ying, YP; Zeng, HY; Zhou, AM; Zhou, J | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI | 1 |
| Bujko, K; Glimelius, B; Michalski, W; Spalek, M; Valentini, V | 1 |
| Benezery, K; Boige, V; Chamorey, E; de Laroche, G; Gérard, JP; Gourgou-Bourgade, S; Juzyna, B; Mahé, MA | 1 |
| Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Kruger, S; Laubender, RP; Märten, A; Modest, DP; Stintzing, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Mo, Y; Yan, Y; Zhang, D | 1 |
| Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC | 1 |
| Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM | 1 |
| Ayez, N; Eggermont, AM; Grünhagen, DJ; Rothbarth, J; van der Stok, EP; van Meerten, E; Verhoef, C | 1 |
| Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J | 1 |
| Li, R; Li, Y; Liu, Y; Qiao, X; Shi, G; Tan, B; Tian, Y; Wang, J; Xu, Q; Yang, P; Zhang, J; Zhao, Q | 1 |
| Calpena, R; Gallego, J; Lacueva, FJ; Martinez-Blasco, A; Mingol, F; Morcillo, MA; Moya, P; Orduña, A; Ruiz, JA; Sola-Vera, J | 1 |
| Korytov, OV; Korytova, LI; Krasnikoval, VG; Meshechkin, AV; Sandalevskaya, AG | 1 |
| Dong, J; Gao, Y; Huang, R; Liu, M; Peng, H; Wang, C; Wen, B; Xiao, W; Zeng, Z; Zhang, L; Zhang, T | 1 |
| Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM | 1 |
| Choi, GS; Kang, SB; Kim, DY; Kim, HC; Kim, HR; Kim, JC; Kim, NK; Kim, SH; Kim, SY; Lee, JB; Lee, KY; Lee, WY; Lim, SB; Oh, JH; Oh, ST; Park, IJ; Yu, CS | 1 |
| El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Aieta, M; Angelini, V; Antonuzzo, L; Azzarello, D; Bertolini, A; Corsi, DC; Di Costanzo, F; Di Fabio, F; Giommoni, E; Latiano, T; Mogavero, S; Pastina, I; Pastorelli, D; Pavese, I; Pazzagli, M | 1 |
| Chen, G; Ding, PR; Fan, WH; Gao, YH; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zeng, ZF | 1 |
| Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F | 1 |
| Asadi, K; Chionh, F; Lee, CK; Mariadason, JM; Murone, C; Nagtegaal, ID; Parry, MM; Price, TJ; Punt, CJ; Scott, AM; Simes, J; Tebbutt, NC; Weickhardt, AJ; Williams, DS; Wilson, K | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K | 1 |
| Anne, PR; Bendell, J; Berger, AC; Crane, C; DeNittis, A; Garofalo, MC; Hong, TS; Jabbour, SK; Lee, RJ; Moughan, J; Nowlan, A; Oldenburg, NB; Perera, F | 1 |
| Figoni, W; Ikenishi, M; Konishi, Y; Kuroda, A; Matsuda, T; Matsuyama, K; Nakao, M; Nakatsuka, E; Ohtori, T; Satoh, H; Sawada, Y; Takeuchi, M; Tsukazaki, H; Ueda, M | 1 |
| Doki, Y; Hata, T; Hiraki, M; Mizushima, T; Mori, M; Nishimura, J; Nonaka, R; Ohtsuka, M; Takemasa, I; Takeyama, H; Uemura, M; Yamamoto, H | 1 |
| Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T | 1 |
| Skoropad, VY | 1 |
| Baken, BC; Erlinghagen, V; Fuhr, U; Kubeš, V; Novotný, V; Peroutka, R; Queckenberg, C; Van Os, SH; Wargenau, M | 1 |
| Bang, SM; Choi, JY; Choi, SH; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Seong, JS | 1 |
| Chen, L; Cheng, HD; Cui, JX; Li, JY; Liu, SF; Lu, CR; Shen, WS; Xi, HQ | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Wu, JR; Zhou, XP; Zhu, B | 1 |
| Higashi, Y; Ishikawa, S; Kubota, H; Maruo, H; Nishiyama, R; Shoji, T; Suzuki, K | 1 |
| de Braud, F; Haller, DG; Hill, M; Hoersch, S; Maroun, J; Price, T; Rittweger, K; Schmoll, HJ; Tabernero, J; Van Cutsem, E | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kimura, M; Kusumoto, T; Maehara, Y; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Shimokawa, M; Shirouzu, K; Tanaka, T; Touyama, T | 1 |
| Beck, JT; Bendell, JC; Clark, J; Garrett, WM; Hunter, DS; Hurwitz, HI; Leopold, L; Levy, RS; Manges, R; Nemunaitis, JJ; Pipas, JM; Sandor, V; Stella, PJ; Uppal, N; Wade, SM; Wagner, SA; Wainberg, ZA | 1 |
| Hoegdall, E; Nielsen, D; Ole Larsen, F; Taksony Solyom Hoegdall, D | 1 |
| Allegra, CJ; Arora, A; Bahary, N; Beart, RW; Eakle, JF; Evans, LS; Landry, JC; Marchello, BT; Moore, DF; Mullane, MR; O'Connell, MJ; Pitot, HC; Robertson, JM; Roh, MS; Ryan, DP; Sharif, S; Shields, AF; Soori, G; Ward, PJ; Wolmark, N; Wozniak, TF; Yothers, G | 1 |
| Geyer, AI; Kelly, DW; O'Reilly, EM; Sahin, IH | 1 |
| Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V | 1 |
| Andersson, R; Ansari, D; Kölby, D; Sasor, A; Thilén, J | 1 |
| Fukunaga, M; Hasegawa, J; Hazama, S; Kono, E; Kotaka, M; Maeda, H; Mishima, H; Nagata, N; Oba, K; Sakamoto, J; Soda, H; Takahashi, T | 1 |
| Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y | 1 |
| Hayakawa, M; Koketsu, H; Matsuda, S; Nagata, N | 1 |
| Abrams, RA; Blazeby, JM; Bridges, S; Bridgewater, J; Crosby, T; Dutton, P; Falk, S; Griffiths, G; Hurt, CN; Johnson, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Staffurth, J | 1 |
| Dai, GH; Mao, H; Shi, Y; Sun, DC; Wang, ZK | 1 |
| Fahimi, A; Payandeh, M; Sadeghi, M; Shahriari-Ahmadi, A | 1 |
| Cai, S; Hu, J; Xu, Y | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G | 1 |
| Cai, G; Cai, S; Hu, J; Xu, Y | 1 |
| Cohen, SA; Fountzilas, G; Gkakou, C; Gourgioti, G; Grady, WM; Kalogeras, KT; Karavasilis, V; Kotoula, V; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Raptou, G; Wirtz, R; Wu, C; Yu, M | 1 |
| Achrekar, MS; Carvalho, MD; D'souza, A; Govindarajan, S; Gupta, S; Murugan, K; Ostwal, V | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Hu, YF; Li, FP; Li, GX; Li, TT; Lin, T; Liu, H; Mou, TY; Yu, J; Zheng, L | 1 |
| Chan, SH; Koo, SX; Ngeow, J | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| André, T; Aparicio, T; Bedenne, L; Carola, E; Cristol-Dalstein, L; Faroux, R; Francois, E; Maillard, E; Paillaud, E; Retornaz, F; Seitz, JF | 1 |
| André, T; Bonnet, I; Bouché, O; Boucher, E; Chibaudel, B; Dauba, J; Faroux, R; Garcia, ML; Guering-Meyer, V; Hug de Larauze, M; Lapeyre-Prost, A; Lièvre, A; Malka, D; Obled, S; Taieb, J; Ychou, M | 1 |
| He, Q; Li, G; Li, Y; Ma, L | 1 |
| Sugihara, K; Tsuji, Y | 1 |
| Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takeda, T; Tanaka, K; Uemura, M; Yamamoto, K | 1 |
| Fukuda, M; Fukunari, H; Hayashi, T; Kato, T; Nakao, K; Okajima, C; Shitara, K; Yamamoto, Y | 1 |
| Arimitsu, H; Chibana, T; Chou, A; Ikeda, A; Kainuma, O; Kobayashi, R; Nabeya, N; Nagata, M; Souda, H; Takiguchi, N; Tokoro, Y; Tonooka, T; Yamamoto, H; Yanagibashi, H | 1 |
| Fujiwara, Y; Higashiyama, M; Miyoshi, N; Noura, S; Ohue, M; Okami, J; Sakon, M; Sugimoto, N; Yano, M; Yasui, M | 1 |
| Kitagawa, Y; Kitasato, K; Kunugi, C; Murai, S; Oto, I; Shimizu, H; Yabe, N; Yoshikawa, T | 1 |
| Egami, T; Ienaga, J; Ikubo, A; Inoue, S; Ishikawa, M; Konomi, H; Manabe, T; Nagayoshi, K; Nakamura, M; Tanaka, M; Ueki, T; Yamanaka, N | 1 |
| Cao, L; Chen, L; Hu, X; Liu, M; Yao, G; Ye, C | 1 |
| Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D | 1 |
| Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T | 1 |
| Costello, E; Cox, T; Ghaneh, P; Greenhalf, W; Middleton, G; Neoptolemos, JP; Palmer, DH; Shaw, V | 1 |
| Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS | 1 |
| Attene, F; Borrego-Estella, V; Hörndler, C; Moro, SS; Paliogiannis, P; Pulighe, F; Scognamillo, F; Serrablo, A | 1 |
| Hiramatsu, K; Ishigure, K; Kamiya, T; Kawai, S; Kobayashi, S; Kodera, Y; Nagino, M; Nakayama, G; Nakayama, H; Sakamoto, E; Tojima, Y; Uehara, K; Yamashita, K | 1 |
| Cao, J; Fisher, B; Florczynski, MM; Leung, E; Louie, AV; Mai, L; Moulin, DE; Pope, JE; Sanatani, MS | 1 |
| Chiang, JM; Hsieh, TY; Hsu, CK; Lai, MW; Liang, KH; Lim, SN; Lin, WR; Tsou, YK; Yeh, CT | 1 |
| Creemers, GJ; Janssen-Heijnen, ML; Lemmens, VE; Maas, HA; Pruijt, JF; Razenberg, LG; van Erning, FN | 1 |
| Cremolini, C; Falcone, A; Masi, G; Moretto, R | 1 |
| Luo, HY; Xu, RH | 1 |
| Shibano, N; Tanaka, M | 1 |
| Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S | 1 |
| Pan, Z; Peng, J | 1 |
| Chen, G; Ding, P; Lu, Z; Pan, Z; Wan, D; Wu, X; Zhang, R | 1 |
| Feng, R; Li, D; Luo, Y; Wu, H; Xiao, Y; Zhong, D | 1 |
| Aisu, N; Daibo, K; Goto, S; Hasegawa, S; Kamigaki, T; Mera, T; Naito, K; Naito, M; Tanaka, T; Yamada, T; Yamashita, Y; Yasumoto, K; Yoshida, Y | 1 |
| Arcidiacono, PG; Balzano, G; Ceraulo, D; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Nicoletti, R; Passoni, P; Pepe, G; Reni, M; Zanon, S | 1 |
| Gao, Y; Liu, M; Xiao, L; Xiao, W; Yu, X; Zeng, Z; Zhang, R; Zhu, Y | 1 |
| Huguet, F; Mornex, F; Orthuon, A | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Aprile, G; Banzi, M; Barni, S; Cantore, M; Ciuffreda, L; Di Bartolomeo, M; Ferrari, D; Labianca, R; Lonardi, S; Maiello, E; Marchetti, P; Massida, B; Pasini, F; Rimassa, L; Ronzoni, M; Rosati, G; Rulli, E; Scartozzi, M; Sobrero, A; Zagonel, V; Zampino, MG; Zaniboni, A | 1 |
| Chen, Y; Cui, Y; Liang, L; Liu, T; Wang, Y; Wang, Z; Yu, Y; Zhou, Y; Zhuang, R | 1 |
| Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, S; Yu, YY; Zhao, NQ; Zhuang, RY | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Chang, HM; Kim, KP; Park, K; Park, S | 1 |
| Grande, C; Groman, A; Iancu, DM; Iyer, RV; Ma, WW; Malhotra, U; Pokuri, VK; Saab, TB | 1 |
| Li, C; Liu, F; Wang, Z; Wu, Y; Xu, Y; Yang, L; Zhao, J; Zheng, H | 1 |
| Altundag, K | 1 |
| Lian, B; Mo, Q; Qin, Q; Tan, Q; Wei, C; Yang, W | 1 |
| Cai, Y; Li, X; Shi, C; Zhou, H | 1 |
| Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP | 1 |
| Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY | 1 |
| Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S | 1 |
| Chao, Y; Hou, MC; Lan, KH; Lee, SD; Lee, WP; Li, CP; Lin, HC | 1 |
| Anthoney, A; Cheeseman, S; Collinson, M; Dent, J; Hall, PS; Howard, H; Jones, M; Last, K; Lord, SR; Lowe, C; Marshall, H; Roy, R; Seymour, MT; Swinson, D; Velikova, G | 1 |
| Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Miwa, H; Murakami, M; Muratsu, A; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshida, Y; Yoshikawa, M | 1 |
| Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Nishimura, J; Ohara, N; Satoh, T; Takahashi, H; Yamamoto, H | 1 |
| Fujii, T; Funahashi, K; Kaneko, H; Kaneko, T; Katayanagi, T; Koda, T; Koike, J; Kurihara, A; Masuhara, H; Sawaguchi, Y; Shimada, H; Shiokawa, H; Suzuki, T; Ushigome, M; Watanabe, Y | 1 |
| Kondo, J; Maeda, Y; Morita, K; Nagashima, A; Nagashima, Y; Nisimura, T; Sakata, K; Setoguchi, M | 1 |
| Hirano, Y; Ishii, Y; Kawamoto, S; Maeno, H; Munechika, T; Nomi, M; Noritomi, T; Okamoto, T; Shibata, R; Tanaka, K; Yanagisawa, J; Yonemitsu, Y | 1 |
| Komatu, T; Nomura, S; Ogasawara, T; Sato, Y; Shida, T; Takahara, Y; Takahashi, M; Uno, H | 1 |
| Hashimoto, Y; Hotta, S; Iwaki, T; Kameyama, H; Kobayashi, T; Oyamatsu, M; Sakata, J; Sato, K; Sato, Y; Shimada, Y; Wakai, T | 1 |
| Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Nagata, M; Soda, H; Takiguchi, N; Tonooka, T; Yamamoto, H | 1 |
| Ebisui, C; Fukuchi, N; Hamano, R; Kinuta, M; Kitahara, T; Minoji, T; Murata, K; Nushijima, Y; Ohishi, K; Okamura, S; Yanagisawa, T; Yokouchi, H | 1 |
| Kaito, A; Kinoshita, T; Nishida, T; Shibasaki, H; Shitara, K | 1 |
| Cross, WE | 1 |
| Cruz-Monserrate, Z; Govindarajan, R; Griffin, J; Hung, SW; Mody, HR; Pathak, RK | 1 |
| Ando, Y; Hayashi, T; Ikeda, Y; Ito, K; Kawada, K; Kumazawa, S; Maeda, K; Matsuoka, H; Murai, S; Ohta, H; Shiouchi, H; Yamada, S; Yasuda, K | 1 |
| Berlin, J; Engebretson, A; Hong, TS; Katz, MHG; Khorana, AA; Maitra, A; Mangu, PB; Mohile, SG; Mumber, M; Schulick, R; Shapiro, M; Urba, S; Zeh, HJ | 1 |
| Li, H; Li, W; Liang, L; Liu, T; Song, D; Zhao, N | 1 |
| Baechmann, S; Boeck, S; Clemens, MR; Esposito, I; Haas, M; Heinemann, V; Jung, A; Kettner, E; Kirchner, T; Kruger, S; Laubender, RP; Ormanns, S; Quietzsch, D; Remold, A; Schlitter, AM; Siveke, JT; Wenzel, P; Westphalen, CB | 1 |
| Huang, ZP; Li, GX; Wang, F; Wang, ZX; Xu, RH; Zhou, ZW | 1 |
| Abe, T; Furuhashi, T; Fuyuno, S; Hatada, T; Sato, N | 1 |
| Büchler, MW; Strobel, O | 2 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Aisu, N; Goto, S; Hamada, Y; Hasegawa, S; Ishii, F; Kamigaki, T; Kato, D; Kodama, S; Kojima, D; Mera, T; Naito, K; Nimura, S; Tanaka, T; Yamauchi, Y; Yasumoto, K; Yoshida, Y | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Sohal, DPS | 1 |
| Hama, T; Inoue, A; Kawakami, K; Kobayashi, K; Machida, Y; Suenaga, M; Sugisaki, T; Suzuki, K; Yamaguchi, K; Yamaguchi, T; Yokokawa, T | 1 |
| Masuda, N; Ohashi, Y; Toi, M | 1 |
| Hizal, M; Şendur, MAN; Yalçin, B | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| Diness, LV; Larsen, FO; Markussen, A; Nielsen, D | 1 |
| Nunes, AA; Pereira, LRL; Peria, FM; Ungari, AQ | 1 |
| Ito, Y; Kobuchi, S; Sakaeda, T; Yazaki, Y | 1 |
| Cheng, X; Lu, Y | 1 |
| Baiu, I; Charville, GW; Visser, BC | 1 |
| Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Murakami, K; Murata, K; Naito, A; Nakatsuka, S; Nose, Y; Omura, Y; Sakamoto, T; Takase, K; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J | 1 |
| Chae, H; Kim, HI; Kim, IH; Kim, MC; Kwon, IK; Lee, CM; Lee, HH; Lee, SI; Min, JS; Park, SS | 1 |
| Baratelli, C; Brizzi, MP; Di Maio, M; Scagliotti, GV; Sonetto, C; Tampellini, M; Zichi, C | 1 |
| Agrawal, N; Arora, A; Baghmar, S; Bihari, C; Chattopadhyay, TK; Kumar, G; Kumar, S; Pamecha, V; Panda, D; Patidar, Y | 1 |
| Chen, LT; Chin, YY; Chu, NS; Wu, IC | 1 |
| Ishibashi, K; Ishida, H; Kato, H; Kato, R; Koda, K; Kosugi, C; Mori, M; Narushima, K; Oya, M; Shuto, K; Tanaka, S; Yoshimatsu, K | 1 |
| Chen, D; Gao, G; Hu, J; Li, L; Liu, B; Qian, X; Shen, L; Yang, M; Zhang, X | 1 |
| Duan, X; Liu, S; Wang, K; Wu, J; Zhang, B; Zhang, D | 1 |
| An, JY; Kim, S; Kim, SM; Lee, J; Sohn, TS | 1 |
| Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Brezault, C; Coriat, R; Guillaumot, MA; Léandri, C; Ribiere, SC | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Baretti, M; Bozzarelli, S; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Tronconi, MC | 1 |
| Fushida, S; Hayashi, H; Hirose, A; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Tajima, H; Takamura, H; Tokoro, T | 1 |
| Barney, C; Diaz, DA; Dillhoff, M; Grieco, C; Manilchuk, A; Pawlik, TM; Salloum, J; Schmidt, C; Walston, S; Williams, TM; Wuthrick, E | 1 |
| Cai, Z; Chen, Z; Shen, C; Wang, J; Yin, X; Yin, Y; Zhang, B; Zhou, Y | 1 |
| Gelderblom, HJ; Mancao, C; Mesker, WE; Putter, H; Tollenaar, RA; van Pelt, GW; Zunder, SM | 1 |
| Bi, F; Cao, D; Chen, Y; Gou, H; Li, Z; Peng, Y; Yang, Y; Zhang, X | 1 |
| Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y | 1 |
| Álvarez-Gallego, R; Cubillo, A; de Vicente, E; Garralda, E; Hidalgo, M; Martin, M; Muñoz, C; Muñoz, M; Perea, S; Pond, G; Quijano, Y; Rodríguez-Pascual, J; Sánchez, G; Toledo, RA; Ugidos, L; Vega, E | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Liotta, L; Quante, M | 1 |
| Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S | 1 |
| Fan, B; Guo, Q; Luo, Y; Shen, C; Wu, M; Zhao, J | 1 |
| Borbath, I; Conroy, T; Malka, D | 1 |
| Chavez-MacGregor, M; Giordano, SH; Kehl, KL; Niu, J | 1 |
| Liang, F; Liu, F; Song, W; Wang, L; Wu, Y; Xu, Y | 1 |
| Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
| Kim, IH | 1 |
| Hajatdoost, L; Kosari, S; Sedaghat, K; Thomas, J; Walker, EJ | 1 |
| Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H | 1 |
| Ahn, JB; Han, SW; Kang, WK; Kim, ST; Kim, TW; Kim, Y; Lee, J; Lim, HY; Park, JO; Park, YS | 1 |
| Taieb, J; Zaanan, A | 1 |
| Akagi, J; Baba, H | 1 |
| Chen, K; Duan, W; Ge, XX; Gong, FR; Shou, LM; Tao, M; Wang, WJ; Wu, J; Wu, MY; Xu, MD; Zhi, Q; Zhu, W | 1 |
| Choi, HJ; Hong, JH; Jang, JS; Kang, JH; Kim, MJ; Kim, S; Kim, ST; Lee, HW; Lee, J; Lee, MA; Lim, HY; Oh, SY; Park, JO; Park, YS; Sohn, BS; Yoon, SY | 1 |
| Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y | 1 |
| Conroy, T; Van Laethem, JL | 1 |
| Barreda-Hernández, D; Fernández-Carballido, AM; Sánchez-Gundín, J; Torres-Suárez, AI | 1 |
| Bachini, M; Bekaii-Saab, T; Crane, C; Edeline, J; El-Khoueiry, A; Feng, M; Katz, MHG; Kennedy, EB; Maithel, SK; Primrose, J; Shroff, RT; Soares, HP; Valle, J | 1 |
| He, D; Liang, Y; Liu, L; Meng, J; Xia, L; Xie, X; Xu, R | 1 |
| Arrazubi, V; Barriuso, J; García-Alfonso, P; Izquierdo-Manuel, M; Jimenez-Fonseca, P; Jimeno, R; Jorge, M; López, C; Martínez, E; Méndez, JC; Muñoz-Unceta, N; Reboredo, M; Rivera, F; Romero, C; Salud, A | 1 |
| Fujita, KI; Ishida, H; Ishikawa, F; Kubota, Y; Ohkuma, R; Sasaki, Y; Sekido, M; Shibanuma, M; Takahashi, T; Tsunoda, T | 1 |
| André, F; Cortés, J; Dent, R; Deurloo, R; Easton, V; Gonçalves, A; Kümmel, S; Martín, M; Pollex, E; Schmid, P; Schuetz, F; Swain, SM | 1 |
| Bae, JM; Bang, D; Cha, Y; Han, H; Han, SW; Jang, H; Jeong, SY; Kang, GH; Kim, H; Kim, HP; Kim, TY; Lee, DW; Lyu, J; Park, KJ; Won, JK | 1 |
| Choi, DW; Choi, SH; Han, IW; Han, S; Heo, JS; Park, DJ; Ryu, Y | 1 |
| Ciardiello, D; Ciardiello, F; Conzo, G; Coppola, N; De Falco, V; De Vita, F; Giunta, EF; Marinaccio, A; Martinelli, E; Napolitano, S; Natalicchio, MI; Troiani, T; Vietri, MT; Vitale, P; Vitiello, PP; Zanaletti, N | 1 |
| Chen, J; Guo, Y; Lin, Z | 1 |
| Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ | 1 |
| Goto, S; Ibe, H; Kamigaki, T; Makita, K; Matsuda, E; Naitoh, K; Oguma, E; Okada, S; Takimoto, R | 1 |
| Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H | 1 |
| Chen, M; Dai, XY; Ding, KF; Fu, DL; He, JJ; Huang, XF; Jiang, K; Kong, XX; Li, GH; Li, J; Li, JS; Li, XL; Lu, M; Song, YM; Sun, LF; Tian, Y; Wang, JW; Xu, D; Xu, JY; Yan, M; Ying, XJ; Yuan, Y; Zhou, JJ | 1 |
| Beijnen, JH; Cats, A; de Vries, N; Deenen, MJ; Huitema, ADR; Jacobs, BAW; Joerger, M; Meulendijks, D; Rosing, H; Schellens, JHM | 1 |
| Huang, GC; Ji, XQ; Jiang, CC; Li, AM; Li, B; Shen, ZT; Yuan, X; Zhou, H; Zhu, XX | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Edeline, J | 1 |
| Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH | 1 |
| Bartoli, L; Messori, A; Trippoli, S | 1 |
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Akhoundova Sanoyan, D; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Li, PC; Lin, GH; Wang, BC; Xiao, BY | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Jin, J; Zhang, Y; Zheng, T; Zhou, L | 1 |
| Chatterjee, D; Hauser, R; Kaufman, PA; Kazmi, S; Raju, D | 1 |
| Boldrini, L; Buwenge, M; Cellini, F; D'Aviero, A; Deodato, F; Dinapoli, N; Frascino, V; Macchia, G; Mattiucci, GC; Morganti, AG; Nardangeli, A; Valentini, V | 1 |
| Ban, D; Esaki, M; Furuse, J; Ioka, T; Ishii, H; Nara, S; Okusaka, T; Shimada, K; Takamoto, T | 1 |
| Abraham, AG; Cox, CM; Hughes, DLI; Hurt, CN; Jones, CM; Maughan, T; Mukherjee, S; O'Neill, EE; Owens, R; Parkes, EE; Sabbagh, A; Wilhelm-Benartzi, CS; Willenbrock, F | 1 |
| Canu, L; De Filpo, G; Mannelli, M | 1 |
| Bhargava, P; Choudhari, A; Goel, M; Gupta, S; Jadhav, P; Mandavkar, S; Ostwal, V; Parulekar, M; Patkar, S; Ramaswamy, A; Sharma, A; Srinivas, S | 1 |
| Chan, SK; Chan, SY; Choi, HC; Kwong, DL; Lam, KO; Lee, AW; Lee, VH; Leung, TW; Luk, MY; Tong, CC | 1 |
| Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y | 1 |
| Brandi, G; Rizzo, A | 1 |
| Ambrosini, R; Berruti, A; Cosentini, D; Ferrari, L; Ferrari, VD; Grisanti, S; Laganà, M; Lazzari, B; Morandi, A; Sigala, S; Volta, AD | 1 |
| Akce, M; Alese, O; Bryson, E; Davis, C; Draper, A; El-Rayes, B; Goyal, S; Hall, K; Patel, U; Sakach, E; Shaib, W; Szabo, S; Watson, M; Wu, C | 1 |
| Goodwin, A; Im, SA; Kim, SB; Lanzalone, S; Lee, KH; Sohn, J; Usari, T | 1 |
| Diasio, RB; King, DA; Saif, MW | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Beenet, L | 1 |
| Hartman, W; Nuyttens, JJME; Oomen-de Hoop, E; Rothbarth, J; van Meerten, E; van Rees, JM; van Vugt, JLA; Verhoef, C | 1 |
| Cao, P; Luo, M; Ni, L; Qiu, M; Shu, X; Zhou, W | 1 |
| Babu, S; Bajaj, V; Bhat, G; Biswas, G; Bondarde, SA; Boya, RR; Choudhury, K; Gupta, S; Joshi, N; Khan, MA; Lakshmaiah, KC; Maksud, TM; Mamillapalli, G; Neve, RS; Patel, AA; Patel, JG; Patel, P; Patil, P; Raja, G | 1 |
| Besselink, MG; Bonsing, BA; Bouwense, SAW; de Jong, EJM; de Meijer, VE; de Vos-Geelen, J; Geurts, SME; Homs, MYV; Janssen, QP; Koerkamp, BG; Simons, TFA; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; van der Geest, LG; van Laarhoven, HWM; Wilmink, JW | 1 |
| Gomatou, G; Kanellis, G; Kotteas, EA; Lagou, S; Rapti, VE; Syrigos, NK; Trontzas, IP | 1 |
| Hao, S; Li, S; Liu, Z; Lu, W; Ouyang, G; Pan, G; Wu, Y | 1 |
| Doki, Y; Eguchi, H; Hasegawa, J; Ikenaga, M; Imasato, M; Kagawa, Y; Kato, A; Kato, T; Kudo, T; Miyoshi, N; Mizushima, T; Mori, M; Murata, K; Nakata, K; Ohtsuru, T; Sakai, D; Satoh, T; Takahashi, H; Tei, M; Uemura, M; Yamamoto, H | 1 |
| Gong, P; Sun, L; Zhang, L; Zhang, X; Zhao, Y | 1 |
| Krishna Sasanka, KSBS; Thangaraju, P; Uppala, PK; Varghese, AM; Velmurugan, H; Yella, SST | 1 |
| Li, WZ; Liu, GY; Xiang, YQ | 1 |
| Ganguly, S; Gogia, A | 1 |
| Pramanik, R; S G, N; Sharma, A | 1 |
| Aliru, M; Bagereka, P; Bhosale, P; Crane, CH; Das, P; Holliday, EB; Ikoma, N; Jacobson, G; Javle, M; Katz, MH; Kim, M; Koay, EJ; Koong, AC; Krishnan, S; Lee, JE; Ludmir, EB; Minsky, BD; Overman, M; Pant, S; Rodriguez, MJ; Smith, GL; Tamm, E; Taniguchi, CM; Tzeng, CW; Van Wieren, A; Varadhachary, G; Wang, H; Wang, X; Wolff, RA; Zaid, M | 1 |
| Hasegawa, A; Okamura, N; Tsujiya, Y; Ueda, A; Yamamori, M | 1 |
| Begg, W; Kibudde, S | 1 |
| Chen, Y; Hu, J; Luo, S; Lv, D; Wu, Z; Xie, X; Yang, B; Zhang, S | 1 |
| Agarwal, P; Bever, K; Christenson, ES; De Jesus-Acosta, A; Durham, J; Laheru, D; Le, DT; Lim, SJ; Ryan, A; Scharpf, RB; Wang, H | 1 |
| Chon, HJ; Hwang, DW; Jeong, H; Jeong, JH; Kim, KH; Kim, KP; Lee, JH; Lee, JS; Lee, MA; Moon, DB; Park, JH; Park, SJ; Ryoo, BY; Yoo, C | 1 |
| Gu, HF; Hu, YF; Jin, YW; Li, FY | 1 |
| Jeong, H; Yoo, C | 1 |
| Hu, H; Wang, Y; Yu, L; Zeng, S | 1 |
501 review(s) available for capecitabine and deoxycytidine
| Article | Year |
|---|---|
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Oral 5-FU analogues in the treatment of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Humans; Tegafur; Uracil | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
The oral fluorouracil prodrugs.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1998 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxidoreductases; Pyridines; Tegafur; Uracil | 1998 |
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Stomach Neoplasms | 1999 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasms; Tegafur; Time Factors; Uracil | 1998 |
Capecitabine: nursing implications of a new oral chemotherapeutic agent.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Nursing Care; Oncology Nursing; Patient Education as Topic | 1999 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
Rational design of new tumoractivated cytotoxic agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Fluorouracil; Humans | 1999 |
Xeloda in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Optimizing chemotherapy for patients with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Treatment Outcome | 1999 |
Potential of Xeloda in colorectal cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 1999 |
Capecitabine.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans | 1999 |
The oral fluoropyrimidines in cancer chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Tegafur | 1999 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; Guanine; Humans; Pemetrexed; Platinum Compounds; Pyridines; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Oral fluoropyrimidines: a closer look at their toxicities.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Tegafur; Uracil | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Oxidoreductases; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidine Phosphorylase; Thymidylate Synthase; Uracil | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
[Discovery and development of novel anticancer drug capecitabine].
Topics: Animals; Antineoplastic Agents; Biological Availability; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Drug Design; Fluorouracil; Humans; Liver; Mice; Neoplasms; Taxoids; Thymidine Phosphorylase; Up-Regulation | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
Oral therapy for colorectal cancer: how to choose.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availability; Capecitabine; Colorectal Neoplasms; Decision Making; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Tegafur; Uracil | 2000 |
Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Treatment Outcome | 2000 |
[Capecitabine--a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2000 |
[Capecitabine for treatment of advanced breast cancers].
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2000 |
Pharmacology and clinical status of capecitabine.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; Humans | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 2000 |
Rational development of capecitabine.
Topics: Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Humans | 2000 |
State-of-the-art chemotherapy for advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
Capecitabine: preclinical pharmacology studies.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Xenograft Model Antitumor Assays | 2000 |
Capecitabine.
Topics: Animals; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Xenograft Model Antitumor Assays | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2000 |
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Oxidoreductases; Prodrugs; Pyrimidines; Tegafur; Uracil | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Treatment Outcome | 2001 |
Role of oral chemotherapy in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
Capecitabine in colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Meta-Analysis as Topic; Middle Aged; Radiation, Ionizing; Survival Rate | 2001 |
Clinical status of capecitabine in the treatment of breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Forecasting; Humans; Neoplasm Recurrence, Local; Prodrugs; Treatment Outcome | 2001 |
Clinical pharmacokinetics of capecitabine.
Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Food; Humans; Intestinal Absorption; Leucovorin; Liver Diseases; Paclitaxel; Protein Binding; Taxoids | 2001 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Neoplasms; Oxidoreductases; Prodrugs; Tegafur; Uracil | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Treatment Outcome | 2001 |
[Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].
Topics: Administration, Oral; Animals; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Design; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Oxidoreductases; Stomach Neoplasms; Thymidine Phosphorylase; Treatment Outcome | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Outpatients; Tegafur; Uracil | 2001 |
The evolution of fluoropyrimidine therapy: from intravenous to oral.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies | 2001 |
Answering patients' needs: oral alternatives to intravenous therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Patient Satisfaction; Quality of Life; Tegafur; Uracil | 2001 |
Optimizing the use of irinotecan in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
Integrating oxaliplatin into the management of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2001 |
Improving chemoradiotherapy in rectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2001 |
Vision of the future: capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Ovarian Neoplasms; Pancreatic Neoplasms | 2001 |
Capecitabine: a novel agent for the treatment of solid tumors.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Prodrugs | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cryosurgery; Deoxycytidine; Drug Combinations; Ethanol; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Injections, Intralesional; Interferons; Liver Cirrhosis; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Tamoxifen; Tegafur; Uracil | 2001 |
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Prodrugs; Randomized Controlled Trials as Topic | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Half-Life; Haplorhini; Humans; Infusions, Intravenous; Injections, Subcutaneous; Methotrexate; Neoplasm Metastasis; Paclitaxel; Safety; Trastuzumab; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Interactions; Enzyme Induction; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Survival Analysis; Up-Regulation | 2001 |
Rational development of capecitabine.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mice; Mice, Nude; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Capecitabine in breast cancer: current status.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs | 2001 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
Prediction of the response of colorectal cancer to systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Capecitabine/irinotecan combination regimens in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan | 2002 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Prodrugs | 2002 |
Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Pyrimidines; Research Design; Safety | 2002 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Pyrimidines; Tegafur; Uracil | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
New drugs for patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Capecitabine; Deoxycytidine; Diphtheria Toxoid; Fluorouracil; Gastrins; History, 16th Century; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic | 2002 |
Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Delayed-Action Preparations; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2002 |
Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
New directions with capecitabine combinations in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Humans | 2002 |
Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Patient Compliance; Prodrugs; Pyridines; Tegafur; Treatment Outcome | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
An adverse interaction between warfarin and capecitabine: a case report and review of the literature.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Hemorrhage; Humans; Warfarin | 2001 |
Capecitabine (Xeloda): from the laboratory to the patient's home.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Design; Fluorouracil; Humans; Kidney; Liver | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2002 |
Moving forward with capecitabine: a glimpse of the future.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Forecasting; Humans; Prodrugs; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Treatment Outcome | 2003 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Hospitalization; Humans; Leucovorin; Multicenter Studies as Topic; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prodrugs | 2002 |
Capecitabine and radiation therapy for advanced gastrointestinal malignancies.
Topics: Antineoplastic Agents; Capecitabine; Celecoxib; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Prodrugs; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides; Treatment Outcome | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
Current Canadian experience with capecitabine: partnering with patients to optimize therapy.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Antimetabolites, Antineoplastic; Benchmarking; Breast Neoplasms; Canada; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Nurse's Role; Oncology Nursing; Safety; Treatment Outcome | 2003 |
Monotherapy options in the management of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Role of capecitabine (Xeloda) in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Practice Guidelines as Topic | 2003 |
The evolving role of capecitabine in breast cancer.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Prodrugs; Taxoids; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2003 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Eruptions; Exudates and Transudates; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Tegafur; Uracil | 2003 |
Thalidomide therapy for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Thalidomide | 2003 |
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.
Topics: Animals; Area Under Curve; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Models, Biological; Neoplasms; Technology, Pharmaceutical; Tissue Distribution | 2003 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2003 |
[Doxifluridine for treatment of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Pentosyltransferases; Prodrugs; Prognosis; Pyrimidine Phosphorylases; Thymidine Phosphorylase | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Oxonic Acid; Prognosis; Pyridines; Tegafur; Thymidylate Synthase; Uracil | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Adjuvant chemotherapy for colorectal carcinoma after curative resection].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colectomy; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Evidence-Based Medicine; Fluorouracil; Humans; Leucovorin; Levamisole; Pharmacogenetics; Polymorphism, Genetic; Prognosis | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Receptors, Growth Factor; Rectal Neoplasms | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Metastasis; Tegafur; United Kingdom; Uracil | 2003 |
Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2003 |
[Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Neoplasms; Treatment Outcome | 2003 |
Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Black People; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Paresthesia; Syndrome; White People | 2004 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotherapy; Methotrexate; Neovascularization, Pathologic; Treatment Outcome | 2004 |
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Radiation-Sensitizing Agents | 2004 |
Bevacizumab in the treatment of breast cancer: rationale and current data.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Vascular Endothelial Growth Factor A | 2004 |
Progress in the development of novel treatments for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current status of adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; United States | 2004 |
[New therapy options in colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2004 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyrimidinones; Tegafur; Uracil | 2004 |
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Fluorouracil; Gastrointestinal Neoplasms; Home Care Services; Humans; Nurse's Role; Oncology Nursing; Safety; Stomatitis; Survival Rate; Treatment Outcome | 2004 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Monitoring; Fluorouracil; Home Care Services; Humans; Nausea; Neutropenia; Nurse's Role; Oncology Nursing; Patient Education as Topic; Safety; Stomatitis; Survival Rate; Treatment Outcome | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Decision Trees; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Monitoring; Fluorouracil; Foot; Hand; Humans; Nurse's Role; Nursing Assessment; Oncology Nursing; Paresthesia; Patient Education as Topic; Primary Prevention; Severity of Illness Index; Skin Care; Syndrome | 2004 |
The vital role of education and information in patients receiving capecitabine (Xeloda).
Topics: Administration, Oral; Aftercare; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Information Services; Fluorouracil; Home Care Services; Humans; Internet; Needs Assessment; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Participation; Quality of Life; Self Administration; Teaching Materials | 2004 |
Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Cancer Care Facilities; Capecitabine; Colorectal Neoplasms; Cost Savings; Critical Pathways; Deoxycytidine; Fluorouracil; Home Care Services; Humans; Medical Oncology; Nurse's Role; Oncology Nursing; Organizational Innovation; Patient Education as Topic; Program Development; State Medicine; Time Factors; United Kingdom | 2004 |
Implications of capecitabine (Xeloda) for cancer nursing practice.
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Communication; Deoxycytidine; Documentation; Drug Monitoring; Fluorouracil; Home Care Services; Humans; Nurse's Role; Nursing Records; Oncology Nursing; Patient Acceptance of Health Care; Patient Care Team; Patient Education as Topic; Professional Autonomy; Time Factors | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Neoplasms; Oxonic Acid; Prodrugs; RNA, Messenger; Tegafur; Thymidylate Synthase | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Patient Education as Topic; Syndrome | 2004 |
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis | 2004 |
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy | 2004 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Peritoneal Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2004 |
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Paclitaxel | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2004 |
Systemic therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Prodrugs; Pyridines | 2005 |
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
Combined modality treatment for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Transforming Growth Factor alpha | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Palmar-plantar erythrodysesthesia.
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Doxorubicin; Drug Eruptions; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Paresthesia; Patient Education as Topic | 2005 |
Capecitabine: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2005 |
Advances in colon cancer chemotheapy: nursing implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Community Health Nursing; Deoxycytidine; Drug Monitoring; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Nurse's Role; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2005 |
Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2005 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Retrospective Studies; Skin Diseases; Treatment Outcome | 2005 |
[Cardiotoxicity of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Coronary Thrombosis; Coronary Vessels; Deoxycytidine; Electrocardiography; Fluorouracil; Heart; Heart Diseases; Humans; Myocarditis | 2004 |
The development of clinical research in CRC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Staging; Palliative Care; Prodrugs; Prognosis; Quality of Life; Sentinel Lymph Node Biopsy; Survival Rate | 2005 |
Adjuvant therapy in colon cancer: which treatment in 2005?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2005 |
Current therapies for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
Capecitabine: effective oral fluoropyrimidine chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Contraindications; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Prodrugs; Randomized Controlled Trials as Topic | 2005 |
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Ischemia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Risk Factors; Thromboembolism | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Quality of Life; Retrospective Studies; Treatment Outcome | 2005 |
An adverse interaction between warfarin and fluoropyrimidines revisited.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Retrospective Studies; Warfarin | 2005 |
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Computer Simulation; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Fluorouracil; Humans; Models, Biological; Product Surveillance, Postmarketing; Quality of Life; Taxoids; Vinblastine | 2004 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Vitamin B Complex | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Pyrimidines; Treatment Outcome | 2005 |
Capecitabine/Oxaliplatin combinations in advanced colorectal cancer: summary of recent randomized studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
[5 -fluoropyrimidines for treatment of biliary tract cancers].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Pyridines; Pyrimidines; Tegafur; Uracil | 2006 |
Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Geriatrics; Humans; Male; Medical Oncology; Quality of Life | 2006 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Rectal Neoplasms | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Postoperative Complications; Radiotherapy Dosage | 2006 |
Capecitabine in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Forecasting; Humans; Prodrugs | 2005 |
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Staging; Quality of Life; Treatment Outcome; United States | 2006 |
Uridine phosphorylase in breast cancer: a new prognostic factor?
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Enzyme Induction; Female; Floxuridine; Fluorouracil; Gene Expression Regulation; Humans; Mice; Prodrugs; Prognosis; Pyrimidinones; Treatment Outcome; Uridine Phosphorylase | 2006 |
Neurological complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Central Nervous System; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Neoplasms; Neuroprotective Agents; Peripheral Nervous System; Peripheral Nervous System Diseases; Vitamin E | 2006 |
Chemoradiotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Palliative Care; Survival Analysis | 2006 |
Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2006 |
[Chemotherapy for metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diphosphonates; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Meta-Analysis as Topic; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Esophageal Diseases; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms | 2006 |
[Irinotecan for the treatment of metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Irinotecan; Maximum Tolerated Dose; Multicenter Studies as Topic; Pharmacogenetics | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; State Medicine; Tegafur; Treatment Outcome; United Kingdom; Uracil | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Neoplasms; Survival Rate | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant | 2006 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neoplasms; Continuity of Patient Care; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Interactions; Fluorouracil; Humans; Infusions, Intravenous; Life Style; Multivariate Analysis; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Care Planning; Risk Factors; Safety Management; Stomatitis; United States; Vomiting | 2006 |
Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging | 2006 |
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Taxoids | 2006 |
Capecitabine-docetaxel combination treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Taxoids | 2006 |
Management of hand-foot syndrome induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Foot Injuries; Hand Injuries; Humans; Paresthesia; Syndrome | 2006 |
Update on capecitabine in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2006 |
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; United Kingdom | 2006 |
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paraneoplastic Polyneuropathy; Prodrugs | 2007 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Staging | 2006 |
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms; Polymorphism, Genetic | 2006 |
Oral capecitabine (Xeloda) in cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Fetus; Fluorouracil; Humans; Nurse's Role; Patient Education as Topic; Treatment Outcome | 2007 |
Capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2007 |
[Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Therapy; Drugs, Chinese Herbal; Fluorouracil; Foot; Hand; Humans; Paresthesia; Phytotherapy; Syndrome | 2007 |
Capecitabine: in advanced gastric or oesophagogastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Treatment Outcome | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
Adjuvant treatment of colon cancer: past, present and future.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate | 2007 |
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Immunologic Factors; Neoplasm Metastasis; Trastuzumab | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
Integration of novel agents into combined-modality treatment for rectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2007 |
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Immunoassay; Medical Oncology; Neoplasms; Pharmacogenetics | 2007 |
Capecitabine in the treatment of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2007 |
Radiotherapy for localized rectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Rectum; Survival Analysis; Treatment Outcome | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2008 |
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central Nervous System; Colorectal Neoplasms; Cytotoxins; Deoxycytidine; Dexamethasone; Dysarthria; Female; Fluorouracil; Granisetron; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Sarcoma, Small Cell; Serotonin Antagonists; Topoisomerase I Inhibitors | 2008 |
Combined-modality therapy for rectal cancer: future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Capecitabine in advanced gastric cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms | 2007 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Stents | 2007 |
How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Oncology Nursing; Patient Education as Topic; Prescription Fees | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Death; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil; Vascular Endothelial Growth Factor A | 2007 |
Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Radiotherapy, Adjuvant; Rectal Neoplasms | 2007 |
Current options for the management of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Endosonography; Fluorouracil; Humans; Leucovorin; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Radiotherapy, Adjuvant; Rectal Neoplasms; Tomography, Emission-Computed | 2007 |
Cardiac toxicity: old and new issues in anti-cancer drugs.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Aromatase Inhibitors; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Heart Diseases; Humans; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Taxoids | 2008 |
Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Neovascularization, Pathologic; Patents as Topic; Radiotherapy; Regional Blood Flow; Thymidine Phosphorylase; Up-Regulation | 2006 |
The role of adjuvant chemotherapy in colon cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2007 |
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2007 |
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2007 |
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Immunologic Factors; Liver Neoplasms; Tegafur | 2008 |
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Fluorouracil; Humans; Taxoids; Treatment Failure; Tubulin Modulators | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Capecitabine in the treatment of advanced gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2008 |
Preclinical investigations with epothilones in breast cancer models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Epothilones; Female; Fluorouracil; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Tubulin Modulators | 2008 |
Clinical studies with epothilones for the treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Tubulin Modulators | 2008 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines | 2008 |
Capecitabine: an overview of the side effects and their management.
Topics: Administration, Oral; Age Factors; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Male; Patient Education as Topic; Prodrugs | 2008 |
Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Taxoids; Tubulin Modulators | 2009 |
Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans | 2008 |
The use of capecitabine in the combined-modality therapy for rectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Prognosis; Radiotherapy, Adjuvant; Rectal Neoplasms; Thymidine Phosphorylase; Vitamin B Complex | 2008 |
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2008 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Capecitabine-induced oromandibular dystonia: a case report and literature review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Asian People; Brain Stem; Capecitabine; Deoxycytidine; Drug Administration Schedule; Dystonia; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Mandible; Middle Aged; Mouth; Rectal Neoplasms | 2008 |
Neoadjuvant chemoradiation for rectal cancer: is more better?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2008 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Treatment Outcome | 2008 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
[Molecular targets for colon cancer. VEGF, EGFR - and what else?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Cetuximab; Colonoscopy; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Genotype; Humans; Mass Screening; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2008 |
Application of epothilones in breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Microtubules; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Tubulin Modulators | 2008 |
Capecitabine in gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Patient Acceptance of Health Care; Protein Binding; Stomach Neoplasms | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Capecitabine: have we got the dose right?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diet; Dose-Response Relationship, Drug; Fluorouracil; Humans; Maximum Tolerated Dose; Neoplasms; Pharmacogenetics; Prodrugs; Treatment Outcome | 2009 |
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Thrombocytopenia; Vitamin B Complex | 2008 |
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Capecitabine and docetaxel combination for the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2008 |
Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Tubulin Modulators | 2008 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Paresthesia; Patient Compliance; Patient Education as Topic; Peripheral Nervous System Diseases; Prodrugs | 2009 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2009 |
The integration of chemoradiation in the care of patient with localized pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2009 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Premedication; Tubulin Modulators | 2009 |
Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2010 |
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2009 |
Emerging role of capecitabine in gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Stomach Neoplasms | 2009 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Nursing Assessment; Oncology Nursing; Pharmacogenetics; Risk Factors; Safety; Vomiting | 2009 |
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Databases, Bibliographic; Deoxycytidine; DNA Mutational Analysis; Fluorouracil; Humans; Microsatellite Instability; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2009 |
Role of liver transplantation in the treatment of cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Liver Transplantation; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Risk Factors; Survival Rate; Treatment Outcome | 2009 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy; Prognosis; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2008 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Helicobacter Infections; Helicobacter pylori; Humans; Male; Overweight; Palliative Care; Pancreatic Neoplasms; Risk Factors; Smoking | 2009 |
[Toxic dermatitis due to capecitabine: presentation of 2 cases and literature review].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Humans; Male; Middle Aged | 2009 |
Capecitabine and vinorelbine in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Practice Guidelines as Topic; Vinblastine; Vinorelbine | 2009 |
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome; Young Adult | 2009 |
Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Irinotecan; Mitomycin; Prospective Studies; Purpura, Thrombotic Thrombocytopenic | 2010 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypertension; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2010 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Profiling; Genes, APC; Genes, p53; Genomic Instability; Humans; Irinotecan; Microsatellite Instability; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
[Chemotherapy of elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Comorbidity; Cooperative Behavior; Decision Making; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Life Expectancy; Organoplatinum Compounds; Oxaliplatin; Patient Care Team | 2009 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2009 |
Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis | 2009 |
Ixabepilone: in locally advanced or metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Epothilones; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2009 |
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
Topics: Age Factors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Comorbidity; Congresses as Topic; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Europe; Evidence-Based Medicine; Female; Fluorouracil; Humans; International Cooperation; Karnofsky Performance Status; Menopause; Patient Selection; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Socioeconomic Factors; Taxoids; Vinblastine; Vinorelbine | 2009 |
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Maximum Tolerated Dose; Palliative Care; Treatment Outcome | 2009 |
Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Confidence Intervals; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Proportional Hazards Models; Risk Assessment; Risk Factors | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Expression; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2009 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Precision Medicine; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2009 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Blood Glucose; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fenofibrate; Fluorouracil; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2009 |
Ixabepilone, a new treatment option for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Epothilones; Female; Fluorouracil; Humans; Multicenter Studies as Topic | 2010 |
Interaction between capecitabine and brivudin in a patient with breast cancer.
Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Bromodeoxyuridine; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Fatal Outcome; Female; Fluorouracil; Herpes Zoster; Humans; Onycholysis; Palliative Care; Peripheral Nervous System Diseases; Salvage Therapy; Stomatitis; Tooth Discoloration | 2010 |
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Japan; Methotrexate; Oxonic Acid; Tegafur; Uracil | 2010 |
Evolution of capecitabine dosing in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Practice Guidelines as Topic; Radiotherapy | 2010 |
Ixabepilone.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Epothilones; Female; Fluorouracil; Humans; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2010 |
Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
Topics: Age Factors; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Remission Induction; Sex Factors | 2010 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2010 |
Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Randomized Controlled Trials as Topic | 2010 |
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure | 2010 |
Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
Topics: Acidosis, Renal Tubular; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Deoxycytidine; Female; Fluid Therapy; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Potassium; Treatment Outcome | 2010 |
Evolution of capecitabine dosing in breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans | 2010 |
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Prodrugs; Treatment Outcome | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Health Care Costs; Humans; Neoplasm Metastasis; Prodrugs | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
[Adjuvant therapy in colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Microsatellite Instability; Neoplasm Staging; Oxaloacetates; Prognosis | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Kidney Diseases; Liver Diseases; Male; Multicenter Studies as Topic; Neoplasms; Paresthesia; Randomized Controlled Trials as Topic; Retrospective Studies; Vulnerable Populations | 2010 |
[Difference of colon cancer and rectal cancer-from the view of an oncological physician].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chromosomal Instability; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Microsatellite Instability; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Rectal Neoplasms; Risk Factors | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Failure; Tubulin Modulators | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Neurotoxicity Syndromes; Patient Selection; Risk Assessment; Risk Factors | 2011 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
Capecitabine for the treatment of advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Palliative Care; Prodrugs; Stomach Neoplasms | 2010 |
Chemotherapy for thymic tumors: induction, consolidation, palliation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Palliative Care; Procarbazine; Thymoma; Thymus Neoplasms; Vincristine | 2011 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Contraindications; Deoxycytidine; Esophagogastric Junction; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization; Paraffin Embedding; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
Capecitabine and hand-foot syndrome.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Racial Groups | 2011 |
[Advances in research on capecitabine as adjuvant treatment for colon cancer after radical resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Semustine; Survival Rate; Vincristine | 2010 |
Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Rectal Neoplasms | 2011 |
XELOX in colorectal cancer: a convenient option for the future?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Humans; Oxaloacetates; Treatment Outcome | 2011 |
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Ixabepilone for the treatment of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Neoplasms; Peripheral Nervous System; Quality of Life; Severity of Illness Index; Skin; Syndrome; Taxoids | 2011 |
Biomarker-based selection of therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; RNA, Messenger; Sequence Analysis, DNA | 2011 |
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Positron-Emission Tomography; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2011 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Complementary Therapies; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2011 |
Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients.
Topics: Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dermatologic Agents; Education, Medical, Continuing; ErbB Receptors; Female; Fluorouracil; Humans; Immunocompromised Host; Male; Organ Transplantation; Patient Education as Topic; Photochemotherapy; Prognosis; Retinoids; Risk Assessment; Skin Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Review Literature as Topic | 2012 |
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors; Treatment Outcome | 2011 |
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Taxoids | 2011 |
[Chemotherapy and rectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genetic Association Studies; Genotype; Half-Life; Humans; Introns; Mutation; Polymorphism, Single Nucleotide; RNA Splice Sites | 2011 |
Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Drug Administration Schedule; Dyspnea; Fluorouracil; Humans; Lung; Lung Diseases, Interstitial; Lung Volume Measurements; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pulmonary Fibrosis; Tomography, X-Ray Computed | 2011 |
Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.
Topics: Antineoplastic Agents; Asian People; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasm Staging; Stomach Neoplasms; White People | 2012 |
[Recurrent autoimmune hemolytic anemia induced by XELOX chemotherapy for colon cancer].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Recurrence | 2011 |
Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
Capecitabine in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Stomach Neoplasms; Treatment Outcome | 2011 |
Oxaliplatin: a review of approved uses.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2012 |
Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Bacteremia; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Pseudomonas Infections; Superinfection | 2011 |
Capecitabine induced cardiotoxicity: a case report and review of literature.
Topics: Antimetabolites, Antineoplastic; Bradycardia; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Myocardial Ischemia; Prodrugs | 2012 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Ultrasonic Therapy | 2012 |
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Carcinoma; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2012 |
Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.
Topics: Capecitabine; Colorectal Neoplasms; Databases, Genetic; Deoxycytidine; Fluorouracil; Folic Acid; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Genotype; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2012 |
First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2012 |
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Pancreatic Neoplasms; Signal Transduction | 2012 |
Role of chemotherapy in treatments for biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
The role of capecitabine in locally advanced rectal cancer treatment: an update.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrimidines | 2014 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Identification of novel germline polymorphisms governing capecitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genome-Wide Association Study; Humans; Male; Polymorphism, Single Nucleotide; Population Surveillance; White People | 2012 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Addisonian crisis secondary to bilateral adrenal metastases in rectal carcinoma: report of a rare case and literature review.
Topics: Addison Disease; Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Rectal Neoplasms | 2013 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Codon; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Treatment Outcome | 2012 |
Tumor endothelial markers as a target in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Cell Adhesion Molecules; Deoxycytidine; Endothelial Cells; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Neoplasms; Neoplastic Stem Cells; Receptors, Growth Factor; Thymidine Phosphorylase | 2012 |
Adjuvant treatments for triple-negative breast cancers.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2012 |
Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hyperglycemia; Hypertriglyceridemia; Middle Aged | 2012 |
Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Survival Rate | 2013 |
Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Agents; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Heart Diseases; Humans | 2013 |
Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2012 |
Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2012 |
[Colorectal carcinoma: what's new?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonoscopy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Endosonography; Fluorouracil; Humans; Liver Neoplasms; Mass Screening; Metastasectomy; Multimodal Imaging; Neoplasm Staging; Occult Blood; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Positron-Emission Tomography; Practice Guidelines as Topic; Pyridines; Salvage Therapy; Tomography, X-Ray Computed | 2012 |
Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
Topics: Antimetabolites, Antineoplastic; Biomarkers; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Prognosis; Thymidine Phosphorylase | 2013 |
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2a; Prognosis; Review Literature as Topic; Temozolomide; Tomography, X-Ray Computed | 2013 |
[A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hydronephrosis; Middle Aged; Peritoneal Neoplasms | 2012 |
Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anthracyclines; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Models, Statistical; Neoadjuvant Therapy; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Risk Assessment; Taxoids; Treatment Outcome | 2013 |
Pharmacokinetic evaluation of capecitabine in breast cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs; Randomized Controlled Trials as Topic | 2013 |
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Deoxycytidine; Endoscopy, Digestive System; Esophagostomy; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Discovery; Fluorouracil; Genetic Variation; Humans; Mercaptopurine; Methyltransferases; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine | 2013 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Mutation; Neoplasms; Polymorphism, Single Nucleotide; RNA, Messenger; Uracil | 2012 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Applications of oral fluoropyrimidines in colon cancer: their role and new directions.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxaloacetates; Oxonic Acid; Tegafur; Uracil | 2003 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Radiochemotherapy in rectal cancer: the role of oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Digestive System Surgical Procedures; Fluorouracil; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Rectal Neoplasms; Survival Rate | 2003 |
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Prospective Studies; Retrospective Studies | 2013 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Neoplasms; Quinazolines; Retrospective Studies; Thiophenes | 2013 |
Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Radiation Dosage; Rectal Neoplasms; Time Factors; Treatment Outcome | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Indoles; Male; Medication Adherence; Mouth Neoplasms; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Review Literature as Topic; Sunitinib | 2013 |
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Niacinamide; Nutritional Status; Nutritional Support; Phenylurea Compounds; Sorafenib | 2013 |
Options for metastatic colorectal cancer beyond the second line of treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cetuximab; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines | 2014 |
Capecitabine in the treatment of esophageal and gastric cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Stomach Neoplasms | 2013 |
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Male; Neutropenia; Thrombocytopenia | 2013 |
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leukoencephalopathies; Male; Middle Aged; Shock, Cardiogenic | 2013 |
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Humans; Neoplasm Staging; Odds Ratio; Oxonic Acid; Publication Bias; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2013 |
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Odds Ratio; Oxonic Acid; Proportional Hazards Models; Publication Bias; Tegafur; Treatment Outcome | 2014 |
[A case of early colorectal cancer with synchronous multiple liver metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Sigmoid Neoplasms; Treatment Outcome | 2013 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate; Treatment Outcome | 2014 |
[Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2014 |
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genetic Markers; Humans; Polymorphism, Genetic; Predictive Value of Tests; Thymidylate Synthase | 2014 |
How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.
Topics: Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Folic Acid Antagonists; Folic Acid Deficiency; Genetic Heterogeneity; Genetic Pleiotropy; Genetic Variation; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Mutation; Thymidylate Synthase | 2015 |
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology.
Topics: Aged; Brain Edema; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Neuroimaging; Neurotoxicity Syndromes; Prodrugs; White Matter | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Colitis; Contraindications; Deoxycytidine; Diagnosis, Differential; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Ileitis; Mutation; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2014 |
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Randomized Controlled Trials as Topic; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hyperglycemia; Hypertriglyceridemia; Male; Middle Aged; Oxaloacetates; Triglycerides | 2015 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Oxaloacetates; Paraneoplastic Syndromes; Sigmoid Neoplasms | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2014 |
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Fluorouracil; Humans; Incidence; Randomized Controlled Trials as Topic; Risk | 2014 |
[Pharmacogenomics of the first-line treatment for gastric cancer: advances in the identification of genomic biomarkers for clinical response to chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers; Biotransformation; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Enzymes; Ethnicity; Fluorouracil; Gastrectomy; Humans; Mexico; Molecular Targeted Therapy; Organoplatinum Compounds; Oxonic Acid; Patient Selection; Pharmacogenetics; Precision Medicine; Prodrugs; Stomach Neoplasms; Tegafur | 2014 |
Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Resveratrol; Stilbenes | 2014 |
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2014 |
Breast carcinoma with choriocarcinomatous features: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Choriocarcinoma; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Cyclobutanes; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Giant Cells; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Organoplatinum Compounds; Prognosis; Retrospective Studies; Taxoids | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ductal, Breast; Deoxycytidine; Epothilones; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
[Early diagnosis of capecitabine-induced acute leukoencephalopathy by using diffusion-weighted MRI].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Early Diagnosis; Female; Fluorouracil; Humans; Leukoencephalopathies; Middle Aged | 2014 |
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2015 |
[A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cecal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Oxaloacetates; Remission Induction | 2014 |
Oxaliplatin-induced Lhermitte sign. A case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Prognosis; Withholding Treatment | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Camptothecin; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Neoplasms; Organoplatinum Compounds; Tegafur | 2015 |
[A case of phenytoin intoxication caused by interaction between phenytoin and capecitabine].
Topics: Adult; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Phenytoin | 2015 |
[A case of juvenile colon cancer with peritoneal dissemination treated effectively by use of resection and chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colostomy; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Oxaloacetates; Peritoneal Neoplasms | 2014 |
Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Odds Ratio; Organoplatinum Compounds; Oxaloacetates; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2015 |
Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Topics: Capecitabine; China; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Oxonic Acid; Severity of Illness Index; Stomach Neoplasms; Tegafur | 2015 |
Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Randomized Controlled Trials as Topic; Rectal Neoplasms; Survival Rate; Watchful Waiting | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Ducts; Pancreatic Neoplasms | 2015 |
Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Japan; Leucovorin; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2016 |
[A Case of Sigmoid Colon Cancer with Metastasis to the Uterus].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Staging; Oxaloacetates; Sigmoid Neoplasms; Treatment Outcome; Uterine Neoplasms | 2015 |
[Resection of the Right External Iliac Artery and Vein after Local Recurrence of Cecal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cecal Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Iliac Artery; Iliac Vein; Middle Aged; Oxaloacetates; Recurrence | 2015 |
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Odds Ratio; Organoplatinum Compounds; Oxaloacetates; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
[A Case of Intussusception Caused by Descending Colon Cancer].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Descending; Colonic Diseases; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Intussusception; Male; Middle Aged; Oxaloacetates | 2016 |
A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Oxaloacetates; Stomach Neoplasms | 2018 |
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2018 |
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Humans; Network Meta-Analysis; Oxaloacetates; Stomach Neoplasms | 2018 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical | 2018 |
[Therapeutic advances in the management of biliary tract carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; France; Gemcitabine; Humans; Medical Oncology | 2018 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Lymph Node Excision; Network Meta-Analysis; Oxaloacetates; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur | 2018 |
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies | 2018 |
The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Leucovorin; Medication Therapy Management; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Time Factors; Treatment Outcome | 2018 |
Chemotherapy in Pancreatic Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Leucovorin; Lymphocytes, Tumor-Infiltrating; Microsatellite Instability; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Phenotype; Prognosis; Pyrimidines | 2019 |
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Oxaliplatin; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
[Adjuvant treatment of biliary tract cancers: Who and how?]
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Multicenter Studies as Topic; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2020 |
Adrenocortical carcinoma: current treatment options.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Mitotane; Randomized Controlled Trials as Topic | 2021 |
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Review Literature as Topic; Standard of Care | 2021 |
Rare capecitabine-induced acute hypertriglyceridemia with angina: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged | 2022 |
Capecitabine-associated enterocolitis: Narrative literature review of a rare adverse event and a case presentation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Enteritis; Enterocolitis; Fluorouracil; Humans | 2023 |
Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
1211 trial(s) available for capecitabine and deoxycytidine
| Article | Year |
|---|---|
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Food-Drug Interactions; Humans; Male; Middle Aged | 1998 |
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1998 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1998 |
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Antineoplastic Agents; Biotransformation; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Half-Life; Humans; Magnesium Hydroxide; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Topics: Analysis of Variance; Antineoplastic Agents; Area Under Curve; Biotransformation; Body Surface Area; Capecitabine; Confidence Intervals; Creatinine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Half-Life; Humans; Male; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Sex Characteristics; Tablets; Therapeutic Equivalency | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1999 |
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressure Liquid; Colon; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Liver; Male; Middle Aged; Oxidoreductases; Prodrugs; Rectum; Spectrophotometry, Ultraviolet; Thymidine Phosphorylase | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Capecitabine in the treatment of metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hospitals; Humans; Leucovorin; Male; Middle Aged; Patient Acceptance of Health Care; Prospective Studies | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Nausea; Stomatitis; Survival Analysis; Treatment Outcome | 2001 |
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Prodrugs; Prospective Studies; Survival Analysis | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Consumer Product Safety; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Survival Analysis | 2002 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Nausea; Prodrugs; Stomatitis; Survival Analysis; Treatment Failure; Treatment Outcome; Vomiting | 2002 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, Liquid; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Mass Spectrometry; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Peripheral Nervous System Diseases | 2001 |
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Evaluation; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Safety; Survival Rate | 2001 |
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Incidence; Keratoderma, Palmoplantar; Male; Middle Aged; Prodrugs; Risk Factors; Severity of Illness Index; Syndrome; Time Factors; Treatment Outcome | 2002 |
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2002 |
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Deoxycytidine; Fluorouracil; Half-Life; Humans; Kidney; Metabolic Clearance Rate; Neoplasms; Regression Analysis; Safety | 2002 |
[Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Recurrence | 2002 |
Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Thymidine Phosphorylase | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Combinations; Fluorouracil; Humans; Leucovorin; Nausea; Survival Rate; Tegafur; Time Factors; Uracil | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs; Pyridines; Tegafur; Treatment Outcome; Uracil | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Germany; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Prodrugs; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2002 |
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2002 |
Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
Topics: Animals; Antimetabolites, Antineoplastic; Bile; Biotransformation; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Hydroxylation; In Vitro Techniques; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Prodrugs; Rats; Tissue Distribution | 2002 |
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Hand, Foot and Mouth Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2003 |
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2003 |
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Switzerland | 2003 |
Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythrocyte Indices; Erythrocytes; Female; Fluorouracil; Folic Acid; Hematinics; Homocysteine; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Retrospective Studies; Thymidylate Synthase; Vitamin B 12 | 2003 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta-Alanine; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2003 |
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Stomach Neoplasms; Treatment Outcome | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Pilot Projects | 2003 |
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Patient Compliance; Treatment Outcome | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; beta-Alanine; Biotransformation; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Half-Life; Humans; Japan; Metabolic Clearance Rate; Middle Aged; Tissue Distribution; White People | 2003 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Rectal Neoplasms | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms | 2003 |
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2003 |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 5; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Phosphoric Diester Hydrolases; Prodrugs; Sulindac | 2003 |
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunologic Factors; Immunotherapy; Interferon-gamma; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins | 2003 |
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life | 2003 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Safety | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
[Combined preoperative xeloda and radiotherapy for lower rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Postoperative Complications; Radiotherapy; Rectal Neoplasms | 2003 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2004 |
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Probability; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids; Treatment Outcome | 2004 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Analysis; Treatment Outcome | 2004 |
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Hormones; Humans; Male; Middle Aged; Neoplasm Metastasis; Prodrugs; Prostatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids | 2004 |
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Evaluation; Fluorouracil; Humans; Mucous Membrane; Otorhinolaryngologic Neoplasms; Prodrugs; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Stomatitis | 2004 |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local | 2004 |
Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Deoxyuridine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Leukocytes, Mononuclear; Male; Models, Chemical; Placebos; Time Factors; Uracil | 2004 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Fluorouracil; Foot Dermatoses; Guideline Adherence; Hand Dermatoses; Humans; Hyperbilirubinemia; Japan; Lymphopenia; Middle Aged; Patient Selection; Survival Rate; Syndrome; Time Factors; Treatment Outcome | 2004 |
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Treatment Outcome | 2004 |
[Phase I clinical trial evaluation of capecitabine in concurrent combination of radiotherapy in nasopharyngeal carcinoma].
Topics: Adult; Aged; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Radiotherapy Dosage | 2004 |
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms | 2004 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Hyperbilirubinemia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Rectal Neoplasms | 2004 |
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Taxoids; Treatment Outcome | 2004 |
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; United States | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Safety; Survival Rate | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Nausea; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Treatment Outcome; Vomiting | 2004 |
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Treatment Outcome | 2004 |
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome | 2004 |
Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Neoplasm Staging; Treatment Outcome | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Patient Selection; Rectal Neoplasms | 2004 |
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
[Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Stomatitis; Thrombocytopenia | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Survival Rate | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Treatment Outcome | 2004 |
Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Confidence Intervals; Data Interpretation, Statistical; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Taxoids; Time Factors; Treatment Outcome | 2004 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2004 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Phenylenediamines; Stomatitis; Thrombocytopenia; Treatment Outcome | 2004 |
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Nails; Paclitaxel; Skin; Switzerland; Treatment Outcome | 2004 |
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
[Capecitabine combined with TACE for advanced liver cancer].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoembolization, Therapeutic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin | 2004 |
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Middle Aged; Neutropenia; Outpatients; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2004 |
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Hematologic Diseases; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Treatment Outcome | 2005 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2005 |
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2005 |
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Italy; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Treatment Outcome | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life | 2005 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2005 |
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Rectal Neoplasms; Treatment Outcome | 2005 |
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Male; Treatment Outcome | 2004 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Kidney Diseases; Treatment Outcome | 2005 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Screening Assays, Antitumor; Female; Fluorouracil; Gene Expression; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Thymidine Phosphorylase; Thymidylate Synthase | 2005 |
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Neoplasms; Taxoids | 2005 |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2005 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Patient Selection; Prodrugs; Safety | 2005 |
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Survival Analysis | 2005 |
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2005 |
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Middle Aged | 2005 |
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male | 2005 |
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Uterine Cervical Neoplasms | 2005 |
Capecitabine plus docetaxel combination therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Quality of Life; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Radiotherapy; Uterine Cervical Neoplasms | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Italy; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms | 2005 |
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage; Rectal Neoplasms | 2005 |
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Macrophages; Male; Middle Aged; Prognosis; Stromal Cells; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome | 2005 |
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2005 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2005 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Italy; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Survival Analysis | 2005 |
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cardiomyopathy, Dilated; Coronary Stenosis; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2005 |
Noninvasive magnetic resonance thermography of recurrent rectal carcinoma in a 1.5 Tesla hybrid system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Hyperthermia, Induced; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Temperature; Thermography | 2005 |
Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Glutamates; Guanine; Humans; Infusions, Intravenous; Middle Aged; Pemetrexed; Taxoids; Treatment Outcome | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer--safety, efficacy and quality of life.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Middle Aged; Quality of Life; Survival Rate | 2005 |
Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hemolysis; Humans; Hyperbilirubinemia; Injections, Intravenous; Leucovorin; Middle Aged | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms | 2005 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome | 2006 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2005 |
A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2005 |
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2005 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Trimetrexate | 2005 |
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms; Treatment Outcome | 2005 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms | 2006 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Greece; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Risk Assessment; Risk Factors; Sex Distribution; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2005 |
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Patient Compliance; Preoperative Care; Rectal Neoplasms | 2006 |
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast Neoplasms; Breath Tests; Capecitabine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Deoxycytidine; Erythromycin; Female; Fluorouracil; Genotype; Humans; Maximum Tolerated Dose; Middle Aged; Polymorphism, Restriction Fragment Length; Vinblastine; Vinorelbine | 2006 |
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pelvis; Preoperative Care; Rectal Neoplasms; Survival Rate | 2006 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure | 2006 |
Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle; Bone Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardia; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2006 |
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Statistics as Topic; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome; Tumor Necrosis Factor-alpha | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Doxorubicin; Fatigue; Female; Fluorouracil; Gemcitabine; Hepatitis B, Chronic; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Proteins; Paresthesia; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Patient Satisfaction; Surveys and Questionnaires | 2006 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Treatment Outcome | 2006 |
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms | 2006 |
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2006 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thalidomide; Treatment Outcome | 2006 |
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2006 |
Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Capecitabine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Lactones; Middle Aged; Neuroendocrine Tumors; Sulfones | 2006 |
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Postoperative Complications; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peptic Ulcer Hemorrhage; Radiotherapy, Adjuvant; Treatment Outcome | 2006 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prodrugs; Sample Size; Survival Rate; Treatment Outcome | 2006 |
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Fatigue; Female; Fluorouracil; Folic Acid; Homocysteine; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Survival Analysis | 2006 |
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2006 |
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Oligodeoxyribonucleotides; Oligonucleotides, Antisense; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2006 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Probability; Prognosis; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Fluorouracil; Health Care Costs; Health Resources; Humans; Injections, Intravenous; Leucovorin; Neoplasm Staging; Quality of Life; Remission Induction; Sensitivity and Specificity; Survival Rate; Time Factors; Treatment Outcome; United Kingdom | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA Repair; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Pain; Peripheral Nervous System Diseases; Pyrazoles; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Vinblastine; Vinorelbine | 2006 |
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2006 |
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Rectal Neoplasms | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2006 |
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Taxoids | 2006 |
Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2006 |
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Nausea; Temozolomide; Treatment Outcome; Vomiting | 2006 |
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2006 |
[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leukopenia; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Vinblastine; Vinorelbine | 2006 |
Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2006 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prodrugs; Sample Size; Survival Analysis; Treatment Outcome | 2007 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones | 2006 |
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Patient Satisfaction | 2006 |
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
[Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Care; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Rectal Neoplasms; Rectum | 2006 |
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Biosynthesis; Thymidine Phosphorylase; Thymidylate Synthase; Uterine Cervical Neoplasms | 2007 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Time Factors | 2007 |
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Premedication; Prospective Studies; Radionuclide Imaging; Remission Induction; Taxoids | 2006 |
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Prodrugs; Survival Analysis; Treatment Outcome | 2006 |
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2006 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2007 |
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Survival Analysis | 2007 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Treatment Outcome | 2007 |
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Neoplasm Staging; Nervous System; Nervous System Diseases; Organoplatinum Compounds; Severity of Illness Index; Treatment Outcome | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Research Design; Safety; Treatment Outcome | 2007 |
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Remission Induction; Treatment Outcome | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2007 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage | 2007 |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2006 |
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Radiotherapy, Conformal; Rectal Neoplasms | 2007 |
A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Prodrugs; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Capecitabine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Treatment Outcome | 2007 |
A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lymph Node Excision; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone | 2007 |
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2007 |
Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Administration Routes; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2007 |
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2007 |
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Intraoperative Period; Male; Maximum Tolerated Dose; Middle Aged; Photons; Quality of Life; Radiotherapy, Intensity-Modulated; Rectal Neoplasms | 2007 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2007 |
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2008 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Taxoids | 2007 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Stomach Neoplasms; Survival Analysis | 2007 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Treatment Outcome | 2007 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Heart Diseases; Humans; Infusions, Intravenous; Japan; Middle Aged; Trastuzumab; Treatment Outcome | 2008 |
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2008 |
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Gene Expression; Humans; Male; Microsatellite Instability; Middle Aged; MutS Homolog 2 Protein; Prodrugs; Prognosis; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Spain; Treatment Outcome | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2007 |
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis | 2008 |
Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Germany; Humans; Middle Aged; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2007 |
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prodrugs; Remission Induction; Survival Rate; Treatment Failure | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 2007 |
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2007 |
Capecitabine therapy of central nervous system metastases from breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Meningeal Neoplasms; Middle Aged; Prodrugs; Retrospective Studies; Treatment Outcome | 2007 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Sesquiterpenes; Treatment Outcome | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel | 2008 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate | 2007 |
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Particle Accelerators; Quality of Life; Radiotherapy Dosage; Rectal Neoplasms; Rectum | 2007 |
A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2008 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure; Vinblastine; Vinorelbine | 2007 |
Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiotherapy Dosage; Stomach Neoplasms | 2007 |
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Vinblastine; Vinorelbine | 2008 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Recombinant Proteins; Thalidomide | 2008 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Pilot Projects; Sample Size; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Preoperative Care; Rectal Neoplasms; Treatment Outcome | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase | 2008 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Radiotherapy, Adjuvant; Stomach Neoplasms; Treatment Outcome | 2007 |
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Sulfonamides | 2008 |
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy; Rectal Neoplasms | 2008 |
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2008 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
Intra-arterial and systemic chemotherapy plus external hyperthermia in unresectable biliary cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Middle Aged; Pilot Projects | 2007 |
Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Survival Analysis; Treatment Outcome | 2007 |
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Survival Analysis | 2007 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2008 |
Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; China; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prodrugs; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2007 |
Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Neoplasm Staging; Patient Compliance; Patient Selection; Preoperative Care; Rectal Neoplasms; Treatment Outcome | 2007 |
A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2007 |
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Nausea; Neoplasms; Skin Diseases; Taxoids; Treatment Outcome; Vomiting | 2007 |
An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Rectal Neoplasms | 2007 |
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Monocytes; Neoplasms; Phosphorylation; Protein Kinase C; Protein Kinase C beta | 2008 |
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prodrugs; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate | 2008 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate | 2008 |
Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy, Conformal; Rectal Neoplasms; Treatment Outcome | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Quality of Life; Stomach Neoplasms; Survival Rate | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Compliance; Survival Analysis | 2008 |
Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2008 |
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2008 |
Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Middle Aged | 2007 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab | 2008 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Artificial Intelligence; Capecitabine; Cetuximab; Combined Modality Therapy; Computational Biology; Data Interpretation, Statistical; Databases, Factual; Deoxycytidine; Fluorouracil; Humans; Least-Squares Analysis; Models, Statistical; Oligonucleotide Array Sequence Analysis; Proteomics; Rectal Neoplasms | 2008 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fatty Liver; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Risk Factors | 2008 |
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Incidence; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2008 |
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxaloacetates; Treatment Failure; Treatment Outcome | 2008 |
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Salvage Therapy; Survival Rate | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabine; Cyclooxygenase 2 Inhibitors; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Edema; Efferent Pathways; Erythema; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Immunohistochemistry; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pioglitazone; PPAR gamma; Predictive Value of Tests; Quality of Life; Sulfones; Temozolomide; Thiazolidinediones; Treatment Outcome | 2007 |
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pelvis; Rectal Neoplasms | 2008 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrazines | 2008 |
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Taxoids; Treatment Outcome; Ultrasonography, Mammary; Vinblastine; Vinorelbine | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Models, Biological; Prodrugs; Soft Tissue Neoplasms; Thoracic Neoplasms | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Rate | 2008 |
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prodrugs; Radiotherapy Dosage; Rectal Neoplasms; Survival Rate | 2007 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placebos | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate | 2007 |
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Maximum Tolerated Dose; Skin Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Treatment Outcome | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Time Factors; Treatment Failure | 2008 |
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Patient Selection; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2008 |
A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 2008 |
Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pyridines; Radiotherapy; Rectal Neoplasms | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neutropenia; Radiotherapy Dosage; Remission Induction; United Kingdom | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Texas; Thalidomide; Treatment Outcome | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2009 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Cross-Over Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2009 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diarrhea; Disease-Free Survival; Feasibility Studies; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Premedication; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Remission Induction | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Stomach Neoplasms | 2009 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Drug Administration Schedule; Endonucleases; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2008 |
Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; Neoplasm Staging; Probability; Prospective Studies; Reference Values; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2008 |
A modern regimen of pre-operative concurrent chemo-radiation therapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prodrugs; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2008 |
A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Taxoids | 2008 |
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2008 |
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proportional Hazards Models; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2008 |
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure | 2008 |
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Pain; Pain Measurement; Palliative Care; Quality of Life; Switzerland; Time Factors; Treatment Outcome | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Quality of Life; Survival Rate; Treatment Outcome | 2008 |
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Paraffin Embedding; Predictive Value of Tests; Stomach Neoplasms; Stromal Cells; Thymidine Phosphorylase | 2008 |
Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Rectal Neoplasms; Survival Analysis; Time Factors | 2009 |
Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Tolerance; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Pancreatic Neoplasms; Survival Analysis | 2008 |
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged | 2008 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; DNA Adducts; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Skin Diseases | 2008 |
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Hypertension; Middle Aged; Treatment Outcome | 2008 |
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Glutathione S-Transferase pi; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic | 2008 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nephrectomy; Survival Rate; Thalidomide; Treatment Outcome | 2008 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2009 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult | 2008 |
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Survival Analysis | 2009 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Tablets; Therapeutic Equivalency | 2008 |
Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Preoperative Care; Vitamin B Complex; Young Adult | 2008 |
XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
[A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2008 |
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proctocolectomy, Restorative; Radiotherapy Planning, Computer-Assisted; Rectal Neoplasms; Rectum | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Treatment Outcome | 2008 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor | 2008 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides | 2008 |
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Models, Biological; Reproducibility of Results; Syndrome; Young Adult | 2009 |
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2009 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; Colorectal Neoplasms; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Treatment Outcome | 2009 |
Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge.
Topics: Administration, Oral; Adult; Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Preoperative Care; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Endonucleases; Female; Fluorouracil; Gene Expression; Humans; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Failure | 2008 |
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Patient Compliance; Patient Selection; Radiotherapy, High-Energy; Survival Analysis; Treatment Outcome | 2009 |
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Organoplatinum Compounds; Oxaliplatin | 2009 |
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Failure; Treatment Outcome | 2009 |
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Prognosis; Tissue Distribution; Treatment Outcome | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nausea; Proctitis; Rectal Neoplasms; Remission Induction; Vomiting | 2009 |
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis | 2009 |
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis | 2009 |
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2009 |
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms; Time Factors; Treatment Outcome | 2009 |
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Common Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Time Factors; Treatment Outcome | 2009 |
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Survival Rate; Treatment Outcome; United Kingdom | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Adenosquamous; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Incidence; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Prognosis; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Remission Induction; Stomach Neoplasms; Survival Rate; Vomiting; Young Adult | 2008 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2009 |
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Treatment Failure; Vascular Endothelial Growth Factor A | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Rectal Neoplasms; Remission Induction | 2009 |
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2009 |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.
Topics: Activities of Daily Living; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pain; Prospective Studies; Rectal Neoplasms; Remission Induction; Sleep Stages; Young Adult | 2009 |
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboxylesterase; Combined Modality Therapy; Cytidine Deaminase; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thymidine Phosphorylase | 2009 |
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2008 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2008 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Carcinoma, Pancreatic Ductal; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Pyrazoles; Sulfonamides | 2009 |
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Receptor, ErbB-2; Taxoids | 2009 |
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Survival Analysis | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Survival Rate; Treatment Outcome | 2009 |
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids | 2009 |
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; International Agencies; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2009 |
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Quinazolines | 2009 |
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Etidronic Acid; Fluorouracil; Humans; Male; Middle Aged; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioisotopes; Radiopharmaceuticals; Rhenium | 2009 |
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Humans; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Oligodeoxyribonucleotides; Organoplatinum Compounds; Oxaliplatin; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Vinblastine; Vinorelbine | 2009 |
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Drug Costs; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Taxoids | 2009 |
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Humans; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2009 |
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Palliative Care; Remission Induction; Salvage Therapy; Stomach Neoplasms | 2009 |
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Thromboembolism; United Kingdom; Warfarin | 2009 |
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Young Adult | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2009 |
Adjuvant chemotherapy in older women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptors, Estrogen; Survival Analysis | 2009 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prognosis; Prostatectomy; Prostatic Neoplasms; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2009 |
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Japan; Kidney Diseases; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2009 |
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Surgical Wound Dehiscence | 2010 |
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Prognosis; PTEN Phosphohydrolase; Thymidylate Synthase; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Health Care Costs; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endosonography; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Rectal Neoplasms | 2009 |
A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2009 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Mucositis; Neutropenia; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids | 2010 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Capecitabine; Cell Cycle Proteins; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Fluorouracil; Humans; Irinotecan; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2009 |
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2009 |
Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Treatment Outcome | 2009 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms | 2010 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxaloacetates; Peripheral Nervous System Diseases; Remission Induction; Stomach Neoplasms; Survival Rate | 2009 |
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Chronotherapy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2010 |
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2010 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2009 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Adjuvant; Stomach Neoplasms | 2010 |
A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Mitomycin | 2010 |
Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Survival Rate; Uterine Cervical Neoplasms | 2009 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2010 |
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Germany; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prodrugs; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epidemiologic Methods; Epothilones; ErbB Receptors; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Rectal Neoplasms | 2009 |
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Neoplasm Metastasis | 2010 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome | 2010 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate | 2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Treatment Outcome | 2010 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2010 |
Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2010 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Deoxycytidine; Diarrhea; Fecal Incontinence; Female; Fluorouracil; Gangrene; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Proctitis; Pyrazoles; Radiation Injuries; Radiation-Sensitizing Agents; Rectal Neoplasms; Sulfonamides | 2010 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Diarrhea; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prodrugs; Radiotherapy, Conformal; Rectal Neoplasms; Remission Induction; Treatment Outcome | 2010 |
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Radiotherapy Dosage | 2010 |
A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2010 |
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Salvage Therapy; Taxoids | 2010 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate | 2009 |
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Period; Taxoids; Treatment Outcome | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Pilot Projects; Salvage Therapy; Survival Analysis; Thymus Neoplasms | 2010 |
Capecitabine in the routine treatment of advanced breast cancer: results from a non-interventional observational study in 876 [corrected] patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Treatment Outcome; United States | 2010 |
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Salvage Therapy; Severity of Illness Index; Survival Rate; Treatment Failure; Vascular Endothelial Growth Factor A | 2010 |
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Receptor, ErbB-2; Taxoids | 2009 |
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids | 2010 |
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Home Care Services; Humans; Male; Middle Aged; Palliative Care; Quality of Life | 2009 |
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2010 |
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2010 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2010 |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Prospective Studies; Recurrence; Stomach Neoplasms; Treatment Outcome | 2011 |
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cluster Analysis; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Pilot Projects; Taxoids | 2010 |
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Thymidine Phosphorylase; Thymidylate Synthase | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; International Agencies; Liver Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Soft Tissue Neoplasms; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2010 |
A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cetuximab; Colectomy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prodrugs; Prospective Studies; Rectal Neoplasms; Treatment Outcome | 2010 |
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheter Ablation; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cryosurgery; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Feasibility Studies; Female; Floxuridine; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Time Factors; Treatment Outcome; United States | 2010 |
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Risk Assessment; Spain; Time Factors; Treatment Outcome | 2010 |
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids | 2010 |
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 2010 |
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pilot Projects | 2010 |
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome | 2010 |
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Fluorouracil; Glycyrrhiza; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paeonia; Pancreatic Neoplasms; Phytotherapy; Scutellaria baicalensis; Ziziphus | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Survival Analysis | 2010 |
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capecitabine; Colorectal Neoplasms; Demography; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Failure | 2011 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Retrospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiometry; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rectal Neoplasms | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms | 2010 |
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin; Recurrence; Retreatment; Salvage Therapy | 2010 |
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Thalidomide | 2010 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leukopenia; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2010 |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Demography; Deoxycytidine; Enhancer Elements, Genetic; Female; Fluorouracil; Gemcitabine; Genotype; Homozygote; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2011 |
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
[Preliminary study of XELOX regimen as the first-line chemotherapy in advanced or recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Stomach Neoplasms | 2010 |
[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult | 2010 |
Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Matched-Pair Analysis; Middle Aged; Mitomycin; Neoadjuvant Therapy; Preoperative Care; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Therapeutic Equivalency | 2010 |
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Indoles; Kaplan-Meier Estimate; Pyrroles; Sunitinib | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome; United States | 2010 |
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Oxaloacetates; Stomach Neoplasms; Survival; Treatment Outcome; Young Adult | 2010 |
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Drug Monitoring; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Linear Models; Logistic Models; Mastectomy; Medication Adherence; Micro-Electrical-Mechanical Systems; Neoplasm Staging; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Outpatients; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2010 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis | 2011 |
Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Syndrome; Thrombocytopenia | 2010 |
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorescent Antibody Technique; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Syndrome; Time Factors; Treatment Outcome | 2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Mucositis; Thrombocytopenia; Treatment Outcome | 2010 |
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Cytarabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prescriptions; Prospective Studies; Proton Therapy; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recombinant Proteins | 2010 |
A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2010 |
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male | 2010 |
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Compliance; Treatment Outcome | 2010 |
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; South America; Taxoids; Time Factors; Treatment Outcome; Tubulin Modulators; United States | 2010 |
Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Profiling; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pharmacogenetics; Proportional Hazards Models; Radiotherapy; Young Adult | 2010 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Sensation Disorders; Treatment Outcome | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Treatment Outcome; Young Adult | 2011 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Platinum Compounds | 2010 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamethasone; Disease Progression; Drug Therapy, Combination; Etoricoxib; Fluorouracil; Humans; Kaplan-Meier Estimate; Lactones; Male; Orchiectomy; Pioglitazone; Prostatic Neoplasms; Pyridines; Sulfones; Thiazolidinediones; Treatment Outcome | 2010 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; China; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged | 2011 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2010 |
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; DNA; Female; Fluorouracil; Genotype; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Predictive Value of Tests; Radiotherapy, Adjuvant; Rectal Neoplasms; Thymidylate Synthase; Treatment Outcome | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australasia; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Hypotension; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Quality of Life; Thrombocytopenia; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Retreatment; Taxoids | 2010 |
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Capecitabine; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Neovascularization, Physiologic; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin | 2010 |
Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Prostatic Neoplasms; Survival Analysis | 2011 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2010 |
Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiography; Rectal Neoplasms; Young Adult | 2011 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2010 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Preoperative Period; Rectal Neoplasms; Remission Induction; Survival Rate | 2011 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Proportional Hazards Models; Pyridoxine; Syndrome; Treatment Failure; Vitamin B Complex; Young Adult | 2010 |
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Salvage Therapy; Survival Rate; Uterine Cervical Neoplasms | 2010 |
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2010 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2011 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Stomach Neoplasms | 2010 |
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dyspnea; Emotions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Sleep Initiation and Maintenance Disorders; Social Behavior; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Young Adult | 2010 |
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab | 2010 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Recurrence | 2011 |
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Germany; Humans; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Phenotype; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids | 2011 |
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden | 2011 |
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Risk Factors; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Remission Induction; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pravastatin; Stomach Neoplasms | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Treatment Outcome | 2010 |
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Ventricular Function, Left | 2010 |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Quality of Life | 2010 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Young Adult | 2011 |
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Mexico; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Placebo Effect; Proportional Hazards Models; Risk Assessment; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2010 |
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaloacetates; Patient Selection; Treatment Outcome | 2011 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult | 2010 |
Clinical study of adjuvant capecitabine monotherapy in Chinese elderly patients (aged 55-70) with stage IIa breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Cyclophosphamide; Cytarabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Stomach Neoplasms; Time Factors; Treatment Outcome | 2012 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Vomiting | 2010 |
High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Brachytherapy; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Preoperative Care; Rectal Neoplasms; Young Adult | 2010 |
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Recombinant Fusion Proteins; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Cell Cycle Proteins; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Europe; Female; Fluorouracil; Granulation Tissue; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; Skin; Thymidine Phosphorylase; Thymidylate Synthase; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2012 |
[Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Pyridoxine; Vitamin B Complex | 2010 |
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Preoperative Care; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Radiotherapy Dosage; ras Proteins; Rectal Neoplasms; Remission Induction | 2011 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Time | 2010 |
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Treatment Outcome | 2010 |
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction | 2011 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2011 |
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Linear Models; Male; Middle Aged; Nutritional Status; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2011 |
[A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Enhancer Elements, Genetic; Fluorouracil; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Multifactor Dimensionality Reduction; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Proportional Hazards Models; Thymidylate Synthase; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Disease Progression; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pilot Projects; Radiometry; Salvage Therapy; Treatment Outcome | 2011 |
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis | 2011 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Keratolytic Agents; Lactic Acid; Male; Middle Aged; Neoplasms; Syndrome; Urea | 2010 |
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Calcium; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Magnesium; Male; Middle Aged; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Neoplasm Staging; Prospective Studies | 2011 |
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Magnesium Sulfate; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Vinblastine; Vinorelbine | 2010 |
Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Taxoids | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Organoplatinum Compounds; Vomiting | 2011 |
Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Prospective Studies; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Survival; Treatment Outcome | 2011 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure | 2012 |
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Palliative Care; Stomach Neoplasms | 2012 |
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms; Treatment Outcome | 2011 |
Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2011 |
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2011 |
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis | 2011 |
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Risk Factors | 2011 |
Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Vinblastine; Vinorelbine | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Quality of Life; Risk Assessment; Risk Factors; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Period; Preoperative Period; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2011 |
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2011 |
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost of Illness; Costs and Cost Analysis; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate | 2012 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; DNA Mutational Analysis; Docetaxel; Female; Fluorouracil; Genomics; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2012 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models | 2011 |
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors | 2011 |
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 2011 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2012 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2011 |
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2011 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.
Topics: Adult; Capecitabine; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Genetic Therapy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Rectal Neoplasms; Tumor Necrosis Factor-alpha | 2010 |
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Rectal Neoplasms; Treatment Outcome | 2011 |
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2011 |
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Fluorouracil; Humans; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Tumor Suppressor Protein p53 | 2011 |
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Stomach Neoplasms; Treatment Outcome | 2011 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2011 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase | 2011 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Frail Elderly; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; United Kingdom | 2011 |
Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Remission Induction; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Europe; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2012 |
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life | 2012 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Capecitabine; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Etoricoxib; Female; Fluorouracil; Follow-Up Studies; Humans; Hypoglycemic Agents; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pioglitazone; Prognosis; Prospective Studies; Pyridines; Sulfones; Survival Rate; Thiazolidinediones | 2012 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Taxoids; Young Adult | 2012 |
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2011 |
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Genes, ras; Humans; Male; Middle Aged; Mitomycin; Mutation; Proto-Oncogene Proteins B-raf; ras Proteins; Treatment Outcome | 2011 |
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Colorectal Surgery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Period; Rectal Neoplasms; Time Factors | 2012 |
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaloacetates; Survival Rate; Treatment Outcome; Young Adult | 2011 |
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Confidence Intervals; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Models, Economic; Probability; Quality-Adjusted Life Years; Quinazolines; State Medicine; Trastuzumab; United Kingdom; Women's Health | 2012 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2012 |
Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemical Phenomena; Chemoradiotherapy, Adjuvant; Deoxycytidine; Diarrhea; Dietary Supplements; Double-Blind Method; Female; Fluorouracil; Gastrointestinal Tract; Glutamine; Humans; Incidence; Male; Middle Aged; Patient Dropouts; Pilot Projects; Preoperative Period; Rectal Neoplasms; Severity of Illness Index | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction; Treatment Outcome | 2012 |
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Molecular Targeted Therapy; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Treatment Outcome | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Rectal Neoplasms | 2012 |
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Treatment Outcome | 2012 |
A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms | 2011 |
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; China; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Neoadjuvant Therapy; Oxaloacetates; Rectal Neoplasms; Research Design; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Tract; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxaloacetates; Papillon-Lefevre Disease; Prospective Studies; Retrospective Studies; Treatment Outcome; Vascular Neoplasms | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Research Design; Stomach Neoplasms | 2011 |
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2011 |
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Dosage Calculations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Quality of Life; Treatment Outcome | 2012 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Placebos; Stomach Neoplasms; Survival Rate; Young Adult | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2012 |
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Metastasis; Quality of Life | 2011 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Treatment Outcome | 2012 |
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy; Rectal Neoplasms; Regression Analysis; Research Design; Safety; Time Factors | 2011 |
[Effectiveness of neoadjuvant chemoradiotherapy of locally advanced rectal cancer in conjunction with local hyperthermia and metronidazole].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intravenous; Male; Metronidazole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2011 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2011 |
Electrochemotherapy: a new technological approach in treatment of metastases in the liver.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bleomycin; Capecitabine; Carcinoma; Combined Modality Therapy; Deoxycytidine; Electrochemotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Liver; Liver Neoplasms; Middle Aged; Necrosis; Oxaloacetates; Sigmoid Neoplasms; Treatment Outcome | 2011 |
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pharmacokinetics; Pilot Projects; Prognosis; Treatment Outcome; Young Adult | 2012 |
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Young Adult | 2012 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazoles; Sulfonamides | 2012 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Time Factors | 2012 |
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine | 2011 |
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged | 2011 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Logistic Models; Lung Neoplasms; Male; Proportional Hazards Models; Treatment Outcome | 2012 |
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine | 2012 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Observation; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Treatment Outcome | 2011 |
Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Quality of Life; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Preoperative Care; Proctitis; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2012 |
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Middle Aged | 2011 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2011 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Protocols; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Laparoscopy; Length of Stay; Leucovorin; Oxaloacetates; Prospective Studies | 2011 |
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Japan; Male; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2012 |
Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Young Adult | 2012 |
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Prospective Studies; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Young Adult | 2012 |
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Rectal Neoplasms; Treatment Outcome | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate | 2012 |
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2012 |
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Mucin-1; Prospective Studies | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2012 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Stomach Neoplasms; Survival Rate; Thrombocytopenia; Vomiting | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Radiotherapy; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2011 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2012 |
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2012 |
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2013 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Statistics, Nonparametric; Treatment Outcome | 2012 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Thailand; Treatment Outcome | 2012 |
Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoembryonic Antigen; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Oxaloacetates; Radiotherapy, Intensity-Modulated; Rectal Neoplasms | 2012 |
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms | 2012 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Treatment Outcome | 2012 |
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2012 |
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Trastuzumab; Vinblastine; Vinorelbine | 2012 |
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab | 2012 |
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy, Adjuvant; Colectomy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Mucosa; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome; United Kingdom | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Radiotherapy Dosage; Rectal Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2 | 2012 |
Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Humans; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Observer Variation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2012 |
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Quinolones; Taxoids; Treatment Outcome | 2012 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Phosphorylase; Treatment Outcome | 2012 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Retrospective Studies; Signal Transduction; Skin; Treatment Outcome | 2013 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Survival Rate; Taxoids; Treatment Outcome; Tubulin Modulators | 2012 |
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2013 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Preoperative Care; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2013 |
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Colorectal Neoplasms; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Republic of Korea | 2012 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Medication Adherence; Methotrexate; Patient Compliance | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Isosorbide Dinitrate; Lung Neoplasms; Male; Middle Aged; Nitroglycerin; Treatment Outcome | 2012 |
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Placebos; Pyridoxine | 2012 |
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab | 2012 |
Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2012 |
Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Preoperative Period; Rectal Neoplasms; Treatment Outcome | 2013 |
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies | 2012 |
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Quality of Life; Treatment Outcome | 2013 |
Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Observer Variation; Quality Assurance, Health Care; Radiography; Tumor Burden | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2012 |
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Tract; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2012 |
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Rectal Neoplasms; Treatment Outcome | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase; Tubulin; Vinblastine; Young Adult | 2013 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Republic of Korea; Tegafur | 2012 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Temozolomide; Treatment Outcome | 2012 |
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids | 2013 |
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Tablets; Therapeutic Equivalency | 2013 |
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Male; Oxaloacetates; Survival Rate; Treatment Outcome | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Stomach Neoplasms; Stroke Volume; Thromboembolism; Treatment Outcome | 2013 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiovascular Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Recombinant Fusion Proteins; Stomach Neoplasms; Treatment Outcome; Young Adult | 2013 |
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2012 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Republic of Korea; Thrombocytopenia; Treatment Outcome | 2014 |
Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Treatment Outcome | 2012 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; DNA Mutational Analysis; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Treatment Outcome | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Young Adult | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2013 |
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
[Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drugs, Chinese Herbal; Erythrocyte Count; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Leucovorin; Leukocyte Count; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Platelet Count | 2012 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyglutamic Acid; Proportional Hazards Models; Treatment Outcome | 2014 |
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Radiotherapy, Intensity-Modulated; ras Proteins; Rectal Neoplasms; Treatment Outcome | 2014 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms | 2013 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms | 2012 |
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Tumor Burden | 2013 |
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin | 2013 |
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Randomized Controlled Trials as Topic | 2013 |
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECO
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Radiotherapy Dosage; Rectal Neoplasms; Survival Analysis | 2013 |
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2013 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2013 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Taxoids | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2013 |
Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; G(M1) Ganglioside; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Sialic Acids; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Taxoids | 2013 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2013 |
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2013 |
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cystitis; Deoxycytidine; Diarrhea; Digestive System Surgical Procedures; Drug Chronotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Oxaloacetates; Proctitis; Rectal Neoplasms; Severity of Illness Index; Treatment Outcome | 2014 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neutropenia; Treatment Outcome | 2013 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2013 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Inflammation; Leucovorin; Lymphocytes; Male; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Reproducibility of Results | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Outcome | 2013 |
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytidine Deaminase; Deoxycytidine; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Dose Fractionation, Radiation; Fatigue; Feasibility Studies; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Pain; Polymorphism, Genetic; Radiodermatitis; Radiotherapy, Intensity-Modulated | 2013 |
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Rectum; Treatment Outcome | 2013 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Quality of Life | 2013 |
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Prevalence; Radiotherapy, Conformal; Stomach Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Patient Compliance; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2013 |
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics | 2013 |
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Brain Stem Neoplasms; Capecitabine; Chemoradiotherapy; Child; Child, Preschool; Deoxycytidine; Female; Fluorouracil; Glioma; Humans; Male; Maximum Tolerated Dose; Neoplasm Grading; Prognosis; Radiotherapy Dosage; Survival Rate; Tablets; Tissue Distribution; Young Adult | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex | 2013 |
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophagogastric Junction; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Protein Kinase Inhibitors; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Republic of Korea; Young Adult | 2013 |
Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms | 2013 |
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperthermia, Induced; Male; Metronidazole; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Rectal Neoplasms; Treatment Outcome; Young Adult | 2013 |
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Male; Middle Aged; Stomach Neoplasms; Vorinostat | 2014 |
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2013 |
Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Organoplatinum Compounds; Survival Analysis; Treatment Failure | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate | 2013 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2013 |
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Cecum; Colon, Descending; Colon, Sigmoid; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum; Sigmoid Neoplasms; Survival; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2013 |
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Outcome | 2013 |
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Middle Aged; Pain; Pain Management; Pain Measurement; Palliative Care; Radiotherapy, Conformal | 2013 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Efficacy of neoadjuvant cisplatin and oral capecitabine in triple-negative breast cancers: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Copy Number Variations; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Prognosis; PTEN Phosphohydrolase; ras Proteins | 2013 |
Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Patient Selection; Positron-Emission Tomography; Prospective Studies; Rectal Neoplasms; Risk Assessment; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting | 2013 |
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome | 2013 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cyclin D1; Deoxycytidine; Diarrhea; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Postoperative Period; Prospective Studies; Rectal Neoplasms; Risk Factors | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Vomiting | 2013 |
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Thalidomide | 2013 |
Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Common Bile Duct Neoplasms; Demography; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Immunohistochemistry; Intestines; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Treatment Outcome | 2013 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; DNA Mutational Analysis; Drug Administration Schedule; Exanthema; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Regression Analysis; Treatment Outcome | 2013 |
Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Oxaloacetates; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Sirolimus; Stomach Neoplasms; Young Adult | 2013 |
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Glomerular Filtration Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Sex Factors | 2013 |
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
[Clinical paired study of comparing docetaxel plus capecitabine versus docetaxel plus epirubicin as first-line treatment in women with HER-2 negative advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Oxaloacetates | 2013 |
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Treatment Outcome | 2013 |
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Treatment Outcome | 2013 |
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Stomach Neoplasms; Sunitinib | 2013 |
Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Time Factors | 2013 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids | 2013 |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Preoperative Care; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2013 |
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Receptor, ErbB-2; Rectal Neoplasms; Retrospective Studies; Single-Blind Method; Treatment Outcome | 2013 |
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaloacetates; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis | 2013 |
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2014 |
Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Treatment Failure; Uracil | 2014 |
Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Survival Analysis | 2013 |
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mitomycin; Quality of Life; Treatment Outcome | 2014 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Salvage Therapy; Survival Rate | 2013 |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Lapatinib; Maytansine; Medication Adherence; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Self Report; Surveys and Questionnaires; Time Factors; Trastuzumab; Treatment Outcome | 2014 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Radiation; Female; Fluorouracil; Humans; Intraoperative Complications; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Photons; Prospective Studies; Radiation Injuries | 2014 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2013 |
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Blood Vessels; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Duodenum; Feasibility Studies; Female; Fluorouracil; Gastric Mucosa; Humans; Induction Chemotherapy; Intestinal Mucosa; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Tumor Burden | 2013 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Estradiol; Female; Fluorouracil; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Proportional Hazards Models; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Herpesvirus 4, Human; Humans; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2014 |
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Radiotherapy; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2014 |
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Capecitabine; Cognition Disorders; Comorbidity; Deoxycytidine; Depression; Doxorubicin; Fatigue; Female; Fluorouracil; Frail Elderly; Geriatric Assessment; Hand-Foot Syndrome; Humans; Mental Status Schedule; Palliative Care; Polyethylene Glycols; Polypharmacy; Risk Factors; Stomatitis; Treatment Outcome | 2014 |
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Preoperative Care; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms | 2014 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Pilot Projects; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Perioperative Care; Preoperative Care; Prospective Studies; Survivors | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2013 |
[Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Cycle; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins p21(ras); Remission Induction; Stomach Neoplasms; Survival Rate; Survivin; Tumor Suppressor Protein p53 | 2013 |
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Capecitabine; Cyclic N-Oxides; Deoxycytidine; Female; Fluorouracil; Humans; Indolizines; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Pyridinium Compounds | 2014 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2014 |
Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Preoperative Care; Prospective Studies; Rectal Neoplasms; Remission Induction | 2014 |
Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2014 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Streptozocin; Surveys and Questionnaires; Treatment Outcome | 2014 |
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2014 |
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival Analysis | 2014 |
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone | 2014 |
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Netherlands; Polyethylene Glycols; Prospective Studies; Treatment Outcome | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Translational Research, Biomedical | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab; Young Adult | 2014 |
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; DNA Methylation; Female; Fluorouracil; Genes, BRCA1; Genes, p53; Germ-Line Mutation; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paraffin Embedding; Prospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2014 |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
[Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Trastuzumab | 2014 |
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Vascular Access Devices | 2014 |
Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Isotope Labeling; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2014 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2015 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; China; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; ras Proteins; Rectal Neoplasms; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2014 |
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycytidine; Disease-Free Survival; Drug Therapy; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Palliative Care; Pancreatic Neoplasms; Quality of Life; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2014 |
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Treatment Outcome | 2014 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Time Factors; Treatment Outcome; Yttrium | 2014 |
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators | 2014 |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Everolimus; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neuropilin-1; Neuropilin-2; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Sirolimus; Vascular Endothelial Growth Factor A | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2014 |
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms | 2014 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2014 |
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
[Prospective multicentric phase III study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Fluorouracil; Germany; Humans; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prevalence; Risk Factors; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2014 |
Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male | 2014 |
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Female; Fluorouracil; Half-Life; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Prodrugs; Severity of Illness Index; Survival Analysis | 2014 |
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids | 2014 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Genes, ras; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Proton Therapy; ras Proteins; Receptors, CXCR | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphopenia; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Quinazolines; Radiography; Severity of Illness Index; Survival Analysis; Tumor Burden | 2014 |
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Pilot Projects; Treatment Outcome | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Biological Availability; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Gastrectomy; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Stomach Neoplasms; Treatment Outcome | 2014 |
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin | 2014 |
Quality of life in the trastuzumab for gastric cancer trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Humans; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Surveys and Questionnaires; Trastuzumab | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2014 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Microspheres; Middle Aged; Neoplasms; Prospective Studies; Yttrium Radioisotopes | 2014 |
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; California; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Frail Elderly; Geriatric Assessment; Health Status; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2014 |
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Proportional Hazards Models; Quality of Life; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2014 |
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drugs, Chinese Herbal; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms | 2014 |
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Chronotherapy; Drug Monitoring; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies | 2014 |
Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Radiotherapy Dosage; Rectal Neoplasms | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Polymerase Chain Reaction; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Differentiation; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prognosis; Retrospective Studies; Stomach Neoplasms; Tertiary Healthcare | 2014 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Topics: Acyl Coenzyme A; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Simvastatin; Stomach Neoplasms; Treatment Outcome; Young Adult | 2014 |
Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Esophagogastric Junction; Female; Fluorouracil; Gene Dosage; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Transforming Growth Factor alpha; Treatment Outcome; Young Adult | 2014 |
Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prospective Studies; Rectal Neoplasms; Sensitivity and Specificity | 2014 |
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Taxoids | 2014 |
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Nitriles; Quinolines | 2014 |
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
Topics: Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs | 2015 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Rectal Neoplasms; Remission Induction; Survival Rate | 2014 |
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Pyrroles; Sunitinib | 2015 |
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids | 2014 |
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United Kingdom | 2015 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Preoperative Care; Radiotherapy; Rectal Neoplasms; Research Design; Valproic Acid; Young Adult | 2014 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Consolidation Chemotherapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Prospective Studies; Rectal Neoplasms | 2014 |
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms; Salvage Therapy; Survival Analysis | 2015 |
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Treatment Outcome | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Meta-Analysis as Topic; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2014 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Positron-Emission Tomography; Retreatment; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Weight Loss | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2015 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2014 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Fluorouracil; Humans; Induction Chemotherapy; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Oxaliplatin and ototoxicity: is it really safe for hearing?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Hearing Loss; Hearing Tests; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2014 |
Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Prospective Studies; Radiotherapy Dosage; Rectal Neoplasms | 2015 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaloacetates; Predictive Value of Tests; Treatment Outcome | 2015 |
Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Pelvis; Prospective Studies; Radiotherapy, Conformal; Survival; Uterine Cervical Neoplasms | 2014 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Taxoids; Young Adult | 2015 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Genes, ras; Humans; Male; Mitomycin; Mutation; Phosphatidylinositol 3-Kinases; Prognosis | 2015 |
Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Male; Neoplasms; Tandem Mass Spectrometry; Therapeutic Equivalency | 2015 |
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2015 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyrimidines; Tegafur | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum; Treatment Outcome | 2015 |
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Morpholines; Nausea; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Vomiting | 2015 |
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors].
Topics: Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bilirubin; Capecitabine; Chemical and Drug Induced Liver Injury; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Glycyrrhizic Acid; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Saponins; Triterpenes | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2015 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Quality of Life; Stomatitis; Young Adult | 2015 |
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Stomach Neoplasms; Survival Rate | 2015 |
[Immediate results of combined therapy for local recurrences of rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Radiation Injuries; Rectal Neoplasms; Severity of Illness Index; Tegafur; Treatment Outcome | 2015 |
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Postoperative Complications; Prognosis; Proportional Hazards Models; Radiotherapy, Conformal; Radiotherapy, High-Energy; Rectal Neoplasms; Young Adult | 2015 |
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2015 |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Fluorouracil; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Prospective Studies; Rectal Neoplasms; Survival Rate | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Germany; Hand-Foot Syndrome; Humans; Incidence; Keratolytic Agents; Male; Middle Aged; Ointments; Primary Prevention; Quality of Life; Severity of Illness Index; Skin Cream; Surveys and Questionnaires; Time Factors; Treatment Failure; Urea | 2015 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mitomycin; Neoplasm Metastasis; Vascular Endothelial Growth Factor D | 2015 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Pyridoxine; Risk Factors; Time Factors; Treatment Failure; Young Adult | 2014 |
NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Quality of Life; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Survival Rate | 2015 |
Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Topics: Activation, Metabolic; Administration, Oral; Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Fluorouracil; Genotype; Humans; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prodrugs; Tablets; Therapeutic Equivalency; Thymidine Phosphorylase; Thymidylate Synthase | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proportional Hazards Models; Treatment Outcome | 2015 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies | 2016 |
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Pancreatic Neoplasms; Prognosis; Pyrazoles; Pyrimidines; Survival Rate | 2015 |
Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2016 |
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2015 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retreatment; Survival Rate | 2016 |
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Fatigue; Feeding and Eating Disorders; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Health Status; Humans; Induction Chemotherapy; Male; Pancreatic Neoplasms; Quality of Life; Statistics, Nonparametric; Surveys and Questionnaires; United Kingdom | 2015 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; CpG Islands; Deoxycytidine; Disease-Free Survival; DNA Methylation; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Phenotype; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Treatment Outcome | 2016 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Quality of Life; Treatment Outcome | 2016 |
A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Oxaloacetates; Pilot Projects; Prospective Studies; Rectal Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2016 |
Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2016 |
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2016 |
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C-Reactive Protein; CA-19-9 Antigen; Cancer Vaccines; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; China; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2016 |
Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Risk; Treatment Outcome | 2016 |
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Prospective Studies; Time Factors; Treatment Outcome | 2016 |
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2016 |
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Patient Compliance | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2018 |
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Frail Elderly; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Palliative Care | 2017 |
Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer.
Topics: Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Capecitabine; CD24 Antigen; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Stomach Neoplasms; Survival Rate; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2017 |
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies | 2018 |
Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Withholding Treatment | 2018 |
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cytokines; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Prospective Studies; Treatment Outcome | 2019 |
[Adjuvant chemotherapy with Capecitabine as new standard for resected cholangiocarcinomas - a look at the BILCAP trial].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Neoplasm Staging | 2018 |
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult | 2018 |
miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Multigene Family; Oxaloacetates; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; Stomach Neoplasms; Treatment Outcome; Young Adult | 2018 |
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution | 2019 |
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Prognosis; Simvastatin; Survival Analysis; Treatment Outcome | 2019 |
Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hydrogen; Japan; Lymphocyte Activation; Male; Masks; Middle Aged; Neoplasm Staging; Oxaloacetates; Prognosis; Programmed Cell Death 1 Receptor; Progression-Free Survival; Respiratory Therapy; Treatment Outcome | 2019 |
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Progression-Free Survival; Survival Rate | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Young Adult | 2019 |
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Oxaloacetates; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Spain; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2019 |
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2019 |
Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Costs and Cost Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Laparoscopy; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Treatment Outcome | 2019 |
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Topics: Aged; Biomarkers, Tumor; Capecitabine; Chemokine CCL5; Chemoradiotherapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Regression Analysis; ROC Curve; Treatment Outcome | 2021 |
Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Middle Aged; Quality of Life; Young Adult | 2021 |
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Sorafenib; Treatment Outcome | 2021 |
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asia; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Furans; Gemcitabine; Germ-Line Mutation; Humans; Ketones; Middle Aged; Phthalazines; Prognosis; Receptor, ErbB-2; Survival Rate; Vinorelbine | 2021 |
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2021 |
A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Tapering; Fluorouracil; Humans; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2022 |
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms | 2022 |
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
1596 other study(ies) available for capecitabine and deoxycytidine
| Article | Year |
|---|---|
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Humans; Mice; Neoplasm Transplantation; Oxidoreductases; Thymidine Phosphorylase | 1998 |
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Induction; Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Up-Regulation | 1998 |
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Half-Life; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Pyrimidines; Subrenal Capsule Assay | 1998 |
Trastuzumab and capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Costs and Cost Analysis; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Trastuzumab | 1998 |
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Topics: Animals; Capecitabine; Carboxylic Ester Hydrolases; Cytidine Deaminase; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Liver; Male; Mice; Neoplasms; Thymidine Phosphorylase | 1998 |
A new-drug roundup.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Capecitabine; Cyclopropanes; Deoxycytidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Etanercept; Fluorouracil; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Phosphodiesterase Inhibitors; Piperazines; Purines; Quinolines; Receptors, Tumor Necrosis Factor; Rifampin; Sildenafil Citrate; Sulfides; Sulfones; Thionucleotides | 1999 |
Positive results achieved with new oral chemotherapy agent.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oncology Nursing | 1999 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1999 |
Oral tumoractivated chemotherapy--an introduction.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans | 1999 |
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Humans; Kinetics; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Thymidine Phosphorylase; Time Factors; Up-Regulation | 1999 |
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
Topics: Animals; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Enzyme Induction; Fluorouracil; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; X-Ray Therapy | 1999 |
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Feces; Female; Fluorouracil; Gas Chromatography-Mass Spectrometry; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasms; Time Factors | 1999 |
Warfarin-5-FU interaction--a consecutive case series.
Topics: Anticoagulants; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Prothrombin Time; Retroperitoneal Space; Time Factors; Warfarin | 1999 |
Radiology's role widens in therapeutic drug development and trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Drug Therapy; Female; Fluorouracil; Humans; Male; Radiology; United States; United States Food and Drug Administration | 1999 |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Japan; Male; Neoplasms; Oxidoreductases; Thymidine Phosphorylase; Transplantation, Heterologous | 2000 |
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Capecitabine; Carbamates; Carboxylic Ester Hydrolases; Deoxycytidine; Drug Delivery Systems; Floxuridine; Fluorouracil; Humans; Intestines; Kinetics; Liver; Macaca fascicularis; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Prodrugs; Structure-Activity Relationship; Substrate Specificity; Transplantation, Heterologous | 2000 |
Severe ocular irritation and corneal deposits associated with capecitabine use.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Corneal Diseases; Deoxycytidine; Female; Fluorouracil; Humans; Keratitis; Keratoconjunctivitis Sicca; Middle Aged; Visual Acuity | 2000 |
Future treatment options with capecitabine.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Forecasting; Humans | 2000 |
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Platelet-Derived Growth Factor | 2000 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoplasm Staging; Randomized Controlled Trials as Topic | 2001 |
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxycytidine; Disease Models, Animal; DNA, Complementary; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Models, Animal; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
[Oral cytostatic drug in colorectal carcinoma. Selective tumor therapy at home].
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2001 |
Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Carrier Proteins; Cell Survival; CHO Cells; Cloning, Molecular; Cricetinae; Deoxycytidine; DNA, Complementary; Drug Screening Assays, Antitumor; Fetus; Floxuridine; Fluorouracil; Humans; Liver; Membrane Transport Proteins; Oocytes; Prodrugs; Transfection; Xenopus laevis | 2001 |
Coronary spasm induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chest Pain; Coronary Angiography; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged | 2001 |
Xeloda in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Prodrugs; Treatment Outcome | 2001 |
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Prodrugs | 2001 |
Onychomadesis and onycholysis associated with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Nails, Malformed; Prodrugs | 2001 |
[Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Taxoids; Treatment Failure; Treatment Outcome | 2001 |
Thymidine phosphorylase (TP) activation: convenience through innovation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Enzyme Activation; Fluorouracil; Humans; Thymidine Phosphorylase | 2001 |
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Blood Proteins; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Kinetics; Models, Biological; Neoplasms; Prodrugs; Protein Binding; Regional Blood Flow; Reproducibility of Results; Tissue Distribution | 2001 |
Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Mucosa; Middle Aged; Mouth Mucosa; Perineum; Stomatitis | 2001 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |
Clinical picture: leopard-like vitiligo with capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Vitiligo | 2001 |
Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue b
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colonic Neoplasms; Cytosol; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Humans; Kidney; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Prodrugs; Subcellular Fractions; Therapeutic Equivalency; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Tegafur; Uracil | 2001 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Fluorouracil; Humans; Immunoenzyme Techniques; Membrane Transport Proteins; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Thioinosine | 2002 |
Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Transplantation, Autologous; Treatment Outcome | 2001 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2002 |
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
An evolving role for oral fluoropyrimidine drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy; Enzyme Inhibitors; Female; Fluorouracil; Humans; Pyrimidines; Uracil | 2002 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2002 |
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Labeling; Female; Fluorouracil; Humans; Kidney; Male; Prodrugs; Topotecan | 2002 |
Xeloda. Warning: drug interaction increase bleeding risks.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Interactions; Fluorouracil; Hemorrhage; Humans; Warfarin | 2002 |
Capecitabine monotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis | 2001 |
Acute oxaliplatin-induced peripheral nerve hyperexcitability.
Topics: Acute Disease; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbamazepine; Clinical Trials, Phase I as Topic; Deoxycytidine; Electromyography; Female; Fluorouracil; Humans; Isaacs Syndrome; Male; Middle Aged; Neural Conduction; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Treatment Failure | 2002 |
Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Transplantation, Heterologous; Trastuzumab; Tumor Cells, Cultured | 2002 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capecitabine; Carbamates; Ceftriaxone; Clonidine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Ethacridine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Indapamide; Isotretinoin; Isoxazoles; Leflunomide; Male; Middle Aged; Nelfinavir; Phenylcarbamates; Rivastigmine; Salicylates; Severity of Illness Index; Sulfonamides; Thiophenes | 2002 |
Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cytosol; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovary; Oxidoreductases; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Time Factors | 2002 |
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Heart; Heart Diseases; Humans; Incidence | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment | 2002 |
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Male; Polymorphism, Genetic; Thymidylate Synthase | 2002 |
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis | 2002 |
Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
Topics: Administration, Oral; Angina Pectoris; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Electrocardiography; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Risk Assessment | 2002 |
Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Hip; Humans; Middle Aged; Radiodermatitis; Radiotherapy | 2002 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2002 |
Capecitabine in the management of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2001 |
Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kidney Diseases; Kidney Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Risk Assessment; Treatment Outcome | 2002 |
Population pharmacokinetic analysis of the major metabolites of capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Capecitabine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Models, Biological; Therapeutic Equivalency | 2002 |
Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Photosensitivity Disorders; Prodrugs | 2002 |
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Fluorouracil; Humans; Hutchinson's Melanotic Freckle; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Nevus, Pigmented; Prodrugs; Skin; Skin Neoplasms | 2002 |
Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Rectal Neoplasms | 2002 |
Radiation recall dermatitis may represent the Koebner phenomenon.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Radiodermatitis; Radiotherapy | 2002 |
Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Program Evaluation; Treatment Outcome; United Kingdom | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Prodrugs; Randomized Controlled Trials as Topic | 2001 |
Capecitabine combinations in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2001 |
Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Spectrometry, Mass, Electrospray Ionization | 2003 |
Fluorouracil for allergic reactions to capecitabine.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Hypersensitivity; Female; Fluorouracil; Humans; Salvage Therapy | 2002 |
Pyogenic granuloma-like lesions during capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Foot Dermatoses; Granuloma, Pyogenic; Humans; Male; Toes | 2002 |
Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs | 2002 |
Clinical colorectal cancer: oral chemotherapy comes of age.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2001 |
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bystander Effect; Capecitabine; Cell Division; Cell Membrane; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Fluorouracil; Humans; Membrane Glycoproteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Cytokines; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Glioblastoma; Humans; Interferon-gamma; Liver; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Oxidoreductases; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Thymidine Phosphorylase; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Electrophoresis, Capillary; Extracellular Space; Floxuridine; Fluorouracil; Humans; Prodrugs; Skin Neoplasms; Tissue Distribution | 2002 |
Design and analysis of non-inferiority mortality trials in oncology.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Research Design; Statistics as Topic | 2003 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Europe; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Hypoxia; Isoenzymes; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Peripheral Nervous System Diseases; Prodrugs; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Syndrome | 2002 |
High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
Topics: Adult; Alleles; Amino Acid Substitution; Antineoplastic Agents; Biotransformation; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Analysis; Exons; Female; Fluorouracil; Genes; Genotype; Humans; Inactivation, Metabolic; Introns; Male; Mutation, Missense; Oxidoreductases; Point Mutation; Polymerase Chain Reaction; Protein Denaturation; Pyrimidines; RNA Splice Sites; Sensitivity and Specificity; Sequence Deletion; Time Factors; White People | 2003 |
[Chemotherapy improves prognosis in colorectal carcinoma. Soon oral therapy at home?].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Home Care Services; Humans; Organoplatinum Compounds; Oxaliplatin | 2002 |
Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma.
Topics: Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Carcinoma, Verrucous; Deoxycytidine; Female; Fluorouracil; Humans; Mouth Neoplasms; Prodrugs | 2003 |
Hormone-refractory prostate cancer responding to capecitabine.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabine; Deoxycytidine; Fluorouracil; Goserelin; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Failure; Treatment Outcome | 2003 |
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Design; Drug Stability; Esterases; Female; Fluorouracil; Humans; Lung Neoplasms; Mice; Oxidoreductases; Prodrugs; Thymidine Phosphorylase; Tissue Distribution; Uracil; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2003 |
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Electrophoresis, Capillary; Fluorouracil; Humans; Microdialysis; Middle Aged | 2003 |
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Predictive Value of Tests | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Activation; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Thymidine Phosphorylase; Treatment Outcome | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prodrugs; Treatment Outcome | 2003 |
Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases.
Topics: Adult; Capecitabine; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radionuclide Imaging | 2003 |
Capecitabine induced cutaneous hyperpigmentation: report of a case.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hyperpigmentation | 2002 |
Isolation of an unknown metabolite of capecitabine, an oral 5-fluorouracil prodrug, and its identification by nuclear magnetic resonance and liquid chromatography-tandem mass spectrometry as a glucuroconjugate of 5'-deoxy-5-fluorocytidine, namely 2'-(beta
Topics: Animals; Bile; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Fluorouracil; Glycoconjugates; Liver; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Prodrugs; Rats; Rats, Wistar | 2003 |
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Capecitabine; Cell Division; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA Primers; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxidoreductases; Polymerase Chain Reaction; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Cardiac toxicity associated with capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnosis, Differential; Electrocardiography; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Prodrugs; Rectal Neoplasms | 2003 |
Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Interactions; Epilepsy, Generalized; Female; Fluorouracil; Humans; Male; Middle Aged; Phenytoin | 2003 |
Capecitabine-induced pancreatitis.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Pancreatitis | 2003 |
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Capecitabine-induced potentiation of warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Male; Warfarin | 2003 |
Lethal toxicity of capecitabine due to abusive folic acid prescription?
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Folic Acid; Humans; Middle Aged | 2003 |
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nail Diseases; Nails | 2003 |
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis | 2003 |
Capecitabine-related neurotoxicity presenting as trismus.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Central Nervous System; Confusion; Deoxycytidine; Diagnosis, Differential; Electroencephalography; Eye Movements; Female; Fluorouracil; Gait Ataxia; Humans; Magnetic Resonance Imaging; Middle Aged; Rectal Neoplasms; Speech Disorders; Trismus | 2003 |
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Eruptions; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Syndrome | 2003 |
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Palliative Care; Vinblastine; Vinorelbine | 2003 |
Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Humans; Hyperpigmentation; Nail Diseases | 2003 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2003 |
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Incidence; Male; Severity of Illness Index; Stomach Neoplasms; Syndrome; Taxoids | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic | 2003 |
[Tumor specific therapy. Targeted breast cancer therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs; Survival Rate | 2003 |
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorine; Fluorouracil; Humans; Liver; Liver Neoplasms; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prodrugs | 2003 |
Complete response of brain metastases originating in breast cancer to capecitabine therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Radiography; Treatment Outcome | 2003 |
Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Survival; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA, Complementary; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Thymidylate Synthase; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2003 |
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Thymidine Phosphorylase; Transplantation, Heterologous | 2003 |
Response of neoplastic meningitis from solid tumors to oral capecitabine.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Ductal, Breast; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Prodrugs | 2003 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperbilirubinemia; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Prodrugs; Retreatment; Salvage Therapy | 2003 |
Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Meningeal Neoplasms; Orbital Neoplasms; Treatment Outcome | 2004 |
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies | 2003 |
Capecitabine induces severe angina-like chest pain.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chest Pain; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prodrugs | 2004 |
Inflammation of actinic keratoses during capecitabine therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diagnosis, Differential; Facial Dermatoses; Female; Fluorouracil; Humans; Keratosis | 2004 |
Tumor lysis syndrome following a single dose of capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Tumor Lysis Syndrome | 2004 |
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Rate | 2004 |
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Transplantation, Heterologous; Up-Regulation | 2004 |
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans; Leukocytes, Mononuclear; Middle Aged; Mutation; Neoplasm Recurrence, Local | 2004 |
Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine.
Topics: Abdominal Neoplasms; Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Pseudomyxoma Peritonei | 2004 |
Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Child; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Immunohistochemistry; Male; Thymidine Phosphorylase; Thymidylate Synthase; Thyroid Neoplasms | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2004 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Neoplasm Metastasis; Survival Rate | 2004 |
Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; DNA, Complementary; Fluorine; Fluorouracil; Humans; Immunohistochemistry; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Phantoms, Imaging; Temperature; Thymidine Phosphorylase; Time Factors; Urinary Bladder Neoplasms | 2004 |
Capecitabine-induced abnormalities in thyroid function tests.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Thyroid Diseases; Thyroid Function Tests | 2004 |
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2004 |
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Netherlands; Palliative Care; Prodrugs; Retrospective Studies | 2004 |
Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cytosol; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Microsomes, Liver; Prodrugs; Pyridines; Thymidine Phosphorylase | 2004 |
Toxic encephalopathy induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Epilepsy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Neurotoxicity Syndromes; Skin Neoplasms | 2004 |
Liver insufficiency due to breast cancer metastases--fast biological response with capecitabine.
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Failure; Liver Neoplasms | 2004 |
Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver.
Topics: Amino Acid Sequence; Capecitabine; Carboxylesterase; Catalysis; Cytosol; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Humans; Liver; Molecular Sequence Data | 2004 |
Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disabled Persons; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polyneuropathies; Severity of Illness Index | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Multivariate Analysis; Probability; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2004 |
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythrocyte Indices; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies | 2004 |
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Green Fluorescent Proteins; Humans; Luminescent Proteins; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Thymidine Phosphorylase; Transplantation, Heterologous | 2004 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local | 2004 |
Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Fluorouracil; Humans; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2004 |
Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Risk Factors; Syndrome | 2004 |
Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Male; Neoplastic Cells, Circulating; Nephrectomy | 2003 |
Nail changes during docetaxel containing combination chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lymphatic Diseases; Middle Aged; Nail Diseases; Stomach Neoplasms; Taxoids | 2004 |
Peripheral neuropathy associated with capecitabine.
Topics: Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Female; Fluorouracil; Forecasting; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prodrugs | 2004 |
[Adjuvant therapy of colonic carcinoma--soon in tablet form].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Multicenter Studies as Topic; Prodrugs; Randomized Controlled Trials as Topic; Tablets; Treatment Outcome | 2004 |
Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies | 2004 |
Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorine Radioisotopes; Fluorouracil; Humans; Isotope Labeling; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Eyelid Neoplasms; Female; Fluorouracil; Humans; Interferon-alpha; Male; Skin Neoplasms; Treatment Outcome | 2005 |
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Survival Rate | 2004 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carboxylesterase; Deoxycytidine; Fluorouracil; Gastrointestinal Tract; Humans; Hydrolysis; Isoenzymes; Loperamide; Prodrugs | 2005 |
Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheters, Indwelling; Colorectal Neoplasms; Cost Savings; Deoxycytidine; Drug Costs; Fee Schedules; Fluorouracil; Germany; Health Care Costs; Hospitals, Municipal; Hospitals, University; Humans; National Health Programs; Patient Admission | 2005 |
Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Vasospasm; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged | 2005 |
Costs of treatment of colorectal cancer in different settings in Germany.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Costs and Cost Analysis; Deoxycytidine; Fluorouracil; Germany; Hospitals, Municipal; Hospitals, University; Humans; Inpatients; Leucovorin; Outpatients; Time Factors | 2004 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms | 2004 |
The effects of capecitabine in Raynaud's disease: a case report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Male; Raynaud Disease; Rectal Neoplasms; Recurrence; Risk Assessment; Severity of Illness Index; Vasoconstriction | 2005 |
Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages.
Topics: Aged; Capecitabine; Cell Movement; Deoxycytidine; Endothelial Cells; Female; Fluorouracil; Humans; Immunohistochemistry; Macrophages; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Thymidine Phosphorylase | 2005 |
The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mutation; Neoplasms; S Phase; Time Factors; Treatment Outcome | 2005 |
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Topics: Atmospheric Pressure; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxyuridine; Drug Stability; Fluorouracil; Humans; Mass Spectrometry; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Tegafur; Thymidine Phosphorylase; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2005 |
Localization of thymidine phosphorylase in breast cancer tissue.
Topics: 5'-Nucleotidase; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Microscopy, Immunoelectron | 2005 |
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Adjuvant therapy for colon cancer--the pace quickens.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Neoplasm Staging | 2005 |
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Analysis | 2005 |
Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Meningeal Neoplasms; Middle Aged | 2006 |
Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Neuroendocrine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy; Tomography, X-Ray Computed | 2005 |
Capecitabine-warfarin interaction.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Interactions; Fluorouracil; Heart Valve Prosthesis Implantation; Humans; International Normalized Ratio; Male; Middle Aged; Mitral Valve; Warfarin | 2005 |
A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prodrugs; Radiotherapy Dosage; Urinary Bladder Neoplasms | 2005 |
Capecitabine-induced pancolitis.
Topics: Adult; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Synergism; Factor VII; Fluorouracil; Half-Life; Humans; Middle Aged; Neoplasms; Prothrombin Time; Vitamin K 1; Warfarin | 2005 |
Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Hemorrhage; Humans; Warfarin | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2005 |
Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Luciferases; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Time Factors; Transfection; Treatment Outcome | 2005 |
Is adjuvant therapy with three-dimensional conformal irradiation combined with capecitabine (Xeloda) for gastric cancer effective?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Stomach Neoplasms | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Safety; Survival Rate | 2005 |
[Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Floxuridine; Fluorouracil; Humans; Middle Aged; Taxoids | 2005 |
[A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2005 |
What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival; Taxoids; Vinblastine; Vinorelbine | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Nanostructures; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Prodrugs | 2005 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
[Healing for more patients].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Staging | 2005 |
[Adjuvant therapy of colon cancer soon in tablet form].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Neoplasm Staging | 2005 |
Patient with angina secondary to capecitabine.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Sigmoid Neoplasms | 2005 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Erythema; Fatal Outcome; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Paresthesia; Taxoids; Vitamin E | 2006 |
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Topics: Animals; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Stability; Floxuridine; Fluorouracil; Humans; Liver; Mice; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2005 |
Effect of capecitabine on mean corpuscular volume of red blood cells.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythrocyte Indices; Fluorouracil; Humans | 2005 |
[Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; France; Hospital Costs; Humans; Middle Aged; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunohistochemistry; Thymidylate Synthase; Treatment Outcome | 2005 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Pancreatic Neoplasms; Withholding Treatment | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Hypertension, Portal; Liver Neoplasms; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Radiopharmaceuticals; Yttrium Radioisotopes | 2005 |
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
Topics: Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sarcoma; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2005 |
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Treatment Outcome | 2006 |
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Confounding Factors, Epidemiologic; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Tomography, X-Ray Computed | 2006 |
Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Spinal Cord Diseases | 2005 |
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes.
Topics: Anthracyclines; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Dendritic Cells; Deoxycytidine; Disease Progression; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorouracil; Genes, Reporter; Green Fluorescent Proteins; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy; Interferon-gamma; Leukocytes, Mononuclear; Microscopy, Fluorescence; Neoplasm Metastasis; Remission Induction; RNA, Messenger; Taxoids; Time Factors; Transcription, Genetic; Treatment Outcome | 2005 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2005 |
Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction | 2005 |
5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Capecitabine; Central Nervous System Diseases; Coma; Deoxycytidine; Fluorouracil; Humans | 2006 |
[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Prodrugs | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung; Lymphatic Metastasis; Lymphatic System; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2005 |
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; Floxuridine; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Thymidine Phosphorylase; Up-Regulation | 2006 |
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohistochemistry; Intestinal Mucosa; Ki-67 Antigen; Lead; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Pyrazoles; RNA, Messenger; Sulfonamides; Xenograft Model Antitumor Assays | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia, Hypochromic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Neutropenia; Platelet Count; Polyethylene Glycols; Treatment Outcome | 2005 |
Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Humans; Organoplatinum Compounds; Pyridines; Rectal Neoplasms | 2006 |
Capecitabine-induced severe hypertriglyceridemia: report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Triglycerides | 2006 |
Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.
Topics: Animals; Base Sequence; Capecitabine; Deoxycytidine; DNA Primers; Drug Synergism; Electrophoretic Mobility Shift Assay; Floxuridine; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Mammary Neoplasms, Experimental; Mice; NF-kappa B; Tumor Necrosis Factor-alpha; Uridine Phosphorylase | 2006 |
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Radiotherapy; Rectal Neoplasms | 2005 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Atherosclerosis; Capecitabine; Comorbidity; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nitroglycerin; Retrospective Studies; Risk Factors; Vasodilator Agents | 2006 |
On prejudice and facts and choices.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Services Accessibility; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Patient Satisfaction; Randomized Controlled Trials as Topic | 2006 |
Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.
Topics: Capecitabine; Carboxylic Ester Hydrolases; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Palliative Care; Prodrugs; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2006 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Male; Megestrol; Thalidomide; Treatment Outcome | 2006 |
An observational study examining the impact of capecitabine on warfarin antithrombotic activity and bleeding complications.
Topics: Aged; Aged, 80 and over; Anticoagulants; Capecitabine; Cohort Studies; Contraindications; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Hemorrhage; Humans; Male; Medical Audit; Michigan; Middle Aged; Patient Satisfaction; Retrospective Studies; Warfarin | 2006 |
Use of capecitabine after renal allograft transplantation in dog erythrocyte antigen-matched dogs.
Topics: Animals; Blood Chemical Analysis; Capecitabine; Cyclosporine; Deoxycytidine; Dogs; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Drug Therapy, Combination; Female; Fluorouracil; Graft Rejection; Immunosuppressive Agents; Ketoconazole; Kidney Transplantation; Nephrectomy; Pilot Projects; Prednisolone; Prospective Studies; Transplantation Immunology; Transplantation, Homologous; Treatment Outcome | 2006 |
Choroidal metastasis from breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Choroid Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2006 |
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pilot Projects; Stomach Neoplasms | 2006 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mitomycin; Neoplasm Metastasis; Patient Selection; Prognosis; Reproducibility of Results; Treatment Outcome | 2006 |
Drug interaction between capecitabine and warfarin: a case report and review of the literature.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Hemorrhage; Humans; International Normalized Ratio; Neoplasm Recurrence, Local; Plasma; Warfarin | 2006 |
Timing of significant adverse events is essential information during early development of new drugs.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Maximum Tolerated Dose; Neoplasms | 2006 |
A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Blood Coagulation Disorders; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Polypharmacy; Retrospective Studies; Warfarin | 2006 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms | 2006 |
Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.
Topics: beta-Alanine; Biological Assay; Calibration; Capecitabine; Case-Control Studies; Child; Child, Preschool; Chromatography, Liquid; Deoxycytidine; Enzymes; Female; Fluorouracil; Humans; Infant, Newborn; Male; Pyrimidines; Spectrometry, Mass, Electrospray Ionization; Uracil | 2006 |
Acute coronary syndrome induced by oral capecitabine.
Topics: Acute Disease; Administration, Oral; Adult; Angina, Unstable; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Liver Neoplasms; Syndrome | 2006 |
Capecitabine as an alternative in a case of fluorouracil-induced photodermatitis.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Photosensitivity Disorders; Rectal Neoplasms | 2006 |
Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gastritis; Gene Expression Regulation, Neoplastic; Humans; Male; Pancreatic Neoplasms; Radiodermatitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine Phosphorylase; Tumor Necrosis Factor-alpha | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2006 |
Capecitabine chemoradiation for rectal cancer after curative surgery.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prodrugs; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
Actinic keratosis and capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Keratosis | 2005 |
Accrual delayed in adjuvant bevacizumab trial.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cause of Death; Chemotherapy, Adjuvant; Colonic Neoplasms; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2006 |
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Meningeal Neoplasms; Methotrexate; Receptor, ErbB-2; Trastuzumab | 2006 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Risk Assessment; Tegafur; Uracil | 2006 |
Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Liver Neoplasms; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Southwestern United States | 2006 |
Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.
Topics: Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; CD83 Antigen; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunoglobulins; Irinotecan; Lymph Nodes; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2006 |
Coronary artery spasm induced by capecitabine.
Topics: Adult; Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2006 |
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Retrospective Studies; Uterine Cervical Neoplasms | 2006 |
Intraventricular metastases from rectal-sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiac Tamponade; Deoxycytidine; Dyspnea; Fatal Outcome; Female; Fluorouracil; Heart Neoplasms; Heart Ventricles; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Radiography; Rectal Neoplasms; Sigmoid Neoplasms; Ultrasonography | 2006 |
In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Choice Behavior; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prejudice | 2006 |
Acute coronary syndrome induced by capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Angiography; Coronary Disease; Deoxycytidine; Diagnosis, Differential; Electrocardiography; Female; Fluorouracil; Humans; Middle Aged; Prodrugs | 2006 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2006 |
Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
[Blisters unlike others].
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Syndrome | 2006 |
Not in the BNF.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Emergency Service, Hospital; Fatal Outcome; Female; Fluorouracil; Heart Arrest; Humans; Ovarian Neoplasms; Pharmacopoeias as Topic | 2006 |
Neoadjuvant therapy with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Treatment Outcome | 2006 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Enzyme Activators; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Follow-Up Studies; Humans; Indoles; Leukocytes, Mononuclear; Monocytes; Neoplasms; Protein Kinase C; Protein Kinase C beta; Reproducibility of Results; Sensitivity and Specificity; Signal Transduction; Structure-Activity Relationship; Treatment Outcome | 2006 |
[Patient with haemolytic anemia and treatment with capecitabine. Review of one case and literature].
Topics: Adult; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gilbert Disease; Humans; Hyperbilirubinemia; Mastectomy, Segmental; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2006 |
Capecitabine-induced cerebellar toxicity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Cerebellar Ataxia; Cerebellum; Deoxycytidine; Fluorouracil; Humans; Male | 2006 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2006 |
Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Meningeal Neoplasms; Middle Aged; Treatment Outcome | 2006 |
Novel interpenetrating network chitosan-poly(ethylene oxide-g-acrylamide) hydrogel microspheres for the controlled release of capecitabine.
Topics: Acrylic Resins; Calorimetry, Differential Scanning; Capecitabine; Chitosan; Delayed-Action Preparations; Deoxycytidine; Diffusion; Fluorouracil; Hydrogel, Polyethylene Glycol Dimethacrylate; Microspheres; Polyethylene Glycols; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2006 |
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Deoxyuridine; Female; Fluorouracil; Humans; Male; Thymidine | 2007 |
Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Rectal Neoplasms; Retrospective Studies | 2006 |
Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2006 |
Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Eruptions; Female; Fluorouracil; Humans; Lichenoid Eruptions; Photosensitivity Disorders | 2007 |
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecitabine; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Liver Neoplasms; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Paraneoplastic Syndromes; Pioglitazone; Prostatic Neoplasms; Thiazolidinediones | 2006 |
[Hand-foot syndrome with capecitabine therapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Scleroderma, Localized; Syndrome | 2007 |
Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Thymidine Phosphorylase; Thyroglobulin; Thyroid Neoplasms | 2006 |
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chromogranin A; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Analysis | 2007 |
Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Predictive Value of Tests; Prospective Studies; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Carbamates; Deoxycytidine; Floxuridine; Fluorouracil; Intestines; Macaca fascicularis; Male; Mice; Rats; Rats, Sprague-Dawley | 2006 |
Bilateral avascular necrosis of the hips after chemoradiotherapy for cervical cancer.
Topics: Adult; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Female; Femur Head Necrosis; Fluorouracil; Humans; Uterine Cervical Neoplasms; X-Rays | 2006 |
Concurrent radiotherapy and capecitabine, followed by high-dose methotrexate consolidation, provided effective palliation in a patient with leptomeningeal metastases from breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Meningeal Neoplasms; Methotrexate; Palliative Care | 2007 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Pharmacogenetics of capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Models, Biological; Molecular Sequence Data; Pilot Projects; Polymorphism, Genetic; Thymidylate Synthase | 2006 |
Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Gene Expression Regulation, Neoplastic; Hemoglobins; HT29 Cells; Humans; Oxidative Stress; Peroxidases; Peroxiredoxins; Reactive Oxygen Species; Superoxide Dismutase | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort Studies; Data Interpretation, Statistical; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Tract; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2006 |
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercalcemia; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Parathyroid Hormone-Related Protein; Tumor Cells, Cultured; Weight Loss | 2007 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Paresthesia; Prodrugs; Rectal Neoplasms; Syndrome | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Skin Neoplasms | 2006 |
[Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Mastectomy; Quality of Life; Trastuzumab | 2006 |
Metastatic hidradenocarcinoma: efficacy of capecitabine.
Topics: Adenoma, Sweat Gland; Antimetabolites, Antineoplastic; Axilla; Capecitabine; Deoxycytidine; Diagnosis, Differential; Drug Administration Schedule; Elbow; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Sweat Gland Neoplasms | 2006 |
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Caco-2 Cells; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression; HT29 Cells; Humans; Inhibitory Concentration 50; Intestinal Mucosa; Male; Middle Aged; Polymorphism, Genetic; Thymidine Phosphorylase; Thymidylate Synthase; Tumor Cells, Cultured | 2006 |
Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Erythema; Fluorouracil; Humans; Keratosis; Male; Paresthesia | 2006 |
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chi-Square Distribution; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies; Statistics, Nonparametric; Survival Analysis | 2006 |
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Radiotherapy; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2006 |
[Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Hand Dermatoses; Humans; Necrosis; Skin; Skin Ulcer; Time Factors; World Health Organization | 2007 |
[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
Topics: Adult; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astringents; Breast Neoplasms; Capecitabine; Deoxycytidine; Exudates and Transudates; Female; Fluorouracil; Hallux; Humans; Keratosis; Mupirocin; Nail Diseases; Ointments; Paclitaxel; Time Factors; Treatment Outcome; Zinc Sulfate | 2006 |
Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
Topics: Animals; Bile; Calibration; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Fluorouracil; Mice; Plasma; Rabbits; Reproducibility of Results; Serum | 2007 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms | 2006 |
Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radiotherapy Dosage; Rectal Neoplasms; Retrospective Studies | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
The effect of capecitabine on the healing of colonic anastomoses in rats.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Capecitabine; Colon; Deoxycytidine; Fluorouracil; Random Allocation; Rats; Rats, Wistar; Statistics, Nonparametric; Surgical Wound Dehiscence; Tissue Adhesions; Wound Healing | 2007 |
Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorine; Fluorouracil; Humans; Liver; Magnetic Resonance Spectroscopy | 2007 |
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Topics: Administration, Oral; Animals; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Pyrrolidines; Sensitivity and Specificity; Thymidine Phosphorylase; Thymine; Treatment Outcome; Trifluridine; Tumor Cells, Cultured; Uracil; Xenograft Model Antitumor Assays | 2007 |
A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Care Facilities; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; Home Care Services, Hospital-Based; Humans; Leadership; Male; Middle Aged; Nurse's Role; Nursing Audit; Nursing Evaluation Research; Outpatient Clinics, Hospital; Patient Satisfaction; Pharmacy Service, Hospital; Program Evaluation; Prospective Studies; Retrospective Studies; Scotland; Surveys and Questionnaires | 2007 |
Targeted therapy for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Rectal Neoplasms; Remission Induction; Retrospective Studies | 2007 |
[Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Mastectomy; Radiography, Abdominal; Tomography, X-Ray Computed | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Fluorouracil; Gene Deletion; Genotype; Heterozygote; Humans; Models, Statistical; Mutation; Polymorphism, Genetic; Quinazolines; Sequence Analysis, DNA; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2007 |
Use of capecitabine to prevent acute renal allograft rejection in dog erythrocyte antigen-mismatched mongrel dogs.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Capecitabine; Cyclosporine; Deoxycytidine; Dogs; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Drug Therapy, Combination; Female; Fluorouracil; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Nephrectomy; Pilot Projects; Postoperative Complications; Prospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2007 |
Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Liver Failure; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Stomach Neoplasms | 2006 |
Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer.
Topics: Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Dermatitis; Diagnosis, Differential; Female; Fluorouracil; Humans; Middle Aged; Skin Neoplasms; Stomach Neoplasms; Treatment Outcome | 2007 |
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Stomach Neoplasms; Survival Analysis | 2007 |
Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy.
Topics: Age Factors; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Rectal Neoplasms; Retrospective Studies; Survival; Treatment Outcome | 2007 |
Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erythema; Fluorouracil; Humans; Male; Middle Aged; Penis; Scrotum | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Esophageal Neoplasms; Fluorouracil; Humans; Prodrugs; Stomach Neoplasms; Thymidine Phosphorylase | 2007 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Neoplasm Recurrence, Local; Quality of Life; Toremifene | 2007 |
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Retrospective Studies; Soft Tissue Neoplasms; Treatment Outcome; Viscera | 2007 |
The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Bupropion; Capecitabine; Citalopram; Clopidogrel; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Monitoring; Drug Prescriptions; Drug Utilization Review; Fluorouracil; Humans; Lactones; Meningococcal Vaccines; Platelet Aggregation Inhibitors; Primary Health Care; Scotland; Sulfones; Ticlopidine; Time Factors | 2007 |
Lapatinib plus capecitabine in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD4-CD8 Ratio; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Endpoint Determination; Female; Fluorouracil; Humans; Immunotherapy; Killer Cells, Natural; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Analysis; Taxoids; Vascular Endothelial Growth Factor A | 2007 |
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Hyperthermia, Induced; Intraoperative Period; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pleural Neoplasms; Pseudomyxoma Peritonei; Thoracic Surgical Procedures | 2007 |
Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: CHRONICLE. A randomised phase III trial of control vs. capecitabine plus oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2007 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Tegafur; United Kingdom; Uracil | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms; Vitamin B Complex | 2007 |
Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Patient Selection; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy, Radical; Middle Aged; Nitriles; Parotid Gland; Parotid Neoplasms; Receptors, Estrogen; Time Factors; Treatment Outcome; Triazoles | 2007 |
A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Mutation; Rectal Neoplasms | 2007 |
Elementary, my dear Watson.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Dose-Response Relationship, Drug; Emigration and Immigration; Female; Fluorouracil; Foot; Hand; Humans; Neoplasm Metastasis | 2007 |
Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Choriocarcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Pregnancy; Risk Factors; Salvage Therapy; Trophoblastic Neoplasms | 2007 |
Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Risk Factors; Syndrome | 2007 |
Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leukemia, Myeloid | 2007 |
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Agents; Capecitabine; Deoxycytidine; Diffusion; Female; Fluorouracil; HT29 Cells; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Transplantation, Heterologous; Treatment Outcome | 2007 |
Capecitabine-induced headache responding to diltiazem.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diltiazem; Female; Fluorouracil; Headache; Humans; Rectal Neoplasms | 2007 |
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy.
Topics: Adenoma, Islet Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Streptozocin; Treatment Outcome | 2007 |
Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Digestive System Surgical Procedures; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome; Vitamin B Complex | 2007 |
Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2007 |
Medullary thyroid cancer treated by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Doxorubicin; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Thyroid Neoplasms; Treatment Outcome | 2007 |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; RNA, Messenger; Treatment Outcome | 2007 |
Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Risk Factors; Scleroderma, Localized | 2007 |
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2007 |
[Myocardial ischaemia as a result of treatment with capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Ischemia | 2007 |
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Thymidine Phosphorylase | 2007 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Electrocardiography; Female; Fluorouracil; Head and Neck Neoplasms; Heart; Heart Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Prospective Studies | 2008 |
[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Paresthesia; Postoperative Period; Syndrome | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Skin Neoplasms; Tegafur; Toremifene | 2007 |
Histological evaluation of colonic anastomotic healing, during perioperative Capecitabine administration. Experimental study in rats.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Disease Models, Animal; Fluorouracil; Necrosis; Preoperative Care; Rats; Rats, Wistar; Wound Healing | 2007 |
[Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Particle Accelerators; Preoperative Care; Radiotherapy, High-Energy; Rectal Neoplasms; Retrospective Studies | 2007 |
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Humans; Male; Treatment Outcome | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2007 |
[Capecitabine-induced hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; Mastectomy, Radical; Middle Aged; Paresthesia | 2007 |
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Edema; Capecitabine; Dementia, Vascular; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Energy Metabolism; Female; Fluorouracil; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Injections, Spinal; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasms; Nerve Fibers, Myelinated; Neurologic Examination; Registries; Remission, Spontaneous; Stroke; Tegafur | 2008 |
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Antigen; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Genetic Markers; Humans; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Pyrimidines; Rectal Neoplasms; RNA, Messenger; Thymidine Phosphorylase; Thymidylate Synthase | 2007 |
Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Recurrence, Local; Radiography; Trastuzumab | 2007 |
[Laparoscopic ovarian transposition and cryopreservation of ovarian tissue before chemo-radiotherapy for rectal cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Cryopreservation; Deoxycytidine; Female; Fluorouracil; Humans; Laparoscopy; Organoplatinum Compounds; Ovary; Oxaliplatin; Rectal Neoplasms | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2007 |
[Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
Topics: Antimetabolites, Antineoplastic; Calendula; Capecitabine; Deoxycytidine; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Matricaria; Phytotherapy; Salvia; Treatment Outcome | 2007 |
Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans | 2007 |
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Routes; Economics, Medical; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2007 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Transitional Cell; Colonic Pouches; Deoxycytidine; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Rectal Neoplasms; Urinary Bladder Neoplasms | 2007 |
Metastatic esophageal adenocarcinoma presenting in the iris.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Iris Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2007 |
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2007 |
Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Intestine, Small; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Contraindications; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2008 |
[Comparison of the suppressing capecitabine and 5-fluorouracil effects on the pronounce of inflammatory cells score in the induction of episcleral fibrosis after trabeculectomy].
Topics: Animals; Capecitabine; Deoxycytidine; Fibrosis; Fluorouracil; Glaucoma; Inflammation; Rabbits; Sclera; Trabeculectomy | 2007 |
Histopathologic evidence of capecitabine corneal toxicity in dogs.
Topics: Animals; Capecitabine; Cornea; Corneal Diseases; Deoxycytidine; Dog Diseases; Dogs; Female; Fluorouracil; Immunosuppressive Agents; Kidney Transplantation | 2007 |
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.
Topics: Antimetabolites, Antineoplastic; Becaplermin; Capecitabine; Carcinoma; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy; Neovascularization, Pathologic; Pelvis; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Rectal Neoplasms; Statistics as Topic; Vascular Endothelial Growth Factor A | 2008 |
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Failure | 2008 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Naphthoquinones; Neoplasms; Paresthesia; Severity of Illness Index; Syndrome; Treatment Outcome | 2008 |
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies | 2007 |
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2008 |
Application of pressure mapping techniques to measure push and gripping forces with precision.
Topics: Capecitabine; Deoxycytidine; Ergonomics; Fluorouracil; Friction; Hand Strength; Humans; Models, Theoretical; Pressure; Upper Extremity; Vibration; Weight-Bearing | 2008 |
Capecitabine induced vasospastic angina.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytidine; Fluorouracil; Humans | 2008 |
Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclooxygenase 2; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Kinetics; Luminescence; Tetrazolium Salts; Vinblastine; Vinorelbine | 2007 |
Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Flow Cytometry; Fluorouracil; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Luminescence; Taxoids; Tetrazolium Salts | 2007 |
Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
[A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Treatment Outcome | 2007 |
[A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Treatment Outcome | 2007 |
Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.
Topics: Blotting, Western; Capecitabine; Cell Cycle; Cell Line; Deoxycytidine; DNA; DNA Primers; DNA Repair; Fluorouracil; Green Fluorescent Proteins; Humans; Mass Spectrometry; Quinazolines; Thiophenes; Thymidylate Synthase; Uracil; Uracil-DNA Glycosidase | 2008 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis | 2007 |
[Myocardial ischaemia as a result of treatment with capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Myocardial Ischemia; Nitrites | 2007 |
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; Male; Vitiligo | 2007 |
Comments on final report of the AIO Colorectal Cancer Group Study: fluorouracil/oxaliplatin versus capecitabine/oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Research Design | 2007 |
Capecitabine plus oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2007 |
Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies | 2008 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Polymorphism, Genetic | 2007 |
FDA approves new breast cancer treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Contraindications; Deoxycytidine; Drug Approval; Drug Labeling; Epothilones; Fluorouracil; Humans; Tubulin Modulators; United States; United States Food and Drug Administration | 2007 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Stomach Neoplasms | 2008 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; HT29 Cells; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Hepatocytes; Liver; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous | 2008 |
Stevens-Johnson syndrome after treatment with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Stevens-Johnson Syndrome | 2008 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Granulomatous septal panniculitis associated with capecitabine (Xeloda).
Topics: Antimetabolites, Antineoplastic; Biopsy; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Panniculitis; Skin | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
Topics: Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; France; Humans; Leucovorin; Treatment Outcome | 2007 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Leukocyte Count; Male; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Platelet Count; Radioisotopes; Receptors, Somatostatin | 2008 |
Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Retrospective Studies; Survival Analysis | 2008 |
Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Retrospective Studies; Taxoids | 2007 |
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Male; Middle Aged; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Survival Analysis; Transcription Factors; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2007 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids | 2008 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Survival Rate | 2008 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Enhancer Elements, Genetic; Female; Fluorouracil; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Thymidylate Synthase | 2008 |
Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2008 |
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Capecitabine-related cardiotoxicity: recognition and management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Incidence; Male; Middle Aged; Prodrugs; Rectal Neoplasms | 2008 |
Capecitabine for treatment of advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genes, erbB-2; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Taxoids; Trastuzumab | 2008 |
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Hepatomegaly; Humans; Immunohistochemistry; Liver Neoplasms; Male; Risk Factors; Stomach Neoplasms; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2008 |
[Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy; Liver Neoplasms; Middle Aged; Neoplasm Staging; Recurrence; Tomography, X-Ray Computed; Trastuzumab | 2008 |
Preoperative chemoradiation with capecitabine in locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Radiotherapy Dosage; Rectal Neoplasms | 2008 |
Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves.
Topics: Algorithms; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Capecitabine; Chi-Square Distribution; Databases, Factual; Deoxycytidine; Fluorouracil; Humans; Hydrocortisone; Models, Statistical; Multivariate Analysis; Pharmaceutical Preparations; Pharmacokinetics | 2008 |
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Polymorphism, Genetic | 2008 |
Oral treatment for gastric cancer: new choices, better choices?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Japan; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Capecitabine induced inflammation of actinic keratoses.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Keratosis; Ultraviolet Rays | 2007 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Forecasting; Humans; Immunohistochemistry; Middle Aged; Retrospective Studies; Therapeutic Equivalency; Thymidine Phosphorylase; Treatment Outcome | 2008 |
Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteroides fragilis; Bacteroides Infections; Bevacizumab; Capecitabine; Cecal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Liver Abscess, Pyogenic; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed | 2008 |
Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine.
Topics: Animals; Antibodies, Antinuclear; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lupus Erythematosus, Discoid; Mice; Middle Aged | 2008 |
Systemic therapy for metastatic colorectal cancer: current questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms | 2008 |
Candidate mechanisms for capecitabine-related hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Cell Proliferation; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Pilot Projects; Skin Diseases | 2008 |
[A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Recurrence; Taxoids; Time Factors; Tomography, X-Ray Computed | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Hand Dermatoses; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Scleroderma, Localized; Severity of Illness Index; Sigmoid Neoplasms; Syndrome | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
Nail and periungual toxicity following capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Nail Diseases; Stomach Neoplasms; Treatment Outcome | 2008 |
Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Staging; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Defining the optimal schedule of drug administration: art or science?
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Fluorouracil; Humans; Models, Biological; Research Design | 2008 |
Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Costs and Cost Analysis; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Survival Rate | 2008 |
Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cerebellar Ataxia; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Odds Ratio; Palliative Care; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Capecitabine; Cytochrome P-450 CYP2C9; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Sulfonamides | 2008 |
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Tegafur; Thrombospondin 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Capecitabine-associated coronary vasospasm: a case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Prodrugs; Sigmoid Neoplasms | 2008 |
Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Survival Analysis | 2009 |
[Therapy of colorectal carcinoma. To combine saves lives].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Randomized Controlled Trials as Topic; Time Factors; Vitamin B Complex | 2004 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Gastrointestinal Diseases; Humans; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Residence Characteristics; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States; Vitamin B Complex; Withholding Treatment | 2008 |
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Fluorouracil; Hospital Costs; Humans; Models, Economic; Neoplasm Metastasis; Patient Selection; Research Design; Treatment Outcome | 2008 |
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Fluorouracil; Hospital Costs; Humans; Infusions, Parenteral; Leucovorin; Models, Economic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Research Design; Treatment Outcome; Vitamin B Complex | 2008 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Costs; Esophageal Neoplasms; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2008 |
[Acute coronary syndrome during oral capecitabine monotherapy].
Topics: Acute Coronary Syndrome; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged | 2008 |
Ten years of HER2-directed therapy: still questions after all these years.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Forecasting; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2009 |
Use of capecitabine in refractory metastatic medullary thyroid carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Medullary; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Thyroid Neoplasms | 2008 |
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy | 2008 |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carboxylesterase; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA, Neoplasm; Female; Fluorouracil; Genotype; Humans; Multivariate Analysis; Pilot Projects; Polymorphism, Genetic; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Pilot Projects; Randomized Controlled Trials as Topic | 2007 |
Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Meningeal Neoplasms; Trastuzumab | 2009 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Time Factors | 2007 |
Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Status; Health Status Indicators; Humans; Least-Squares Analysis; Leucovorin; Male; Middle Aged; Prospective Studies; Psychological Tests; Quality of Life; Sex Factors; Surveys and Questionnaires; Vitamin B Complex | 2008 |
Pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Naturopathy; Pancreatic Neoplasms; Pastoral Care; Physical Therapy Modalities | 2008 |
Combined cetuximab, capecitabine, oxaliplatin, and radiotherapy in rectal cancer: Dr. Jekyll or Mr. Hyde? In regard to Rödel et al. (Int J Radiat Oncol Biol Phys 2008;70:1081-1086.).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiotherapy; Rectal Neoplasms | 2008 |
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2008 |
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Topics: Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Metabolic Networks and Pathways; Prodrugs; Tetrahydrouridine | 2008 |
Large bowel perforation associated with capecitabine treatment for breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Perforation; Sigmoid Diseases | 2008 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Pyogenic granuloma-like lesions caused by capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Eruptions; Fingers; Fluorouracil; Granuloma, Pyogenic; Hand Dermatoses; Humans; Male; Middle Aged | 2008 |
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Topics: Acute Disease; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Severity of Illness Index; Steroids; Stomach Neoplasms | 2008 |
Mesojejunoileac liposarcoma with intrahepatic metastasis in a dog.
Topics: Animals; Capecitabine; Deoxycytidine; Dog Diseases; Dogs; Doxorubicin; Fatal Outcome; Fluorouracil; Ileal Neoplasms; Jejunal Neoplasms; Laparotomy; Liposarcoma; Liver Neoplasms; Radiography | 2008 |
Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cholesterol; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Middle Aged; Prodrugs; Triglycerides | 2009 |
New treatment strategies provide more options for patients with breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Female; Fluorouracil; Humans; Imidazoles; Zoledronic Acid | 2008 |
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Herbal Medicine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Plant Preparations | 2008 |
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Analysis; Treatment Outcome | 2008 |
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Leucovorin; Mutation; Organoplatinum Compounds; Oxaliplatin; Prognosis; Research Design; Treatment Outcome | 2008 |
Capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Coronary Vasospasm; Deoxycytidine; Echocardiography; Electrocardiography; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2008 |
Drug development in the targeted therapy era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disclosure; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Quinazolines; Receptor, ErbB-2 | 2008 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pleural Neoplasms; Prodrugs; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2009 |
Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Preoperative Care; Radiography, Interventional; Tomography, X-Ray Computed | 2009 |
Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Radiotherapy, Conformal; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2008 |
[The prevention of diarrhea while under capecitabine therapy].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fluorouracil; Humans; Lactase; Lactose | 2008 |
[Clinical effect and positioning of capecitabine for metastatic breast carcinoma].
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
[Management of hand-foot syndrome in patient treated with capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Nervous System Diseases; Skin Diseases; Syndrome | 2008 |
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Thymidine Phosphorylase; Time Factors; Treatment Outcome; Ubiquitin-Protein Ligases | 2009 |
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Infusions, Parenteral; Italy; Leucovorin; Male; Middle Aged; National Health Programs; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Young Adult | 2008 |
Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; Treatment Failure; Treatment Outcome | 2008 |
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Neoplasms, Second Primary; Paclitaxel; Receptor, ErbB-2; Remission Induction; Skin Neoplasms; Survival Rate; Trastuzumab | 2008 |
[A recurrent case of lipid-secreting carcinoma of the breast successfully treated with capecitabine].
Topics: Biopsy; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lipid Metabolism; Mammography; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Infusions, Intravenous; Italy; Leucovorin; Male; Middle Aged; Retrospective Studies; Young Adult | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2009 |
A case of cardiogenic shock caused by capecitabine treatment.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Biomarkers; Biopsy; Capecitabine; Cardiotonic Agents; Chemotherapy, Adjuvant; Coronary Angiography; Deoxycytidine; Echocardiography; Electrocardiography; Female; Fluorouracil; Humans; Middle Aged; Shock, Cardiogenic; Treatment Outcome | 2008 |
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chest Pain; Colorectal Neoplasms; Coronary Vasospasm; Deoxycytidine; Diagnosis, Differential; Electrocardiography; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Treatment Outcome | 2008 |
Capecitabine-associated cerebellar ataxia.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cerebellar Ataxia; Deoxycytidine; Female; Fluorouracil; Humans | 2008 |
Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Remission Induction; Treatment Outcome | 2008 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Lung; Male; Oxygen Inhalation Therapy; Pancreatic Neoplasms; Pneumonia; Tomography, X-Ray Computed | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; International Normalized Ratio; Pancreatic Neoplasms; Prothrombin Time; Stents; Warfarin | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Ginsenosides; Humans; Immunohistochemistry; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Time Factors; Vascular Endothelial Growth Factor A | 2008 |
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorodeoxyglucose F18; Fluorouracil; Humans; Mitomycin; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Statistics, Nonparametric | 2009 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Invasiveness; Radiography; Radiotherapy, Adjuvant; Renal Veins; Vena Cava, Inferior; Venous Thrombosis | 2008 |
Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fascia; Fasciotomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Enhancement; Image Processing, Computer-Assisted; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Rectal Neoplasms; Rectum; Software; Survival Rate; Tomography, X-Ray Computed | 2008 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Conformal; Rectal Neoplasms | 2009 |
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Stomach Neoplasms | 2008 |
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Palliative Care; Pyrimidinones; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2008 |
Sequential or combination chemotherapy for a patient with mCRC?
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male | 2008 |
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
Topics: Adrenal Cortex Neoplasms; Antimetabolites, Antineoplastic; Capecitabine; Cytidine Deaminase; Deoxycytidine; Female; Fluorouracil; Humans; Metabolic Clearance Rate; Polymorphism, Genetic; Young Adult | 2009 |
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Topics: Animals; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immunosorbent Assay; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Predictive Value of Tests; Regression Analysis; Reverse Transcriptase Polymerase Chain Reaction; Statistics, Nonparametric; Thymidine Phosphorylase; Tumor Cells, Cultured | 2009 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Caveolin 1; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Array Analysis; Rectal Neoplasms; Remission Induction; RNA, Messenger | 2009 |
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Prospective Studies; Receptor, ErbB-2; Research Design; Trastuzumab | 2009 |
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Drug Tolerance; Fluorouracil; Humans; Immunotherapy; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Xenograft Model Antitumor Assays | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Rectal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2009 |
Chemotherapy side-effect management using mobile phones.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Capecitabine; Cell Phone; Colonic Neoplasms; Deoxycytidine; Drug Therapy, Computer-Assisted; England; Female; Fluorouracil; Humans; Male; Middle Aged; Remote Consultation | 2008 |
Fatal drug-drug interaction of brivudine and capecitabine.
Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Antimetabolites, Antineoplastic; Antiviral Agents; Bromodeoxyuridine; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fatal Outcome; Female; Fluorouracil; Herpes Zoster; Humans; Switzerland | 2009 |
Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2009 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Remission Induction; Survival Rate; Taxoids; Vomiting | 2008 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Rate; Taxoids | 2008 |
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Topics: Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fees, Pharmaceutical; Female; Fluorouracil; Health Expenditures; Humans; Male; Middle Aged; Retrospective Studies | 2009 |
Targeted therapy for advanced colorectal cancer--more is not always better.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Treatment Failure; Vascular Endothelial Growth Factor A | 2009 |
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Regression Analysis; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome | 2009 |
Oxaliplatin-mediated autoimmune thrombocytopenia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Purpura, Thrombocytopenic, Idiopathic | 2009 |
Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fatal Outcome; Fluorouracil; Gastrointestinal Hemorrhage; Hodgkin Disease; Humans; Immunohistochemistry; Lymph Nodes; Male; Oxaloacetates; Tomography, X-Ray Computed | 2010 |
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, Transgenic, Suicide; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Survival Analysis | 2009 |
[A case of metastatic breast cancer with liver metastasis effectively treated with capecitabine and vinorelbine].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Remission Induction; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Selection; Prognosis; Survival Analysis; Time Factors | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaloacetates | 2009 |
Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Combined Modality Therapy; Deoxycytidine; Education, Medical, Continuing; Female; Fluorouracil; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Remission Induction | 2009 |
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Analysis | 2009 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes | 2009 |
Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma.
Topics: Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Dansyl Compounds; Deoxycytidine; Fluorouracil; Humans; Indicators and Reagents; Mass Spectrometry; Methyl Ethers; Quality Control; Reference Standards; Reproducibility of Results; Specimen Handling | 2009 |
Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathy, Dilated; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Analysis; Echocardiography; Fluorouracil; Germ-Line Mutation; Humans; Male; Middle Aged; Mutation, Missense; Pancreatic Neoplasms; Polymerase Chain Reaction; Prodrugs; Pulmonary Valve Insufficiency; Thymidylate Synthase | 2009 |
Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Middle Aged | 2009 |
[A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy; Lymphatic Metastasis; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2009 |
A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Hyperpigmentation | 2009 |
Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chest Pain; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Myocardial Ischemia; Nitroglycerin; Prognosis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2009 |
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Quality-Adjusted Life Years | 2009 |
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fatal Outcome; Fluorouracil; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Oxaloacetates; Time Factors; Treatment Outcome | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Muscle, Skeletal; Muscular Diseases; Neoplasm Metastasis; Prospective Studies | 2009 |
A glucuronidation pathway of capecitabine occurs in rats but not in mice and humans.
Topics: Animals; Antimetabolites, Antineoplastic; Bile; Capecitabine; Deoxycytidine; Fluorouracil; Glucuronides; Humans; Liver; Male; Mice; Microsomes, Liver; Rats; Rats, Wistar; Species Specificity | 2007 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Assessing software impact on clinical workflow and resource utilization.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Efficiency, Organizational; Evaluation Studies as Topic; Fluorouracil; Health Resources; Humans; Medical Oncology; Medication Systems, Hospital; Pharmacy Service, Hospital; Software | 2009 |
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2009 |
Blepharoptosis following oxaliplatin administration.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Vision Disorders | 2009 |
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Creatinine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kidney; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Stomach Neoplasms | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Regression Analysis; Retrospective Studies; Treatment Outcome | 2009 |
Nursing considerations for capecitabine-based combination therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Monitoring; Fluorouracil; Humans; Oncology Nursing; Patient Education as Topic; Safety | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Fluorouracil; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; Male; Middle Aged | 2008 |
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Sex Distribution | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Subacute cutaneous lupus erythematosus induced by capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous | 2009 |
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Orotate Phosphoribosyltransferase; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2009 |
[Palliative chemotherapy for metastatic breast cancer with capecitabine].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
[A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Positron-Emission Tomography; Taxoids; Thoracic Neoplasms; Thoracic Wall; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Capecitabine-induced acute myeloid leukaemia.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Male; Prodrugs; Sigmoid Neoplasms | 2009 |
Travel warning with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dermatoglyphics; Emigration and Immigration; Fingers; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Skin; Travel; United States | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2009 |
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Genetic Variation; Hematologic Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Staging; Open Reading Frames; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
Topics: Adenoma, Villous; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluorouracil; Hernia, Inguinal; Humans; Ileocecal Valve; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Treatment Outcome | 2009 |
Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermoscopy; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Pigmentation Disorders; Tongue Diseases | 2009 |
Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer.
Topics: Adolescent; Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Health Status; Humans; Middle Aged; Multicenter Studies as Topic; New Zealand; Outcome Assessment, Health Care; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sickness Impact Profile; Surveys and Questionnaires; Survival Analysis; Young Adult | 2009 |
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2009 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Colostomy; Deoxycytidine; Female; Fluorouracil; HIV Infections; Humans; Male; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Retrospective Studies | 2009 |
[Coronary artery disease attack caused by cytotoxic chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chest Pain; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Male; Middle Aged | 2009 |
Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
Topics: Administration, Buccal; Antimetabolites, Antineoplastic; Betamethasone; Breast Neoplasms; Capecitabine; Chlorhexidine; Deoxycytidine; Female; Fluorouracil; Glucocorticoids; Humans; Middle Aged; Skin; Stomatitis | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Frequency; Genetic Variation; Haplotypes; Humans; Introns; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; Sequence Analysis, DNA; Severity of Illness Index; Stomach Neoplasms; White People | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Palliative Care; Pemetrexed; Prospective Studies; Radiation Tolerance; Radiotherapy Dosage; Young Adult | 2010 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2009 |
Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fanconi Syndrome; Female; Fluorouracil; Humans; Irinotecan | 2009 |
Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary Angiography; Coronary Vasospasm; Deoxycytidine; Diltiazem; Electrocardiography; Fluorouracil; Heart Rate; Humans; Male; Middle Aged; Tachycardia, Ventricular; Vasodilator Agents | 2009 |
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Middle Aged; RNA, Messenger; Thymidine Phosphorylase | 2009 |
Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Taxoids | 2009 |
Current role of bevacizumab in colorectal cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Severe palmar-plantar erytrodysesthesia after treatment with capecitabine.
Topics: Antineoplastic Agents; Blister; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged | 2010 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Vomiting; Young Adult | 2009 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Goserelin; Hematoma, Subdural, Intracranial; Humans; Indoles; Letrozole; Leukopenia; Nitriles; Pyrroles; Skull; Sunitinib; Triazoles | 2009 |
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mucin-1; Quinazolines; Receptor, ErbB-2; Thrombocytopenia; Trastuzumab | 2009 |
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclin D1; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; NF-kappa B; Receptors, CXCR4; Vascular Endothelial Growth Factor A | 2009 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sex Factors; Tegafur | 2009 |
Health utility scores of colorectal cancer based on societal preference in Japan.
Topics: Adaptation, Psychological; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Knowledge, Attitudes, Practice; Health Status Indicators; Health Surveys; Humans; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Patient Satisfaction; Quality of Life; Sex Factors; Social Perception; Statistics as Topic; Stress, Psychological; Surveys and Questionnaires | 2009 |
Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Intestinal Perforation; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Stents | 2009 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cause of Death; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Middle Aged; Multicenter Studies as Topic; Netherlands; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; Decision Support Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Models, Biological; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Treatment Outcome | 2009 |
A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Topics: 1-Propanol; Acetonitriles; Antimetabolites, Antineoplastic; Capecitabine; Chemical Precipitation; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Fluorouracil; Furans; Humans; Linear Models; Pyrimidines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Trichloroacetic Acid; Uracil; Vidarabine | 2010 |
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged | 2009 |
Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Markov Chains; Middle Aged | 2009 |
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prognosis; Survival Analysis; Thymidine Phosphorylase | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Research Design; Retrospective Studies; SEER Program; Unnecessary Procedures | 2009 |
Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Immunosuppressive Agents; Male; Middle Aged; Organ Transplantation; Precancerous Conditions; Skin Neoplasms | 2009 |
Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Decision Making; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Patient Satisfaction; Quality of Life; Surveys and Questionnaires | 2010 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pelvis; Pyridines; Radiation Injuries; Rectal Neoplasms; Retreatment; Retrospective Studies; Survival Rate; Tumor Burden | 2010 |
Capecitabine-induced pancreatitis.
Topics: Adult; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Pancreatitis; Sigmoid Neoplasms | 2010 |
Cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Interpersonal Relations; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Social Support | 2009 |
Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.
Topics: Aged; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy | 2009 |
Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Socioeconomic Factors; Treatment Outcome; United Kingdom | 2010 |
The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Chemotherapy in older women with breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Radiotherapy, Adjuvant | 2009 |
[Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Child; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Obstruction; Intestinal Perforation; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Child; Colonic Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Remission Induction; Young Adult | 2009 |
Chemotherapy in older women with breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Receptors, Estrogen | 2009 |
Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Infusions, Intravenous; Linear Models; Middle Aged; SEER Program; Taxoids | 2009 |
Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Feasibility Studies; Fluorouracil; HT29 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neural Networks, Computer; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Time Factors; Transplantation, Heterologous; Treatment Outcome; Tumor Burden | 2009 |
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Male; Middle Aged; Retrospective Studies | 2009 |
[A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Skin Ulcer | 2009 |
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Hot Temperature; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Time Factors; Treatment Outcome | 2010 |
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Insurance, Health, Reimbursement; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; United States | 2009 |
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Therapy; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Methotrexate; Neoplasm Recurrence, Local; Neutropenia; Patient Compliance; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Therapeutic Equivalency | 2009 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Neoplasm Metastasis; Pyridoxine; Retrospective Studies; Vitamin B Complex | 2010 |
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Variation; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies | 2010 |
Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2009 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Retrospective Studies; Survival Analysis; Vitamin B Complex | 2010 |
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cerebellar Diseases; Colorectal Neoplasms; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; Humans; Liver Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2010 |
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Epidermal Growth Factor; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Survival Rate; Thymidylate Synthase; Treatment Outcome | 2010 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Forecasting; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2009 |
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dideoxynucleosides; Fluorouracil; Humans; Positron-Emission Tomography; Regional Blood Flow; Thymidylate Synthase | 2009 |
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Octreotide; Radiography; Treatment Outcome | 2009 |
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radiation Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Thymidine Phosphorylase; Treatment Outcome; Young Adult | 2010 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies | 2010 |
Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colectomy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prodrugs; Prospective Studies; Rectal Neoplasms; Time Factors; Treatment Outcome | 2010 |
Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Stomach Neoplasms | 2010 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Taxoids; Treatment Outcome | 2009 |
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Quality of Life; Retrospective Studies; Time Factors; Treatment Failure | 2009 |
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Survival Rate; Young Adult | 2010 |
Longitudinal melanonychia induced by capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Nail Diseases; Pigmentation Disorders | 2009 |
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2009 |
Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe.
Topics: Adsorption; Amphibians; Animals; Bacteria; Capecitabine; Daphnia; Deoxycytidine; Embryo, Nonmammalian; Environmental Monitoring; Environmental Pollutants; Europe; Fluorouracil; Fungi; Geologic Sediments; Humans; Larva; Prodrugs; Risk Assessment; Sewage; Waste Disposal, Fluid | 2010 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Radiography; Temozolomide; Treatment Outcome | 2011 |
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Sickle cell crisis in a patient receiving capecitabine chemotherapy.
Topics: Adenocarcinoma; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Pain | 2010 |
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leg; Middle Aged; Muscle Cramp; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Paresthesia; Treatment Outcome | 2010 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
An epigenetic mechanism for capecitabine resistance in mesothelioma.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; CpG Islands; Deoxycytidine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pericardium; Promoter Regions, Genetic; Sequence Analysis, DNA; Thymidine Phosphorylase | 2010 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Child; Colorectal Neoplasms; Deoxycytidine; Drug Hypersensitivity; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Sex Factors; Young Adult | 2010 |
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Retrospective Studies; Syndrome | 2009 |
Cost comparison of capecitabine in patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Taxoids; United States | 2010 |
[Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Heart; Heart Diseases; Humans; Isosorbide Dinitrate; Nitroglycerin; Prodrugs; Risk Factors; Vasodilator Agents | 2010 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genes, ras; Genetic Predisposition to Disease; Genetic Testing; Humans; Leucovorin; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pathology, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2009 |
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Incidence; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies; Scotland | 2010 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromosome Mapping; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Rectal Neoplasms; Tumor Suppressor Proteins | 2010 |
An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women.
Topics: Adult; Aged; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deglutition Disorders; Deoxycytidine; Dyspnea; Female; Fluorouracil; Hoarseness; Humans; Hypokalemia; Incidence; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Respiratory Sounds; Sex Factors | 2010 |
Capecitabine cardiac toxicity presenting as effort angina: a case report.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cardiovascular Agents; Coronary Vasospasm; Deoxycytidine; Echocardiography, Doppler, Color; Echocardiography, Doppler, Pulsed; Electrocardiography; Female; Fluorouracil; Humans; Middle Aged | 2010 |
Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bezafibrate; Capecitabine; Cecum; Deoxycytidine; Fluorouracil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Staging | 2010 |
Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Enteritis; Female; Fluorouracil; Humans; Ileostomy; Intestinal Obstruction; Korea; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Postoperative Complications; Preoperative Care; Radiotherapy Dosage; Rectal Fistula; Rectal Neoplasms; Rectovaginal Fistula; Rectum; Urinary Bladder Fistula; Young Adult | 2010 |
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Capecitabine; Caspases; Cell Cycle Proteins; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; DNA Damage; Doxorubicin; Flow Cytometry; Fluorouracil; Glutamates; Guanine; Histones; Humans; Immunoenzyme Techniques; Mitomycin; Nuclear Proteins; Pemetrexed; Phosphorylation; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rats; Rats, Inbred F344; Rats, Nude; Xenograft Model Antitumor Assays | 2010 |
Increased anticoagulant activity of warfarin used in combination with doxifluridine.
Topics: Administration, Oral; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Humans; International Normalized Ratio; Warfarin | 2010 |
Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Male; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Haplotypes; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Polymorphism, Single Nucleotide; Predictive Value of Tests; Vascular Endothelial Growth Factor A | 2011 |
Renal atrophy secondary to chemoradiotherapy of abdominal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrophy; Capecitabine; Cisplatin; Combined Modality Therapy; Creatinine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Gemcitabine; Humans; Kidney; Male; Middle Aged; Organ Size; Radiation Injuries; Radiography; Regression Analysis; Retrospective Studies; ROC Curve | 2010 |
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Capecitabine; Carotid Stenosis; Coronary Artery Disease; Cyclophosphamide; Deoxycytidine; Diabetes Mellitus; Fluorouracil; Humans; Immunohistochemistry; Leuprolide; Male; Nitriles; Osteoarthritis; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Pulmonary Disease, Chronic Obstructive; Tomography, X-Ray Computed; Tosyl Compounds | 2010 |
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Papillary; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epothilones; Female; Fluorouracil; Follow-Up Studies; Humans; Long-Term Care; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
[Long-term response of liver metastases of breast cancer to capecitabine--case report].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged | 2010 |
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost Sharing; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Financing, Personal; Fluorouracil; Humans; Japan; Multicenter Studies as Topic; Oxaloacetates; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2010 |
Neoadjuvant chemotherapy in MRI-staged rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2010 |
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. In regard to MG Zampino et al. (Int J Radiat Oncol Biol Phys 2009;75:421-427).
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Postoperative Complications; Rectal Neoplasms; Remission Induction; Time Factors; Urogenital System | 2010 |
Chemotherapy-associated peripheral sensory neuropathy assessed using in vivo corneal confocal microscopy.
Topics: Aged; Capecitabine; Carcinoma; Colorectal Neoplasms; Cornea; Deoxycytidine; Fluorouracil; Humans; Male; Microscopy, Confocal; Paresthesia | 2010 |
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Intensive Care Units; Male | 2010 |
Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Count; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Mast Cells; Middle Aged; Syndrome | 2010 |
Cutaneous metastasis as first clinical manifestation of signet ring cell gastric carcinoma.
Topics: Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Signet Ring Cell; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Skin Neoplasms; Stomach Neoplasms; Taxoids | 2010 |
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Erythema; Fluorouracil; Foot; Functional Laterality; Hand; Humans; Male; Stomach Neoplasms | 2010 |
Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacy.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Medication Errors; Mycophenolic Acid; Pharmacy Service, Hospital | 2011 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Netherlands; Proportional Hazards Models; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Stomach Neoplasms; Time Factors; Treatment Outcome | 2010 |
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2010 |
Steroids, cancer and vertebral fractures: a dreaded combination.
Topics: Adrenal Cortex Hormones; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Organoplatinum Compounds; Osteoporosis; Oxaliplatin; Palliative Care; Quality of Life; Risk Factors; Spinal Fractures; Time Factors; Treatment Outcome; Vertebroplasty | 2011 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2011 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
[More effective positioning of capecitabine for advanced and metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Survival Rate | 2010 |
[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Skin Neoplasms; Taxoids; Tomography, X-Ray Computed; Vitamin B 6 | 2010 |
[Chemotherapy of colonic cancer].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Neoplasms; Risk Factors; Stomach Neoplasms | 2010 |
Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
Topics: Age Factors; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Health Expenditures; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sex Factors | 2010 |
Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A | 2010 |
Anal cancer with cerebral metastasis: a case report.
Topics: Antineoplastic Agents; Anus Neoplasms; Brain Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Middle Aged; Neurosurgical Procedures; Radiotherapy | 2011 |
Trastuzumab beyond progression: a cost-utility analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lymphatic Metastasis; Markov Chains; Prognosis; Quality-Adjusted Life Years; Sensitivity and Specificity; Survival Rate; Time Factors; Trastuzumab | 2010 |
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hematologic Tests; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prodrugs; Radiation-Sensitizing Agents; Receptors, Peptide; Retrospective Studies; Survival Analysis; Time Factors; Young Adult | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
Capecitabine dosing is not yet optimized for breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Prodrugs | 2010 |
Novel targeted therapies in inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2010 |
Overcoming radiation resistance in inflammatory breast cancer.
Topics: Breast Neoplasms; Capecitabine; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2010 |
Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Topics: Adenoma, Pleomorphic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Salivary Gland Neoplasms; Trastuzumab | 2010 |
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Mice; Models, Theoretical; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma.
Topics: Area Under Curve; Capecitabine; Chromatography, Liquid; Deoxycytidine; Drug Stability; Fluorouracil; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tetrahydrouridine | 2010 |
Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Capecitabine; Cardiotoxins; Cardiovascular Diseases; Coronary Vasospasm; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged | 2010 |
Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Capecitabine; Cell Cycle Proteins; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Endonucleases; Fluorouracil; Humans; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2010 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2010 |
Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer.
Topics: Aged; Aortic Aneurysm, Abdominal; Aortic Dissection; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Treatment Outcome | 2010 |
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Germany; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Patient Care Team; Statistics as Topic; Statistics, Nonparametric | 2011 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids | 2010 |
Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
PharmGKB summary: fluoropyrimidine pathways.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Databases, Factual; Deoxycytidine; Fluorouracil; Genome, Human; Humans; Pharmacogenetics; Tegafur | 2011 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; United Kingdom | 2010 |
Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Analysis; Young Adult | 2010 |
High frequency of hand foot syndrome with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional Studies; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Syndrome | 2010 |
Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Care; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Analysis | 2011 |
Development of bronchiolitis obliterans organizing pneumonia with platinum-based chemotherapy for metastatic rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cryptogenic Organizing Pneumonia; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2010 |
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2011 |
[Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radiation; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Treatment Outcome | 2010 |
Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Qualitative Research; Risk Factors | 2011 |
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult | 2011 |
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pyrazoles; Rectal Neoplasms; Sulfonamides; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Young Adult | 2011 |
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslipidemias; Fenofibrate; Fluorouracil; Humans; Hypertriglyceridemia; Middle Aged; Prospective Studies; Risk | 2010 |
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Indoles; Least-Squares Analysis; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Phosphotransferases; Pyrroles; Radiation Tolerance; Rectal Neoplasms; Rectum; Remission Induction; Signal Transduction; Substrate Specificity; Sunitinib; Treatment Outcome | 2010 |
Capecitabine with radiation is an effective adjuvant therapy in gastric cancers.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; gamma-Aminobutyric Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pregabalin | 2010 |
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2010 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Chromatography, Affinity; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Female; Fluorouracil; Glutathione S-Transferase pi; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neurophysiology; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Phenotype; Survival Rate; Treatment Outcome | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Motor Neuron Disease; Neoplasm Staging; Neurophysiology; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2010 |
Are we ready to use an early alternative end point as the primary end point of a phase III study in rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Outcome | 2010 |
Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: is there still a place for ecoendoscopic ultrasound?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endosonography; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Preoperative Care; Rectal Neoplasms; Sensitivity and Specificity; Treatment Outcome | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2011 |
[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Phase I studies of drug combinations.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Evidence-Based Medicine; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Maximum Tolerated Dose; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
[Oxaliplatin plus capecitabine for advanced gastric cancer: report of 38 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2010 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome | 2010 |
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2010 |
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neprilysin; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sister Mary Joseph's Nodule; Skin Neoplasms; Treatment Outcome; Umbilicus; Vimentin; WT1 Proteins | 2010 |
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fluorouracil; Foot; Hand; Humans; Pyridoxine; Syndrome; Vitamin B Complex | 2010 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Weight Loss | 2011 |
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models | 2010 |
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2012 |
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
Topics: Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cancer Vaccines; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Dendritic Cells; Deoxycytidine; Fluorouracil; Humans; Hypersensitivity, Delayed; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; T-Lymphocytes | 2010 |
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation | 2011 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2010 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection | 2010 |
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate | 2011 |
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Floxuridine; Fluorouracil; Gene Expression Regulation, Enzymologic; Histone Deacetylase Inhibitors; Hydroxamic Acids; Mice; Mice, Inbred BALB C; Thymidine Phosphorylase; Thymidylate Synthase; Up-Regulation; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Effects of capecitabine and celecoxib in experimental pancreatic cancer.
Topics: Animals; Capecitabine; Celecoxib; Cricetinae; Deoxycytidine; Fluorouracil; Lipid Peroxidation; Lipid Peroxides; Male; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2010 |
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance.
Topics: Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Heterogeneous-Nuclear Ribonucleoprotein Group F-H; Humans; Prodrugs; Protein Splicing; RNA Precursors; Thymidine Phosphorylase | 2011 |
Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Colitis, Ischemic; Deoxycytidine; Endoscopy, Digestive System; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed | 2011 |
Outcomes from chemoradiotherapy for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Trastuzumab for gastric cancer treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Humans; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab | 2010 |
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Topics: Capecitabine; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA, Circular; Drug Screening Assays, Antitumor; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphocytes; Mutagens; Neoplasms, Squamous Cell; Plasmids; Spin Labels; Time Factors | 2011 |
Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Diseases; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Organoplatinum Compounds; Oxaliplatin; Rupture, Spontaneous; Stents | 2010 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheter Ablation; Cetuximab; Cytokine-Induced Killer Cells; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Oxaloacetates; Positron-Emission Tomography; Quality of Life; Quinazolines; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Comparison of the 5-fluorouracil-warfarin and capecitabine-warfarin drug interactions.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Retrospective Studies; Warfarin | 2010 |
CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies | 2011 |
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Prodrugs; Rectal Neoplasms; Tegafur | 2010 |
ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Retrospective Studies | 2010 |
Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Treatment Outcome | 2011 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2010 |
Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
Topics: Antineoplastic Agents; Capecitabine; Cell Death; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Emodin; Endonucleases; Fluorouracil; Gene Knockdown Techniques; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proteasome Endopeptidase Complex; Protein Stability; Rad51 Recombinase; RNA, Messenger; Thymidine Phosphorylase | 2011 |
Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2011 |
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2011 |
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Remission Induction; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2011 |
Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antioxidants; Capecitabine; Cricetinae; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Lipid Peroxides; Male; Melatonin; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Prodrugs | 2011 |
Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy Dosage; Rectal Neoplasms; Rectum; Retrospective Studies; Treatment Outcome | 2011 |
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; France; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2011 |
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Monitoring; Drug Stability; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2010 |
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms | 2011 |
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neuropilin-1; Vascular Endothelial Growth Factor C | 2011 |
[Our experiences of XELOX + bevacizumab for two cases of metastatic sigmoid colon cancer].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Quality of Life; Sigmoid Neoplasms | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Colostomy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Pyrimidines; Radiotherapy, Adjuvant; Survival Rate | 2011 |
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Humans; Liver Function Tests; Oxaloacetates; Retrospective Studies; S-Adenosylmethionine | 2012 |
Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Eruptions; Fluorouracil; Humans; Male; Melanoma; Scalp Dermatoses; Severity of Illness Index; Skin Neoplasms | 2011 |
Capecitabine-induced, nonneutropenic enterocolitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Enterocolitis; Fluorouracil; Humans; Male; Middle Aged; Tomography, X-Ray Computed | 2011 |
Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Care; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hyperammonemia; Liver Neoplasms; Rectal Neoplasms; Treatment Outcome | 2011 |
Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Pancreatic Neoplasms | 2011 |
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Preoperative Period; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Time Factors | 2012 |
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Japan; Leucovorin; Lung Diseases, Interstitial; Male; Medical Records Systems, Computerized; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pulmonary Fibrosis; Retrospective Studies; Severity of Illness Index; Smoking; Tomography, X-Ray Computed | 2011 |
Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Defibrillators, Implantable; Deoxycytidine; Fluorouracil; Humans; Male; Ventricular Fibrillation | 2012 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; E2F Transcription Factors; Erythema; Female; Fluorouracil; Foot Dermatoses; Genetic Association Studies; Genetic Predisposition to Disease; Hand Dermatoses; Haplotypes; Humans; Logistic Models; Male; Middle Aged; Pain; Polymorphism, Single Nucleotide; Prodrugs; Promoter Regions, Genetic; Sequence Analysis, DNA; Syndrome; Transcription, Genetic | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prospective Studies; Radiotherapy; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Fluorouracil; Follow-Up Studies; Gamma Rays; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Epidemiologic Methods; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Treatment Outcome | 2011 |
Novel approach to Gorlin syndrome: a patient treated with oral capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Basal Cell Nevus Syndrome; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Skin Neoplasms | 2011 |
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Thalidomide | 2012 |
Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Conformal; Rectal Neoplasms | 2012 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Severe hypertriglyceridaemia during treatment with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Middle Aged | 2011 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Infusions, Parenteral; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphangitis; Middle Aged; Pleurisy; Quality of Life; Recurrence; Tomography, X-Ray Computed | 2011 |
[A resected case of gastric regional lymph node metastasis from ascending colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Staging; Remission Induction; Stomach Neoplasms | 2011 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Metabolome; Metabolomics; Middle Aged; Neoplasm Metastasis; Nuclear Magnetic Resonance, Biomolecular; Prognosis; Salvage Therapy | 2011 |
Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Retinal Vein Occlusion; Risk Factors; Vision Disorders | 2012 |
Is capecitabine efficacious in triple negative metastatic breast cancer?
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2010 |
Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Survival; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin | 2012 |
Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-a chemotherapy agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Survival; Deoxycytidine; Drug Stability; Female; Fluorouracil; Inhibitory Concentration 50; Liquid Crystals; Mice; Phase Transition; Prodrugs; Treatment Outcome | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2011 |
Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine--a chemotherapy agent.
Topics: Animals; Calorimetry, Differential Scanning; Capecitabine; Cell Line; Cell Line, Tumor; Cell Proliferation; Colloids; Cryoelectron Microscopy; Deoxycytidine; Female; Fluorouracil; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Molecular Structure; Nanoparticles; Particle Size; Prodrugs; Scattering, Small Angle; Thermogravimetry; Transition Temperature; Tumor Burden; Water; X-Ray Diffraction | 2011 |
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Sensation Disorders; Surveys and Questionnaires; Treatment Outcome | 2011 |
[Ileitis following capecitabine use].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Ileitis; Male; Rectal Neoplasms | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomarkers, Tumor; Capecitabine; Carcinoma; Case-Control Studies; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Haplotypes; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2011 |
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2011 |
Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Japan; Maximum Tolerated Dose; Models, Statistical; Retrospective Studies | 2011 |
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Predictive Value of Tests; Promyelocytic Leukemia Protein; Retrospective Studies; Survival Rate; Transcription Factors; Tumor Suppressor Proteins | 2012 |
MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prospective Studies; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Full-dose capecitabine with local radiotherapy: one of the treatment options for inoperable T4 breast cancer.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Treatment Outcome | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors | 2011 |
Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2011 |
[A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
Topics: Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Epilepsy; Female; Fluorouracil; Humans; Phenytoin | 2011 |
[Comparison of two types of digestive tract reconstruction after total gastrectomy in patients with gastric carcinoma].
Topics: Anastomosis, Roux-en-Y; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Jejunum; Nutritional Status; Oxaloacetates; Plastic Surgery Procedures; Postoperative Period; Quality of Life; Retrospective Studies; Stomach Neoplasms | 2011 |
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; China; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome; Tubulin | 2011 |
Do we need oncology trials tailored for the elderly or frail?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Frail Elderly; Health Services Needs and Demand; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Treatment Outcome | 2011 |
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; Retrospective Studies; Tumor Burden | 2012 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Patient Compliance; Prospective Studies; Self Report; Stomatitis; Vomiting | 2011 |
Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Smad4 Protein; Statistics as Topic; Statistics, Nonparametric | 2011 |
Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.
Topics: Antineoplastic Agents; Bayes Theorem; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Empirical Research; Fluorouracil; Hand-Foot Syndrome; Humans; Markov Chains | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Topics: Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine Phosphorylase; Vorinostat | 2011 |
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
First-line treatment of advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2011 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
[Acute coronary syndrome in patient treated with capecitabine].
Topics: Acute Coronary Syndrome; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male | 2012 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
[Adjuvant chemotherapy for gastric cancer: more drugs do not mean better efficacy].
Topics: Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Postoperative Care; Prognosis; Retrospective Studies; Stomach Neoplasms | 2011 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cecal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Male; Medication Adherence; Neoplasms; Outpatients; Patient-Centered Care; Pharmacists; Physician's Role; Pilot Projects; Piperazines; Prospective Studies; Pyrimidines; Switzerland; Time Factors; Treatment Outcome | 2011 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecitabine; Carcinoma, Hepatocellular; Cell Line; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Glycoproteins; Hep G2 Cells; Humans; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Oxides; Peptides; Rhodamine 123; Thy-1 Antigens | 2011 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Making; Deoxycytidine; Drug Costs; Female; Fluorouracil; Health Care Costs; Hong Kong; Hospitalization; Humans; Insurance, Health, Reimbursement; Length of Stay; Leucovorin; Male; Middle Aged; Office Visits; Organoplatinum Compounds; Oxaloacetates; Travel | 2011 |
[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Plasmids; Recombinant Proteins; RNA, Messenger; Sensitivity and Specificity; Stomach Neoplasms; Thymidine Phosphorylase; Transfection | 2011 |
Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids | 2011 |
[Eighty-five-year-old patient with recurrent rectal cancer effectively treated with CapeOX chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Recurrence; Tomography, X-Ray Computed | 2011 |
[A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Humans; Neoplasm Staging; Ovarian Neoplasms; Oxaloacetates; Rectal Neoplasms; Tomography, X-Ray Computed | 2011 |
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemokines; Colorectal Neoplasms; Cytokines; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Variation; Genotype; Humans; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pharmacogenetics; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
Topics: Animals; Biotransformation; Capecitabine; Carboxylesterase; Chromatography, High Pressure Liquid; Cytidine Deaminase; Cytosol; Deoxycytidine; Fluorouracil; Humans; Hydrolysis; In Vitro Techniques; Intestinal Mucosa; Intestines; Liver; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Microsomes; Microsomes, Liver; Prodrugs; Rats; Rats, Sprague-Dawley; Species Specificity | 2011 |
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Topics: Adaptation, Physiological; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Hand-Foot Syndrome; Humans; Markov Chains; Metabolic Clearance Rate; Models, Biological; Prodrugs; Prognosis; Treatment Outcome | 2012 |
[End results of combined treatment in metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pelvic Exenteration; Positron-Emission Tomography; Proctocolectomy, Restorative; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Rectal Neoplasms; Retrospective Studies; Time Factors | 2012 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Prospective Studies; Risk Factors; Thromboembolism | 2012 |
Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment.
Topics: Acrospiroma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Remission Induction; Scalp; Sweat Gland Neoplasms | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Rectal Neoplasms; Statistics, Nonparametric; Transketolase; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2011 |
Chemotherapy for older patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Diseases; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Frail Elderly; Humans; Prodrugs | 2011 |
Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Facial Dermatoses; Fluorouracil; Humans; Keratosis, Actinic; Male | 2012 |
Capecitabine-phenytoin interaction is dose dependent with an unexpected time course.
Topics: Aged; Anticonvulsants; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Epilepsy; Female; Fluorouracil; Humans; Phenytoin | 2011 |
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase | 2012 |
[Recurrent liver sigmoid cancer responding remarkably to neoadjuvant chemotherapy using bevacizumab/XELOX: report of a case].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Oxaloacetates; Recurrence; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2011 |
[A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Tomography, X-Ray Computed | 2011 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Gastrectomy; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Risk Factors; Stomach Neoplasms; Venous Thromboembolism | 2011 |
3rd congress of the International Academy of Oral Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; International Cooperation; Medical Oncology; Mouth Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Singapore; Tongue Neoplasms | 2011 |
Genital erythrodysesthesia as a severe manifestation of capecitabine therapy: a report of 3 cases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythema; Fluorouracil; Genital Diseases, Male; Humans; Male; Paresthesia; Scrotum | 2011 |
Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Prodrugs; Pyrimidines; Treatment Outcome; Uridine Phosphorylase | 2011 |
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2011 |
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Imatinib Mesylate; Neoplasms; Netherlands; Pharmacies; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
Clinical and electrocardiography changes in patients treated with capecitabine.
Topics: Capecitabine; Cardiovascular Diseases; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Long QT Syndrome; Male; Middle Aged; Neoplasms; Treatment Outcome | 2011 |
Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Securin; Treatment Outcome | 2011 |
Inappropriate continuation of medication when patients are admitted acutely: the example of capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Labeling; Emergency Service, Hospital; Fluorouracil; Humans; Inappropriate Prescribing; Medical Records; Oncology Service, Hospital | 2011 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2012 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Genes, Reporter; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thymidine Phosphorylase; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Practice Guidelines as Topic; Spain | 2011 |
[A woman with palmar and plantar hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; Middle Aged | 2011 |
Reporting of adjuvant breast cancer trials: when is the right time?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans | 2012 |
Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; France; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies; Tegafur; Vitamin B Complex | 2012 |
Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Registries; Treatment Outcome; Young Adult | 2012 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Radiotherapy; Translocation, Genetic | 2012 |
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fluorouracil; Follow-Up Studies; Humans; Male; Prednisone; Prostatic Neoplasms; Retrospective Studies; Thalidomide | 2012 |
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dehydration; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gastrectomy; Heart; Humans; Induction Chemotherapy; Kidney; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Capecitabine; Cell Differentiation; Cell Proliferation; Curcuma; Cyclin D1; Deoxycytidine; Down-Regulation; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Mice; NF-kappa B; Osteoclasts; Paclitaxel; Plant Extracts; RANK Ligand; Reactive Oxygen Species; Receptors, CXCR4; Receptors, Death Domain; STAT3 Transcription Factor; X-Linked Inhibitor of Apoptosis Protein | 2012 |
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Male; Microarray Analysis; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sensitivity and Specificity | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Death, Sudden; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
[A case of local-recurring breast cancer under long term-treatment by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Time Factors; Tomography, X-Ray Computed | 2011 |
[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates | 2011 |
[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node].
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Inguinal Canal; Lymphatic Metastasis; Middle Aged; Oxaloacetates; Tomography, X-Ray Computed | 2011 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorouracil; Hand-Foot Syndrome; Humans; Leukopenia; Nausea; Neutropenia; Reproducibility of Results; Thrombocytopenia; United States; United States Food and Drug Administration; Vomiting | 2012 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Prospective Studies | 2013 |
Mobile health for drug dose optimisation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Glucose Self-Monitoring; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Computer-Assisted; Female; Fluorouracil; Humans; Hypoglycemic Agents; Insulin; Neoplasms; Telemedicine; Treatment Outcome | 2011 |
A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; Treatment Outcome | 2012 |
Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Urea Nitrogen; Capecitabine; Chemoradiotherapy; Creatinine; Cystatin C; Deoxycytidine; Female; Fluorouracil; Glomerular Filtration Rate; Humans; Iran; Kidney; Kidney Diseases; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radiation Dosage; Radiation Injuries; Stomach Neoplasms; Time Factors; Treatment Outcome | 2012 |
Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure | 2012 |
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Health Services Needs and Demand; Hospitals, Teaching; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Satisfaction; Surveys and Questionnaires; United Kingdom | 2012 |
Chemotherapy and fingerprint loss: beyond cosmetic.
Topics: Capecitabine; Deoxycytidine; Dermatoglyphics; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Quality of Life | 2012 |
Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
Topics: Adult; Aged; Analysis of Variance; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pelvis; Postoperative Care; Probability; Prognosis; Rectal Neoplasms; Retrospective Studies; Selection Bias | 2012 |
Multilevel latent variable models for global health-related quality of life assessment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Models, Psychological; Models, Statistical; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2012 |
[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Paclitaxel; Tomography, X-Ray Computed | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leukopenia; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Rate | 2011 |
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Disease-Free Survival; Erythrocyte Volume; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Young Adult | 2012 |
First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chromans; Cyclin D1; Cyclooxygenase 2; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Intercellular Adhesion Molecule-1; Ki-67 Antigen; Matrix Metalloproteinase 9; Mice; Mice, Nude; Mitochondria; Neovascularization, Pathologic; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-bcl-2; Receptors, CXCR4; Repressor Proteins; Stomach Neoplasms; Survivin; Vascular Endothelial Growth Factor A; Vitamin E; Xenograft Model Antitumor Assays | 2012 |
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2011 |
Current treatment options for metastatic breast cancer: what now?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Tubulin Modulators | 2011 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Menstrual Cycle; Methotrexate; Middle Aged; Multivariate Analysis; Premenopause; Prognosis; Proportional Hazards Models; Retrospective Studies; Taxoids; Young Adult | 2012 |
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Peripheral Nervous System Diseases; Proportional Hazards Models; Risk Factors; Severity of Illness Index; Time Factors; Tubulin Modulators; Young Adult | 2012 |
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neoplasms; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed | 2012 |
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Young Adult | 2012 |
The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; G(M1) Ganglioside; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2012 |
[Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hyperpigmentation; Male; Remission, Spontaneous | 2012 |
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2012 |
Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Bone Marrow; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Logistic Models; Male; Middle Aged; Models, Biological; Organs at Risk; Pelvic Bones; Probability; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Sex Factors; Tumor Burden | 2012 |
Severe hypertriglyceridaemia associated with the use of capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Rectal Neoplasms | 2012 |
[Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging | 2012 |
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dacarbazine; Deoxycytidine; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Male; Paraganglioma; Retroperitoneal Neoplasms; Succinate Dehydrogenase; Temozolomide; Treatment Outcome | 2012 |
[Chemoembolization of liver metastasis].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed | 2012 |
MR imaging of rectal cancer before and after chemoradiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Radiotherapy, Conformal; Rectal Neoplasms; Treatment Outcome | 2012 |
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Defecation; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Intestine, Large; Intestine, Small; Male; Massachusetts; Middle Aged; Pain; Quality of Life; Rectal Neoplasms | 2012 |
A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.
Topics: Acute Kidney Injury; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prednisone; Thrombocytopenia | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Meta-Analysis as Topic; Models, Statistical | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2012 |
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Fluorouracil; Humans; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Peplomycin; Thymidine Phosphorylase; Uterine Cervical Neoplasms | 2012 |
Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gene Expression; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Taxoids; Thymidine Phosphorylase; Tubulin | 2012 |
Bilateral acute ptosis leading to the diagnosis of a presumed metastatic gastric adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capecitabine; Deoxycytidine; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Radiotherapy, Adjuvant; Stomach Neoplasms | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
[Reduction of vascular pain due to drop-infusion of oxaliplatin (L-OHP) in peripheral vein with heated infusion route].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hot Temperature; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pain | 2012 |
[A case of rectal hemorrhage during chemotherapy with bevacizumab for local recurrence of rectal cancer].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Male; Oxaloacetates; Rectal Neoplasms; Recurrence | 2012 |
[A case of locally advanced rectal cancer had a pathological complete response to XELOX Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Rectal Neoplasms | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Liver Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Scalp; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Hand-foot syndrome related to chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
X-ACT: an important step on an unfinished journey.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Cryosurgery; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Retrospective Studies; Tumor Burden; Young Adult | 2012 |
[Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Leukoencephalopathies; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged | 2012 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; E-Selectin; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Female; Fibroblast Growth Factor 2; Fluorouracil; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Oxaloacetates; Platelet-Derived Growth Factor; Prognosis; Vascular Endothelial Growth Factor A | 2012 |
[Side effect analyses in consideration of renal functions for capecitabine-administered patients].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Diseases; Male; Middle Aged | 2012 |
[A case of primary adenocarcinoma of small intestine responding to XELOX chemotherapy and leading to a partial metabolic response].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Ileal Neoplasms; Male; Middle Aged; Multimodal Imaging; Oxaloacetates; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Radiography; Recombinant Fusion Proteins; Thymidine Phosphorylase; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lupus Erythematosus, Systemic; Middle Aged; Prodrugs | 2012 |
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neuromuscular Diseases; Organoplatinum Compounds; Oxaliplatin | 2012 |
Capecitabine in the treatment of rectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Rectal Neoplasms | 2012 |
Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabine; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Deglutition Disorders; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Perforation; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prosthesis Failure; Retrospective Studies; Stents; Taxoids | 2012 |
Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Middle Aged; Prodrugs; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
[A case report of pathologically complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Oxaloacetates; Rectal Neoplasms; Tomography, X-Ray Computed | 2012 |
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Capecitabine; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gold; Humans; Liver Neoplasms; Metal Nanoparticles; Microscopy, Electron, Transmission; Tumor Cells, Cultured | 2012 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbachol; Chemotherapy, Adjuvant; Cholinergic Agonists; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Ganglia, Autonomic; Gastric Emptying; Gastric Mucosa; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Neoadjuvant Therapy; Stomach; Stomach Neoplasms | 2012 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2012 |
[Increased INR from concomitant use of acenocoumarol and capecitabine].
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Atrial Fibrillation; Capecitabine; Deoxycytidine; Drug Interactions; Erythrocyte Transfusion; Female; Fluorouracil; Gastrointestinal Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Rectal Neoplasms | 2012 |
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; ROC Curve; Sensitivity and Specificity; Stomach Neoplasms; Tubulin; Young Adult | 2012 |
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.
Topics: 2-Propanol; Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Camphor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dermatologic Agents; Drug Combinations; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Plant Extracts; Treatment Outcome | 2010 |
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt | 2012 |
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Synthesis and biological activity evaluation of cytidine-5'-deoxy-5-fluoro-N-[(alkoxy/aryloxy)] carbonyl-cyclic 2',3'-carbonates.
Topics: Animals; Antineoplastic Agents; Capecitabine; Cell Line, Tumor; Chemistry Techniques, Synthetic; Deoxycytidine; Drug Design; Fluorouracil; Humans; Inhibitory Concentration 50; Mice; Salmonella typhimurium; Xenograft Model Antitumor Assays | 2012 |
Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Pancreatic Neoplasms; Venous Thromboembolism | 2012 |
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Leucovorin; Oligodeoxyribonucleotides; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Thionucleotides | 2012 |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA; DNA-Binding Proteins; Drug Eruptions; Female; Fluorouracil; Gastrointestinal Neoplasms; Gene Frequency; Humans; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Minisatellite Repeats; Mucositis; Osteosarcoma; Polymorphism, Genetic; Thymidylate Synthase; Turkey; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein; Young Adult | 2012 |
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; CA-19-9 Antigen; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fluorouracil; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Signal Transduction; STAT3 Transcription Factor; Triterpenes; Tumor Suppressor Proteins; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2012 |
Colon carcinoma in a child treated with oxaliplatin and antiangiogenic treatment regimens.
Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2012 |
Effectiveness of oxaliplatin desensitization protocols.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Desensitization, Immunologic; Drug Hypersensitivity; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Skin Tests | 2013 |
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated | 2012 |
[Breast cancer and the hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paris; Prospective Studies; Risk Factors | 2012 |
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiography, Abdominal; Radiography, Thoracic; Rectal Neoplasms; Rectum; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cross-Sectional Studies; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluorouracil; Humans; Indoles; MicroRNAs; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
[A case of metastatic pancreatic cancer which trastuzumab+capecitabine combination therapy was effective].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Trastuzumab | 2012 |
[Therapy traces on hands and feet in a patient with colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Palliative Care | 2012 |
Subacute cutaneous lupus erythematosus after treatment with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous | 2013 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Office Visits; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Palliative Care; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Retrospective Studies; Scandinavian and Nordic Countries; Sweden | 2012 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Capecitabine; Carcinoma, Squamous Cell; Chest Pain; Colorectal Neoplasms; Coronary Vasospasm; Deoxycytidine; Diltiazem; Electrocardiography; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Prodrugs; Secondary Prevention; Treatment Outcome | 2012 |
Isolated hypomagnesemia in a patient treated with capecitabine.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hypercalciuria; Magnesium; Middle Aged; Nephrocalcinosis; Renal Tubular Transport, Inborn Errors | 2013 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2012 |
Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Topics: 3' Untranslated Regions; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Polymorphism, Genetic; Rectal Neoplasms; Sequence Deletion; Thymidylate Synthase | 2013 |
Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible.
Topics: Capecitabine; Coronary Thrombosis; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Myocardial Infarction | 2012 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Databases as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Models, Statistical; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hypoxia; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vorinostat | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Primary carcinoma of jejunum--a case report.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Dissection; Fluorouracil; Humans; Intestinal Obstruction; Jejunal Neoplasms; Jejunum; Male; Perioperative Care; Remission Induction; Treatment Outcome | 2012 |
Preparation of embolic NEMs loading capecitabine.
Topics: Antineoplastic Agents; Biocompatible Materials; Capecitabine; Capsules; Deoxycytidine; Fluorouracil; Molecular Weight; Particle Size | 2013 |
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Patient Compliance; Retrospective Studies; Severity of Illness Index; Taxoids; Vinblastine; Vinorelbine | 2012 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2012 |
[A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Male; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates | 2012 |
[A case of cutaneous mammary re-irradiation].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lymphatic Irradiation; Mastectomy, Segmental; Neoplasm Recurrence, Local; Skin Neoplasms | 2012 |
Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Safety; Survival Rate | 2013 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deglutition Disorders; Deoxycytidine; Drug Administration Schedule; Dyspnea; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Paresthesia; Prospective Studies; Spasm | 2012 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
Primary systemic treatment of breast-cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; SEER Program; Survival Rate | 2013 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Prognosis; Tegafur | 2012 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2012 |
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2012 |
Indian drug maker cuts price of three cancer drugs by between 50% and 63%.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Costs; Drug Industry; Erlotinib Hydrochloride; Fluorouracil; Humans; India; Quinazolines; Taxoids | 2012 |
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Pilot Projects; Radiation Tolerance; Rectal Neoplasms; Retrospective Studies; RNA, Neoplasm; Thymidylate Synthase; Treatment Outcome | 2012 |
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Time Factors | 2012 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Genetic Testing; Genotype; Humans; Male; Middle Aged; Neoplasms; Risk Assessment; Tegafur | 2012 |
[Resolution of actinic keratosis with capecetabin].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Keratosis, Actinic; Male; Neoplasms, Radiation-Induced; Precancerous Conditions; Skin Neoplasms | 2012 |
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Chloride-Bicarbonate Antiporters; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression; Humans; Membrane Proteins; Neoadjuvant Therapy; Nerve Tissue Proteins; Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; RNA, Messenger; Sulfate Transporters; Taxoids; Transcortin; Treatment Outcome | 2013 |
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prevalence; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Turkey | 2012 |
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Odds Ratio; Receptor, ErbB-2; Taxoids | 2012 |
Slow dissolution behaviour of amorphous capecitabine.
Topics: Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Capecitabine; Crystallization; Deoxycytidine; Drug Compounding; Drug Stability; Excipients; Feasibility Studies; Fluorouracil; Gels; Reproducibility of Results; Solubility; Spectroscopy, Fourier Transform Infrared; Transition Temperature | 2013 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; CA-125 Antigen; Capecitabine; Carcinoembryonic Antigen; Carrier Proteins; CDX2 Transcription Factor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cytokines; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Glycoproteins; Hepatectomy; Homeodomain Proteins; Humans; Immunohistochemistry; Keratin-20; Keratins; Liver; Liver Neoplasms; Lymph Node Excision; Magnetic Resonance Imaging; Membrane Transport Proteins; Phenotype; Portal Vein; Pregnancy; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Hypertriglyceridemia; Pancreatitis, Acute Necrotizing; Triglycerides | 2012 |
Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Mice; Mice, Nude; Neoplasms; Nucleoside-Phosphate Kinase; Orotate Phosphoribosyltransferase; Ribonucleotide Reductases; RNA, Messenger; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Uridine Kinase; Uridine Phosphorylase | 2013 |
Solitary bulky mediastinal lymph node metastasis from colon cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Differentiation; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Positron-Emission Tomography; Reoperation; Thoracic Surgery, Video-Assisted; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Topics: Adenocarcinoma, Scirrhous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2012 |
[A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colon, Transverse; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxaloacetates | 2012 |
Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Coix; Deoxycytidine; Docetaxel; Drugs, Chinese Herbal; Female; Fluorouracil; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phytotherapy; Prognosis; Quality of Life; Remission Induction; Seeds; Stomach Neoplasms; Taxoids; Young Adult | 2012 |
A rare case of non-immune hemolytic anemia in a patient with metastatic breast cancer treated with capecitabine.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Salvage Therapy | 2013 |
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Survival; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Glycation End Products, Advanced; HMGB1 Protein; Humans; Pancreatic Neoplasms; Prospective Studies; Statistics, Nonparametric; Treatment Outcome | 2013 |
Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Topics: 3' Untranslated Regions; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Paclitaxel; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Thymidylate Synthase | 2013 |
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neovascularization, Pathologic; Paclitaxel; ROC Curve; Spectroscopy, Near-Infrared; Trastuzumab; Treatment Outcome; Ultrasonography, Interventional | 2013 |
[Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Outpatients; Quality of Life | 2012 |
Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Topics: Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Fluorouracil; Humans; Linear Models; Mass Spectrometry; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Unsupported off-label chemotherapy in metastatic colon cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Insurance Claim Review; Middle Aged; Off-Label Use; Panitumumab; Practice Patterns, Physicians'; Retrospective Studies; United States | 2012 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer - authors' reply.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neuroendocrine; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Necrolytic Migratory Erythema; Neoplasm Staging; Pancreatic Neoplasms; Paraneoplastic Syndromes; Risk Assessment; Temozolomide; Treatment Outcome | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thymus Neoplasms; Treatment Outcome | 2013 |
[Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Costs and Cost Analysis; Czech Republic; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2012 |
[Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms | 2013 |
[A case report of successful treatment for rectosigmoid cancer with peritoneal dissemination after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Peritoneal Neoplasms; Rectal Neoplasms; Sigmoid Neoplasms | 2013 |
[A case of advanced rectal cancer with bladder carcinoma salvaged from myocardial infarction during operation, showing tumor regression by XELOX treatment, good quality of life].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Intraoperative Complications; Male; Myocardial Infarction; Neoplasms, Multiple Primary; Oxaloacetates; Quality of Life; Rectal Neoplasms; Salvage Therapy; Urinary Bladder Neoplasms | 2013 |
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Venous Thrombosis | 2013 |
[Oral chemotherapy for advanced breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Molecular Targeted Therapy; Oxonic Acid; Tegafur | 2012 |
[Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Steroid | 2012 |
[A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Combined Modality Therapy; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Oxaloacetates; Pilot Projects; Stomach Neoplasms; Treatment Outcome | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Survival Rate | 2013 |
Bevacizumab in breast cancer: fundamental questions remain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Thoracic Neoplasms; Tomography, X-Ray Computed | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Retrospective Studies; Stomach | 2013 |
Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Child; Child, Preschool; Deoxycytidine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Neoplasms, Squamous Cell; Organ Transplantation; Skin Neoplasms; Tumor Burden; Young Adult | 2013 |
Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Sigmoid; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Pilot Projects; Postoperative Care; Prognosis; Survival Rate; Time Factors | 2013 |
Severe or lethal toxicities with nucleosidic analogs: time for action.
Topics: Animals; Capecitabine; Cytidine Deaminase; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Nucleosides | 2013 |
Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Operative Time; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Survival Rate; Tomography, X-Ray Computed | 2013 |
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Association Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2013 |
[Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Receptor, ErbB-2; Trastuzumab | 2013 |
For breast cancer patients with brain mets, new drug combo may be option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome | 2012 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Hepatic Veins; Hepatic Veno-Occlusive Disease; Humans; Hyaluronic Acid; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Predictive Value of Tests; Prospective Studies; Radial Artery; Severity of Illness Index | 2013 |
Chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Common Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Proton Therapy; Radiation Injuries; Radiotherapy Dosage; Retrospective Studies | 2013 |
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Retrospective Studies; Risk Factors | 2013 |
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Stomach Neoplasms | 2013 |
Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Genetic Markers; Genome-Wide Association Study; Genotyping Techniques; Humans; Leucovorin; Male; Microfilament Proteins; Middle Aged; Preoperative Care; Radiation Tolerance; Rectal Neoplasms | 2013 |
Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Colonic Neoplasms; Cost of Illness; Deoxycytidine; Female; Fluorouracil; Hospitalization; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2013 |
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line, Tumor; Cohort Studies; Colon; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectum; Up-Regulation | 2013 |
[Study of tolerability of capecitabine in postoperative adjuvant chemotherapy in colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged | 2013 |
Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leukoencephalopathy, Progressive Multifocal; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Thymoma; Thymus Neoplasms; Treatment Outcome | 2013 |
Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Clinical Audit; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Home Care Services; Humans; Longitudinal Studies; Male; Middle Aged; Practice Patterns, Nurses'; Prospective Studies; Standard of Care; Telemedicine; Telephone; United Kingdom | 2013 |
Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium.
Topics: Animals; Antineoplastic Agents; Capecitabine; Cattle; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Endothelial Cells; Epirubicin; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Models, Molecular; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type III; Protein Conformation; Protein Structure, Tertiary; Signal Transduction; Tamoxifen | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Sepsis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Etoposide; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Methotrexate; Organoplatinum Compounds; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Remission Induction; Treatment Outcome | 2013 |
[Combination therapy herceptin+xeloda].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Staging; Patient Participation; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2002 |
Fluorouracil in the environment: analysis, occurrence, degradation and transformation.
Topics: Biotransformation; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Environmental Monitoring; Fluorouracil; Photolysis; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Heterozygote; Humans; Male; Mutation; Patient Selection; Polymerase Chain Reaction | 2013 |
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2014 |
Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Radiotherapy, Conformal; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer.
Topics: Acenaphthenes; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Pyrroles; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; Young Adult | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies | 2013 |
[Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lymphocyte Subsets; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2013 |
Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2013 |
From trial highlights to clinical context: putting American Society of Clinical Oncology gastrointestinal news into practice.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Medical Oncology; Meta-Analysis as Topic; San Francisco; United States | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Catheterization, Peripheral; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Perioperative Period; Pulmonary Embolism; Retrospective Studies; Stomach Neoplasms; Survival Rate; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2014 |
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cognition; Deoxycytidine; Female; Fluorouracil; Humans; Neuropsychological Tests; Quality of Life; Risk Factors; Surveys and Questionnaires | 2013 |
Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Markov Chains; Models, Molecular; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2014 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colectomy; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2013 |
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaloacetates; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Using continuous data on tumour measurements to improve inference in phase II cancer studies.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II as Topic; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Neoplasms | 2013 |
Virchow lymph node metastatic recurrence of sigmoid colon cancer with severe lymph node metastases successfully treated using systemic chemotherapy combined with radiotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Clavicle; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Remission Induction; Sigmoid Neoplasms | 2013 |
Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslipidemias; Female; Fluorouracil; Humans; Hypertriglyceridemia; Israel; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Risk Factors | 2013 |
[Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Oxaloacetates; Postoperative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2013 |
On 5-fluorouracil therapy of colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Prospective Studies; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2013 |
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Incidence; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Voltage-Gated Sodium Channels | 2013 |
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Evolving role of neoadjuvant therapy in rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Rectal Neoplasms | 2013 |
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bone Marrow; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Rectal Neoplasms | 2014 |
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization; Male; MicroRNAs; Microvessels; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Oxaloacetates; Prognosis; Young Adult | 2013 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines | 2013 |
[A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[A case of relapsed colon cancer successfully treated by capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Sigmoid Neoplasms; Splenic Neoplasms | 2013 |
Financial incentives in cancer care and impact on prescribing practice.
Topics: Aged; Antineoplastic Agents; Australia; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Prescriptions; Fluorouracil; Hospitals, Private; Hospitals, Public; Humans | 2013 |
[A case of necrotizing fasciitis developed in a patient with recurrent rectal cancer treated with chemotherapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fasciitis, Necrotizing; Fatal Outcome; Female; Fluorouracil; Humans; Middle Aged; Oxaloacetates; Rectal Neoplasms; Recurrence | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaloacetates; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2013 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Receptor, ErbB-2; Salvage Therapy; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5-fluorouracil, and capecitabine throughout the sewage effluents and surface waters of Europe.
Topics: Capecitabine; Carboplatin; Cyclophosphamide; Cytostatic Agents; Deoxycytidine; Environmental Monitoring; Europe; Fluorouracil; Rivers; Sewage; Water Pollutants, Chemical | 2013 |
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Upper Gastrointestinal Tract | 2013 |
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2013 |
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation | 2013 |
Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Rectal Neoplasms; Treatment Outcome | 2013 |
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbamates; Carboxylesterase; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Hydrolysis; Mice; Mice, Inbred BALB C; Neoplasms; Quinazolines; Thymidine Phosphorylase | 2013 |
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Topics: Aminoglycosides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Enediynes; Enzyme Induction; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Up-Regulation | 2013 |
[Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism].
Topics: Animals; Capecitabine; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Fluorouracil; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Transcription Factor RelA | 2013 |
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genotype; Humans; Incidental Findings; Male; Risk Assessment; Sex Factors; Tegafur | 2013 |
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; Rectal Neoplasms; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53; Young Adult | 2014 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Naphthoquinones; Pancreatic Neoplasms | 2014 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2013 |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2013 |
Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Topics: Apoptosis; Capecitabine; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; MAP Kinase Signaling System; Orotic Acid; RNA, Small Interfering; Stomach Neoplasms; Thymidine Phosphorylase; Up-Regulation | 2013 |
Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson's disease worsened after capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnostic Errors; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Parkinson Disease; Prognosis; Stiff-Person Syndrome | 2013 |
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Capecitabine; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Enteritis; Fatal Outcome; Fatty Liver; Female; Fluorouracil; Heart Diseases; Humans; Multiple Organ Failure; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pancreaticoduodenectomy; Pancreatitis, Chronic | 2013 |
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dichloroacetic Acid; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Proteins; Prodrugs; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Random Allocation; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2014 |
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum; Retrospective Studies; Surgical Wound Infection; Treatment Outcome | 2013 |
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 18; Colonic Neoplasms; Colonoscopy; Deoxycytidine; Early Detection of Cancer; Europe; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Mucosa; Leucovorin; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Occult Blood; Organoplatinum Compounds; Oxaloacetates; Risk; Risk Assessment; Risk Factors; Sigmoidoscopy; Treatment Outcome | 2013 |
Gastrointestinal cancer: AVEX: opportunities in elderly patients with mCRC.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Fluorouracil; Humans; Prognosis | 2013 |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Interleukin-10; Mexico; Middle Aged; Paclitaxel; Polymorphism, Genetic; Spain; Tamoxifen | 2013 |
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Survival Analysis | 2013 |
Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Stomach Neoplasms | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Cholangitis, Sclerosing; Deoxycytidine; Female; Fibrosis; Fluorouracil; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Monitoring, Physiologic; Necrosis; Neoadjuvant Therapy; Radiosurgery; Retrospective Studies; Treatment Outcome | 2014 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; ROC Curve; Survival Analysis; Treatment Outcome | 2013 |
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Topics: Adult; Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2013 |
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Recombinant Proteins; Survival Analysis; Taxoids; Young Adult | 2013 |
Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Topics: Antineoplastic Agents; Articulation Disorders; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Trastuzumab-induced systemic capillary leak syndrome in a breast cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Capillary Leak Syndrome; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Trastuzumab | 2014 |
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hyperbilirubinemia; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms | 2014 |
Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma?
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2013 |
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postoperative Period; Preoperative Period; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Biotransformation; Capecitabine; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Floxuridine; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Interferon-alpha; Kidney Tubules, Proximal; Kinetics; Nucleosides; Signal Transduction; Thymidine Phosphorylase | 2013 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary ACTH Hypersecretion; Temozolomide | 2014 |
[A case wherein bevacizumab/XELOX combination therapy was remarkably effective for the treatment of extensive dissemination in advanced colon cancer, and the primary lesion could be resected].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Peritoneal Neoplasms | 2013 |
Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; DNA; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Protein Binding; Simvastatin; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; CpG Islands; Deoxycytidine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; RNA, Small Interfering; Transfection | 2014 |
Epicardial coronary artery spasm as cause of capecitabine-induced tako tsubo cardiomyopathy.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Coronary Angiography; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Takotsubo Cardiomyopathy | 2014 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Time Factors | 2014 |
Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; China; Databases, Factual; Deoxycytidine; Diarrhea; Digestive System Surgical Procedures; Drug Administration Schedule; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proctitis; Radiodermatitis; Rectal Neoplasms; Remission Induction; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2014 |
Preparation and characterization of a gastric floating dosage form of capecitabine.
Topics: Acrylic Resins; Alginates; Breast Neoplasms; Capecitabine; Chemistry, Pharmaceutical; Deoxycytidine; Drug Dosage Calculations; Female; Fluorouracil; Gastrointestinal Diseases; Glucuronic Acid; Hexuronic Acids; Humans; Hypromellose Derivatives; Methylcellulose; Sodium Bicarbonate; United States; United States Food and Drug Administration | 2013 |
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD11b Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Vaccination | 2014 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2014 |
Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Calorimetry, Differential Scanning; Capecitabine; Chemistry, Pharmaceutical; Delayed-Action Preparations; Deoxycytidine; Desiccation; Drug Compounding; Excipients; Fluorouracil; Models, Chemical; Povidone; Silicon Dioxide; Solubility; Stearic Acids; Tablets; X-Ray Diffraction | 2014 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Hemorrhage; Humans; Hypertension; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proteinuria; Rectal Neoplasms; Remission Induction; Young Adult | 2013 |
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Postoperative Period; Radiotherapy, Conformal; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabolic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Hyperammonemia; Liver Neoplasms; Male; Oxaloacetates; Rectal Neoplasms | 2013 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; Humans; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaloacetates; Pharmacogenetics; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies | 2014 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Middle Aged; Models, Statistical; Oxaloacetates; Oxonic Acid; Probability; Quality-Adjusted Life Years; Stomach Neoplasms; Tegafur | 2013 |
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2016 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2013 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hong Kong; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaloacetates; Prognosis; Survival Rate; Time Factors | 2014 |
Crystal structure and tautomerism of capecitabine.
Topics: Alcohols; Antimetabolites, Antineoplastic; Capecitabine; Crystallization; Deoxycytidine; Fluorouracil; Models, Molecular; Molecular Conformation; Stereoisomerism; X-Ray Diffraction | 2014 |
[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates | 2013 |
[Recurrent rectal cancer with multiple liver and lung metastases treated effectively with oxaliplatin and capecitabine plus bevacizumab chemotherapy-a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Recurrence; Sigmoid Neoplasms | 2013 |
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemorrhage; Hepatectomy; Humans; Liver Neoplasms; Ovarian Neoplasms; Sigmoid Neoplasms | 2013 |
[A case of locally advanced rectal cancer successfully resected after preoperative chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Peritonitis; Sigmoid Neoplasms | 2013 |
[A case in which chemotherapy-resistant sigmoid colon cancer was controlled effectively by radiotherapy and resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Recurrence; Sigmoid Neoplasms | 2013 |
[A case of recurrent rectal cancer successfully treated for a long period with capecitabine plus oxaliplatin and bevacizumab therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Remission Induction; Sigmoid Neoplasms; Time Factors | 2013 |
[A case in which XELOX plus bevacizumab chemotherapy was effective in an elderly patient with heart failure and multiple liver metastases after sigmoidectomy].
Topics: Abdominal Abscess; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Deoxycytidine; Female; Fluorouracil; Heart Failure; Humans; Intestinal Perforation; Liver Neoplasms; Oxaloacetates; Sigmoid Neoplasms | 2013 |
[A case of a recurrent hepatic metastasis occurred after curative resection of ascending colon cancer and a hepatic metastasis responding completely to capecitabine plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Ascending; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Recurrence | 2013 |
[Neoadjuvant chemoradiotherapy with capecitabine and oxaliplatin for the treatment of locally advanced lower rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Oxaloacetates; Rectal Neoplasms | 2013 |
[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2013 |
[Recurrent gastric cancer treated with fourth-line chemotherapy consisting of capecitabine and cisplatin leading to partial response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Staging; Recurrence; Salvage Therapy; Stomach Neoplasms | 2013 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Muscle, Skeletal; Stomach Neoplasms | 2013 |
[Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Arginine; Butyrates; Capecitabine; Deoxycytidine; Female; Fluorouracil; Glutamine; Hand-Foot Syndrome; Humans; Hydroxy Acids; Male; Middle Aged; Neoplasms | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2014 |
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; China; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Rectal Neoplasms | 2014 |
Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
[A case of endocrine cell carcinoma of the ascending colon with liver metastasis treated with hepatectomy after excision of the primary lesion and systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Endocrine Gland Neoplasms; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoembryonic Antigen; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pilot Projects; Prognosis; Prospective Studies; Treatment Outcome | 2014 |
Dermatomyositis associated with capecitabine in the setting of malignancy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy, Needle; Capecitabine; Deoxycytidine; Dermatomyositis; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Male; Risk Assessment; Stomach Neoplasms | 2014 |
Folate-decorated PEG-PLGA nanoparticles with silica shells for capecitabine controlled and targeted delivery.
Topics: Capecitabine; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Folic Acid; Nanoparticles; Polyesters; Polyethylene Glycols; Silicon Dioxide | 2014 |
Colon carcinoma treated with oxaliplatin and capecitabine in a 12-year-old child.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Oxaloacetates | 2014 |
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Survival Rate | 2014 |
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prodrugs; Prognosis; Survival Rate | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Stomach Neoplasms | 2014 |
Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Erythrocyte Indices; Female; Fluorouracil; Humans; Male; Mean Platelet Volume; Middle Aged; Oxaloacetates; Platelet Count; Retrospective Studies; Treatment Outcome | 2014 |
Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Precision Medicine; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2014 |
MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Retrospective Studies; ROC Curve; Treatment Outcome | 2014 |
Over compliance with capecitabine oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Medication Adherence; Middle Aged; Rectal Neoplasms | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
[Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gastrectomy; Humans; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies | 2014 |
Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Thymidylate Synthase | 2014 |
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genome-Wide Association Study; Genomics; Hand-Foot Syndrome; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide | 2014 |
Increase in triglyceride blood level in patients treated with capecitabine: a retrospective survey.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Triglycerides | 2014 |
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2014 |
[Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Recombinant Fusion Proteins; Rectal Neoplasms; Thrombopoietin | 2014 |
Patients with advanced disease: the value of patient reported outcomes.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Pain; Pancreatic Neoplasms; Quality of Life | 2014 |
Are we systematically under-dosing patients with fluorouracil?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Duodenal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2015 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2014 |
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Community Mental Health Centers; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Medical Oncology; Middle Aged; Retrospective Studies; Vinblastine; Vinorelbine | 2015 |
Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: prognostic significance.
Topics: Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Capecitabine; Chemoradiotherapy; Colorectal Surgery; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prospective Studies; Rectal Neoplasms; Treatment Outcome | 2014 |
CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2014 |
Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Cell Cycle Proteins; China; Cisplatin; Deoxycytidine; DNA Methylation; Fluorouracil; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Retrospective Studies; Stomach Neoplasms; Ubiquitin-Protein Ligases | 2014 |
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Association Studies; Humans; Hydro-Lyases; Male; Middle Aged; Polymorphism, Genetic; Proteins; Thymidylate Synthase; Young Adult | 2015 |
Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Data Collection; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Patient Preference | 2014 |
To treat or not to treat: who should decide?
Topics: Aged; Capecitabine; Colonic Neoplasms; Decision Making; Deoxycytidine; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Patient Participation; Quality of Life; Treatment Refusal | 2014 |
Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Liver injury possibly related to drug interaction after liver transplant: a case report.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Monitoring; Fluorouracil; Follow-Up Studies; Humans; Liver Transplantation; Male; Tissue Distribution; Vitamin K 1; Warfarin | 2014 |
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Czech Republic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hypertension; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Registries; Retrospective Studies; Thromboembolism | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Rectum; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
[Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2014 |
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Female; Fluorouracil; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Stomach Neoplasms | 2013 |
Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Biopsy; Capecitabine; Colon; Colonic Diseases; Colonic Pouches; Deoxycytidine; Diarrhea; Endoscopy, Gastrointestinal; Etanercept; Fluorouracil; Humans; Immunoglobulin G; Immunohistochemistry; Infliximab; Intestinal Mucosa; Methotrexate; Receptors, Tumor Necrosis Factor; Risk Factors; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Oral chemotherapy in elderly women with metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Infusions, Intravenous; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2014 |
[A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Trastuzumab | 2014 |
[A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Time Factors | 2014 |
[A case of sigmoid colon cancer with a sigmoidovesical fistula treated with preoperative XELOX+bevacizumab therapy and urinary bladder-conserving surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Intestinal Fistula; Male; Middle Aged; Oxaloacetates; Sigmoid Neoplasms; Urinary Bladder Fistula | 2014 |
[A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Duodenal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Peritoneal Neoplasms; Recurrence | 2014 |
[Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases].
Topics: Anticonvulsants; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Middle Aged; Phenytoin; Seizures; Valproic Acid | 2014 |
Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; HCT116 Cells; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Random Allocation; Thrombospondin 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Gastrointestinal: bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Drug Substitution; Fluorouracil; Humans; Leukoencephalopathies; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Syndrome | 2014 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2014 |
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Erythrocyte Indices; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2014 |
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Phone; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects | 2014 |
The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Exercise Test; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxygen Consumption; Physical Fitness; Postoperative Complications; Prospective Studies; Rectal Neoplasms; Rectum; ROC Curve | 2014 |
Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy.
Topics: Animals; Capecitabine; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gene Knockout Techniques; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Intestinal Pseudo-Obstruction; Lentivirus; Male; Mice; Mice, Inbred C57BL; Mitochondrial Encephalomyopathies; Muscular Dystrophy, Oculopharyngeal; Ophthalmoplegia; Thymidine Phosphorylase | 2014 |
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheterization, Peripheral; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Pain; Retrospective Studies; Vascular Access Devices | 2015 |
First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Frail Elderly; Humans; Male; Retrospective Studies; Treatment Outcome | 2014 |
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Erythrocyte Indices; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2013 |
Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Rectal Neoplasms; Rectum; Survival Analysis | 2014 |
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); rac1 GTP-Binding Protein; ras Proteins | 2014 |
Maintenance therapy for colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospital Mortality; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2015 |
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2015 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Uracil; Young Adult | 2014 |
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Czech Republic; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proportional Hazards Models; Registries; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Rectal Neoplasms; Tegafur | 2014 |
[The combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Neoadjuvant Therapy; Radiation Tolerance; Rectal Neoplasms | 2014 |
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Deoxycytidine; Fatal Outcome; Fluorouracil; Graft vs Host Disease; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Keratolytic Agents; Lung Transplantation; Male; Skin Neoplasms | 2014 |
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Severity of Illness Index | 2014 |
Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Anastomotic Leak; Antimetabolites, Antineoplastic; Blood Transfusion; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Prognosis; Radiotherapy, Conformal; Rectal Neoplasms; Reoperation; Retrospective Studies; Surgical Wound Dehiscence; Surgical Wound Infection; Treatment Outcome | 2014 |
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease Progression; Fatal Outcome; Fluorouracil; Genes, ras; Humans; Indoles; Male; Melanoma; Mutation; Neoplasms, Second Primary; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
Capecitabine induced colitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms | 2014 |
Helical tomotherapy combined with capecitabine in the preoperative treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Treatment Outcome | 2014 |
[Hepatotoxicity of acetaminophen in a patient treated with capecitabine due to breast cancer].
Topics: Acetaminophen; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Overdose; Female; Fluorouracil; Humans; Liver; Middle Aged; Virus Diseases | 2014 |
Radiation recall after a transarterial hepatic chemoembolization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Chemoembolization, Therapeutic; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Fluoroscopy; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Radiodermatitis; Radiography, Interventional; Risk Factors; Temozolomide; Time Factors | 2014 |
Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Floxuridine; Fluorouracil; Humans; Pantoprazole; Proton Pump Inhibitors | 2014 |
Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged | 2014 |
Colon cancer, version 3.2014.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Liver Neoplasms; Membrane Proteins; Organoplatinum Compounds; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fecal Incontinence; Female; Fluorouracil; Humans; Ileostomy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Rectal Neoplasms; Risk Factors; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperature; Colorectal Neoplasms; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Liver Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prognosis; Retrospective Studies | 2014 |
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines | 2015 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Capecitabine; Cervical Vertebrae; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Endometrial Neoplasms; Female; Fluorouracil; Humans; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Paclitaxel; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Spine; Thoracic Vertebrae; Uterine Cervical Neoplasms | 2014 |
Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cell Line, Tumor; Cell Survival; Cisplatin; Clinical Trials, Phase II as Topic; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Paclitaxel; Stomach Neoplasms; tau Proteins; Transfection; Treatment Outcome; Tubulin; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Preoperative Care; Proportional Hazards Models; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Remission Induction; Retrospective Studies; Survival Rate | 2014 |
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Capecitabine; Cell Cycle Checkpoints; Cell Line, Tumor; Citric Acid Cycle; Cytotoxins; Deoxycytidine; Fluorouracil; Glutamine; Humans; Mutation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; DNA Repair; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Genetic Testing; Genomics; Humans; Ligands; Male; Middle Aged; Rectal Neoplasms; Treatment Outcome | 2015 |
[Neoadjuvant chemoradiotherapy in the combined treatment of patients with stage IB2-III cervical cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Russia; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cells, Cultured; Deoxycytidine; Fluorouracil; Male; Myocytes, Cardiac; Rats, Sprague-Dawley; Rats, Wistar | 2015 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
Photosensitive lichenoid drug eruption to capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Female; Fluorouracil; Humans; Photosensitivity Disorders | 2014 |
The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous System; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2014 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Survival Rate | 2014 |
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Topics: Animals; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Mice, Inbred BALB C; Tubulin Modulators; Tumor Microenvironment; Vascular Remodeling; Xenograft Model Antitumor Assays | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Community Health Services; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; Young Adult | 2014 |
[Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytokine-Induced Killer Cells; Deoxycytidine; Fluorouracil; Humans; Immunotherapy, Adoptive; Oxaloacetates; Prospective Studies; Stomach Neoplasms | 2014 |
Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Calibration; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Fluorouracil; Humans; Liquid-Liquid Extraction; Online Systems; Prodrugs; Quality Control; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2014 |
Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Quality of Life; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome | 2014 |
Role of neoadjuvant therapy in management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2014 |
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Liver Cirrhosis; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2014 |
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2014 |
Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Capecitabine; Chemotherapy, Adjuvant; Choice Behavior; Colonic Neoplasms; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Preference; Retrospective Studies; Survival Rate; Vitamin B Complex | 2014 |
Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Health Status; Humans; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2015 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
Capecitabine: toxic epidermal necrolysis and Stevens-Johnson syndrome.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Risk Assessment; Risk Factors; Stevens-Johnson Syndrome; Time Factors; United Kingdom | 2014 |
[Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Recurrence; Retrospective Studies; Treatment Outcome | 2014 |
[Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Tolerance; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Retrospective Studies | 2014 |
Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2014 |
S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis.
Topics: Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Care; Preoperative Care; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression; Humans; Immunohistochemistry; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Stomach Neoplasms; Thymidylate Synthase; Treatment Outcome | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Oxonic Acid; Panitumumab; Practice Guidelines as Topic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxaloacetates; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Haptoglobins; Hematologic Diseases; Hemolytic-Uremic Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2014 |
Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2014 |
IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Kidney; Kidney Diseases; Leucovorin; Male; Middle Aged; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Stomach Neoplasms | 2014 |
Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.
Topics: Adult; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Coronary Angiography; Coronary Thrombosis; Coronary Vasospasm; Deoxycytidine; Drug Therapy, Combination; Electrocardiography; Female; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2014 |
[Survey of the current status of capecitabine-induced hypertriglyceridemia].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fatal Outcome; Fluorouracil; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Markov Chains; Models, Economic; Neoplasm Recurrence, Local; Neoplasm Staging; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Remission Induction; Reproducibility of Results; Secondary Prevention | 2014 |
Intussusception due to rectal adenocarcinoma in a young adult: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Cell Differentiation; Chemotherapy, Adjuvant; Colonoscopy; Deoxycytidine; Fluorouracil; Humans; Immunohistochemistry; Intussusception; Magnetic Resonance Imaging; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Treatment Outcome; Young Adult | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
[Capecitabine-induced subacute cutaneous lupus: a case report].
Topics: Adverse Drug Reaction Reporting Systems; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; France; Humans; Lupus Erythematosus, Cutaneous; Middle Aged | 2014 |
Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Femur; Fluorouracil; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Pelvic Bones; Platelet Count; Radiometry; Radiotherapy Dosage; Radiotherapy, Conformal; Rectal Neoplasms; Regression Analysis; Retrospective Studies; Sacrum | 2014 |
Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cyclooxygenase 1; Cyclooxygenase 2; Deoxycytidine; Enteritis; Female; Fluorouracil; Humans; Inflammation; Interleukin-1beta; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Polymorphism, Genetic; Proctitis; Pyridines; Radiation Tolerance; Radiotherapy, Conformal; Rectal Neoplasms; Retrospective Studies; Young Adult | 2014 |
IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; ras GTPase-Activating Proteins; Rectal Neoplasms; Young Adult | 2015 |
[Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Radiotherapy Dosage; Rectal Neoplasms; Retrospective Studies | 2014 |
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tissue Array Analysis; Treatment Outcome | 2014 |
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Turkey; Young Adult | 2014 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Oxaloacetates; Predictive Value of Tests; Risk Factors | 2015 |
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; Deoxycytidine; Female; Fluorouracil; Humans; Malaysia; Male; Medication Adherence; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Sex Factors; Vomiting | 2014 |
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Rectal Neoplasms; Retreatment; Retrospective Studies; Survival Rate | 2015 |
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Cytotoxins; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
[Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Peritoneal Neoplasms; Stomach Neoplasms; Trastuzumab | 2014 |
Length of chemotherapy and use of bevacizumab for breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Taxoids | 2014 |
Improving prognosis after surgery for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
A 21-year-old patient with a HER2-positive colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Molecular Imaging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Predictive Value of Tests; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult; Zirconium | 2015 |
Association between the cytogenetic profile of tumor cells and response to preoperative radiochemotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Chromosome Aberrations; Clonal Evolution; Cohort Studies; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcome | 2014 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine; Young Adult | 2014 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Sarcopenia; Stomach Neoplasms; Tomography, X-Ray Computed | 2015 |
Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Survival Rate; Vitamin B Complex | 2014 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged | 2014 |
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiography; Thymidine Phosphorylase; Withholding Treatment | 2014 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Models, Economic; Oxaloacetates; Oxonic Acid; Quality-Adjusted Life Years; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Trichotomous gastric retention of amorphous capecitabine: an attempt to overcome pharmacokinetic gap.
Topics: Adhesiveness; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Deoxycytidine; Excipients; Fluorouracil; Gastric Mucosa; Goats; Half-Life; Polysaccharides, Bacterial; Rats, Wistar; Solubility | 2015 |
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Germany; Hand-Foot Syndrome; Humans; Middle Aged; Product Surveillance, Postmarketing; Quality of Life; Risk Assessment; Surveys and Questionnaires | 2014 |
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2 | 2015 |
Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials as Topic; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Leucovorin; Male; Markov Chains; Middle Aged; Models, Economic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quality-Adjusted Life Years; Time Factors; Treatment Outcome | 2014 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Capecitabine; Carcinoma; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2014 |
[Blindness and symmetrical neurological deficit in a patient with colon cancer receiving adjuvant chemotherapy: is it always cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Posterior Leukoencephalopathy Syndrome; Seizures; Steroids | 2014 |
Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Receptors, CXCR4; Receptors, Interleukin-8B; Signal Transduction | 2015 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Prospective Studies; Recovery of Function | 2014 |
Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Radiation Injuries; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carboxylesterase; Cytidine Deaminase; Deoxycytidine; Enzyme Activation; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2015 |
[Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Oxaloacetates; Peritoneal Neoplasms; Recurrence | 2014 |
[A case of lacrimal duct obstruction caused by capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorometholone; Fluoroquinolones; Fluorouracil; Gatifloxacin; Hand-Foot Syndrome; Humans; Lacrimal Duct Obstruction | 2015 |
[Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Male; Sigmoid Neoplasms | 2015 |
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hypertension; Male; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Proteinuria; Retrospective Studies; Treatment Outcome | 2015 |
Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; Camptothecin; Capecitabine; Carcinoid Tumor; Carcinoma, Signet Ring Cell; Cytoreduction Surgical Procedures; Deoxycytidine; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Retrospective Studies | 2015 |
Observational study of adjuvant therapy with capecitabine in colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Retrospective Studies | 2015 |
[Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Genotype; Humans; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2015 |
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Salvage Therapy | 2015 |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Germ-Line Mutation; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Thymidylate Synthase | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Down-Regulation; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Risk Factors; Smad4 Protein; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaloacetates; Retrospective Studies; Stomach Neoplasms; Young Adult | 2014 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
[Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Humans; Ileus; Male; Neoplasm Staging; Rectal Neoplasms | 2014 |
[A case of pathological complete response with neoadjuvant XELOX chemotherapy for locally advanced rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Laparoscopy; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Rectal Neoplasms | 2014 |
[A case report of the use of laparoscopic surgery to remove an adrenal tumor following resection of sigmoid colon cancer].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Laparoscopy; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Recurrence; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2014 |
[Preoperative chemotherapy enabled radical resection of tumors in a patient with multiple liver metastases].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; Sigmoid Neoplasms; Treatment Outcome | 2014 |
[Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Young Adult | 2014 |
[A case of rectal cancer with brain metastasis successfully treated with combined modality therapy - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Rectal Neoplasms; Treatment Outcome | 2014 |
[A case of sigmoid colon cancer with abdominal wall abscess].
Topics: Abdominal Abscess; Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colostomy; Combined Modality Therapy; Deoxycytidine; Drainage; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Sigmoid Neoplasms; Treatment Outcome | 2014 |
[A case of descending colon cancer with multiple liver metastases effectively treated with capecitabine/oxaliplatin (CapeOX) and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colon, Descending; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Oxaloacetates; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms | 2014 |
[A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hepatitis; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Rectal Neoplasms | 2014 |
[A case report of hepatectomy for liver metastasis of colon cancer after heavy particle radiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Heavy Ion Radiotherapy; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxaloacetates; Sigmoid Neoplasms | 2014 |
[A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of advanced gastric cancer successfully treated with trastuzumab, capecitabine, and Cisplatin therapy followed by curative resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Stomach Neoplasms; Trastuzumab; Young Adult | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Lymphatic Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2014 |
[A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Ascending; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2014 |
[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
[A case of stage IV gastric cancer resected after chemotherapy with capecitabine plus cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Middle Aged; Neoplasm Staging; Stomach Neoplasms | 2015 |
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2015 |
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Treatment Outcome | 2015 |
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis | 2015 |
[The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2015 |
[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2015 |
Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer.
Topics: Angiogenic Proteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Dose-Response Relationship, Drug; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; NF-kappa B; Quercetin; Signal Transduction; Stomach Neoplasms; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Images in clinical medicine. Loss of fingerprints.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Female; Fingers; Fluorouracil; Hand-Foot Syndrome; Humans | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Low percentage of CD24hiCD27⁺CD19⁺ B cells decelerates gastric cancer progression in XELOX-treated patients.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte Subsets; B-Lymphocytes; Biomarkers, Pharmacological; Capecitabine; Carcinoma; CD24 Antigen; China; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Prognosis; Stomach Neoplasms; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uracil | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Role of Adjuvant Chemotherapy in ypT0-2N0 Patients Treated with Preoperative Chemoradiation Therapy and Radical Resection for Rectal Cancer.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Preoperative Care; Propensity Score; Radiotherapy Dosage; Rectal Neoplasms; Regression Analysis; Treatment Outcome | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis | 2015 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
A Study on Drug Interaction between Warfarin and Capecitabine with Special Reference to the Co-Administered Term or the Discontinuation Term of Capecitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Retrospective Studies; Treatment Outcome; Warfarin | 2015 |
[A Case of Concurrent Cancer in a Giant Rectal Villous Adenoma That Resulted in Extensive Lymph Node Metastases].
Topics: Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Oxaloacetates; Rectal Neoplasms; Recurrence | 2015 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2015 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Veins | 2015 |
Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; Stomach Neoplasms | 2015 |
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2015 |
[Stage IV Gastric Cancer Made Resectable Following a Chemotherapy Regimen That Included Trastuzumab-A Case Report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Trastuzumab | 2015 |
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alcohol-Related Disorders; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Pneumonia; Retrospective Studies; Risk Factors; Severity of Illness Index; Smoking | 2016 |
Unilateral Capecitabine-related Hand-foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Risk Factors; Syndrome | 2015 |
[Prognostic Factors of Stage 3 Colorectal Cancer in 433 Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Lymph Nodes; Neoplasm Staging; Oxaloacetates; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypercalciuria; Iran; Leucovorin; Male; Middle Aged; Nephrocalcinosis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Renal Tubular Transport, Inborn Errors; Risk Factors | 2015 |
Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Oxaloacetates; Retrospective Studies; ROC Curve | 2015 |
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids | 2016 |
The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Line; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; HCT116 Cells; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; NFI Transcription Factors; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2016 |
Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Management; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Education as Topic; Quality of Life; Self Care; Young Adult | 2016 |
Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Case-Control Studies; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Monitoring; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Gastrectomy; Humans; In Situ Hybridization; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Oxaloacetates; Phenotype; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Genetic Predisposition to Disease; Glutathione Transferase; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Sigmoid Neoplasms | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Central Venous Catheters; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Retrospective Studies | 2016 |
A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pilot Projects; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate | 2016 |
[XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Oxaloacetates; Recurrence; Renal Dialysis; Sigmoid Neoplasms | 2015 |
[A Case of Para-Aortic Lymph Node Metastases of Sigmoid Colon Cancer Treated with Complete Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Ileus; Lymph Node Excision; Lymphatic Metastasis; Male; Oxaloacetates; Sigmoid Neoplasms; Treatment Outcome | 2015 |
[A Patient with Rectal Cancer and Multiple Lung Metastases Treated with XELOX plus Bevacizumab (Bev) Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Deoxycytidine; Female; Fluorouracil; Humans; Lung Neoplasms; Oxaloacetates; Rectal Neoplasms; Treatment Outcome | 2015 |
Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Fibrosis; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver; Liver Neoplasms; Metastasectomy; Mitotic Index; Multivariate Analysis; Necrosis; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Prognosis; Retrospective Studies; Tumor Burden | 2016 |
Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report.
Topics: Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Humans; Male; Myositis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2016 |
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis | 2016 |
Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Multivariate Analysis; Netherlands; Organoplatinum Compounds; Oxaliplatin | 2016 |
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates | 2016 |
Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates | 2016 |
[A Case of Unresectable Rectal Cancer with Multiple Liver Metastases Treated Effectively with 22 Courses of XELOX Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[Research hotspot and progress of preoperative chemoradiotherapy for rectal cancer].
Topics: Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Rectal Neoplasms | 2016 |
[Clinical study on locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaloacetates; Rectal Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
[Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Topics: AC133 Antigen; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms | 2016 |
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Retrospective Studies; T-Lymphocyte Subsets; Treatment Outcome | 2016 |
Pancreatic Cancer Survival Increases with Chemo Combo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2016 |
[Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Retrospective Studies | 2016 |
[Radiation therapy of pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Neoadjuvant Therapy; Organs at Risk; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Image-Guided | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gamma Rays; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Stents; Survival Analysis | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2017 |
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Organoplatinum Compounds; Oxaloacetates; Platelet Count; Prognosis; Retrospective Studies; Treatment Outcome | 2016 |
First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Taxoids; Vinblastine; Vinorelbine | 2017 |
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study.
Topics: Aged; Antimetabolites, Antineoplastic; Brachytherapy; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2016 |
A Retrospective Analysis on Two-week Short-course Pre-operative Radiotherapy in Elderly Patients with Resectable Locally Advanced Rectal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Leucovorin; Male; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Oxaloacetates; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Parenteral; Male; Middle Aged; Oxaloacetates; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Survival Rate | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; CD3 Complex; CD56 Antigen; CD8 Antigens; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2017 |
The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
Topics: Administration, Metronomic; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Ovarian Neoplasms; Telomere Homeostasis; Telomeric Repeat Binding Protein 2 | 2017 |
[Pathological Complete Response in a Case of Multiple Liver Metastases from Rectal Cancer Treated with XELOX plus Bevacizumab(Bev)Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxaloacetates; Rectal Neoplasms; Treatment Outcome | 2016 |
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Female; Fluorouracil; Humans; Ileal Neoplasms; Jejunal Neoplasms; Middle Aged; Ovarian Neoplasms; Ovariectomy; Oxaloacetates; Recurrence | 2016 |
[A Case of Aortoesophageal Fistula Rupture Due to Descending Thoracic Aortic Dissection with Recurrent Colon Cancer during Chemotherapy Containing Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aortic Diseases; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Esophageal Fistula; Fatal Outcome; Female; Fluorouracil; Humans; Oxaloacetates; Postoperative Complications; Recurrence | 2016 |
[A Case of Small Bowel Adenocarcinoma That Was Diagnosed and Treated using Laparoscopic Surgery].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Ileus; Jejunal Neoplasms; Laparoscopy; Male; Oxaloacetates; Treatment Outcome | 2016 |
[A Case of Locally Far-Advanced Colon Cancer Resected by Laparoscopic Surgery after Colonic Stent Insertion and Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Ileus; Laparoscopy; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxaloacetates; Sigmoid Neoplasms; Stents; Treatment Outcome | 2016 |
[A Case Report of Clinical Complete Response with Chemotherapy for Descending Colon Cancer Complicated with Severe Pulmonary Dysfunction].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Descending; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Lung Diseases; Male; Oxaloacetates; Pneumonectomy; Treatment Outcome | 2016 |
[A Case of Mucinous Adenocarcinoma of the Appendix with Peritoneal Dissemination Diagnosed by Laparoscopic Abdominal Exploration and Appendectomy].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Hernia, Inguinal; Humans; Intestinal Perforation; Laparoscopy; Male; Oxaloacetates; Peritoneal Neoplasms | 2016 |
[A Case of Advanced Rectal Cancer Resulting in a Pathologically Complete Response after Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Rectal Neoplasms; Treatment Outcome | 2016 |
Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
Topics: Abdominal Abscess; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Laparotomy; Lymph Node Excision; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pancreatic Fistula; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Time-to-Treatment | 2017 |
Ecological Factors in Human Development.
Topics: Capecitabine; Deoxycytidine; Friends; Gemcitabine; Humans; Pancreatic Neoplasms; Social Identification | 2017 |
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Drug Hypersensitivity; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Risk Factors | 2017 |
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Decision-Making; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nomograms; Organoplatinum Compounds; Oxaloacetates; Patient Selection; Postoperative Care; Pyrimidines; Stomach Neoplasms | 2017 |
[A Case of Advanced Transverse Colon Cancer with Nephrotic Syndrome Treated with Curative Resection and Complete Adjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Transverse; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Glomerulonephritis, Membranous; Humans; Laparoscopy; Nephrotic Syndrome; Oxaloacetates; Treatment Outcome | 2017 |
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; T-Lymphocyte Subsets; Treatment Outcome | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2017 |
Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Medication Adherence; Middle Aged; Oxaloacetates; Retrospective Studies; Self Report | 2017 |
Adjuvant Capecitabine for Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Treatment Outcome | 2017 |
Adjuvant Capecitabine for Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Treatment Outcome | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Capecitabine; Colonic Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Hospitals, Public; Humans; Models, Theoretical; Neoplasm Metastasis; Oxaloacetates; Treatment Outcome | 2017 |
Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Circadian Rhythm; Deoxycytidine; Floxuridine; Fluorouracil; Male; Prodrugs; Rats, Wistar | 2018 |
When Lightning Strikes Twice.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Second Primary; Pancreaticoduodenectomy; Reoperation; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
[A Case of Ascending Colon Cancer with Lynch Syndrome Who Underwent XELOX Adjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Deoxycytidine; Fluorouracil; Humans; Male; Oxaloacetates; Pedigree | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2018 |
Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Nail Diseases; Nails; Neoplasm Recurrence, Local; Oxaloacetates; Stomach Neoplasms | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pyridines; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2018 |
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Colon; Colonic Neoplasms; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Progression-Free Survival; Rectal Neoplasms; Rectum; Retrospective Studies | 2018 |
[A Case of Colon Cancer with Brain, Liver and Lung Metastasis Successfully Treated with Bevacizumab plus Xelox Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Oxaloacetates; Rectal Neoplasms | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Failure | 2018 |
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Prognosis; Stromal Cells | 2018 |
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Chemotherapy for pancreatic cancer: the rise of multidrug regimens.
Topics: Adenocarcinoma; Albumins; Capecitabine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Linear Models; Neoplasm Staging; Retrospective Studies; SEER Program; Survival Analysis | 2018 |
Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Patient Safety; Proctectomy; Propensity Score; Retrospective Studies; Treatment Outcome | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Lymph Node Excision; Oxaloacetates; Retrospective Studies | 2018 |
Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Eosinophils; Female; Fluorouracil; Humans; Leucovorin; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Organoplatinum Compounds; Oxaloacetates; Prognosis | 2019 |
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care | 2019 |
Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer?
Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Emotions; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2019 |
Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Stomach; Stomach Neoplasms; Treatment Outcome; Tumor Burden | 2019 |
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cell Proliferation; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2019 |
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Prognosis; Rectum; Signal Transduction; Survival Analysis; Transforming Growth Factor beta | 2019 |
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Selection Bias; Survival Analysis; Survival Rate; Treatment Outcome | 2020 |
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates | 2019 |
Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Mixed Tumor, Malignant; Oxaloacetates; Stomach Neoplasms; Treatment Outcome | 2019 |
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Choice Behavior; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Predictive Value of Tests; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Uracil | 2019 |
Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cell- and Tissue-Based Therapy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis | 2019 |
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Neoplasms; Pharmacogenomic Variants; Prodrugs | 2019 |
Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiosurgery; Retrospective Studies | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms | 2020 |
Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Gemcitabine; Humans; Oxaliplatin; Survival Analysis | 2020 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Liver; Lung Neoplasms; Retrospective Studies; Survival Analysis | 2020 |
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Retrospective Studies; Survival Rate | 2021 |
Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinom
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Progression-Free Survival; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2021 |
Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Pharmacogenetics | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Capecitabine Treatment: A Safe and Effective Therapy in the Field of Oncology.
Topics: Capecitabine; Deoxycytidine; Fluorouracil; Humans; Medical Oncology | 2021 |
Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Clinical Efficacy of Bevacizumab Plus XELOX Chemotherapy in Colorectal Cancer and Application Value of Mindfulness-Based Stress Reduction Intervention.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mindfulness; Oxaloacetates; Quality of Life; Treatment Outcome | 2022 |
Capecitabine and Hand-foot Syndrome: A Case Report.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged | 2023 |
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Topics: Animals; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cytochrome P-450 Enzyme System; Deoxycytidine; Drug Interactions; Fluorouracil; Rats; Warfarin | 2022 |
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Hospitals; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Mice; Pyroptosis; Quality of Life; Thymidine Phosphorylase | 2023 |
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Cell-Free Nucleic Acids; Cisplatin; Deoxycytidine; Humans; Irinotecan; Pancreatic Neoplasms; Pilot Projects; Proto-Oncogene Proteins p21(ras) | 2022 |
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 2023 |